

CANPOLAT & OLGAC DÜNDAR

Çocukluk Çağında Otizm Spektrum Bozukluğu Multidisipliner Yaklaşım

Editörler

Prof. Dr. Mehmet CANPOLAT

Prof. Dr. Nihal OLGAC DÜNDAR



© Copyright 2026

Bu kitabın, basım, yayın ve satış hakları Akademisyen Yayınevi A.Ş.'ne aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kayıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçlı kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.

ISBN	Sayfa ve Kapak Tasarımı
978-625-375-804-2	Akademisyen Dizgi Ünitesi
Kitabın Adı	Yayıncı Sertifika No
Canpolat & Olgaç Dündar, Çocukluk Çağında Otizm Spektrum Bozukluğu Multidisipliner Yaklaşım	47518
Editörler	Baskı ve Cilt
Mehmet CANPOLAT ORCID iD: 0000-0002-2197-8433 Nihal OLGAÇ DÜNDAR ORCID iD: 0000-0002-5902-3501	Vadi Matbaacılık
Bisac Code	DOI
MED105000	10.37609/akya.3934

Yayın Koordinatörü
Yasin DİLMEN

Kütüphane Kimlik Kartı
Canpolat & Olgaç Dündar, Çocukluk Çağında Otizm Spektrum Bozukluğu Multidisipliner Yaklaşım / ed. Mehmet Canpolat, Nihal Olgaç Dündar.
Ankara : Akademisyen Yayınevi Kitabevi, 2026.
585 s. : tablo, şekil. ; 160x235 mm.
Kaynakça ve İndeks var.
ISBN 9786253758042

UYARI

Bu üründe yer alan bilgiler sadece lisanslı tıbbi çalışanlar için kaynak olarak sunulmuştur. Herhangi bir konuda profesyonel tıbbi danışmanlık veya tıbbi tanı amacıyla kullanılmamalıdır. Akademisyen Kitabevi ve alıcı arasında herhangi bir şekilde doktor-hasta, terapist-hasta ve/veya başka bir sağlık sunum hizmeti ilişkisi oluşmaz. Bu ürün profesyonel tıbbi kararların eşleniği veya yedeği değildir. Akademisyen Kitabevi ve bağlı şirketleri, yazarları, katılımcıları, partnerleri ve sponsorları ürün bilgilerine dayalı olarak yapılan bütün uygulamalardan doğan, insanlarda ve cihazlarda yaralanma ve/veya hasarlardan sorumlu değildir. İlaçların veya başka kimyasalların reçete edildiği durumlarda, tavsiye edilen dozunu, ilacın uygulanacak süresi, yöntemi ve kontraendikasyonlarını belirlemek için, okuyucuya üretici tarafından her ilaca dair sunulan güncel ürün bilgisini kontrol etmesi tavsiye edilmektedir. Dozun ve hasta için en uygun tedavinin belirlenmesi, tedavi eden hekimin hastaya dair bilgi ve tecrübelerine dayanak oluşturması, hekimin kendi sorumluluğundadır.

Akademisyen Kitabevi, üçüncü bir taraf tarafından yapılan kitaba dair değişikliklerden sorumlu değildir.

GENEL DAĞITIM
Akademisyen Yayınevi A.Ş.

Halk Sokak 5 / A Yenışehir / Ankara
Tel: 0312 431 16 33
siparis@akademisyen.com

www.akademisyen.com

ÖNSÖZ

Otizm spektrum bozukluğu, sosyal iletişim ve sosyal etkileşimde bozulmayla birlikte sınırlı ve tekrarlayıcı davranışlar, ilgi alanları ve / veya aktivitelerle karakterize nörogelişimsel bir bozukluk olup sıklığının 1000'de 23 olduğu tahmin edilmektedir. Sıklığı son yıllarda tanı uygulamalarına, sunulan imkanlara ve daha çok tanınmasına bağlı olarak belirgin artış göstermiştir.

Otizmin adı konmadan önce otistik bulgular ve tedavisinin tanımlandığı bilinmektedir. Neo-Latin autismus sözcüğünü, İsviçreli psikiyatri uzmanı Eugen Bleuler şizofreninin belirtilerini tanımlarken 1910 yılında Yunanca autos (αὐτός, kendi anlamında) sözcüğünden türetmiş ve kişinin kendisine olan hastalıklı hayranlığı anlamında kullanmıştır. Otizm sözcüğü günümüzdeki anlamında ilk defa 1938 yılında Viyana Üniversite Hastanesi'nden Hans Asperger tarafından çocuk psikolojisi üzerine verdiği bir derste otistik psikopatlar terminolojisi ile kullanılmıştır. Johns Hopkins Hastanesi'nden Leo Kanner 1943 yılında ilk olarak erken infantil otizm terimini kullanmıştır. Aynı makalede tanımlanan, otistik yalnızlık ve tek düzelikte ısrar gibi özelliklerin tümü hala otistik spektrum bozukluklarının tipik özellikleri olarak görülmektedir. 1960'lı yılların sonunda otizm, yaşam boyu süren, zekâ geriliği, şizofreni ve diğer gelişimsel bozukluklardan farklı ayrı bir sendrom olarak kabul edilmiştir. Otizmin net bir etiyolojisi yoktur. Multifaktöryel etyolojiye sahiptir Çeşitli mutasyonların, genetik, çevresel ve epigenetik faktörlerin etkileşime girdiği ve bozukluğun gelişimi için risk faktörleri olarak katkıda bulunduğu düşünülmektedir. Otizm şüphesi olan her çocuk multidisipliner bir ekip tarafından değerlendirilmelidir. Amerikan Pediatri Akademisi, 18 ve 24 ay arasındaki tüm çocuklarda rutin tarama önermektedir.

Günlük hasta pratiğinde hekimlerimizin sıklıkla karşılaştığı başlıca nörogelişimsel bozukluklardan olan otizm konusunu ele alan bu kitapta, epidemiyoloji, genetik, patogenez, klinik bulgular, eşlik eden komorbid durumlar, tanısal yaklaşım ve testler, biyobelirteçler ve güncel gelişmeler, farmakolojik tedavi dışında davranışsal ve eğitimsel girişimler, gelecekteki tedaviler Çocuk Ruh Sağlığı ve Hastalıkları ve Çocuk Nörolojisi alanında yetkin bilim insanları tarafından ele alınmıştır.

Alanında temel eser niteliği taşıyan bu kitabın, pediatrik hasta tanı ve tedavisini gerçekleştiren çok değerli asistan ve uzman hekimlerimize, eğitim süreçleri boyunca ve günlük pratik uygulamalarında yararlı olmasını temenni ediyor. Bu vesile ile 14 Mart Tıp Bayramımızı kutluyoruz. Yine "Çocukluk Çağında Otizm Spektrum Bozukluğu Multidisipliner Yaklaşım" kitabının baskısında yer alarak katkı sağlayan çok değerli hekimlerimize, Akademisyen Kitabevi'nin çok değerli yönetici ve çalışanlarına teşekkürlerimizi sunarız.

Saygılarımızla,

Editörler

Prof. Dr. Mehmet CANPOLAT, MD, PhD.

Prof. Dr. Nihal OLGAÇ DÜNDAR, MD

14 Mart 2026

İÇİNDEKİLER

KISIM 1 OTİZME EŞLİK EDEN KOMORBİD SAĞLIK SORUNLARI VE YÖNETİMİ

BÖLÜM 1	Otizm Tanım ve Tarihçesi 3 Serkan KIRIK
BÖLÜM 2	Çocukluk Çağında Otizm Spektrum Bozukluğu: Epidemiyoloji 13 Fatma SARGIN Hurşit FERAH KAYA Ahmet Sami GÜVEN
BÖLÜM 3	Otizm Spektrum Bozukluğu Etiyolojisi 23 Mürşide ŞAHİN Esra DEMİRCİ
BÖLÜM 4	Otizm Genetiği 37 Elif Funda ŞENER
BÖLÜM 5	Otizm Spektrum Bozukluğu Patogenezi 73 Ceyda ÖNEY YILMAZ Edibe PEMBEGÜL YILDIZ

KISIM 2 KLİNİK BULGULAR VE TANISAL YAKLAŞIM 85

BÖLÜM 6	Otizm Klinik Bulguları 87 Emine Aylin ŞENOL Nilüfer ELDEŞ HACİFAZLIOĞLU Şaziye Senem BAŞGÜL
---------	--



BÖLÜM 7	Otizm Sınıflaması ve Tanı Kriterleri.....	111
	Pınar ARICAN	
BÖLÜM 8	Otizm Olgularına Tanısal Yaklaşım: Pediatrik ve Nörolojik Değerlendirme	117
	Elif DİDİNMEZ TAŞKIRDI Nihal OLGAÇ DÜNDAR	
BÖLÜM 9	Otizm Olgularına Tanısal Yaklaşım: Psikiyatrik Değerlendirme	131
	Özlem ŞİRELİ	
BÖLÜM 10	Otizm Olgularında Temel Laboratuvar Testleri	153
	Turgay ÇOKYAMAN	
BÖLÜM 11	Otizm Biyobelirteçleri ve Güncel Gelişmeler	167
	Seray AĞCA HAŞIMOĞLU Tuğçe AKSU UZUNHAN	
BÖLÜM 12	Otizm Olgularında Nörogörüntüleme Bulguları	193
	Sevim TÜRAY Hilal AYDIN	
BÖLÜM 13	Otizm Olgularında Temel Genetik Testler ve Sendromik Nedenler ..	207
	Hakan ERÇELEBİ	
BÖLÜM 14	Rett Sendromu	219
	Olca GÜNGÖR Beste KİPÇAK YÜZBAŞI	
BÖLÜM 15	Asperger Sendromu	235
	Mustafa DİNÇER Müge AYANOĞLU	

KISIM 3 TEDAVİ

BÖLÜM 16	Otizmde Tedavinin Genel İlkeleri.....	259
	Begüm YULUĞ TAŞ Gonca ÖZYURT	



BÖLÜM 17	Otizimde Davranışsal ve Eğitimsel Müdahaleler	273
	Ayla UZUN ÇİÇEK	
	Elif ABANOZ	
	İlknur UCUZ	
BÖLÜM 18	Otizm Spektrum Bozukluğunda Farmakolojik Tedaviler	299
	Esra DEMİRCİ	
BÖLÜM 19	Otizimde Deneysel Terapötik Yaklaşımlar	317
	Fatma HANCI	
	Pınar ÖZKAN KART	

KISIM 4 GELECEKTEKİ TEDAVİLER

BÖLÜM 20	Transkraniyal Manyetik Uyarım (TMS)	355
	Saban KARAYAĞIZ	
BÖLÜM 21	Otizm Spektrum Bozukluğu ve Kök Hücre Tedavisi	381
	Mehmet CANPOLAT	
BÖLÜM 22	Otizm Spektrum Bozukluğunda Genetik ve Moleküler Temelli Tedavi Yaklaşımları	423
	Elif Perihan ÖNCEL	
	Pınar GENÇPINAR	

KISIM 5 OTİZME EŞLİK EDEN KOMORBİD SAĞLIK SORUNLARI VE YÖNETİMİ

BÖLÜM 23	Otizm Spektrum Bozukluğu ve Epilepsi	457
	Sait AÇIK	
	Furkan DONBALOĞLU	
	Şenay HASPOLAT	
BÖLÜM 24	Otizm Spektrum Bozukluğu ve Dikkat Eksikliği Hiperaktivite Bozukluğu: Tanı ve Tedavi	471
	Ezgi KARAGÖZ TANIGÖR	
	Gonca ÖZYURT	



BÖLÜM 25	Otizm ve Uyku Bozuklukları: Tanı ve Tedavi	477
	Taha ÖZÇELİK	
	Ebru ARHAN	
BÖLÜM 26	Otizm ve Zihinsel Yetersizlik: Tanı ve Tedavi.....	495
	Dilek ÇAVUŞOĞLU	
BÖLÜM 27	Otizm Spektrum Bozukluğunda Dil ve İletişim Bozuklukları: Tanı ve Tedavi	505
	Yunus Emre DÖNMEZ	
	Serkan KIRIK	
BÖLÜM 28	Otizmde Diyet ve Beslenme	517
	Gamze YURTDAŞ DEPBOYLU	
	Gülşah KANER	
BÖLÜM 29	Otizm Spektrum Bozukluğu Olgularında Yaşam Kalitesi	531
	Fatma Duygu ÖZTÜRK ÖNSAL	
	Nilüfer ELDEŞ HACİFAZLIOĞLU	
	Şaziye Senem BAŞGÜL	
BÖLÜM 30	Otizmde Adli Sorunlar ve Yönetimi	545
	Elif AKÇAY	
	Meryem Hilal ALTAŞ	
	Nesrin CEYLAN	
KISIM 5	İLAÇ REHBERİ.....	551
BÖLÜM 31	Otizmde İlaç Rehberi.....	553
	Özlem ATEŞ YAMAN	
	Mehmet CANPOLAT	
	Nihal OLGAÇ DÜNDAR	

YAZARLAR

Dr. Öğr. Üyesi Elif ABANOZ

Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD.

Dr. Öğr. Üyesi Elif AKÇAY

Sağlık Bilimleri Üniversitesi, Ankara Bilkent Şehir Hastanesi, Çocuk ve Ruh Sağlığı ve Hastalıkları AD.

Uzm. Dr. Meryem Hilal ALTAŞ

Sağlık Bilimleri Üniversitesi, Ankara Bilkent Şehir Hastanesi, Çocuk Nöroloji Kliniği

Prof. Dr. Ebru ARHAN

Gazi Üniversitesi Tıp Fakültesi Hastanesi, Çocuk Nöroloji Kliniği

Doç. Dr. Pınar ARICAN

Çocuk Nöroloji Kliniği, Başakşehir Çam ve Sakura Şehir Hastanesi

Doç. Dr. Müge AYANOĞLU

Adnan Menderes Üniversitesi Çocuk Sağlığı ve Hastalıkları AD., Çocuk Nöroloji BD.

Doç. Dr. Hilal AYDIN

Balıkesir Üniversitesi, Tıp Fakültesi, Çocuk Nöroloji AD.

Uzm. Dr. Sait AÇIK

Antalya Şehir Hastanesi

Prof. Dr. Şaziye Senem BAŞGÜL

Hasan Kalyoncu Üniversitesi, Psikoloji Bölümü

Prof. Dr. Mehmet CANPOLAT

Erciyes Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları AD., Çocuk Nörolojisi BD.

Prof. Dr. Nesrin CEYLAN

Sağlık Bilimleri Üniversitesi, Ankara Bilkent Şehir Hastanesi, Çocuk Nöroloji Kliniği

Doç. Dr. Dilek ÇAVUŞOĞLU

Afyonkarahisar Sağlık Bilimleri Üniversitesi Hastanesi, Tıp Fakültesi, Çocuk Nöroloji BD.

Doç. Dr. Ayla UZUN ÇİÇEK

Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD.

Doç. Dr. Turgay ÇOKYAMAN

Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi, Çocuk Nörolojisi BD.

Prof. Dr. Esra DEMİRCİ

Erciyes Üniversitesi Tıp Fakültesi Hastanesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD.



Doç. Dr. Gamze YURTDAS DEPBOYLU

İzmir Katip Çelebi Üniversitesi, Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü

Dr. Öğr. Üyesi Mustafa DİNÇER

Adnan Menderes Üniversitesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD.

Uzm. Dr. Furkan DONBALOĞLU

Akdeniz Üniversitesi Hastanesi, Çocuk Nöroloji Kliniği

Doç. Dr. Yunus Emre DÖNMEZ

İnönü Üniversitesi Tıp Fakültesi, Çocuk Psikiyatrisi AD.

Prof. Dr. Nihal OLGAÇ DÜNDAR

İzmir Katip Çelebi Üniversitesi Çocuk Nöroloji BD., Sinirbilimleri Uygulama ve Araştırma Merkezi

Öğr. Gör. Dr. Hakan ERÇELEBİ

Başkent Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD., Çocuk Nörolojisi BD.

Dr. Öğr. Üyesi Hurşit FERAH KAYA

Necmettin Erbakan Üniversitesi Tıp Fakültesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD.

Prof. Dr. Pınar GENÇPINAR

İzmir Katip Çelebi Üniversitesi Çocuk Nöroloji BD., İzmir Katip Çelebi Üniversitesi Sinirbilimleri Uygulama ve Araştırma Merkezi, Çocuk Nöroloji Kliniği

Prof. Dr. Olcay GÜNGÖR

Pamukkale Üniversitesi Tıp Fakültesi Çocuk Nörolojisi BD.

Prof. Dr. Ahmet Sami GÜVEN

Necmettin Erbakan Üniversitesi Tıp Fakültesi, Çocuk Nöroloji BD.

Doç. Dr. Nilüfer ELDEŞ HACİFAZLIOĞLU

Sağlık Bilimleri Üniversitesi, Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi

Doç. Dr. Fatma HANCI

Trabzon Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD.

Prof. Dr. Şenay HASPOLAT

Akdeniz Üniversitesi Hastanesi, Çocuk Nöroloji Kliniği

Uzm. Dr. Seray AĞCA HAŞİMOĞLU

İstanbul Atlas Üniversitesi Tıp Fakültesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD.

Prof. Dr. Gülşah KANER

İzmir Katip Çelebi Üniversitesi, Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü

Uzm. Dr. Saban KARAYAĞIZ

Psikiyatrist, TMS Klinik

Uzm. Dr. Pınar ÖZKAN KART

Sağlık Bilimleri Üniversitesi, Trabzon Kanuni Eğitim ve Araştırma Hastanesi, Çocuk Nörolojisi Bölümü

Doç. Dr. Serkan KIRIK

SBÜ Elazığ Fethi Sekin Şehir Hastanesi, Çocuk Nöroloji Kliniği

Uzm. Dr. Elif Perihan ÖNCEL

Ankara Etlik Şehir Hastanesi, Çocuk Nöroloji BD., Çocuk Nöroloji Kliniği

**Dr. Fatma Duygu ÖZTÜRK ÖNSAL**

Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi

Doç. Dr. Gonca ÖZYURT

İzmir Katip Çelebi Üniversitesi Tıp Fakültesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD.

Uzm. Dr. Taha ÖZÇELİK

Gazi Üniversitesi Tıp Fakültesi Hastanesi, Çocuk Nöroloji Kliniği

Uzm. Dr. Fatma SARGIN

Necmettin Erbakan Üniversitesi Tıp Fakültesi, Çocuk Nöroloji BD.

Mürşide ŞAHİN

Kayseri Şehir Hastanesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Departmanı

Prof. Dr. Elif Funda ŞENER

Erciyes Üniversitesi Tıp Fakültesi Tıbbi Biyoloji AD.

Doç. Dr. Özlem ŞİRELİ

Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD.

Ezgi KARAGÖZ TANIGÖR

İzmir Katip Çelebi Üniversitesi, Tıp Fakültesi, Atatürk Eğitim Araştırma Hastanesi Çocuk ve Ergen Psikiyatrisi

Uzm. Dr. Begüm YULUĞ TAŞ

İzmir Tepecik Eğitim ve Araştırma Hastanesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Kliniği

Uzm. Dr. Elif DİDİNMEZ TAŞKIRDI

İzmir Şehir Hastanesi, Çocuk Nörolojisi Kliniği

Doç. Dr. Sevim TÜRAY

Düzce Üniversitesi Tıp Fakültesi, Çocuk Nöroloji BD.

Doç. Dr. İlknur UCUZ

İnönü Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD.

Dç. Dr. Tuğçe AKSU UZUNHAN

İstanbul Atlas Üniversitesi Tıp Fakültesi, Çocuk Nöroloji Bölümü

Dr. Özlem ATEŞ YAMAN

İzmir Şehir Hastanesi, Çocuk Nöroloji Kliniği

Prof. Dr. Edibe PEMBEGÜL YILDIZ

İstanbul Üniversitesi, İstanbul Tıp Fakültesi ,Çocuk Sağlığı ve Hastalıkları AD., Çocuk Nörolojisi BD.

Uzm. Dr. Ceyda ÖNEY YILMAZ

İstanbul Üniversitesi, İstanbul Tıp Fakültesi ,Çocuk Sağlığı ve Hastalıkları AD., Çocuk Nörolojisi BD.

Dr. Emine Aylin YILMAZ

Sağlık Bilimleri Üniversitesi, Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi

Dr. Öğr. Üyesi Beste KİPÇAK YÜZBAŞI

Dr. Pamukkale Üniversitesi Tıp Fakültesi Çocuk Nörolojisi

OTİZM TANIM VE TARİHÇESİ

Serkan KIRIK¹

GİRİŞ VE TANIM

Otizm spektrum bozukluğu (OSB), son yıllarda önemi giderek artan, bulguları erken çocukluk çağında başlayan, iletişim ve sosyal etkileşim alanlarında belirgin yetersizlik, basmakalıp ve stereotipik yani yineleyici davranışlar, sınırlı ilgi alanları ve kısıtlı işlevsellik ile kendini ortaya koyan, ömür boyu devam edebilen nörogelişimsel bir bozukluktur. Klinik durumun şiddeti, hastalar arasında hafiften ağıra doğru değişkenlik gösterir. “Otizm” terimi, Yunanca “Autos” kelimesinden türemiş olup “Kendi” anlamına gelir. Bleuler tarafından bu terim ilk olarak 1911 yılında kullanılmıştır. Hem şizofreni hastalarında hem de dementia praecox hastalarında “Bireyin kendi iç dünyasına kapanıp, dış dünya ile olan ilişkilerini kaybetmesi ya da minimize etmesi” durumunu bu terimle açıklamıştır.¹

Otizm Spektrum Bozukluğu (OSB), yaygın ancak karmaşık ve heterojen bir nörogelişimsel bozukluktur. Bu nedenle, kişiye özel değerlendirmeler ve müdahale stratejileri, tıbbi, eğitimsel ve toplumsal destek hizmetlerinin koordinasyonu ve uzun vadeli bakım gerektirir. Son 15 yılda, bu alanda önemli değişiklikler yaşanmıştır. Bu değişiklikler arasında; OSB’nin yaygınlığındaki artış, en yaygın kabul gören tanı kriterleri ve sınıflandırma sistemlerindeki değişiklikler, OSB ile ilişkili özelliklerin ve eşlik eden hastalıkların öneminin daha iyi anlaşılması, kanıta dayalı tedavi yöntemlerinin genişlemesi, genetik nedenlerin belirlenmesinde hızlı ilerleme kaydedilmesi, OSB ile ilgili araştırmalara ayrılan fonların ve yapılan yayınların önemli ölçüde artması yer almaktadır. OSB’nin tanı ve yönetimine yönelik klinik kılavuzlar, Amerikan Çocuk ve Ergen Psikiyatrisi Akademisi

¹ Doç. Dr. Serkan KIRIK, SBÜ Elazığ Fethi Sekin Şehir Hastanesi, Çocuk Nöroloji Kliniği, srknkrk@hotmail.com, ORCID iD: 0000-0002-8658-2448



sınıflandırma sisteminde otizm tanısı zamanla birlikte değişime uğrayarak, ICD 10' da YGB başlığı ile isimlendirilmiştir.^{2,3,10,16}

Sonuç olarak otizm, yıllar içinde farklı isimler ve tanımlamalar altında incelenmiş; bu tanımlamalar zamanla evrimleşmiştir. Ancak günümüzdeki anlamıyla ilk kez 20. yüzyılda tanımlanmıştır. Otizmin tanı kriterlerindeki değişikliklere ek olarak bireysel eğitimin etkisinin kanıtlanmasıyla önemli mesafeler katılmıştır. Genetik ve nörobiyolojik çalışmaların hızlanmasıyla otizmin kalıtsal yönü daha iyi anlaşılmıştır. Tüm bunlar OSB'nun erken teşhisinin, bireyselleştirilmiş eğitimin ve sosyal desteklerin otizmlili bireylerin yaşam kalitesini artırmada kritik bir rol oynadığı ortaya koymaktadır. İlerleyen zamanda yapılacak araştırmalar; genetik faktörler, çevresel etkileşimler ve bireyselleştirilmiş tedavi yaklaşımlarını daha iyi anlamaya odaklanacaktır.

KAYNAKLAR

1. Autism spectrum disorder. Capute and Accardo' s Neurodevelopmental Disabilities in Infancy and Childhood. Ismail FY, Accardo PJ, Shapiro BK eds. Capute and Accardo' s Neurodevelopmental Disabilities in Infancy and Childhood (Fourth Edition), Academic Press, 2025, 589-683.
2. Whyatt CP, Torres EB. Autism Research: An Objective Quantitative Review of Progress and Focus Between 1994 and 2015. Front Psychol. 2018 Aug 23;9:1526.
3. Muratori, F., Calderoni, S., & Bizzari, V. (2021). George Frankl: an undervalued voice in the history of autism. Eur Child Adolesc Psychiatry. 30(8), 1273-1280.
4. Kanner LJNc. Autistic disturbances of affective contact. 1943;2(3):217-50.
5. Wing, L. Asperger's syndrome: a clinical account. Psychological medicine. 1981: 11(1), 115-129.
6. Hyman SL, Levy SE, Myers SM, et al. Identification, evaluation, and management of children with autism spectrum disorder. Pediatrics. 2020: 145(1).
7. Lord C, Charman T, Havdahl A, et al The Lancet Commission on the future of care and clinical research in autism. Lancet. 2022 Jan 15;399(10321):271-334.
8. Hirota T, King BH. Autism Spectrum Disorder: A Review. JAMA. 2023 Jan 10;329(2):157-168.
9. Interagency Autism Coordinating Committee. Interagency Autism Coordinating Committee (ICAC) 2021–2023 strategic plan for autism research, services, and policy draft. January 2023. Retrieved on 2/28/2023 from the U.S. Department of Health and Human Services Interagency Autism Coordinating Committee website:https://iacc.hhs.gov/meetings/iacc-meetings/2023/full-committee-meeting/january18/strategic_plan_draft.pdf.
10. American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5™ (5th ed.). 2013. American Psychiatric Publishing, Inc.
11. American AP. Text Revision. Diagnostic and statistical manual of mental disorders (5th ed.), American Psychiatric Association, Arlington, VA (2022).
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed., text rev.).2022;p:1-55.



13. Dawson G, Rieder AD, Johnson MH. Prediction of autism in infants: progress and challenges. *Lancet Neurol.* 2023; 22(3):244-254.
14. Singer A, Lutz A, Escher J, Halladay, A. A full semantic toolbox is essential for autism research and practice to thrive. *Autism Research.* 2023; 16(3), 497-501.
15. Solmi M, Song M, Yon DK, et al. Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries. *Mol Psychiatry.* 2022; Oct;27(10):4172-4180.
16. World Health Organization. ICD-11: International classification of diseases (11th revision). 2022. <https://icd.who.int/>

ÇOCUKLUK ÇAĞINDA OTİZM SPEKTRUM BOZUKLUĞU: EPİDEMİYOLOJİ

*Fatma SARGIN¹
Hurşit FERAH KAYA²
Ahmet Sami GÜVEN³*

GİRİŞ

Otizm Spektrum Bozukluğu (OSB), bireylerin sosyal etkileşimde bulunma, iletişim kurma ve davranışsal esneklik konusunda zorluk yaşadıkları, geniş bir klinik spektrumda yer alan nörogelişimsel bir bozukluktur. OSB semptomları genellikle erken çocukluk döneminde başlamaktadır ve etiyojisinde genetik, çevresel ve nörobiyolojik faktörlerin etkileşimi önemli rol oynamaktadır. Çocukluk çağında OSB'nin prevalansı, tanı kriterlerinin ve tanı süreçlerine dair bilgi ve veriler zamanla değişim göstermiştir. Bu bölümde, çocukluk çağındaki OSB'nin epidemiyolojik özellikleri, prevalansı, risk faktörleri ve coğrafi farklılıklar ile birlikte eşlik eden tıbbi durumlar ele alınacaktır.

EPİDEMİYOLOJİK ÖZELLİKLERİ, PREVALANSI, RİSK FAKTÖRLERİ VE COĞRAFİ FARKLILIKLAR

Otizm Spektrum Bozukluğu prevalansına ilişkin tahminler, çalışma metodolojisine ve değerlendirilen popülasyona göre değişiklik göstermektedir. Avrupa, Asya ve Amerika Birleşik Devletleri'nde genel OSB prevalansı, 1000 kişide 2 ile

¹ Uzm. Dr., Necmettin Erbakan Üniversitesi Tıp Fakültesi, Çocuk Nöroloji BD., fatmasargin@yahoo.com.tr, ORCID iD: 0000-0002-4514-1857

² Dr. Öğr. Üyesi, Necmettin Erbakan Üniversitesi Tıp Fakültesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., drhursitferahkaya@gmail.com, ORCID iD: 0000-0001-8611-0435

³ Prof. Dr., Necmettin Erbakan Üniversitesi Tıp Fakültesi, Çocuk Nöroloji BD., asamiguven@hotmail.com, ORCID iD: 0000-0002-6085-1582



şı, tanı süreçlerinin iyileşmesi ve çevresel faktörlerin etkisi ile ilişkilidir. OSB'de erken tanının öneminin vurgulanması gerektiği bu alanda yapılan çalışmalarda öne çıkmaktadır. Gelecekte, genetik ve çevresel etkileşimlerin daha derinlemesine incelenmesi, otizm spektrumundaki bireylerin ihtiyaçlarına yönelik daha etkili tedavi ve destek stratejilerinin geliştirilmesine olanak sağlayacaktır.

KAYNAKLAR

1. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). *Lancet*. 2006;368(9531):210-215. doi: 10.1016/S0140-6736(06)69041-7.
2. Webb E, Morey J, Thompson W, et al. Prevalence of autistic spectrum disorder in children attending mainstream schools in a Welsh education authority. *Dev Med Child Neurol*. 2003;45(6):377-384. doi: 10.1017/s0012162203000720.
3. Williams E, Thomas K, Sidebotham H, et al. Prevalence and characteristics of autistic spectrum disorders in the ALSPAC cohort. *Dev Med Child Neurol*. 2008;50(9):672-677. doi: 10.1111/j.1469-8749.2008.03042.x.
4. Chien IC, Lin CH, Chou YJ, et al. Prevalence and incidence of autism spectrum disorders among national health insurance enrollees in Taiwan from 1996 to 2005. *J Child Neurol*. 2011;26(7):830-834. doi: 10.1177/0883073810393964
5. Zablotsky B, Black LI, Maenner MJ, et al. Estimated Prevalence of Autism and Other Developmental Disabilities Following Questionnaire Changes in the 2014 National Health Interview Survey. *Natl Health Stat Report*. 2015;87:1-20.
6. Xu G, Strathearn L, Liu B, et al. Prevalence of Autism Spectrum Disorder Among US Children and Adolescents, 2014-2016. *JAMA*. 2018;319(1):81-82. doi: 10.1001/jama.2017.17812.
7. Brugha TS, Spiers N, Bankart J, et al. Epidemiology of autism in adults across age groups and ability levels. *Br J Psychiatry*. 2016;209(6):498-503. doi: 10.1192/bjp.bp.115.174649.
8. Schendel DE, Thorsteinsson E. Cumulative Incidence of Autism Into Adulthood for Birth Cohorts in Denmark, 1980-2012. *JAMA*. 2018;320(17):1811-1813. doi: 10.1001/jama.2018.11328.
9. Shaw KA, Maenner MJ, Bakian AV, et al. Early Identification of Autism Spectrum Disorder Among Children Aged 4 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018. *MMWR Surveill Summ*. 2021;70(10):1-14. doi:10.15585/mmwr.ss7010a1.
10. Zhou H, Xu X, Yan W, et al. Prevalence of Autism Spectrum Disorder in China: A Nationwide Multi-center Population-based Study Among Children Aged 6 to 12 Years. *Neurosci Bull*. 2020;36(9):961-971. doi:10.1007/s12264-020-00530-6.
11. Sasayama D, Kuge R, Toibana Y, et al. Trends in Autism Spectrum Disorder Diagnoses in Japan, 2009 to 2019. *JAMA Netw Open*. 2021;4(5):e219234. doi:10.1001/jamanetworkopen.2021.9234
12. Maenner MJ, Warren Z, Williams AR, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. *MMWR Surveill Summ*. 2023;72(2):1-14. doi:10.15585/mmwr.ss7202a1.
13. Lai MC, Lombardo MV, Baron-Cohen S. Autism. *Lancet*. 2014; 383:896-910. [https://doi.org/10.1016/S0140-6736\(13\)61539-1](https://doi.org/10.1016/S0140-6736(13)61539-1).



14. Williams JG, Higgins JP, Brayne CE. Systematic review of prevalence studies of autism spectrum disorders. *Arch Dis Child*. 2006;91(1):8-15. doi:10.1136/adc.2004.062083.
15. Wing L, Potter D. The epidemiology of autistic spectrum disorders: is the prevalence rising? *Ment Retard Dev Disabil Res Rev*. 2002;8(3):151-161. doi:10.1002/mrdd.10029.
16. Baxter AJ, Brugha TS, Erskine HE, et al. The epidemiology and global burden of autism spectrum disorders. *Psychol Med*. 2015;45(3):601-613. doi:10.1017/S003329171400172X.
17. Zablotzky B, Black LI, Maenner MJ, et al. Estimated Prevalence of Autism and Other Developmental Disabilities Following Questionnaire Changes in the 2014 National Health Interview Survey. *Natl Health Stat Report*. 2015;(87):1-20.
18. Croen LA, Grether JK, Hoogstrate J, et al. The changing prevalence of autism in California. *J Autism Dev Disord*. 2002;32(3):207-215. doi:10.1023/a:1015453830880.
19. Mandell DS, Palmer R. Differences among states in the identification of autism spectrum disorders. *Arch Pediatr Adolesc Med*. 2005;159(3):266-269. doi:10.1001/archpedi.159.3.266.
20. Bishop DV, Whitehouse AJ, Watt HJ, et al. Autism and diagnostic substitution: evidence from a study of adults with a history of developmental language disorder. *Dev Med Child Neurol*. 2008;50(5):341-345. doi:10.1111/j.1469-8749.2008.02057.x.
21. Parner ET, Schendel DE, Thorsen P. Autism prevalence trends over time in Denmark: changes in prevalence and age at diagnosis. *Arch Pediatr Adolesc Med*. 2008;162(12):1150-1156. doi:10.1001/archpedi.162.12.1150.
22. Loomes R, Hull L, Mandy WPL. What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis. *J Am Acad Child Adolesc Psychiatry*. 2017;56(6):466-474. doi: 10.1016/j.jaac.2017.03.013.
23. Brugha T, Bankart J, McManus S, et al. CDC autism rate: misplaced reliance on passive sampling? *Lancet*. 2018;392(10149):732-733. doi: 10.1016/S0140-6736(18)31494-6.
24. Baxter AJ, Brugha TS, Erskine HE, et al. The epidemiology and global burden of autism spectrum disorders. *Psychol Med*. 2015;45(3):601-613. doi: 10.1017/S003329171400172X.
25. Elsabbagh M, Divan G, Koh YJ, et al. Global prevalence of autism and other pervasive developmental disorders. *Autism Res*. 2012;5(3):160-179. doi: 10.1002/aur.239.
26. Magnusson C, Rai D, Goodman A, et al. Migration and autism spectrum disorder: population-based study. *Br J Psychiatry*. 2012;201:109-115. doi: 10.1192/bjp.bp.111.095125.
27. Goodman R, Richards H. Child and adolescent psychiatric presentations of second-generation Afro-Caribbeans in Britain. *Br J Psychiatry*. 1995;167(3):362-369. doi: 10.1192/bjp.167.3.362.
28. Keen DV, Reid FD, Arnone D. Autism, ethnicity and maternal immigration. *Br J Psychiatry*. 2010;196(4):274-281. doi: 10.1192/bjp.bp.109.065490.
29. McManus S, Bebbington P, Jenkins R, et al. *Adult Psychiatric Morbidity Survey: mental health and wellbeing in England, 2014*. NHS <https://digital.nhs.uk/data-and-information/publications/statistical/adult-psychiatric-morbidity-survey/adult-psychiatric-morbidity-survey-of-mental-health-and-wellbeing-england-2014> (2016).
30. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7.
31. Lord C, Brugha TS, Charman T, et al. Autism spectrum disorder. *Nat Rev Dis Primers*. 2020;6(1):5. doi: 10.1038/s41572-019-0138-4.



32. Brugha TS, Spiers N, Bankart J, et al. Epidemiology of autism in adults across age groups and ability levels. *Br J Psychiatry*. 2016;209(6):498-503. doi: 10.1192/bjp.bp.115.174649.
33. Lundström S, Reichenberg A, Anckarsäter H, et al. Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general population samples. *BMJ*. 2015;350:h1961. doi:10.1136/bmj.h1961.
34. Tromans S, Chester V, Kiani R, et al. The Prevalence of Autism Spectrum Disorders in Adult Psychiatric Inpatients: A Systematic Review. *Clin Pract Epidemiol Ment Health*. 2018;14:177-187. doi: 10.2174/1745017901814010177.
35. Yenikoyan K, Mkhitaryan M, Björklund G. Environmental Risk Factors in Autism Spectrum Disorder: A Narrative Review. *Curr Med Chem*. 2024;31(17):2345-2360. doi: 10.2174/0109298673252471231121045529.
36. Wu S, Wu F, Ding Y, et al. Advanced parental age and autism risk in children: a systematic review and meta-analysis. *Acta Psychiatr Scand*. 2017;135(1):29-41. doi: 10.1111/acps.12666.
37. Modabbernia A, Velthorst E, Reichenberg A. Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses. *Mol Autism*. 2017;8:13. doi: 10.1186/s13229-017-0121-4.
38. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. *Vaccine*. 2014;32(29):3623-9. doi: 10.1016/j.vaccine.2014.04.085.
39. Lukmanji S, Manji SA, Kadhimi S, et al. The co-occurrence of epilepsy and autism: A systematic review. *Epilepsy Behav*. 2019;98:238-248. doi:10.1016/j.yebeh.2019.07.037.
40. Simonoff E, Pickles A, Charman T, et al. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. *J Am Acad Child Adolesc Psychiatry*. 2008 ;47(8):921-929. doi: 10.1097/CHI.0b013e318179964f.
41. Hyman SL, Levy SE, Myers SM. ; Council on children with disabilities, section on developmental and behavioral pediatrics. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. *Pediatrics*. 2020;145(1):e20193447. doi: 10.1542/peds.2019-3447.
42. Gillberg C, Coleman M. Autism and medical disorders: a review of the literature. *Dev Med Child Neurol*. 1996;38(3):191-202. doi:10.1111/j.1469-8749.1996.tb15081.x
43. Rutter M, Bailey A, Bolton P, et al. Autism and known medical conditions: myth and substance. *J Child Psychol Psychiatry*. 1994; 35:311.
44. Oxelgren UW, Myrelid Å, Annerén G, et al. Prevalence of autism and attention-deficit-hyperactivity disorder in Down syndrome: a population-based study. *Dev Med Child Neurol*. 2017;59(3):276-283. doi:10.1111/dmcn.13217.
45. Wong V. Study of the relationship between tuberous sclerosis complex and autistic disorder. *J Child Neurol*. 2006;21(3):199-204. doi:10.2310/7010.2006.00046.
46. Richards C, Jones C, Groves L, et al. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. *Lancet Psychiatry*. 2015;2(10):909-916. doi:10.1016/S2215-0366(15)00376-4.
47. Numis AL, Major P, Montenegro MA, et al. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. *Neurology*. 2011;76(11):981-987. doi:10.1212/WNL.0b013e3182104347.
48. Weinstein V, Tanpaiboon P, Chapman KA, et al. Do the data really support ordering fragile X testing as a first-tier test without clinical features?. *Genet Med*. 2017;19(12):1317-1322. doi:10.1038/gim.2017.64.
49. Bolton PF, Dennis NR, Browne CE, et al. The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders. *Am J Med*



- Genet.* 2001;105(8):675-685. doi:10.1002/ajmg.1551.
50. Baker P, Piven J, Schwartz S, et al. Brief report: duplication of chromosome 15q11-13 in two individuals with autistic disorder. *J Autism Dev Disord.* 1994;24(4):529-535. doi:10.1007/BF02172133.
 51. Nurmi EL, Dowd M, Tadevosyan-Leyfer O, et al. Exploratory subsetting of autism families based on savant skills improves evidence of genetic linkage to 15q11-q13. *J Am Acad Child Adolesc Psychiatry.* 2003;42(7):856-863. doi:10.1097/01.CHI.0000046868.56865.0F.
 52. Wang H, Xin B, Wensel C, et al. *Cohen Syndrome.* 2006 Aug 29 [Updated 2025 Dec 4]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1482/>
 53. Deardorff MA, Noon SE, Krantz ID. *Cornelia de Lange Syndrome.* 2005 Sep 16 [Updated 2020 Oct 15]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1104/>

OTİZM SPEKTRUM BOZUKLUĞU ETİYOLOJİSİ

Mürşide ŞAHİN¹
Esra DEMİRCİ²

GİRİŞ

Otizm spektrum bozukluğu (OSB), DSM 5'te sosyal iletişim ve etkileşiminde kısıtlılık anormal ve sabit ilgi alanları ve tekrarlayan davranışlarla kendini gösteren bir nörogelişimsel bozukluk olarak tanımlanmaktadır.¹ Amerika Birleşik Devletleri'ndeki en son tahminlere göre, 36 çocuktan 1'i OSB'den etkilenmektedir.² Prevelansı gittikçe artmakla birlikte etyopatogenezi hala gizemini korumaktadır.

OSB'ye ilişkin ilk araştırmalar davranışsal gözlemlere ve psikanalize odaklanmıştır. Yirminci yüzyılın ikinci yarısında, genetik ve nörobilimdeki ilerlemelerle birlikte araştırmacıların OSB'nin biyolojik temelini keşfetmeye başlamasıyla birlikte çalışmalar genetik faktörlere, beyin yapısı ve işlevindeki anormalliklere odaklanmıştır. Yirmibirinci yüzyılda araştırmacılar yalnızca OSB ile ilişkili belirli genetik varyantları tanımlamakla kalmamış, aynı zamanda çevresel faktörler ile genetik duyarlılık arasındaki etkileşimi de keşfetmeye başlamışlardır.³

Yapılan çalışmalar OSB'nin etyolojisinde hem genetik hem de çevresel faktörlerin önemli bir rol oynadığını göstermekte⁴ olup; etyolojisinde genetik temelin bulunduğu, çevresel etmenlerin epigenetik değişiklikler üzerinden riski arttırdığı, nöroimmünojenik mekanizmaların nöronal bağlantırlığı etkilediği nörogelişimsel bir bozukluk olarak tanımlanmaktadır.⁵ Etyopatogenezine dair yapılan

¹ Uzm. Dr., Kayseri Şehir Hastanesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Departmanı, mursidesahin@erciyes.edu.tr, ORCID iD: 0000-0002-9719-2920

² Prof. Dr., Erciyes Üniversitesi, Tıp Fakültesi Hastanesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., esrademirci@erciyes.edu.tr, ORCID iD: 0000-0002-8424-4947



ğunu ve epigenetik mekanizmaların otizmin gelişimine nasıl katkıda bulunduğunu anlamak önemli bir araştırma alanıdır.

3. **Multi-Omik Veri Entegrasyonu:** Genomik, transkriptomik, proteomik ve metabolomik verilerin entegrasyonu, otizmin moleküler düzeyde daha kapsamlı bir şekilde anlaşılmasına ve tedavi hedeflerinin belirlenmesine yardımcı olabilir.
4. **Nörogelişimsel ve Beyin Görüntüleme Çalışmaları:** Beyin gelişimiyle ilgili yapısal ve fonksiyonel farklılıkları inceleyen nörogörüntüleme tekniklerinin kullanımı, erken dönemde biyomarkerler belirlememize ve müdahale için kritik zaman dilimlerini saptamamıza yardımcı olabilir.
5. **Bireysel Farklılıklar ve Kişiyeye Özel Tedavi Yaklaşımları:** OSB'nin heterojen doğası göz önünde bulundurularak, bireysel genetik, nörobiyolojik ve davranışsal özelliklere dayalı otizm alt gruplarının belirlenmesi ve kişiyeye özel tedavi yöntemlerinin geliştirilmesi önemlidir.

Bu alanlarda yapılacak araştırmalar, OSB'nin çok faktörlü doğasını daha derinlemesine anlamamıza, daha erken tanı konmasına ve daha etkili müdahalelere olanak sağlayarak, otizmlili bireylerin yaşam kalitesini artıracaktır.

KAYNAKLAR

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington DC: American Psychiatric Association; 2013.
2. Maenner MJ, Warren Z, Williams AR, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years — Autism and Developmental Disabilities Monitoring Network, United States, 2020. MMWR Surveill Summ. 2023; 72:1-14.
3. Qin L, Wang H, Ning W, Cui M, Wang Q. New advances in the diagnosis and treatment of autism spectrum disorders. Eur J Med Res. 2024; 29:322.
4. Cheroni C, Caporale N, Testa G. Autism spectrum disorder at the crossroad between genes and environment: contributions, convergences and interactions in ASD developmental pathophysiology. Mol Autism. 2020; 11:69.
5. Mukaddes NM. Otizm spektrum bozuklukları. İstanbul: Nobel Tıp Kitabevleri; 2013: 317-320.
6. Wiśniowiecka-Kowalik B, Nowakowska BA. Genetics and epigenetics of autism spectrum disorder: current evidence in the field. J Appl Genet. 2019; 60:37-47.
7. Bailey A, Le Couteur A, Gottesman I, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med. 1995; 25:63-77.
8. Rosenberg RE, Law JK, Yenokyan G, et al. Characteristics and concordance of autism spectrum disorders among 277 twin pairs. Arch Pediatr Adolesc Med. 2009; 163:907-914.
9. Ozonoff S, Young GS, Carter A, et al. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics. 2011;128: e488-e495.
10. Ramaswami G, Geschwind DH. Genetics of autism spectrum disorder. Handb Clin Neurol. 2018; 147:321-329.



11. Jiang CC, Lin LS, Long S, et al. Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications. *Signal Transduct Target Ther.* 2022; 7:229.
12. Yoo H. Genetics of autism spectrum disorder: current status and possible clinical applications. *Exp Neurobiol.* 2015; 24:257-272.
13. Knight D, Xie W, Boulianne GL. Neurexins and neuroligins: recent insights from invertebrates. *Mol Neurobiol.* 2011; 44:426-440.
14. Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. *Nature.* 2008; 455:903-911.
15. Berg JM, Geschwind DH. Autism genetics: searching for specificity and convergence. *Genome Biol.* 2012; 13:247.
16. La Monica I, Di Iorio MR, Sica A, et al. Autism spectrum disorder: genetic mechanisms and inheritance patterns. *Genes (Basel).* 2025; 16:478.
17. Ascano M Jr, Mukherjee N, Bandaru P, et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. *Nature.* 2012; 492:382-386.
18. Uysal SP, Sahin M. Tuberous sclerosis: a review of the past, present and future. *Turk J Med Sci.* 2020; 50:1665-1676.
19. Wang L, Wang B, Wu C, Wang J, Sun M. Autism spectrum disorder: neurodevelopmental risk factors, biological mechanisms and precision therapy. *Int J Mol Sci.* 2023; 24:1819.
20. Bucan M, Abrahams BS, Wang K, et al. Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. *PLoS Genet.* 2009; 5:e1000536.
21. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. *Curr Opin Genet Dev.* 2012; 22:229-237.
22. Bolton P, Macdonald H, Pickles A, Rios P, Goode S, Crowson M, et al. A case-control family history study of autism. *J Child Psychol Psychiatry.* 1994; 35:877-900.
23. Hartley SL, Hickey EJ, DaWalt L, Rodriguez G. Broader autism phenotype and couple interactions in parents of children with autism. *Autism.* 2019; 23:2068-2079.
24. Dawson G, Estes A, Munson J, et al. Quantitative assessment of autism symptom-related traits in probands and parents. *J Autism Dev Disord.* 2007; 37:523-536.
25. Courchesne E, Karns CM, Davis HR, et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. *Neurology.* 2001; 57:245-254.
26. Lange N, Travers BG, Bigler ED, et al. Longitudinal volumetric brain changes in autism spectrum disorder ages 6-35 years. *Autism Res.* 2015; 8:82-93.
27. Hazlett HC, Poe MD, Gerig G, et al. Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. *Arch Gen Psychiatry.* 2005; 62:1366-1376.
28. Li C, Zhang R, Zhu Y, et al. Gray matter asymmetry alterations in children and adolescents with comorbid autism spectrum disorder and ADHD. *Eur Child Adolesc Psychiatry.* 2023; 32:1-12.
29. Ohta H, Nordahl CW, Iosif AM, et al. Increased surface area, but not cortical thickness, in a subset of young boys with autism spectrum disorder. *Autism Res.* 2016; 9:232-248.
30. Hazlett HC, Poe MD, Gerig G, et al. Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. *Arch Gen Psychiatry.* 2011; 68:467-476.
31. Hazlett HC, Gu H, Munsell BC, et al. Early brain development in infants at high risk for autism spectrum disorder. *Nature.* 2017; 542:348-351.
32. Yu X, Taylor AM, Nagai J, et al. Reducing astrocyte calcium signaling in vivo alters striatal microcircuits and causes repetitive behavior. *Neuron.* 2018; 99:1170-1187.
33. Duerden EG, Mak-Fan KM, Taylor MJ, Roberts SW. Regional differences in grey and white matter in children and adults with autism spectrum disorders. *Autism Res.* 2012; 5:49-66.



34. Qiu T, Chang C, Li Y, et al. Two-year changes in development of caudate nucleus in children with autism spectrum disorder. *Dev Cogn Neurosci*. 2016; 19:137-143.
35. Kumar M, Hiremath C, Khokhar SK, et al. Altered cerebellar lobular volumes correlate with clinical deficits in siblings and children with ASD. *J Transl Med*. 2023; 21:246.
36. Herringshaw AJ, Ammons CJ, DeRamus TP, Kana RK. Hemispheric differences in language processing in autism spectrum disorders. *Autism Res*. 2016; 9:1046-1057.
37. He Y, Byrge L, Kennedy DP. Functional connectivity differences in autism spectrum disorder across multiple sites. *Hum Brain Mapp*. 2020; 41:1334-1350.
38. Fernandez M, Mollinedo-Gajate I, Penagarikano O. Neural circuits for social cognition: implications for autism. *Neuroscience*. 2018; 370:148-162.
39. Tan Z, Wei H, Song X, et al. Positron emission tomography in the neuroimaging of autism spectrum disorder. *Front Neurosci*. 2022; 16:806876.
40. Scott-Van Zeeland AA, Dapretto M, Ghahremani DG, Poldrack RA, Bookheimer SY. Reward processing in autism. *Autism Res*. 2010; 3:53-67.
41. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Cohen RM. Low medial prefrontal dopaminergic activity in autistic children. *Lancet*. 1997; 350:638.
42. Vinithakumari AA, Padhi P, Hernandez B, et al. Clostridioides difficile infection dysregulates brain dopamine metabolism. *Microbiol Spectr*. 2022; 10: e0007322.
43. Islam KUS, Meli N, Blaess S. Development of the mesoprefrontal dopaminergic system in health and disease. *Front Neural Circuits*. 2021; 15:746582.
44. Schiele MA, Domschke K. Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders. *Genes Brain Behav*. 2017; 17: e12423.
45. Schuebel K, Gitik M, Domschke K, Goldman D. Making sense of epigenetics. *Int J Neuropsychopharmacol*. 2016; 19: pyw058.
46. Trerotola M, Relli V, Simeone P, Alberti S. Epigenetic inheritance and the missing heritability. *Hum Genomics*. 2015; 9:17.
47. Yoon SH, Choi J, Lee WJ, Do JT. Genetic and epigenetic etiology underlying autism spectrum disorder. *J Clin Med*. 2020; 9:966.
48. Peters SU, Hundley RJ, Wilson AK, et al. The behavioral phenotype in MECP2 duplication syndrome. *Autism Res*. 2013; 6:42-50.
49. Nagarajan R, Hogart A, Gwyne Y, Martin MR, LaSalle JM. Reduced MeCP2 expression is frequent in autism frontal cortex. *Epigenetics*. 2006; 1:172-182.
50. Hultman CM, Sparen P, Cnattingius S. Perinatal risk factors for infantile autism. *Epidemiology*. 2002; 13:417-423.
51. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Advanced parental age and autism risk in children. *Acta Psychiatr Scand*. 2017; 135:29-41.
52. Sandin S, Hultman CM, Klevzon A, Gross R, MacCabe JH, Reichenberg A. Advancing maternal age is associated with increasing risk for autism. *J Am Acad Child Adolesc Psychiatry*. 2012; 51:477-486.
53. Malaspina D, Gilman C, Kranz TM. Paternal age and mental health of offspring. *Fertil Steril*. 2015; 103:1392-1396.
54. Oztenekecioglu B, Mavis M, Osum M, Kalkan R. Genetic and epigenetic alterations in autism spectrum disorder. *Glob Med Genet*. 2021; 8:144-148.
55. Botelho RM, Silva ALM, Borbely AU. Autism spectrum disorder and its possible origins in pregnancy. *Int J Environ Res Public Health*. 2024; 21:244.
56. Knuesel I, Chicha L, Britschgi M, et al. Maternal immune activation and abnormal brain development across CNS disorders. *Nat Rev Neurol*. 2014; 10:643-660.
57. Love C, Sominsky L, O'Hely M, et al. Prenatal environmental risk factors for autism spectrum disorder. *BMC Med*. 2024; 22:393.



58. Moore GS, Kneitel AW, Walker CK, Gilbert WM, Xing G. Autism risk in small and large for gestational age infants. *Am J Obstet Gynecol.* 2012; 206:314.
59. Lyall K, Croen L, Daniels J, et al. The changing epidemiology of autism spectrum disorders. *Annu Rev Public Health.* 2017; 38:81-102.
60. Modabbernia A, Velthorst E, Reichenberg A. Environmental risk factors for autism. *Mol Autism.* 2017; 8:13.

OTİZM GENETİĞİ

Elif Funda ŞENER¹

OTİZMİN GENETİK TEMELLERİ

Otizm spektrum bozukluğu (OSB), anormal sosyal etkileşim, tekrarlayıcı davranışlar ve gecikmiş dil ve bilişsel beceriler ile karakterize bir hastalıktır.^{1,2} OSB, çocukluk döneminde ortaya çıkan ve yaşam boyu devam eden nörolojik bir işlev bozukluğudur.^{3,4} Dünya genelinde nüfusun yaklaşık %1'inde OSB teşhis edilir ve erkek:kız prevalans oranı 3-4:1'dir.^{5,6} Dil gelişiminde gecikme olmayanlar veya kızlar genellikle daha geç teşhis alırlar.⁷ Hatta bazı OSB vakalarının önemli bir kısmı, yetişkinliğe kadar bile göz ardı edilebilir.⁸ OSB'nin altında yatan nedenleri belirlemek, hasta ve ailelerine destek sağlamak için çok önemlidir. Bu alanda atılacak her adım erken teşhis konulmasına ve tedaviye destek sağlayabilir. Birincil klinik semptomların ötesinde, otizm teşhisi konulan önemli sayıda bireye aynı zamanda zihinsel engellilik, epilepsi, anksiyete, obsesif-kompulsif bozukluk, uyku bozuklukları, depresyon ve gastrointestinal sorunlar, otoimmün bozukluklar ve obezite gibi fiziksel rahatsızlıklar da eşlik etmektedir.^{9,10}

OSB'nin etiyopatogenezi karmaşıktır ve heterojen bir doğaya sahiptir. Klinik fenotipteki değişkenlikle birlikte bu heterojenlik, OSB için kesin bir temel oluşturulmasını engelleyen en önemli faktör arasında yer almaktadır¹¹. OSB'nin etiyolojisinde çeşitli ve kümülatif yollarla etkileşime giren çevresel, metabolik, immün ve genetik mekanizmalar bulunmaktadır.^{12,13} OSB'ye katkıda bulunduğu bilinen çevresel faktörler arasında ebeveyn yaşı, perinatal faktörler, seks steroidleri, anne sağlığı ve anne beslenmesi ve ayrıca fetüsün uyuşturuculara, toksinle-

¹ Prof. Dr., Erciyes Üniversitesi Tıp Fakültesi Tıbbi Biyoloji AD., eliffunda@erciyes.edu.tr, ORCID iD: 0000-0002-5644-5442



luyla tanımlanabilir. Bugün için bozulduğunda saf OSB ile benzersiz bir şekilde ilişkili olduğu bilinen tek bir moleküler yolak yoktur. Sadece OSB'ye neden olan ve diğer nörogelişimsel veya psikiyatrik bozukluklara atfedilemeyen gen varyantlarının sınıflandırılması araştırılmaktadır.⁹ Sinaptik işlevlerle ilişkili genlere odaklanmak, OSB'nin altında yatan genetik ve nöral mekanizmaların daha iyi anlaşılmasına yol açabilir.

Özetle; otizmin genetik kökeni olsa da bu genetik risk genellikle tek bir gen mutasyonundan değil, potansiyel olarak yüzlerce ila binlerce gendeki birçok küçük varyasyonun kümülatif etkisinden kaynaklanır ve bu durum vakaların büyük bir çoğunluğunu açıklamak için yetersiz kalır.^{15,35,203,204} Gen ifadesindeki bu ince değişiklikler, toplu olarak bir bireyin OSB'ye yakalanma olasılığı üzerinde önemli bir etkiye sahip olabilir. Gen ifade profilindeki değişiklikler, OSB patogenezi ve ilerlemesini belirlemede çok önemlidir ve OSB nedenlerini anlamada gen ifadesi çalışmalarının ayrıca bir önemi vardır. Gelecekte de OSB'nin genetiğini anlamaya yönelik yapılacak çalışmalarda bu noktaların ve özellikle epigenetiğin etkilerinin de dikkate alınması yararlı olacaktır. Davranışsal terapiler ve müdahaleler OSB'li bireylerin yaşam kalitesini artırabilse de, şu anda bu bozukluk için genel bir tedavi seçeneği yoktur.³⁸ Gelecekte daha etkili farmakolojik tedavilerin geliştirilmesi için yeni ilaç hedeflerinin bu alanda belirlenmesi gereklidir.

KAYNAKLAR

1. Sivalingam AM. Advances in understanding biomarkers and treating neurological diseases-Role of the cerebellar dysfunction and emerging therapies. *Ageing Res Rev.* 2024;101:102519. doi: 10.1016/j.arr.2024.102519.
2. Romanovsky E, Choudhary A, Peles D, et al. Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients' neurons. *Mol Psychiatry.* 2025;30(3):1019-1028. doi: 10.1038/s41380-024-02740-0.
3. Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. *Lancet.* 2018;392(10146):508-520. doi: 10.1016/S0140-6736(18)31129-2.
4. Martinez B, Peplow PV. Autism spectrum disorder: difficulties in diagnosis and microRNA biomarkers. *Neural Regen Res.* 2025;20(10):2776-2786. doi: 10.4103/NRR.NRR-D-24-00712.
5. Zeidan J, Fombonne E, Scora J, et al. Global prevalence of autism: A systematic review update. *Autism Res.* 2022;15(5):778-790. doi: 10.1002/aur.2696.
6. Mendes M, Chen DZ, Engchuan W, et al. Chromosome X-wide common variant association study in autism spectrum disorder. *Am J Hum Genet.* 2025;112(1):135-153. doi: 10.1016/j.ajhg.2024.11.008.
7. Maenner MJ, Warren Z, Williams AR, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. *MMWR Surveill Summ.* 2023;72(2):1-14. doi:



- 10.15585/mmwr.ss7202a1.
8. Lai MC, Baron-Cohen S. Identifying the lost generation of adults with autism spectrum conditions. *Lancet Psychiatry*. 2015;2(11):1013-27. doi: 10.1016/S2215-0366(15)00277-1.
 9. Zhang Y, Tang R, Hu ZM, et al. Key Synaptic Pathology in Autism Spectrum Disorder: Genetic Mechanisms and Recent Advances. *J Integr Neurosci*. 2024;23(10):184. doi: 10.31083/j.jin2310184.
 10. Rydzewska E, Dunn K, Cooper SA. Umbrella systematic review of systematic reviews and meta-analyses on comorbid physical conditions in people with autism spectrum disorder. *Br J Psychiatry*. 2021;218(1):10-19. doi: 10.1192/bjp.2020.167.
 11. Kereszturi É. Database-assisted screening of autism spectrum disorder related gene set. *Mol Brain*. 2024;17(1):55. doi: 10.1186/s13041-024-01127-0.
 12. Kim JY, Son MJ, Son CY, Radua J, Eisenhut M, Gressier F, Koyanagi A, Carvalho AF, Stubbs B, Solmi M, Rais TB, Lee KH, Kronbichler A, Dragioti E, Shin JI, Fusar-Poli P. Environmental risk factors and biomarkers for autism spectrum disorder: an umbrella review of the evidence. *Lancet Psychiatry*. 2019;6(7):590-600. doi: 10.1016/S2215-0366(19)30181-6.
 13. Kılıçaslan F, Öz Ö, Mutlu MB. Investigation of chromosomal anomalies and copy number variations in children diagnosed with autism spectrum disorder by array CGH method. *Int J Dev Neurosci*. 2025;85(1):e10397. doi: 10.1002/jdn.10397.
 14. Yu R, Hafeez R, Ibrahim M, Alonazi WB, et al. The complex interplay between autism spectrum disorder and gut microbiota in children: A comprehensive review. *Behav Brain Res*. 2024;473:115177. doi: 10.1016/j.bbr.2024.115177.
 15. Gevezova M, Sbirkov Y, Sarafian V, et al. Autistic spectrum disorder (ASD) - Gene, molecular and pathway signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling, and neurodevelopment. *Brain Behav Immun Health*. 2023;30:100646. doi: 10.1016/j.bbih.2023.100646.
 16. Belyeu JR, Brand H, Wang Hi, et al. De novo structural mutation rates and gamete-of-origin biases revealed through genome sequencing of 2,396 families. *Am J Hum Genet*. 2021;108(4):597-607. doi: 10.1016/j.ajhg.2021.02.012.
 17. Ali NMH, Chawner SJRA, Kushan-Wells L, et al. Comparison of autism domains across thirty rare variant genotypes. *EBioMedicine*. 2025;112:105521. doi: 10.1016/j.ebiom.2024.105521.
 18. Klei L, McClain LL, Mahjani B, et al. How rare and common risk variation jointly affect liability for autism spectrum disorder. *Mol Autism*. 2021;12(1):66. doi: 10.1186/s13229-021-00466-2.
 19. Havdahl A, Niarchou M, Starnawska A, et al. Genetic contributions to autism spectrum disorder. *Psychol Med*. 2021;51(13):2260-2273. doi: 10.1017/S0033291721000192.
 20. Vicari S, Napoli E, Cordeddu V, et al. Copy number variants in autism spectrum disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019;92:421-427. doi: 10.1016/j.pnpbp.2019.02.012.
 21. Abedini SS, Akhavantabasi S, Liang Y et al. A critical review of the impact of candidate copy number variants on autism spectrum disorder. *Mutat Res Rev Mutat Res*. 2024;794:108509. doi: 10.1016/j.mrrev.2024.108509.
 22. Villanueva R. Stem cell therapy for the treatment of psychiatric disorders: a real hope for the next decades. *Front Psychiatry*. 2025;15:1492415. doi: 10.3389/fpsy.2024.1492415.
 23. Kushima I, Aleksic B, Nakatochi M, et al. Comparative Analyses of Copy-Number Variation in Autism Spectrum Disorder and Schizophrenia Reveal Etiological Overlap and Biological Insights. *Cell Rep*. 2018;24(11):2838-2856. doi: 10.1016/j.celrep.2018.08.022.
 24. Kushima I, Nakatochi M, Aleksic B, et al. Cross-Disorder Analysis of Genic and Regulatory Copy Number Variations in Bipolar Disorder, Schizophrenia, and Autism Spectrum Disorder. *Biol Psychiatry*. 2022;92(5):362-374. doi: 10.1016/j.biopsych.2022.04.003.
 25. Vashisth S, Chahrour MH. Genomic strategies to untangle the etiology of autism: A primer.



- Autism Res.* 2023;16(1):31-39. doi: 10.1002/aur.2844.
26. Al-Beltagi M, Saeed NK, Bediwy AS et al. Decoding the genetic landscape of autism: A comprehensive review. *World J Clin Pediatr.* 2024;13(3):98468. doi: 10.5409/wjcp.v13.i3.98468.
 27. Huguet G, Ey E, Bourgeron T. The genetic landscapes of autism spectrum disorders. *Annu Rev Genomics Hum Genet.* 2013;14:191-213. doi: 10.1146/annurev-genom-091212-153431.
 28. Baribeau D, Anagnostou E. Novel treatments for autism spectrum disorder based on genomics and systems biology. *Pharmendresrmacol Ther.* 2022;230:107939. doi: 10.1016/j.pharmthera.2021.107939.
 29. Ali NMH, Chawner SJRA, Kushan-Wells L, et al. Comparison of autism domains across thirty rare variant genotypes. *EBioMedicine.* 2025;112:105521. doi: 10.1016/j.ebiom.2024.105521.
 30. Raznahan A, Won H, Glahn DC, et al. Convergence and Divergence of Rare Genetic Disorders on Brain Phenotypes: A Review. *JAMA Psychiatry.* 2022;79(8):818-828. doi: 10.1001/jamapsychiatry.2022.1450.
 31. Molloy CJ, Quigley C, McNicholas Á, et al. A review of the cognitive impact of neurodevelopmental and neuropsychiatric associated copy number variants. *Transl Psychiatry.* 2023;13(1):116. doi: 10.1038/s41398-023-02421-6.
 32. Mollon J, Almasy L, Jacquemont S, et al. The contribution of copy number variants to psychiatric symptoms and cognitive ability. *Mol Psychiatry.* 2023;28(4):1480-1493. doi: 10.1038/s41380-023-01978-4.
 33. Rylaarsdam L, Guemez-Gamboa A. Genetic Causes and Modifiers of Autism Spectrum Disorder. *Front Cell Neurosci.* 2019;13:385. doi: 10.3389/fncel.2019.00385.
 34. Genovese AC, Butler MG. Behavioral and Psychiatric Disorders in Syndromic Autism. *Brain Sci.* 2024;14(4):343. doi: 10.3390/brainsci14040343.
 35. Grove J, Ripke S, Als TD, et al. Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet.* 2019;51(3):431-444. doi: 10.1038/s41588-019-0344-8.
 36. Matoba N, Liang D, Sun H, et al. Common genetic risk variants identified in the SPARK cohort support DDHD2 as a candidate risk gene for autism. *Transl Psychiatry.* 2020;10(1):265. doi: 10.1038/s41398-020-00953-9.
 37. King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. *PLoS Genet.* 2019;15(12):e1008489. doi: 10.1371/journal.pgen.1008489.
 38. Jiang R, Huang W, Qiu X, et al. Unveiling promising drug targets for autism spectrum disorder: insights from genetics, transcriptomics, and proteomics. *Brief Bioinform.* 2024;25(4):bbae353. doi: 10.1093/bib/bbae353.
 39. Loomes R, Hull L, Mandy WPL. What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A Systematic Review and Meta-Analysis. *J Am Acad Child Adolesc Psychiatry.* 2017;56(6):466-474. doi: 10.1016/j.jaac.2017.03.013.
 40. Kreiser NL, White SW. ASD in females: are we overstating the gender difference in diagnosis? *Clin Child Fam Psychol Rev.* 2014;17(1):67-84. doi: 10.1007/s10567-013-0148-9.
 41. Leow KQ, Tonta MA, Lu J, Coleman HA, et al. Towards understanding sex differences in autism spectrum disorders. *Brain Res.* 2024;1833:148877. doi: 10.1016/j.brainres.2024.148877.
 42. Ratto AB, Kenworthy L, Yerys BE, et al. What About the Girls? Sex-Based Differences in Autistic Traits and Adaptive Skills. *J Autism Dev Disord.* 2018;48(5):1698-1711. doi: 10.1007/s10803-017-3413-9.
 43. Laine MA, Greiner EM, Shansky RM. Sex differences in the rodent medial prefrontal cortex - What Do and Don't we know? *Neuropharmacology.* 2024;248:109867. doi: 10.1016/j.neuropharm.2024.109867.
 44. Ferri SL, Abel T, Brodtkin ES. Sex Differences in Autism Spectrum Disorder: a Review. *Curr*



- Psychiatry Rep.* 2018;20(2):9. doi: 10.1007/s11920-018-0874-2.
45. Mitra I, Tsang K, Ladd-Acosta C, et al. Correction: Pleiotropic Mechanisms Indicated for Sex Differences in Autism. *PLoS Genet.* 2017;13(6):e1006831. doi: 10.1371/journal.pgen.1006831. Erratum for: *PLoS Genet.* 2016;12(11):e1006425. doi: 10.1371/journal.pgen.1006425.
 46. Pejhan S, Rastegar M. Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease. *Biomolecules.* 2021;11(1):75. doi: 10.3390/biom11010075.
 47. Jiang CC, Lin LS, Long S, et al. Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications. *Signal Transduct Target Ther.* 2022;7(1):229. doi: 10.1038/s41392-022-01081-0.
 48. Cast TP, Boesch DJ, Smyth K, et al. An Autism-Associated Mutation Impairs Neuroligin-4 Glycosylation and Enhances Excitatory Synaptic Transmission in Human Neurons. *J Neurosci.* 2021;41(3):392-407. doi: 10.1523/JNEUROSCI.0404-20.2020.
 49. Nguyen TA, Wu K, Pandey S, et al. A Cluster of Autism-Associated Variants on X-Linked NLGN4X Functionally Resemble NLGN4Y. *Neuron.* 2020;106(5):759-768.e7. doi: 10.1016/j.neuron.2020.03.008.
 50. Montanaro FAM, Mandarino A, Alesi V, Schwartz C, Sepulveda DJC, Skinner C, Friez M, Piccolo G, Novelli A, Zanni G, Dentici ML, Vicari S, Alfieri P. PTCHD1 gene mutation/deletion: the cognitive-behavioral phenotyping of four case reports. *Front Psychiatry.* 2024;14:1327802. doi: 10.3389/fpsy.2023.1327802.
 51. Shansky RM. Sex differences in mechanisms of disease. *Genes Brain Behav.* 2020;19(3):e12646. doi: 10.1111/gbb.12646.
 52. de Giambattista C, Ventura P, Trerotoli P, et al. Sex Differences in Autism Spectrum Disorder: Focus on High Functioning Children and Adolescents. *Front Psychiatry.* 2021;12:539835. doi: 10.3389/fpsy.2021.539835.
 53. Werling DM. The role of sex-differential biology in risk for autism spectrum disorder. *Biol Sex Differ.* 2016;7:58. doi: 10.1186/s13293-016-0112-8.
 54. Zhang Y, Li N, Li C, Zhang Z, Teng H, Wang Y, Zhao T, Shi L, Zhang K, Xia K, Li J, Sun Z. Genetic evidence of gender difference in autism spectrum disorder supports the female-protective effect. *Transl Psychiatry.* 2020;10(1):4. doi: 10.1038/s41398-020-0699-8.
 55. Gao L, Zhang T, Zhang Y, et al. Sex Differences in Spatiotemporal Consistency and Effective Connectivity of the Precuneus in Autism Spectrum Disorder. *J Autism Dev Disord.* 2024;28. doi: 10.1007/s10803-024-06696-6.
 56. Lee JK, Amaral DG, Solomon M, et al. Sex Differences in the Amygdala Resting-State Connectome of Children With Autism Spectrum Disorder. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2020;5(3):320-329. doi: 10.1016/j.bpsc.2019.08.004.
 57. Reinhardt VP, Iosif AM, Libero L, et al. Understanding Hippocampal Development in Young Children With Autism Spectrum Disorder. *J Am Acad Child Adolesc Psychiatry.* 2020;59(9):1069-1079. doi: 10.1016/j.jaac.2019.08.008.
 58. Velmeshev D, Schirmer L, Jung D, et al. Single-cell genomics identifies cell type-specific molecular changes in autism. *Science.* 2019;364(6441):685-689. doi: 10.1126/science.aav8130.
 59. Willsey HR, Willsey AJ, Wang B, et al. Genomics, convergent neuroscience and progress in understanding autism spectrum disorder. *Nat Rev Neurosci.* 2022;23(6):323-341. doi: 10.1038/s41583-022-00576-7.
 60. Trabzuni D, Ramasamy A, Imran S, et al. North American Brain Expression Consortium. Widespread sex differences in gene expression and splicing in the adult human brain. *Nat Commun.* 2013;4:2771. doi: 10.1038/ncomms3771.
 61. Wingo AP, Liu Y, Gerasimov ES, et al. Sex differences in brain protein expression and disease. *Nat Med.* 2023;29(9):2224-2232. doi: 10.1038/s41591-023-02509-y.



62. Fass SB, Mulvey B, Chase R, et al. Relationship between sex biases in gene expression and sex biases in autism and Alzheimer's disease. *Biol Sex Differ.* 2024;15(1):47. doi: 10.1186/s13293-024-00622-2.
63. Simerly RB. Wired for reproduction: organization and development of sexually dimorphic circuits in the mammalian forebrain. *Annu Rev Neurosci.* 2002;25:507-36. doi: 10.1146/annurev.neuro.25.112701.142745.
64. Auyeung B, Baron-Cohen S, Ashwin E, Knickmeyer R, Taylor K, Hackett G. Fetal testosterone and autistic traits. *Br J Psychol.* 2009;100(Pt 1):1-22. doi: 10.1348/000712608X311731.
65. Baron-Cohen S, Tsompanidis A, Auyeung B et al. Foetal oestrogens and autism. *Mol Psychiatry.* 2020;25(11):2970-2978. doi: 10.1038/s41380-019-0454-9.
66. Cherskov A, Pohl A, Allison C, et al. Polycystic ovary syndrome and autism: A test of the prenatal sex steroid theory. *Transl Psychiatry.* 2018;8(1):136. doi: 10.1038/s41398-018-0186-7.
67. Kosidou K, Dalman C, Widman L, et al. Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. *Mol Psychiatry.* 2016;21(10):1441-8. doi: 10.1038/mp.2015.183.
68. Jiang L, Tian L, Yuan J, Xu X, Qu F, Zhang R, Wang J. Associations Between Sex Hormone Levels and Autistic Traits in Infertile Patients With Polycystic Ovary Syndrome and Their Offspring. *Front Endocrinol (Lausanne).* 2022;12:789395. doi: 10.3389/fendo.2021.789395.
69. Genovese A, Butler MG. Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD). *Int J Mol Sci.* 2020;21(13):4726. doi: 10.3390/ijms21134726.
70. Lintas C, Persico AM. Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. *J Med Genet.* 2009;46(1):1-8. doi: 10.1136/jmg.2008.060871.
71. Schaefer GB, Mendelsohn NJ; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med.* 2013;15(5):399-407. doi: 10.1038/gim.2013.32.
72. Waye MMY, Cheng HY. Genetics and epigenetics of autism: A Review. *Psychiatry Clin Neurosci.* 2018;72(4):228-244. doi: 10.1111/pcn.12606.
73. Genovese A, Butler MG. The Autism Spectrum: Behavioral, Psychiatric and Genetic Associations. *Genes (Basel).* 2023;14(3):677. doi: 10.3390/genes14030677.
74. Miyake N, Tsurusaki Y, Fukai R, et al. Molecular diagnosis of 405 individuals with autism spectrum disorder. *Eur J Hum Genet.* 2024;32(12):1551-1558. doi: 10.1038/s41431-023-01335-7.
75. Miles JH. Autism spectrum disorders--a genetics review. *Genet Med.* 2011;13(4):278-94. doi: 10.1097/GIM.0b013e3181ff67ba.
76. Woodbury-Smith M, Paterson AD, O'Connor I, et al. A genome-wide linkage study of autism spectrum disorder and the broad autism phenotype in extended pedigrees. *J Neurodev Disord.* 2018;10(1):20. doi: 10.1186/s11689-018-9238-9.
77. Sener EF, Canatan H, Ozkul Y. Recent Advances in Autism Spectrum Disorders: Applications of Whole Exome Sequencing Technology. *Psychiatry Investig.* 2016;13(3):255-64. doi: 10.4306/pi.2016.13.3.255.
78. Yuen T, Carter MT, Szatmari P, et al. Cost-effectiveness of Genome and Exome Sequencing in Children Diagnosed with Autism Spectrum Disorder. *Appl Health Econ Health Policy.* 2018;16(4):481-493. doi: 10.1007/s40258-018-0390-x.
79. Miyake N, Tsurusaki Y, Fukai R, et al. Molecular diagnosis of 405 individuals with autism spectrum disorder. *Eur J Hum Genet.* 2024;32(12):1551-1558. doi: 10.1038/s41431-023-01335-7.
80. Searles Quick VB, Wang B, et al. Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders. *Neuropsychopharmacology.* 2021;46(1):55-69. doi: 10.1038/s41386-020-0768-y.
81. Kimura H, Nakatochi M, Aleksic B, et al. Exome sequencing analysis of Japanese autism spectrum disorder case-control sample supports an increased burden of synaptic function-rela-



- ted genes. *Transl Psychiatry*. 2022;12(1):265. doi: 10.1038/s41398-022-02033-6.
82. Enriquez KD, Gupta AR, Hoffman EJ. Signaling Pathways and Sex Differential Processes in Autism Spectrum Disorder. *Front Psychiatry*. 2021;12:716673. doi: 10.3389/fpsy.2021.716673.
83. Satterstrom FK, Kosmicki JA, Wang J, et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. *Cell*. 2020;180(3):568-584.e23. doi: 10.1016/j.cell.2019.12.036.
84. Feliciano P, Zhou X, Astrovskaya I, et al. Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes. *NPJ Genom Med*. 2019;4:19. doi: 10.1038/s41525-019-0093-8.
85. Shi X, Lu C, Corman A et al. Heterozygous deletion of the autism-associated gene CHD8 impairs synaptic function through widespread changes in gene expression and chromatin compaction. *Am J Hum Genet*. 2023;110(10):1750-1768. doi: 10.1016/j.ajhg.2023.09.004.
86. Blázquez A, Rodriguez-Reventa L, Alvarez-Mora MI et al. Clinical and genetic findings in autism spectrum disorders analyzed using exome sequencing. *Front Psychiatry*. 2025;16:1515793. doi: 10.3389/fpsy.2025.1515793.
87. Brlek P, Bulić L, Bračić M et al. Implementing Whole Genome Sequencing (WGS) in Clinical Practice: Advantages, Challenges, and Future Perspectives. *Cells*. 2024;13(6):504. doi: 10.3390/cells13060504.
88. Bocher O, Willer CJ, Zeggini E. Unravelling the genetic architecture of human complex traits through whole genome sequencing. *Nat Commun*. 2023;14:3520 doi: 10.1038/s41467-023-39259.
89. Zhou J, Park CY, Theesfeld CL et al. Whole-genome deep-learning analysis identifies contribution of noncoding mutations to autism risk. *Nat Genet*. 2019;51(6):973-980. doi: 10.1038/s41588-019-0420-0.
90. Satam H, Joshi K, Mangrolia U et al. Next-Generation Sequencing Technology: Current Trends and Advancements. *Biology (Basel)*. 2023;12(7):997. doi: 10.3390/biology12070997. Erratum in: *Biology (Basel)*. 2024;13(5):286. doi: 10.3390/biology13050286.
91. Yoo H. Genetics of Autism Spectrum Disorder: Current Status and Possible Clinical Applications. *Exp Neurobiol*. 2015;24(4):257-72. doi: 10.5607/en.2015.24.4.257.
92. Qiu Z, Du A. Revisiting the genetic architecture of autism spectrum disorders in the genomic era: Insights from East Asian studies. *Curr Opin Neurobiol*. 2025;90:102936. doi: 10.1016/j.conb.2024.102936.
93. Furukawa S, Kushima I, Kato H, et al. Whole-genome sequencing analysis of Japanese autism spectrum disorder trios. *Psychiatry Clin Neurosci*. 2025;79(3):87-97. doi: 10.1111/pcn.13767.
94. Ćuk M, Unal B, Bagarić M, et al. Novel TBR1 c.1303C>T Variant Led to Diagnosis of Intellectual Developmental Disorder with Autism and Speech Delay: Application of Comprehensive Family-Based Whole-Genome Analysis. *Genes (Basel)*. 2025;16(2):120. doi: 10.3390/genes16020120.
95. Ruzzo EK, Pérez-Cano L, Jung JY, et al. Inherited and De Novo Genetic Risk for Autism Impacts Shared Networks. *Cell*. 2019;178(4):850-866.e26. doi: 10.1016/j.cell.2019.07.015.
96. LaMantia AS. Polygenicity in a box: Copy number variants, neural circuit development, and neurodevelopmental disorders. *Curr Opin Neurobiol*. 2024;89:102917. doi: 10.1016/j.conb.2024.102917.
97. Bryers A, Hawkes CA, Parkin E, Dawson N. Progress towards understanding risk factor mechanisms in the development of autism spectrum disorders. *Biochem Soc Trans*. 2024;52(5):2047-2058. doi: 10.1042/BST20231004.
98. Leppa VM, Kravitz SN, Martin CL, et al. Rare Inherited and De Novo CNVs Reveal Complex Contributions to ASD Risk in Multiplex Families. *Am J Hum Genet*. 2016;99(3):540-554. doi: 10.1016/j.ajhg.2016.06.036.



99. Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo copy number mutations with autism. *Science*. 2007;316(5823):445-9. doi: 10.1126/science.1138659.
100. Tamada K, Takumi T. Neurodevelopmental impact of CNV models in ASD: Recent advances and future directions. *Curr Opin Neurobiol*. 2025;92:103001. doi: 10.1016/j.conb.2025.103001.
101. Weiner DJ, Ling E, Erdin S, et al. Statistical and functional convergence of common and rare genetic influences on autism at chromosome 16p. *Nat Genet*. 2022;54(11):1630-1639. doi: 10.1038/s41588-022-01203-y.
102. Sandweiss AJ, Brandt VL, Zoghbi HY. Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies. *Lancet Neurol*. 2020;19(8):689-698. doi: 10.1016/S1474-4422(20)30217-9.
103. Vervoort L, Dierckxens N, Pereboom Z, et al. 22q11.2 Low Copy Repeats Expanded in the Human Lineage. *Front Genet*. 2021;12:706641. doi: 10.3389/fgene.2021.706641.
104. Dinneen TJ, Ghrálaigh FN, Walsh R, et al. How does genetic variation modify ND-CNV phenotypes? *Trends Genet*. 2022;38(2):140-151. doi: 10.1016/j.tig.2021.07.006.
105. Tabbaa M, Knoll A, Levitt P. Mouse population genetics phenocopies heterogeneity of human Chd8 haploinsufficiency. *Neuron*. 2023;111(4):539-556.e5. doi: 10.1016/j.neuron.2023.01.009.
106. Min S, Kinnear C, D'Alessandro LCA, et al. Genetic Diagnosis and the Severity of Cardiovascular Phenotype in Patients With Elastin Arteriopathy. *Circ Genom Precis Med*. 2020;13(6):e002971. doi: 10.1161/CIRCGEN.120.002971.
107. Akula SK, Exposito-Alonso D, Walsh CA. Shaping the brain: The emergence of cortical structure and folding. *Dev Cell*. 2023;58(24):2836-2849. doi: 10.1016/j.devcel.2023.11.004.
108. Kushima I, Nakatochi M, Aleksic B, et al. Cross-Disorder Analysis of Genic and Regulatory Copy Number Variations in Bipolar Disorder, Schizophrenia, and Autism Spectrum Disorder. *Biol Psychiatry*. 2022;92(5):362-374. doi: 10.1016/j.biopsych.2022.04.003.
109. Feliciano P, Zhou X, Astrovskaya I, Turner TN, Wang T, Brueggeman L, Barnard R, Hsieh A, Snyder LG, Muzny DM, Sabo A; SPARK Consortium; Gibbs RA, Eichler EE, O'Roak BJ, Michaelson JJ, Volfovsky N, Shen Y, Chung WK. Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes. *NPJ Genom Med*. 2019;4:19. doi: 10.1038/s41525-019-0093-8.
110. Pruitt A, Gupta AR, Hoffman EJ. Molecular and Genetic Mechanisms in Autism Spectrum Disorder. *Ann Neurol*. 2025;98(6):1163-1177. doi: 10.1002/ana.70013.
111. Trost B, Thiruvahindrapuram B, Chan AJS, et al. Genomic architecture of autism from comprehensive whole-genome sequence annotation. *Cell*. 2022;185(23):4409-4427.e18. doi: 10.1016/j.cell.2022.10.009.
112. Furukawa S, Kushima I, Kato H et al. Whole-genome sequencing analysis of Japanese autism spectrum disorder trios. *Psychiatry Clin Neurosci*. 2025;79(3):87-97. doi: 10.1111/pcn.13767.
113. Inbar-Feigenberg M, Choufani S, Butcher DT, et al. Basic concepts of epigenetics. *Fertil Steril*. 2013;99(3):607-15. doi: 10.1016/j.fertnstert.2013.01.117.
114. Yao TT, Chen L, Du Y, et al. MicroRNAs as Regulators, Biomarkers, and Therapeutic Targets in Autism Spectrum Disorder. *Mol Neurobiol*. 2025;62(4):5039-5056. doi: 10.1007/s12035-024-04582-x.
115. Yasuda Y, Matsumoto J, Miura K, et al. Genetics of autism spectrum disorders and future direction. *J Hum Genet*. 2023;68(3):193-197. doi: 10.1038/s10038-022-01076-3.
116. Csoka AB, El Kouhen N, Bennani S, et al. Roles of Epigenetics and Glial Cells in Drug-Induced Autism Spectrum Disorder. *Biomolecules*. 2024;14(4):437. doi: 10.3390/biom14040437.
117. Jin Z, Liu Y. DNA methylation in human diseases. *Genes Dis*. 2018;5(1):1-8. doi: 10.1016/j.gendis.2018.01.002.
118. Kimura R, Nakata M, Funabiki Y et al. An epigenetic biomarker for adult high-functioning autism spectrum disorder. *Sci Rep*. 2019;9(1):13662. doi: 10.1038/s41598-019-50250-9.



119. Li J, Xu X, Liu J, Zhang S, et al. Decoding microRNAs in autism spectrum disorder. *Mol Ther Nucleic Acids*. 2022;30:535-546. doi: 10.1016/j.omtn.2022.11.005.
120. Beygo J, Grosser C, Kaya S et al. Common genetic variation in the Angelman syndrome imprinting centre affects the imprinting of chromosome 15. *Eur J Hum Genet*. 2020;28(6):835-839. doi: 10.1038/s41431-020-0595-y.
121. Ryan NM, Heron EA. Evidence for parent-of-origin effects in autism spectrum disorder: a narrative review. *J Appl Genet*. 2023;64(2):303-317. doi: 10.1007/s13353-022-00742-8.
122. Wang L, Wang B, Wu C, et al. Autism Spectrum Disorder: Neurodevelopmental Risk Factors, Biological Mechanism, and Precision Therapy. *Int J Mol Sci*. 2023;24(3):1819. doi: 10.3390/ijms24031819.
123. Grafodatskaya D, Chung B, Szatmari P, Weksberg R. Autism spectrum disorders and epigenetics. *J Am Acad Child Adolesc Psychiatry*. 2010;49(8):794-809. doi: 10.1016/j.jaac.2010.05.005.
124. Siniscalco D, Cirillo A, Bradstreet JJ, Antonucci N. Epigenetic findings in autism: new perspectives for therapy. *Int J Environ Res Public Health*. 2013;10(9):4261-73. doi: 10.3390/ijerph10094261.
125. Huang F, Zhou T, Yao X, Yi J, Zhou F, Long Z, Hou X, Wang C, Chen Z, Jiang H. miRNA profiling in autism spectrum disorder in China. *Genom Data*. 2015 Aug 12;6:108-9. doi: 10.1016/j.gdata.2015.08.006.
126. Miyake K, Hirasawa T, Koide T, et al. Epigenetics in autism and other neurodevelopmental diseases. *Adv Exp Med Biol*. 2012;724:91-8. doi: 10.1007/978-1-4614-0653-2_7.
127. Abdul QA, Yu BP, Chung HY, et al. Epigenetic modifications of gene expression by lifestyle and environment. *Arch Pharm Res*. 2017;40(11):1219-1237. doi: 10.1007/s12272-017-0973-3.
128. Blum K, Bowirrat A, Sunder K, et al. Dopamine Dysregulation in Reward and Autism Spectrum Disorder. *Brain Sci*. 2024;14(7):733. doi: 10.3390/brainsci14070733.
129. Qin L, Ma K, Wang ZJ, et al. Social deficits in Shank3-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition. *Nat Neurosci*. 21(4):564-575. doi: 10.1038/s41593-018-0110-8.
130. Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. *J Mol Biol*. 2013;425(19):3582-600. doi: 10.1016/j.jmb.2013.03.007.
131. Kim JY, Kim W, Lee KH. The role of microRNAs in the molecular link between circadian rhythm and autism spectrum disorder. *Anim Cells Syst (Seoul)*. 2023;27(1):38-52. doi: 10.1080/19768354.2023.2180535.
132. Cao DD, Li L, Chan WY. MicroRNAs: Key Regulators in the Central Nervous System and Their Implication in Neurological Diseases. *Int J Mol Sci*. 2016;17(6):842. doi: 10.3390/ijms17060842.
133. Lang MF, Shi Y. Dynamic Roles of microRNAs in Neurogenesis. *Front Neurosci*. 2012;6:71. doi: 10.3389/fnins.2012.00071.
134. Khodoruth MAS, Khodoruth WNC, Uroos M, et al. Diagnostic and mechanistic roles of MicroRNAs in neurodevelopmental & neurodegenerative disorders. *Neurobiol Dis*. 2024;202:106717. doi: 10.1016/j.nbd.2024.106717.
135. Tsujimura K, Shiohama T, Takahashi E. microRNA Biology on Brain Development and Neuroimaging Approach. *Brain Sci*. 2022;12(10):1366. doi: 10.3390/brainsci12101366.
136. Yao Q, Chen Y, Zhou X. The roles of microRNAs in epigenetic regulation. *Curr Opin Chem Biol*. 2019;51:11-17. doi: 10.1016/j.cbpa.2019.01.024.
137. Hu Y, Ehli EA, Boomsma DI. MicroRNAs as biomarkers for psychiatric disorders with a focus on autism spectrum disorder: Current progress in genetic association studies, expression profiling, and translational research. *Autism Res*. 2017;10(7):1184-1203. doi: 10.1002/aur.1789.
138. Parkins EV, Gross C. Small Differences and Big Changes: The Many Variables of MicroRNA Expression and Function in the Brain. *J Neurosci*. 2024;44(32):e0365242024. doi: 10.1523/



- JNEUROSCI.0365-24.2024.
139. Ander BP, Barger N, Stamova B, et al. Atypical miRNA expression in temporal cortex associated with dysregulation of immune, cell cycle, and other pathways in autism spectrum disorders. *Mol Autism*. 2015;37. doi: 10.1186/s13229-015-0029-9.
 140. Yu D, Jiao X, Cao T, et al. Serum miRNA expression profiling reveals miR-486-3p may play a significant role in the development of autism by targeting ARID1B. *Neuroreport*. 2018;29(17):1431-1436. doi: 10.1097/WNR.0000000000001107.
 141. Sarachana T, Zhou R, Chen G, et al. Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. *Genome Med*. 2010;2(4):23. doi: 10.1186/gm144.
 142. Hicks SD, Carpenter RL, Wagner KE, et al. MicroRNA Differentiates Children With Autism From Peers With Typical and Atypical Development. *J Am Acad Child Adolesc Psychiatry*. 2020;59(2):296-308. doi: 10.1016/j.jaac.2019.03.017.
 143. Kaysheva AL, Isaeva AI, Pleshakova TO, et al. Detection of Circulating Serum microRNA/Protein Complexes in ASD Using Functionalized Chips for an Atomic Force Microscope. *Molecules*. 2021;26(19):5979. doi: 10.3390/molecules26195979.
 144. Hicks SD, Middleton FA. A Comparative Review of microRNA Expression Patterns in Autism Spectrum Disorder. *Front Psychiatry*. 2016;7:176. doi: 10.3389/fpsy.2016.00176.
 145. Mirabella F, Randazzo M, Rinaldi A, et al. Glycosylation Pathways Targeted by Dysregulated miRNAs in Autism Spectrum Disorder. *Int J Mol Sci*. 2025;26(2):783. doi: 10.3390/ijms26020783.
 146. Hosokawa R, Yoshino Y, Funahashi Y et al. MiR-15b-5p Expression in the Peripheral Blood: A Potential Diagnostic Biomarker of Autism Spectrum Disorder. *Brain Sci*. 2022;13(1):27. doi: 10.3390/brainsci13010027.
 147. Ozkul Y, Taheri S, Bayram KK, et al. A heritable profile of six miRNAs in autistic patients and mouse models. *Sci Rep*. 2020;10(1):9011. doi: 10.1038/s41598-020-65847-8.
 148. Kichukova T, Petrov V, Popov N, et al. Identification of serum microRNA signatures associated with autism spectrum disorder as promising candidate biomarkers. *Heliyon*. 2021;7(7):e07462. doi: 10.1016/j.heliyon.2021.e07462.
 149. Jyonouchi H, Geng L, Toruner GA, et al. Serum microRNAs in ASD: Association With Monocyte Cytokine Profiles and Mitochondrial Respiration. *Front Psychiatry*. 2019;10:614. doi: 10.3389/fpsy.2019.00614.
 150. Nt P, Ds M, Mm N, In M, Ti V. Investigation of Circulating Serum MicroRNA-328-3p and MicroRNA-3135a Expression as Promising Novel Biomarkers for Autism Spectrum Disorder. *Balkan J Med Genet*. 2018;21(2):5-12.
 151. Ren J, Bai Y, Gao J et al. Diagnostic Value of Serum miR-499a-5p in Chinese Children with Autism Spectrum Disorders. *J Mol Neurosci*. 2025;75(1):8. doi: 10.1007/s12031-024-02296-2.
 152. Shen L, Lin Y, Sun Z, et al. Knowledge-Guided Bioinformatics Model for Identifying Autism Spectrum Disorder Diagnostic MicroRNA Biomarkers. *Sci Rep*. 2016;6:39663. doi: 10.1038/srep39663.
 153. Gholamalizadeh H, Amiri-Shahri M, Rasouli F, Ansari A, Baradaran Rahimi V, Reza Askari V. DNA Methylation in Autism Spectrum Disorders: Biomarker or Pharmacological Target? *Brain Sci*. 2024;14(8):737. doi: 10.3390/brainsci14080737.
 154. Cheung WA, Shao X, Morin A, et al. Functional variation in allelic methylomes underscores a strong genetic contribution and reveals novel epigenetic alterations in the human epigenome. *Genome Biol*. 2017;18(1):50. doi: 10.1186/s13059-017-1173-7. Erratum in: *Genome Biol*. 2019;20(1):89. doi: 10.1186/s13059-019-1702-7.
 155. Kuodza GE, Kawai R, LaSalle JM. Intercontinental insights into autism spectrum disorder: a synthesis of environmental influences and DNA methylation. *Environ Epigenet*.



- 2024;10(1):dvae023. doi: 10.1093/eep/dvae023.
156. LaSalle JM. Epigenomic signatures reveal mechanistic clues and predictive markers for autism spectrum disorder. *Mol Psychiatry*. 2023;28(5):1890-1901. doi: 10.1038/s41380-022-01917-9.
157. Moore LD, Le T, Fan G. DNA methylation and its basic function. *Neuropsychopharmacology*. 2013;38(1):23-38. doi: 10.1038/npp.2012.112.
158. Tremblay MW, Jiang YH. DNA Methylation and Susceptibility to Autism Spectrum Disorder. *Annu Rev Med*. 2019;70:151-166. doi: 10.1146/annurev-med-120417-091431.
159. Christian DL, Wu DY, Martin JR, et al. DNMT3A Haploinsufficiency Results in Behavioral Deficits and Global Epigenomic Dysregulation Shared across Neurodevelopmental Disorders. *Cell Rep*. 2020;33(8):108416. doi: 10.1016/j.celrep.2020.108416.
160. Herrera ML, Paraíso-Luna J, Bustos-Martínez I, Barco Á. Targeting epigenetic dysregulation in autism spectrum disorders. *Trends Mol Med*. 2024;30(11):1028-1046. doi:10.1016/j.mol-med.2024.06.004.
161. Liu XS, Wu H, Krzisch M, et al. Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene. *Cell*. 2018;172(5):979-992.e6. doi: 10.1016/j.cell.2018.01.012.
162. Zhu L, Wang X, Li XL, Towers A, et al. Epigenetic dysregulation of SHANK3 in brain tissues from individuals with autism spectrum disorders. *Hum Mol Genet*. 2014;23(6):1563-78. doi: 10.1093/hmg/ddt547.
163. Aung MT, M Bakulski K, Feinberg JI, F Dou J, D Meeker J, Mukherjee B, Loch-Caruso R, Ladd-Acosta C, Volk HE, Croen LA, Hertz-Picciotto I, Newschaffer CJ, Fallin MD. Maternal blood metal concentrations and whole blood DNA methylation during pregnancy in the Early Autism Risk Longitudinal Investigation (EARLI). *Epigenetics*. 2022;17(3):253-268. doi: 10.1080/15592294.2021.1897059.
164. Garrido N, Cruz F, Egea RR, et al. Sperm DNA methylation epimutation biomarker for paternal offspring autism susceptibility. *Clin Epigenetics*. 2021;13(1):6. doi: 10.1186/s13148-020-00995-2.
165. Feinberg JI, Schrott R, Ladd-Acosta C, et al. Epigenetic changes in sperm are associated with paternal and child quantitative autistic traits in an autism-enriched cohort. *Mol Psychiatry*. 2024;29(1):43-53. doi: 10.1038/s41380-023-02046-7.
166. Gallo R, Stoccoro A, Cagiano R, et al. Correlation among maternal risk factors, gene methylation and disease severity in females with autism spectrum disorder. *Epigenomics*. 2022;14(4):175-185. doi: 10.2217/epi-2021-0494.
167. Zhao Y, Zhou C, Yu H, et al. Association between the methylation of six apoptosis-associated genes with autism spectrum disorder. *Mol Med Rep*. 2018;18(5):4629-4634. doi: 10.3892/mmr.2018.9473.
168. Abdolmaleky HM, Zhou JR, Thiagalingam S. Cataloging recent advances in epigenetic alterations in major mental disorders and autism. *Epigenomics*. 2021;13(15):1231-1245. doi: 10.2217/epi-2021-0074.
169. Vlasakova K, Tsuchiya T, Garfinkel IN, et al. Performance of biomarkers NF-L, NSE, Tau and GFAP in blood and cerebrospinal fluid in rat for the detection of nervous system injury. *Front Neurosci*. 2024;17:1285359. doi: 10.3389/fnins.2023.1285359.
170. Uddin LQ, Dajani DR, Voorhies W, et al. Progress and roadblocks in the search for brain-based biomarkers of autism and attention-deficit/hyperactivity disorder. *Transl Psychiatry*. 2017;7(8):e1218. doi: 10.1038/tp.2017.164.
171. Wakefield JC. Diagnostic Issues and Controversies in DSM-5: Return of the False Positives Problem. *Annu Rev Clin Psychol*. 2016;12:105-32. doi: 10.1146/annurev-clinpsy-032814-112800.
172. Krämer J, Beer M, Bode H, et al. Two Novel Compound Heterozygous Mutations in the TRAPPC9 Gene Reveal a Connection of Non-syndromic Intellectual Disability and Autism Spectrum Disorder. *Front Genet*. 2021;11:972. doi: 10.3389/fgene.2020.00972.



173. Jiang HY, Xu LL, Shao L, et al. Maternal infection during pregnancy and risk of autism spectrum disorders: A systematic review and meta-analysis. *Brain Behav Immun*. 2016;58:165-172. doi: 10.1016/j.bbi.2016.06.005.
174. de Sena Barbosa MG, Vilela de Souza RL, et al. Biomarkers for autism spectrum disorder: a short review. *Ann Med Surg (Lond)*. 2024;86(12):7227-7231.
175. Frye RE, Vassall S, Kaur G, Lewis C, Karim M, Rossignol D. Emerging biomarkers in autism spectrum disorder: a systematic review. *Ann Transl Med*. 2019;7(23):792. doi: 10.21037/atm.2019.11.53.
176. Kong X, Liu J, Cetinbas M, et al. New and Preliminary Evidence on Altered Oral and Gut Microbiota in Individuals with Autism Spectrum Disorder (ASD): Implications for ASD Diagnosis and Subtyping Based on Microbial Biomarkers. *Nutrients*. 2019;11(9):2128. doi: 10.3390/nu11092128.
177. Volkmar FR, McPartland JC. From Kanner to DSM-5: autism as an evolving diagnostic concept. *Annu Rev Clin Psychol*. 2014;10:193-212. doi: 10.1146/annurev-clinpsy-032813-153710.
178. Patel J, Lukkes JL, Shekhar A. Overview of genetic models of autism spectrum disorders. *Prog Brain Res*. 2018;241:1-36. doi: 10.1016/bs.pbr.2018.10.002.
179. Silverman JL, Thurm A, Ethridge SB, et al. Reconsidering animal models used to study autism spectrum disorder: Current state and optimizing future. *Genes Brain Behav*. 2022;21(5):e12803. doi: 10.1111/gbb.12803.
180. Fard YA, Sadeghi EN, Pajoohesh Z et al. Epigenetic underpinnings of the autistic mind: Histone modifications and prefrontal excitation/inhibition imbalance. *Am J Med Genet B Neuropsychiatr Genet*. 2024;195(8):e32986. doi: 10.1002/ajmg.b.32986.
181. Kazdoba TM, Leach PT, Yang M, et al. Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics. *Curr Top Behav Neurosci*. 2016;28:1-52. doi: 10.1007/7854_2015_5003.
182. Narvaiz DA, Nolan SO, Smith GD, et al. Rapamycin improves social and stereotypic behavior abnormalities induced by pre-mitotic neuronal subset specific Pten deletion. *Genes Brain Behav*. 2023;22(4):e12854. doi: 10.1111/gbb.12854.
183. Thomas SD, Jha NK, Ojha S, Sadek B. mTOR Signaling Disruption and Its Association with the Development of Autism Spectrum Disorder. *Molecules*. 2023;28(4):1889. doi: 10.3390/molecules28041889.
184. Hamilton SM, Green JR, Veeraragavan S, Yuva L, McCoy A, Wu Y, Warren J, Little L, Ji D, Cui X, Weinstein E, Paylor R. Fmr1 and Nlgn3 knockout rats: novel tools for investigating autism spectrum disorders. *Behav Neurosci*. 2014;128(2):103-9.
185. Meshalkina DA, N Kizlyk M, V Kysil E, et al. Zebrafish models of autism spectrum disorder. *Exp Neurol*. 2018;299(Pt A):207-216. doi: 10.1016/j.expneurol.2017.02.004.
186. Crawley JN. Twenty years of discoveries emerging from mouse models of autism. *Neurosci Biobehav Rev*. 2023;146:105053. doi: 10.1016/j.neubiorev.2023.105053.
187. Ornoy, A. Echefu, B. Becker, M. Valproic Acid in Pregnancy Revisited: Neurobehavioral, Biochemical and Molecular Changes Affecting the Embryo and Fetus in Humans and in Animals: A Narrative Review. *Int J Mol Sci*. 2024, 25, 390. doi.org/10.3390/ijms25010390
188. Dana H, Bayramov KK, Delibaşı N et al. Disregulation of Autophagy in the Transgenerational Cc2d1a Mouse Model of Autism. *Neuromolecular Med*. 2020;22(2):239-249. doi: 10.1007/s12017-019-08579x.
189. Sener EF, Dana H, Tahtasakal R et al. Heterozygous Cc2d1a mice show sex-dependent changes in the Beclin-1/p62 ratio with impaired prefrontal cortex and hippocampal autophagy. *Prog Neuropsychopharmacol Biol Psychiatry*. 2023;125:110764. doi: 10.1016/j.pnpbp.2023.110764.
190. Manzini MC, Xiong L, Shaheen R et al. CC2D1A regulates human intellectual and social function as well as NF-κB signaling homeostasis. *Cell Rep*. 2014;8(3):647-55. doi: 10.1016/j.



- celrep.2014.06.039.
191. Bhattacharya A, Parlanti P, Cavallo L et al. A novel framework for functional annotation of variants of uncertain significance in ID/ASD risk gene CC2D1A. *Hum Mol Genet.* 2024;33(14):1229-1240. doi: 10.1093/hmg/ddae070.
 192. Yi S, Tang X, Zhang Q et al. A nonsense CC2D1A variant is associated with congenital anomalies, motor delay, hypotonia, and slight deformities. *Heliyon.* 2024;10(6):e27946. doi: 10.1016/j.heliyon.2024.e27946.
 193. Sener EF, Onal MG, Dal F et al. Novel alterations of CC2D1A as a candidate gene in a Turkish sample of patients with autism spectrum disorder. *Int J Neurosci.* 2022 Nov;132(11):1072-1079. doi: 10.1080/00207454.2020.1860968.
 194. Zamarbide M, Mossa A, Muñoz-Llanca P et al. Male-Specific cAMP Signaling in the Hippocampus Controls Spatial Memory Deficits in a Mouse Model of Autism and Intellectual Disability. *Biol Psychiatry.* 2019;85(9):760-768. doi: 10.1016/j.biopsych.2018.12.013.
 195. Mossa A, Manzini MC. Molecular causes of sex-specific deficits in rodent models of neurodevelopmental disorders. *J Neurosci Res.* 2021;99(1):37-56. doi: 10.1002/jnr.24577.
 196. Ornoy A, Echefu B, Becker M. Valproic Acid in Pregnancy Revisited: Neurobehavioral, Biochemical and Molecular Changes Affecting the Embryo and Fetus in Humans and in Animals: A Narrative Review. *Int J Mol Sci.* 2023;25(1):390. doi: 10.3390/ijms25010390.
 197. Kurahashi H, Kunisawa K, Tanaka KF, et al. Autism spectrum disorder-like behaviors induced by hyper-glutamatergic NMDA receptor signaling through hypo-serotonergic 5-HT1A receptor signaling in the prefrontal cortex in mice exposed to prenatal valproic acid. *Neuropsychopharmacology.* 2025;50(5):739-750. doi: 10.1038/s41386-024-02004-z.
 198. Ghahremani R, Mohammadkhani R, Salehi I et al. Sex Differences in Spatial Learning and Memory in Valproic Acid Rat Model of Autism: Possible Beneficial Role of Exercise Interventions. *Front Behav Neurosci.* 2022;16:869792. doi: 10.3389/fnbeh.2022.869792.
 199. Szatmari P, Liu XQ, Goldberg J et al. Sex differences in repetitive stereotyped behaviors in autism: implications for genetic liability. *Am J Med Genet B Neuropsychiatr Genet.* 2012;159B(1):5-12. doi: 10.1002/ajmg.b.31238.
 200. Beggiato A, Peyre H, Maruani A et al. Gender differences in autism spectrum disorders: Divergence among specific core symptoms. *Autism Res.* 2017;10(4):680-689. doi: 10.1002/aur.1715.
 201. Feleke R, Jazayeri D, Abouzeid M, et al. Integrative genomics reveals pathogenic mediator of valproate-induced neurodevelopmental disability. *Brain.* 2022;145(11):3832-3842. doi: 10.1093/brain/awac296.
 202. Guerra M, Medici V, Weatheritt R, et al. Fetal exposure to valproic acid dysregulates the expression of autism-linked genes in the developing cerebellum. *Transl Psychiatry.* 2023;13(1):114. doi: 10.1038/s41398-023-02391-9.
 203. Mattheisen M, Grove J, Als TD, et al. Identification of shared and differentiating genetic architecture for autism spectrum disorder, attention-deficit hyperactivity disorder and case subgroups. *Nat Genet.* 2022;54(10):1470-1478. doi: 10.1038/s41588-022-01171-3.
 204. Ramaswami G, Won H, Gandal MJ, Haney J, Wang JC, Wong CCY, Sun W, Prabhakar S, Mill J, Geschwind DH. Integrative genomics identifies a convergent molecular subtype that links epigenomic with transcriptomic differences in autism. *Nat Commun.* 2020;11(1):4873. doi: 10.1038/s41467-020-18526-1.

OTİZM SPEKTRUM BOZUKLUĞU PATOGENEZİ

Ceyda ÖNEY YILMAZ¹
Edibe PEMBEGÜL YILDIZ²

GİRİŞ

Otizm spektrum bozukluğu (OSB); erken başlangıçlı anormal sosyal iletişim, kısıtlı tekrarlayıcı davranışlar ve ilgi alanlarıyla karakterize bir grup gelişimsel nörolojik bozukluktur. İlk olarak 1980 yılında ebeveyn davranışından ziyade beyindeki yapısal farklılıklar nedeniyle ortaya çıktığı dile getirilmiştir.¹ OSB, genetik ve çevresel faktörlerin karmaşık bir etkileşiminden kaynaklanan, davranışsal anormallikler olarak ortaya çıkan etiyolojisi son derece karmaşık heterojen bir durumdur. Etiyolojik, fenotipik ve prognositik heterojenite OSB için klinik tanıyı ve tedavinin bireyselleştirilmesini zorlaştırır ve çeşitlendirir.²

1.GENETİK FAKTÖRLER

Otizm, genetik ve çevresel faktörlerin etkileşimi ile ortaya çıkmaktadır. Yapılan çalışmalarda, otizmin gelişiminde hem nadir mutasyonların hem de sık görülen genetik varyasyonların önemli rol oynadığını gösterilmiştir. Bu çalışmalar, transkripsiyon, translasyon, sinaptik bağlantılar, epigenetik modifikasyonlar ve bağışıklık sistemine ilişkin sinyal yolları gibi ortak moleküler mekanizmaların otizmin patogenezinde önemli bir rol aldığını ortaya koymaktadır. Sinaptik proteinlerin işlevindeki bozukluklar, nöronlar arasındaki iletişimin bozulmasına ve otizme özgü klinik semptomların gelişimine zemin hazırlamaktadır. İkiz,

¹ Uzm. Dr., İstanbul Üniversitesi, İstanbul Tıp Fakültesi ,Çocuk Sağlığı ve Hastalıkları AD., Çocuk Nörolojisi BD., ceydaoney@hotmail.com, ORCID iD: 0000-0002-5734-0175

² Prof. Dr., İstanbul Üniversitesi, İstanbul Tıp Fakültesi ,Çocuk Sağlığı ve Hastalıkları AD., Çocuk Nörolojisi BD., edibepembegul@hotmail.com, ORCID iD: 0000-0002-8016-0404



göre daha güçlü olması ve oksidatif strese karşı daha az duyarlılık koruyucu etki olarak değerlendirilmiştir.⁴⁷

7.BEYİN – BAĞIRSAK AKSI

OSB tanılı çocuklarda kabızlık, diyare, reflü ve besin intoleransı gibi gastroin-testinal sorunlar sık karşımıza çıkmaktadır. Otizm ve mikrobiyaya ilişkisini inceleyen çeşitli çalışmalar bulunmaktadır. Bu çalışmalar, otizimli çocuklarda gastrointestinal işlev bozukluklarının yaygın olduğunu göstermektedir. Bağırsak geçirgenliğinin artışı ve mikrobiyom değişiklikleri, enflamatuvar süreçleri tetikleyerek serebral fonksiyonlarını etkilemektedir. Ayrıca, bazı genetik mutasyonların bağırsak motilite bozukluklarına yol açtığı bildirilmiştir. Bağırsak-mikrobiyom-beyin ekseninin ASD'deki rolü giderek daha fazla önem kazanmaktadır.⁴⁸⁻⁴⁹ Ketojenik diyetin ASD hayvan çalışmasında bağırsak mikrobiyal dengesini düzenleyerek sosyal iletişimi ve davranış biçimini iyileştirdiği gösterilmiştir.⁵⁰ Ketojenik diyet; mitokondriyal fonksiyonun desteklenmesini, oksidatif stresin azaltılmasını ve GABA seviyelerinin düzenlenmesini sağlamaktadır.⁵¹

KAYNAKLAR

1. Williams RS, Hauser SL, Purpura DP, DeLong GR, Swisher CN. Autism and mental retardation: neuropathologic studies performed in four retarded persons with autistic behavior. Arch Neurol. 1980;37(12):749-53.
2. Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol. 2007;17(1):103-11.
3. Jiang CC, Lin LS, Long S, Ke XY, Fukunaga K, Lu YM, Han F. Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications. Signal Transduct Target Ther. 2022;7(1):229.
4. Sauer AK, Stanton JE, Hans S, Grabrucker AM. Autism spectrum disorders: etiology and pathology. In: Grabrucker AM, editor. Autism spectrum disorders. Brisbane (AU): Exon Publications; 2021.
5. Nisar S, Ajaz AB, Masoodi T, et al. Genetics of glutamate and its receptors in autism spectrum disorder. Mol Psychiatry. 2022;27(5):2380-2392.
6. Hussein Y, Tripathi U, Choudhary A, et al. Early maturation and hyperexcitability is a shared phenotype of cortical neurons derived from different ASD-associated mutations. Transl Psychiatry. 2023;13:246.
7. Förster E, Jossin Y, Zhao S, Chai X, Frotscher M, Goffinet AM. Recent progress in understanding the role of Reelin in radial neuronal migration, with specific emphasis on the dentate gyrus. Eur J Neurosci. 2006;23(4):901-9.
8. Kelemenova S, Ostatnikova D. Neuroendocrine pathways altered in autism. Special role of reelin. Neuro Endocrinol Lett. 2009;30(4):429-36.
9. Pejhan S, Rastegar M. Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett syndrome pathobiology and mechanism of disease. Biomolecules. 2021;11(1).



10. Cheon S, Dean M, Chahrour M. The ubiquitin proteasome pathway in neuropsychiatric disorders. *Neurobiol Learn Mem.* 2019;165:106791.
11. Zhuang H, Liang Z, et al. Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy. *MedComm.* 2024;5(3):e497.
12. Herman GE, Butter E, Enrile B, Pastore M, Prior TW, Sommer A. Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly. *Am J Med Genet A.* 2006;143A:589-593.
13. Kwan V, Unda BK, Singh KK. Wnt signaling networks in autism spectrum disorder and intellectual disability. *J Neurodev Disord.* 2016;8:45.
14. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Advanced parental age and autism risk in children: a systematic review and meta-analysis. *Acta Psychiatr Scand.* 2017;135(1):29-41.
15. Byars SG, Boomsma JJ. Opposite differential risks for autism and schizophrenia based on maternal age, paternal age, and parental age differences. *Evol Med Public Health.* 2016;2016(1):286-98.
16. Rieseke RD, Matson JL. Parental age at conception and the relationship with severity of autism symptoms. *Dev Neurorehabil.* 2020;23(5):265-270.
17. Yenkovyan K, Mkhitarian M, Bjørklund G. Environmental risk factors in autism spectrum disorder: a narrative review. *Curr Med Chem.* 2024;31(17):2345-2360.
18. Usui N, Kobayashi H, Shimada S. Neuroinflammation and oxidative stress in the pathogenesis of autism spectrum disorder. *Int J Mol Sci.* 2023;24(6):5487.
19. Shi L, Fatemi SH, Sidwell RW, Patterson PH. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. *J Neurosci.* 2003;23(1):297-302.
20. Meltzer A, Van de Water J. The role of the immune system in autism spectrum disorder. *Neuropsychopharmacology.* 2017;42(1):284-298.
21. Velloso FJ, Zaritsky R, Houbekia RY, Rios N, Levison SW. Interleukin-6 produces behavioral deficits in pre-pubescent mice independent of neuroinflammation. *Brain Behav Immun.* 2025;126:275-288.
22. Meador KJ. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. *Lancet Neurol.* 2013;12(3):244-52.
23. Hernandez-Diaz S, Straub L, Bateman BT, et al. Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure. *N Engl J Med.* 2024;390(12):1069-1079.
24. Brown HK, Hussain-Shamsy N, Lunskey Y, Dennis CE, Vigod SN. The association between antenatal exposure to selective serotonin reuptake inhibitors and autism: a systematic review and meta-analysis. *J Clin Psychiatry.* 2017;78(1):e48-e58.
25. Liu X, Agerbo E, Ingstrup KG, et al. Antidepressant use during pregnancy and psychiatric disorders in offspring: Danish nationwide register-based cohort study. *BMJ.* 2017;358:j3668.
26. Gidaya NB, Lee BK, Burstyn I, Michael Y, Newschaffer CJ, Mortensen EL. In utero exposure to β_2 -adrenergic receptor agonist drugs and risk for autism spectrum disorders. *Pediatrics.* 2016;137(2):e20151316.
27. Yin W, Pulakka A, Reichenberg A, et al. Association between parental psychiatric disorders and risk of offspring autism spectrum disorder: a Swedish and Finnish population-based cohort study. *Lancet Reg Health Eur.* 2024;40:100902.
28. Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism: a review and future directions. *Int J Dev Neurosci.* 2005;23(2-3):183-7.
29. Juranek J, Filipek PA, Berenji GR, Modahl C, Osann K, Spence MA. Association between amygdala volume and anxiety level: magnetic resonance imaging study in autistic children. *J Child Neurol.* 2006;21(12):1051-8.
30. Courchesne E, Karns CM, Davis HR, et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. *Neurology.* 2001;57(2):245-54.



31. Courchesne E, Mouton PT, Calhoun ME, et al. Neuron number and size in prefrontal cortex of children with autism. *JAMA*. 2011;306(18):2001-10.
32. Badhe S. Abnormal development of the corpus callosum in autism spectrum disorder: an MRI study. *Top Magn Reson Imaging*. 2024;33(3):e0312.
33. Baizer JS. Neuroanatomy of autism: what is the role of the cerebellum? *Cereb Cortex*. 2024;34(13):94-103.
34. Sydnor LM, Aldinger KA. Structure, function, and genetics of the cerebellum in autism. *J Psychiatr Brain Sci*. 2022;7.
35. Pardo CA, Eberhart CG. The neurobiology of autism. *Brain Pathol*. 2007;17(4):434-47.
36. Dedeoğlu Ö, Çetinkaya M, Derinkuyu BE, et al. Aspects of autism spectrum disorder and correlation with neuroimaging findings in tuberous sclerosis complex. *Clin Neurol Neurosurg*. 2023;224:107550.
37. Rojas DC, Singel D, Steinmetz S, Hepburn S, Brown MS. Decreased left perisylvian GABA concentration in children with autism and unaffected siblings. *Neuroimage*. 2014;86:28-34.
38. Horder J. Glutamate and GABA in autism spectrum disorder—a translational magnetic resonance spectroscopy study in man and rodent models. *Transl Psychiatry*. 2018;8(1):106.
39. Blatt GJ, Fatemi SH. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. *Anat Rec*. 2011;294:1646-1652.
40. Rodnyy AY, Kondaurova EM, Tsybko AS, Popova NK, Kudlay DA, Naumenko VS. The brain serotonin system in autism. *Rev Neurosci*. 2023;35(1):1-20.
41. Schain RJ, Freedmann DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. *J Pediatr*. 1961;58:315-320.
42. Leboyer M, Philippe A, Bouvard M, et al. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. *Biol Psychiatry*. 1999.
43. Pourhamzeh M, Moravej FG, Arabi M, et al. The roles of serotonin in neuropsychiatric disorders. *Cell Mol Neurobiol*. 2022;42(6):1671-1692.
44. Spivak B, Golubchik P, Mozes T, et al. Low platelet-poor plasma levels of serotonin in adult autistic patients. *Neuropsychobiology*. 2004;50(2):157-160.
45. Hernández-del Caño C, Varela-Andrés N, Cebrián-León A, Deogracias R. Neurotrophins and their receptors: BDNF's role in GABAergic neurodevelopment and disease. *Int J Mol Sci*. 2024;25(15):8312.
46. Steeb H, Ramsey JM, Guest PC, et al. Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome. *Mol Autism*. 2014;5:1-10.
47. Lai MC, Lombardo MV, Auyeung B, Chakrabarti B, Baron-Cohen S. Sex/gender differences and autism: setting the scene for future research. *J Am Acad Child Adolesc Psychiatry*. 2015;54:11.
48. Fröhlich H, Kollmeyer ML, Linz VC, et al. Gastrointestinal dysfunction in autism displayed by altered motility and achalasia in Foxp1+/- mice. *Proc Natl Acad Sci USA*. 2019;116(44):22237-45.
49. Wang LW, Tancredi DJ, Thomas DW. The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members. *J Dev Behav Pediatr*. 2011;32(5):351-60.
50. Ruskin DN, Svedova J, Cote JL, et al. Ketogenic diet improves core symptoms of autism in BTBR mice. *PLoS One*. 2013;8(6):e65021.
51. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. *Brain Res Rev*. 2009;59:293-315.

OTİZM KLİNİK BULGULARI

Emine Aylin ŞENOL¹
 Nilüfer ELDEŞ HACİFAZLIOĞLU²
 Şaziye Senem BAŞGÜL³

GİRİŞ

Otizm spektrum bozukluğu (OSB); sözel ya da sözel olmayan iletişimde zorluk, sosyal etkileşimde bozukluk, tekrarlayıcı davranışlar ve kısıtlı ilgi alanı ile karakterize nörogelişimsel bir bozukluktur (DSM 5, *Diagnostic and Statistical Manual of Mental Disorders*).¹ Klinik belirtilerin hastalar arasında ve zaman içinde değişebildiği, yaşam boyu devam eden bir durumdur.² Çevresel faktörler (klinik heterojenite, yaş, zeka düzeyi, bireyselleştirilmiş eğitim hizmetleri, konuşma, dil ve davranışsal müdahaleler) fenotipi etkileyebilirler.³ Ayrıca OSB'ye özgü belirtiler diğer nörolojik, genetik ve metabolik hastalıklarda da görülebilirler.

OSB terimi ilk kez 1911'de Bleuler tarafından gerçekte bağın kopması ve iletişim kurmada zorluk olarak tanımlanmıştır.⁴ Leo Kanner, iletişim ve sosyal becerilerde eksiklikleri olan, amaçsız tekrarlayan davranış kalıpları sergileyen ve zamirleri tersten kullanan çocuk ve ergenler için infantil OSB terimini kullanmıştır.^{5,6} Hans Asperger tarafından 1944 yılında otistik psikopati teriminin kullanılması nedeni ile OSB uzun yıllar şizofreninin erken bir belirtisi olarak düşünülmüştür.⁴ Rutter, OSB'ye 1978 yılında klinik bulguların 30 aydan önce başlaması, heterojen davranışlar, sosyal etkileşimde ve iletişimde bozukluk kriterle-

¹ Dr., Sağlık Bilimleri Üniversitesi, Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi, emineaylin91@gmail.com, ORCID iD: 0000-0001-8656-9967

² Doç. Dr., Sağlık Bilimleri Üniversitesi, Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi, niluferhacifazlioglu@gmail.com, ORCID iD: 0000-0001-8828-8587

³ Prof. Dr., Hasan Kalyoncu Üniversitesi, Psikoloji Bölümü, senembasgul@gmail.com, ORCID iD: 0000-0002-5205-0275



SONUÇ

OSB yaşam boyu devam eden, klinik belirtilerin zaman içinde değişebildiği, erken tanı ve tedavi ile çocuğun ve ailesinin yaşam kalitesinin yükseltilebildiği, gelişimsel ve heterojen bir bozukluktur. Mümkün olan en erken zamanda OSB olan çocuklara özel eğitim fırsatı sağlanabilmesi amacıyla ve olası gecikmeleri engellemek için ailelerin OSB'nin erken dönemlerdeki belirtileri konusunda farkındalıklarının yüksek olması hayati bir önem taşımaktadır. Bu noktada, ailelerin “Çocuğum büyüdükçe açılır.” düşüncesi oldukça yanıltıcıdır. Çünkü gelişim üst üste konan basamaklar halinde ilerler ve beyin gelişimi açısından ilk üç yaş hayati öneme sahiptir. Ancak; OSB'nin erken fark edilmesi ve tanı konulması noktası kadar, bu tanının güvenilirliği de çok kritiktir. Aşırı tanısal değerlendirme yapılmasının da önüne geçilmelidir. Özellikle akraba evliliği ve ailesinde nörolojik hastalığı olan birey bulunan hastalar ile doğum öncesi, doğum sırası ve doğum sonrasında risk faktörleri olan çocuklar başta olmak üzere; etiolojinin saptanması ve eşlik eden komorbid durumların tespit edilebilmesi için riskli tüm çocuklar bir hekim tarafından değerlendirilmelidir. Öncelikle tanı ve ayırıcı tanı açısından bir çocuk ve ergen psikiyatristi tarafından muayene edilmeli, sonrasında etioloji ve ilave nörolojik bozuklukların değerlendirilmesi için bir çocuk nöroloğu tarafından ayrıntılı olarak değerlendirilmelidirler. Tüm bu değerlendirmeler sonrasında da, OSB'li çocuklarda kanıta dayalı tek uygulama olan özel eğitim desteğine mümkün olan en erken zamanda başlanmalıdır.

KAYNAKLAR

1. American Psychiatric Association. diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013.
2. Waye MMY, Cheng HY. genetics and epigenetics of autism: A Review. Psychiatry Clin Neurosci . 2018 Apr 13;72:228–44.
3. Hirota T, King BH. autism Spectrum Disorder: A Review. Vol. 329, JAMA. American Medical Association; 2023. p. 157–68.
4. Asperger H. die „Autistischen Psychopathen” im Kindesalter. Arch Psychiatr Nervenkr . 1944 Jun;117:76–136.
5. Kanner L. autistic disturbances of affective contact Nerv. Child.1943;2:217-50. Nerv Child. 1943;2.
6. Harris J. leo Kanner and autism. 75-year perspective. Vol. 30, International Review of Psychiatry. Taylor and Francis Ltd; 2018. p. 3–17.
7. Rutter M, Schopler E. classification of Pervasive Developmental Disorders: Some Concepts and Practical Considerations. Vol. 29, Journal of Autism attd Developmental Disorders. 1992.
8. Fuentes J, Bakare M, Munir K, Aguayo P, Gaddour N, Öner Ö. iACAPAP e-Textbook of Child and Adolescent Mental Health. Geneva: International Association for Child and Adolescent



- Psychiatry and Allied Professions . 2014 .
9. Blum NJ, Tasker RC, Wilson KM, Schuh AM, Mack CL. nelson Textbook of Pediatrics. 22nd ed. St. Geme III JWM, Kliegman RMM, editors. Vol. 22. 2024.
 10. Swaiman KF, Ashwal Stephen, Ferriero DM, Schor NFelice, Finkel RS., Gropman AL., et al. Swaiman's pediatric neurology : principles and practice. Elsevier; 2018. 1–1403 p.
 11. Spinazzi NA, Santoro JD, Pawlowski K et al. co-occurring conditions in children with Down syndrome and autism: a retrospective study. J Neurodev Disord. 2023 Dec 1;15.
 12. Carman KB, Kayhan M, Bilge U et al. aile Hekimlerinin Gelişimsel Tarama Testleri Hakkındaki Bilgi Düzeylerinin ve Uygulama Alışkanlıklarının Değerlendirilmesi. OSMANGAZİ JOURNAL OF MEDICINE . 2017 Sep 8;39:44–8.
 13. Leboyer M, Philippe A, Bouvard M et al. ORIGINAL ARTICLES Whole Blood Serotonin and Plasma Beta-Endorphin in Autistic Probands and Their First-Degree Relatives. Vol. 45, Biol Psychiatry. 1999.
 14. Barbaresi WJ. the Meaning of “Regression” in Children with Autism Spectrum Disorder: Why Does It Matter? Journal of Developmental & Behavioral Pediatrics. 2016 Jul;37:506–7.
 15. Bradley CC, Boan AD, Cohen AP, Charles JM, Carpenter LA. reported History of Developmental Regression and Restricted, Repetitive Behaviors in Children with Autism Spectrum Disorders. Journal of Developmental & Behavioral Pediatrics . 2016 Jul;37:451–6.
 16. Werner E, Dawson G. validation of the Phenomenon of Autistic Regression Using Home Videotapes. Arch Gen Psychiatry . 2005 Aug 1;62:889.
 17. Mandell DS, Novak MM, Zubritsky CD. factors associated with age of diagnosis among children with autism spectrum disorders. Pediatrics . 2005 Dec;116:1480–6.
 18. Centers for Disease Control and Prevention. signs and Symptoms of Autism Spectrum Disorder. 2024.
 19. Salari N, Rasoulpoor S, Rasoulpoor S et al. the global prevalence of autism spectrum disorder: a comprehensive systematic review and meta-analysis. Ital J Pediatr. 2022 Dec 1;48.
 20. Pierce K, Gazestani VH, Bacon E et al. evaluation of the Diagnostic Stability of the Early Autism Spectrum Disorder Phenotype in the General Population Starting at 12 Months. JAMA Pediatr . 2019 Jun 1;173:578.
 21. Salley B, Colombo J. conceptualizing Social Attention in Developmental Research. Vol. 25, Social Development. Blackwell Publishing Ltd; 2016. p. 687–703.
 22. Lima LJC de, Britto DB de O e, Nogueira GDR, Lemos SMA. language functioning in Autism Spectrum Disorder: A scoping review. Revista CEFAC. 2024;26.
 23. WING L. syndromes of autism and atypical development. Handbook of autism and pervasive developmental disorders . 1987 ;3–19.
 24. Kern JK, Trivedi MH, Garver CR et al. the pattern of sensory processing abnormalities in autism. Autism . 2006 Sep 1;10:480–94.
 25. Baranek GT, Foster LG, Berkson G. sensory Defensiveness in Persons With Developmental Disabilities. Vol. 17. 1997.
 26. Baranek GT, Foster LG, Berkson G. tactile Defensiveness and Stereotyped Behaviors. American Journal of Occupational Therapy. 1997;51:91–5.
 27. Dimitrova-Radojichikj D. bLINDNESS AND AUTISM SPECTRUM DISORDERS. The Annual of the Faculty of Philosophy in Skopje. 2020;73:377–84.
 28. Maski KP, Jeste SS, Spence SJ. common neurological co-morbidities in autism spectrum disorders. Vol. 23, Current Opinion in Pediatrics. 2011. p. 609–15.
 29. Mukaddes NM, Kilincaslan A, Kucukyazici G, Sevetoglu T, Tuncer S. autism in visually impaired individuals. Psychiatry Clin Neurosci. 2007 Feb;61:39–44.
 30. Pili R, Zolo B, Farris P et al. autism and Visual impairment: A First Approach to a Complex Relationship. Clinical Practice & Epidemiology in Mental Health. 2021 Dec 22;17:212–6.



31. Miller M, Chukoskie L, Zinni M, Townsend J, Trauner D. dyspraxia, motor function and visual-motor integration in autism. *Behavioural brain research* . 2014 Aug 1;269:95–102.
32. Ouss L, Leunen D, Laschet J et al. autism spectrum disorder and cognitive profile in children with Dravet syndrome: Delineation of a specific phenotype. *Epilepsia Open*. 2019 Mar 1;4:40–53.
33. Tordjman S, Anderson GM, Botbol M et al. pain reactivity and plasma β -endorphin in children and adolescents with autistic disorder. *PLoS One*. 2009 Aug 26;4.
34. Deonna T, Roulet E. autistic spectrum disorder: Evaluating a possible contributing or causal role of epilepsy. *Epilepsia*. 2006 Nov;47(SUPPL. 2):79–82.
35. Rossignol DA, Frye RE. mitochondrial dysfunction in autism spectrum disorders: A systematic review and meta-analysis. Vol. 17, *Molecular Psychiatry*. 2012. p. 290–314.
36. Manzi B, Loizzo AL, Giana Grazia G, Curatolo P. autism and metabolic diseases. Vol. 23, *Journal of Child Neurology*. 2008. p. 307–14.
37. Spilioti M, Evangeliou AE, Tramma D et al. evidence for treatable inborn errors of metabolism cohort of 187 greek patients with autism spectrum (ASD). *Front Hum Neurosci*. 2013 Dec 24;7(DEC).
38. Campistol J, Díez-Juan M, Callejón L et al. inborn error metabolic screening in individuals with nonsyndromic autism spectrum disorders. *Dev Med Child Neurol*. 2016 Aug 1;58:842–7.
39. Schiff M, Benoist JF, Aïssaoui S et al. should metabolic diseases be systematically screened in nonsyndromic autism spectrum disorders? *PLoS One*. 2011;6.
40. Bilder DA, Bakian A V , Stevenson DA, Carbone PS, Cunniff C, Goodman AB, et al. Brief Report: The Prevalence of Neurofibromatosis Type 1 among Children with Autism Spectrum Disorder Identified by the Autism and Developmental Disabilities Monitoring Network. *J Autism Dev Disord*. 2016 Oct 1;46:3369–76.
41. Chen Q, Chen M, Bao W et al. association of cerebral palsy with autism spectrum disorder and attention-deficit/hyperactivity disorder in children: a large-scale nationwide population-based study. *BMJ Paediatr Open*. 2024 Apr 9;8.
42. Davis PE, Peters JM, Krueger DA, Sahin M. tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism. Vol. 12, *Neurotherapeutics*. Springer New York LLC; 2015. p. 572–83.
43. Devitt N, Gallagher L, Reilly R. autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS): Two Overlapping Disorders Reviewed through Electroencephalography—What Can be Interpreted from the Available Information? *Brain Sci*. 2015 Mar 27;5:92–117.
44. Haebich KM, Pride NA, Walsh KS et al. understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: Protocol for a cross-sectional multimodal study. *BMJ Open*. 2019 Sep 1;9.
45. Kaufmann WE, Kidd SA, Andrews HF et al. autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment. Vol. 139, *PEDIATRICS*. 2017.
46. Passos-Bueno MR, Costa CIS, Zatz M. dystrophin genetic variants and autism. *Discover Mental Health*. 2022 Dec 1;2.
47. Plasschaert E, Descheemaeker MJ, Van Eylen L, Noens I, Steyaert J, Legius E. prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1. *American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics*. 2015 Jan 1;168:72–80.
48. Simone M, Margari L, Pompamea F et al. autism spectrum disorder and duchenne muscular dystrophy: A clinical case on the potential role of the dystrophin in autism neurobiology. *J Clin Med*. 2021 Oct 1;10.
49. Srivastava AK, Schwartz CE. intellectual disability and autism spectrum disorders: Causal genes and molecular mechanisms. Vol. 46, *Neuroscience and Biobehavioral Reviews*. Elsevier Ltd; 2014. p. 161–74.



50. Bilder DA, Bakian A V , Stevenson DA, Carbone PS, Cunniff C, Goodman AB, et al. Brief Report: The Prevalence of Neurofibromatosis Type 1 among Children with Autism Spectrum Disorder Identified by the Autism and Developmental Disabilities Monitoring Network. *J Autism Dev Disord*. 2016 Oct 1;46:3369–76.
51. Capal JK, Williams ME, Pearson DA et al. profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study. *Ann Neurol* . 2021 Dec 29;90:874–86.
52. Ozonoff S, Young GS, Carter A et al. recurrence Risk for Autism Spectrum Disorders: A Baby Siblings Research Consortium Study:e488-e495. Vol. 128, *Pediatrics*. 2011.
53. Nabbout R, Chemaly N, Chipaux M et al. encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. *Orphanet J Rare Dis*. 2013 Nov 13;8.
54. Zecavati N, Spence SJ. neurometabolic disorders and dysfunction in autism spectrum disorders. *Curr Neurol Neurosci Rep* . 2009 Mar 8;9:129–36.
55. Balasopoulou A, Kokkinos P, Pagoulatos D et al. symposium Recent advances and challenges in the management of retinoblastoma Globe - saving Treatments. *BMC Ophthalmol* . 2017;17:1.
56. Grønberg TK, Schendel DE, Parner ET. recurrence of autism spectrum disorders in full- and half-siblings and trends over time: A population-based cohort study. *JAMA Pediatr*. 2013 Oct;167:947–53.
57. Sandin S, Hultman CM, Klevzon A, Gross R, MacCabe JH, Reichenberg A. advancing maternal age is associated with increasing risk for autism: A review and meta-analysis. *J Am Acad Child Adolesc Psychiatry*. 2012;51.
58. Sathe, Nila A. therapies for Children With Autism Spectrum Disorder: Behavioral Interventions Update Comparative Effectiveness Review Number 137.
59. Dodds L, Fell DB, Shea S, Armson BA, Allen AC, Bryson S. the role of prenatal, obstetric and neonatal factors in the development of autism. *J Autism Dev Disord*. 2011 Jul;41:891–902.
60. Krakowiak P, Walker CK, Bremer AA et al. maternal metabolic conditions and risk for autism and other neurodevelopmental disorders. *Pediatrics*. 2012 May;129.
61. Pesch MH, Leung J, Lanzieri TM et al. autism Spectrum Disorder Diagnoses and Congenital Cytomegalovirus. *Pediatrics*. 2024 Jun 1;153.
62. S. t. S. Does thimerosal or other mercury exposure increase the risk for autism? A review of current literature. *Acta Neurobiol Exp (Wars)* . 2010 Jun 30;70:187–95.
63. Strasser L, Downes M, Kung J, Cross JH, De Haan M. prevalence and risk factors for autism spectrum disorder in epilepsy: a systematic review and meta-analysis. *Dev Med Child Neurol* . 2018 Jan 9;60:19–29.
64. Roy N, Ghaziuddin M, Mohiuddin S. consanguinity and Autism. Vol. 22, *Current Psychiatry Reports*. Springer; 2020.
65. Zhu Z, Lu X, Yuan D, Huang S. close genetic relationships between a spousal pair with autism-affected children and high minor allele content in cases in autism-associated SNPs. *Genomics*. 2017 Jan 1;109:9–15.
66. Mohameddessa M, Waliddqoronn Eh Editors M. advances in Neurobiology 24 Personalized Food Intervention and Therapy for Autism Spectrum Disorder Management.
67. Precenzano F, Parisi L, Lanzara V et al. electroencephalographic abnormalities in autism spectrum disorder: Characteristics and therapeutic implications. Vol. 56, *Medicina (Lithuania)*. MDPI AG; 2020. p. 1–13.
68. Kurata H, Shirai K, Saito Y et al. neurodevelopmental disorders in children with macrocephaly: A prevalence study and PTEN gene analysis. *Brain Dev*. 2018 Jan 1;40:36–41.
69. Ciriigliaro L, Clericò L, Russo LC et al. head circumference growth in children with Autism Spectrum Disorder: trend and clinical correlates in the first five years of life. *Front Psychiatry*. 2024;15.



70. Ozgen H, Hellemann GS, de Jonge M V , Beemer FA, van Engeland H. Predictive Value of Morphological Features in Patients with Autism versus Normal Controls. *J Autism Dev Disord* . 2013 Jan 6;43:147–55.
71. Leclezio L, de Vries PJ. advances in the treatment of tuberous sclerosis complex. *Curr Opin Psychiatry* . 2015 Mar 6;28:113–20.
72. Baieli S, Pavone L, Meli C, Fiumara A, Coleman M. autism and Phenylketonuria. Vol. 33, *Journal of Autism and Developmental Disorders*. 2003.
73. Sikora DM, Pettit-Kekel K, Penfield J, Merckens LS, Steiner RD. the near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. *Am J Med Genet A* . 2006 Jul 15;140:1511–8.
74. Spence SJ, Schneider MT. the Role of Epilepsy and Epileptiform EEGs in Autism Spectrum Disorders. *Pediatr Res*. 2009 Jun;65(6):599–606.
75. Quintana Hernández D, Lantigua Cruz A, Piti Fajardo M, Habana L, Pediátrico Docente H, Manuel Márquez J. revista Cubana de Neurología y Neurocirugía. 2021;11:e443 1 Dysmorphic variations in primary autism Hospital Materno Infantil “.
76. Dover CJ, Le Couteur A. how to diagnose autism. *Arch Dis Child* . 2007 Jun 1;92:540–5.
77. Mcdonald-McGinn DM, Hain HS, Emanuel BS. 2 Deletion Syndrome. 1999.
78. Hartshorne TS, Grialou TL, Parker KR. autistic-like behavior in CHARGE syndrome. *Am J Med Genet A* . 2005 Mar 15;133A:257–61.
79. Amiet C, Gourfinkel-An I, Bouzamondo A et al. epilepsy in Autism is Associated with Intellectual Disability and Gender: Evidence from a Meta-Analysis. *Biol Psychiatry*. 2008 Oct 1;64:577–82.
80. Bolton PF, Carcani-Rathwell I, Hutton J, Goode S, Howlin P, Rutter M. epilepsy in autism: Features and correlates. *British Journal of Psychiatry*. 2011 Apr;198:289–94.
81. Rashid FB, Sumi SK, Parvin J et al. association of autism spectrum disorder with epilepsy and abnormal electroencephalogram in children. *Int J Contemp Pediatrics* . 2024 Oct 24;11:1527–33.
82. Frye RE, Sreenivasula S, Adams JB. traditional and non-traditional treatments for autism spectrum disorder with seizures: an on-line survey. *BMC Pediatr* . 2011 Dec 18;11:37.
83. Pacheva I, Ivanov I, Yordanova R et al. epilepsy in Children with Autistic Spectrum Disorder. *Children* . 2019 Jan 25;6:15.
84. Li BM, Liu XR, Yi YH et al. autism in Dravet syndrome: Prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. *Epilepsy and Behavior*. 2011 Jul;21:291–5.
85. Pavone P, Incorpora G, Fiumara A, Parano E, Trifiletti RR, Ruggieri M. epilepsy is not a Prominent Feature of Primary Autism. *Neuropediatrics* . 2004 Aug;35:207–10.
86. Woolfenden S, Sarkozy V, Ridley G, Coory M, Williams K. a systematic review of two outcomes in autism spectrum disorder - Epilepsy and mortality. *Dev Med Child Neurol*. 2012;54:306–12.
87. Rahman S. mitochondrial disease in children. *J Intern Med*. 2020 Jun 1;287:609–33.
88. Chakrabarti S. pervasive Developmental Disorders in Preschool Children. *JAMA* . 2001 Jun 27;285:3093.
89. Feero WG, Guttmacher AE, Mefford HC, Batshaw ML, Hoffman EP. genomic Medicine Genomics, Intellectual Disability, and Autism. Vol. 8, *n engl j med*. 2012.
90. Newschaffer CJ, Croen LA, Daniels J et al. the epidemiology of autism spectrum disorders. In: *Annual Review of Public Health*. 2007. p. 235–58.
91. Postorino V, Fatta LM, Sanges V et al. intellectual disability in Autism Spectrum Disorder: Investigation of prevalence in an Italian sample of children and adolescents. *Res Dev Disabil*. 2016 Jan 1;48:193–201.



92. Wilkins J, Matson JL. a comparison of social skills profiles in intellectually disabled adults with and without ASD. *Behav Modif*. 2009 Mar;33:143–55.
93. Billstedt E, Gillberg IC, Gillberg C. aspects of quality of life in adults diagnosed with autism in childhood: A population-based study. *Autism*. 2011 Jan;15:7–20.
94. Dworzynski K, Ronald A, Bolton P, Happé F. how different are girls and boys above and below the diagnostic threshold for autism spectrum disorders? *J Am Acad Child Adolesc Psychiatry*. 2012 Aug;51:788–97.
95. Harrop C, Tomaszewski B, Putnam O, Klein C, Lamarche E, Klinger L. are the diagnostic rates of autistic females increasing? An examination of state-wide trends. *Journal of Child Psychology and Psychiatry* . 2024 Jul 5;65:973–83.
96. Ratto AB, Kenworthy L, Yerys BE et al. what About the Girls? Sex-Based Differences in Autistic Traits and Adaptive Skills. *J Autism Dev Disord*. 2018 May 1;48:1698–711.
97. Ostrowski J, Religioni U, Gellert B, Sytnik-Czetwertyński J, Pinkas J. autism Spectrum Disorders: Etiology, Epidemiology, and Challenges for Public Health. *Medical Science Monitor*. 2024 Jun 1;30.
98. Madra M, Ringel R, Margolis KG. gastrointestinal Issues and Autism Spectrum Disorder. *Child Adolesc Psychiatr Clin N Am* . 2020 Jul 1;29:501–13.
99. Jolanta Wasilewska J, Klukowski M. gastrointestinal symptoms and autism spectrum disorder: links and risks – a possible new overlap syndrome. *Pediatric Health Med Ther*. 2015 Sep;153.
100. Fields VL, Soke GN, Reynolds A et al. pica, autism, and other disabilities. *Pediatrics*. 2021 Feb 1;147.
101. Wang LW, Tancredi DJ, Thomas DW. the Prevalence of Gastrointestinal Problems in Children Across the United States With Autism Spectrum Disorders From Families With Multiple Affected Members. Vol. 32, Original Article. 2011.
102. Žigman T, Petković Ramadža D, Šimić G, Barić I. inborn Errors of Metabolism Associated With Autism Spectrum Disorders: Approaches to Intervention. *Front Neurosci* . 2021 May 28;15.
103. Mulligan CA, Shipon-Blum E. selective Mutism: Identification of Subtypes and Implications for Treatment. *Journal of Education and Human Development*. 2015;4.
104. Suzuki T, Takeda A, Takadaya Y, Fujii Y. examining the Relationship between Selective Mutism and Autism Spectrum Disorder. *Asian Journal of Human Services*. 2020 Oct 1;19:55–62.
105. O'Brien G, Pearson J. autism and Learning Disability. *Autism* . 2004 Jun 1;8:125–40.
106. Percy AK. rett syndrome: exploring the autism link. *Arch Neurol* . 2011 Aug;68:985–9.
107. Richards C, Jones C, Groves L, Moss J, Oliver C. prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. *Lancet Psychiatry* . 2015 Oct 1;2:909–16.
108. Fazzi E, Micheletti S, Galli J, Rossi A, Gitti F, Molinaro A. autism in Children With Cerebral and Peripheral Visual Impairment: Fact or Artifact? *Semin Pediatr Neurol*. 2019 Oct 1;31:57–67.
109. Lueck AH, Dutton GN, Chokron S. profiling Children With Cerebral Visual Impairment Using Multiple Methods of Assessment to Aid in Differential Diagnosis. *Semin Pediatr Neurol* . 2019 Oct 1;31:5–14.
110. Molinaro A, Micheletti S, Rossi A et al. autistic-like features in visually impaired children: A review of literature and directions for future research. Vol. 10, *Brain Sciences*. MDPI AG; 2020. p. 1–17.
111. Dell'Osso L, Amatori G, Bonelli C et al. autism spectrum disorder, social anxiety and obsessive-compulsive disorders: beyond the comorbidity. *BMC Psychiatry*. 2025 Jan 13;25:37.



112. Johnson KA, Worbe Y, Foote KD, Butson CR, Gunduz A, Okun MS. tourette syndrome: clinical features, pathophysiology, and treatment. Vol. 22, *The Lancet Neurology*. Elsevier Ltd; 2023. p. 147–58.
113. Kalyva E, Kyriazi M, Vargiami E, Zafeiriou DI. a review of co-occurrence of autism spectrum disorder and Tourette syndrome. Vol. 24, *Research in Autism Spectrum Disorders*. Elsevier Ltd; 2016. p. 39–51.
114. Prato A, Saia F, Ferrigno M, Finocchiaro V, Barone R, Rizzo R. sensory phenomena in children with Tourette syndrome or autism spectrum disorder. *Front Psychiatry* . 2024 Apr 2;15.
115. Orth U, Robins RW, Widaman KF. life-span development of self-esteem and its effects on important life outcomes. *J Pers Soc Psychol* . 2012 Jun;102:1271–88.
116. McClain MB, Hasty Mills AM, Murphy LE. inattention and hyperactivity/impulsivity among children with attention-deficit/hyperactivity-disorder, autism spectrum disorder, and intellectual disability. *Res Dev Disabil*. 2017 Nov 1;70:175–84.
117. Attoni T, Coelho R, Martins R et al. the language aspects of children with high abilities/giftedness: an integrative literature review. *Revista CEFAC* . 2020;22.
118. Whitehouse AJO, Robinson M, Zubrick SR. late talking and the risk for psychosocial problems during childhood and adolescence. *Pediatrics* . 2011 Aug;128:e324-32.
119. Wang X, Bouton S, Kojovic N, Giraud AL, Schaer M. atypical audio-visual neural synchrony and speech processing in early autism. *J Neurodev Disord*. 2025 Dec 1;17.
120. Muris P, Ollendick TH. current challenges in the diagnosis and management of selective mutism in children. Vol. 14, *Psychology Research and Behavior Management*. Dove Medical Press Ltd; 2021. p. 159–67.
121. Zimmer M, Desch L. sensory integration therapies for children with developmental and behavioral disorders. Vol. 129, *Pediatrics*. American Academy of Pediatrics; 2012. p. 1186–9.
122. Gourley SL, Olevska A, Zimmermann KS, Ressler KJ, Dileone RJ, Taylor JR. the orbitofrontal cortex regulates outcome-based decision-making via the lateral striatum. *European Journal of Neuroscience*. 2013 Aug;38:2382–8.
123. Hazen EP, Stornelli JL, O'Rourke JA, Koesterer K, McDougale CJ. sensory Symptoms in Autism Spectrum Disorders. *Harv Rev Psychiatry* . 2014 Mar;22:112–24.
124. Galiana-Simal A, Vela-Romero M, Romero-Vela VM et al. sensory processing disorder: Key points of a frequent alteration in neurodevelopmental disorders. *Cogent Med*. 2020 Mar 4;7.
125. Crozier SC, Goodson JZ, Mackay ML et al. sensory processing patterns in children born very preterm. *American Journal of Occupational Therapy*. 2016 Jan 1;70.

OTİZM SINIFLAMASI VE TANI KRİTERLERİ

Pınar ARICAN¹

GİRİŞ

Otizm spektrum bozukluğu (OSB) tanı kriterleri, 1967 yılında uluslararası sınıflandırma sistemlerine dahil edilmesinden sonra 2013 yılında yayınlanan DSM-V (Diagnostic and Statistical Manual of Mental Disorders; Ruhsal Bozuklukların Tanısal ve İstatistiksel El Kitabı, beşinci baskı)'e kadar birçok kez değiştirilmiştir. Komite, DSM-V'in birincil hedefinin, klinisyenlerin hem yaşam boyu hem de bilişsel ve dil işlevlerinin tüm davranış aralığında OSB'yi teşhis etmek için mümkün olduğunca doğru bir şekilde yansıtan tanı kriterlerini sağlamak olduğuna karar vermiştir. DSM-V'e önerilen revizyonlar, klinisyenlerin tanı kategorileri içinde psikiyatrik ve ilgili semptomların hem varlığını hem de şiddetini derecelendirmesine olanak sağlamayı amaçlamıştır. Otizm spektrum bozukluğunun uygun destek ve tedavisi öncelikle doğru tanı ve sınıflandırmayı gerektirmektedir.¹⁻³ Bu nedenle tanı kriterlerinin ve sınıflandırma sistemlerinin güvenilirliği klinisyenler ve araştırmacılar açısından oldukça önemlidir.

Amerikan psikoloji derneği, 2013 yılında DSM-V'i yayınladığında, tanısal duyarlılığı korumak ve tanısal özgüllüğü geliştirmeye devam etmek amacıyla OSB tanı kriterlerinde önemli değişiklikler yapmıştır.⁴ DSM-V tanı kriterlerindeki yapılan değişiklikler, OSB'nin tanısında önemli iki konuyu vurgulamaktadır. İlk konu, bu bozukluğun tanısına yardımcı olacak net bir nesnel tanı ölçüsünün olmamasıdır. Tanı kliniklidir ve daha nesnel testler bile yorumlamada hala biraz öznelidir. Belirli bir otizm tanısına yol açan tek bir gen, toksik maruziyet

¹ Doç. Dr., Çocuk Nöroloji Kliniği, Başakşehir Çam ve Sakura Şehir Hastanesi, pınararican@windowslive.com, ORCID iD: 0000-0003-3990-7489



KAYNAKLAR

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
2. Yu Y, Ozonoff S, Miller M. Assessment of autism spectrum disorder. *Assessment*. 2024;31(1):24-41.
3. Kaba D, Soykan Aysev A. Evaluation of Autism Spectrum Disorder in Early Childhood According to the DSM-5 Diagnostic Criteria. *Türk Psikiyatri Derg* 2020;31(2):106-112.
4. Wiggins LD, Rice CE, Barger B, et al. DSM-5 criteria for autism spectrum disorder maximizes diagnostic sensitivity and specificity in preschool children. *Soc Psychiatry Psychiatr Epidemiol*. 2019;54(6):693-701.
5. Hartley-McAndrew M, Mertz J, Hoffman M, Crawford D. Rates of autism spectrum disorder diagnosis under the DSM-5 criteria compared to DSM-IV-TR criteria in a hospital-based clinic. *Pediatr Neurol*. 2016;57:34-38.
6. Genovese A, Butler MG. Clinical assessment, genetics, and treatment approaches in autism spectrum disorder (ASD). *Int J Mol Sci*. 2020;21(13):4726.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Publishing; 2000.
8. Hyman SL, Levy SE, Myers SM, et al. Identification, evaluation, and management of children with autism spectrum disorder. *Pediatrics*. 2020;145(1):e20193447.
9. Jadav N, Bal VH. Associations between co-occurring conditions and age of autism diagnosis: Implications for mental health training and adult autism research. *Autism Res*. 2022;15(11):2112-2125.
10. Lord C, Bishop SL. Recent advances in autism research as reflected in DSM-5 criteria for autism spectrum disorder. *Annu Rev Clin Psychol*. 2015;11(1):53-70.
11. Burns CO, Matson JL. An evaluation of the clinical application of the DSM-5 for the diagnosis of autism spectrum disorder. *Expert Rev Neurother*. 2017;17(9):909-917.
12. Weitlauf AS, Gotham KO, Vehorn AC, Warren ZE. Brief report: DSM-5 "levels of support:" A comment on discrepant conceptualizations of severity in ASD. *J Autism Dev Disord*. 2014;44(2):471-476.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Publishing; 2022.
14. Barton ML, Robins DL, Jashar D, et al. Sensitivity and specificity of proposed DSM-5 criteria for autism spectrum disorder in toddlers. *J Autism Dev Disord*. 2013;43:1184-1195.
15. Christiansz JA, Gray KM, Taffe J, et al. Autism spectrum disorder in the DSM-5: diagnostic sensitivity and specificity in early childhood. *J Autism Dev Disord*. 2016;46:2054-2063.
16. Frazier TW, Youngstrom EA, Speer L, et al. Validation of proposed DSM-5 criteria for autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry*. 2012;51:28-40.e3.
17. McPartland JC, Reichow B, Volkmar FR. Sensitivity and specificity of proposed DSM-5 diagnostic criteria for autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry*. 2012;51:368-383.
18. Peters WJ, Matson JL. Comparing rates of diagnosis using DSM-IV-TR versus DSM-5 criteria for autism spectrum disorder. *J Autism Dev Disord*. 2020;50:1898-1906.
19. Huerta M, Bishop SL, Duncan A, Hus V, Lord C. Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. *Am J Psychiatry*. 2012;169(10):1056-64.
20. Risi S, Lord C, Gotham K, et al. Combining information from multiple sources in the diagnosis of autism spectrum disorders. *J Am Acad Child Adolesc Psychiatry*. 2006;45(9):1094-103.
21. King BH, Navot N, Bernier R, Webb J. Update on diagnostic classification in autism. *Curr Opin Psychiatry*. 2014;27:105-109.

OTİZM OLGULARINA TANISAL YAKLAŞIM: PEDIATRİK VE NÖROLOJİK DEĞERLENDİRME

Elif DİDİNMEZ TAŞKIRDI¹

Nihal OLGAÇ DÜNDAR²

GİRİŞ

Otizm spektrum bozukluğu (OSB), sosyal iletişim ve etkileşimde bozulmayla birlikte sınırlı ve tekrarlayıcı davranışlar, ilgi alanları ve/veya aktivitelerle karakterize, erken başlangıçlı bir nörogelişimsel bozukluktur. Klinik belirtiler hastalar arasında ve çocuğun gelişim süreci boyunca oldukça değişkenlik gösterebilir. Dil gecikmeleri ve alışılmadık sosyal beceriler genellikle 12 ila 24 ay arasında fark edilirken, garip ve tekrarlayıcı davranışlar genellikle yaşamın ikinci yılında belirgin hale gelir.¹ Kapsamlı otizm değerlendirmesi multidisipliner bir ekip tarafından yapılan değerlendirmeleri içerir. Değerlendirme ekibinde birden fazla uzmanın bulunması, teşhis sürecini hem kolaylaştırır hem de kapsamlı bir yönetim planının oluşturulmasına yardımcı olur. Tanı ayrıntılı gelişimsel öykü, klinik değerlendirme ve standart tanı araçlarının kullanımı temelinde konulur. Tanıyı doğrulayan herhangi kesin bir biyobelirteç bulunmamaktadır; tanı, **DSM-5-TR** kriterlerine dayanarak konur ve alternatif tanıların dikkatlice dışlanması gerektiren uzman değerlendirmesiyle kesinleştirilir. Bu süreçte, birinci basamak testler (örneğin, kromozomal mikrodizi analizi, erkekler için Frajl X sendromu DNA testi, odyoloji değerlendirmesi,vb.) yapılmalı ve erken müdahale hizmetleri başlatılmalıdır.^{2,3} Amerikan Pediatri Akademisi, 18. ve 24.aylarda rutin tarama

¹ Uzm. Dr., İzmir Şehir Hastanesi, Çocuk Nörolojisi Kliniği, edidinmez@hotmail.com, ORCID iD: 0000-0002-7614-2844

² Prof. Dr., İzmir Katip Çelebi Üniversitesi Çocuk Nöroloji BD., Sinirbilimleri Uygulama ve Araştırma Merkezi, nodundar@gmail.com, ORCID iD: 0000-0002-5902-3501



olarak işitme değerlendirmesi yapılmalıdır. Gerekli görüldüğünde uygun işitme cihazları sağlanmalıdır.^{72, 73}

Genel popülasyondaki çocuklara kıyasla OSB'li çocuklarda kaba motor becerilerde ve koordinasyonda hafif gecikmeler yaşama olasılığı daha yüksektir ve erken motor gecikmeleri ile sonraki dil ve uyumsal gelişim arasındaki bir ilişki olduğu öne sürülmektedir.^{74, 75} Genel tarama testleri veya uyumsal ölçümler, çocuk nöroloğu veya fizyoterapist tarafından yapılacak resmi bir değerlendirmeden fayda sağlayabilecek motor gecikmeleri gösterebilir.

Görsel olarak dikkatsiz olan, tekrarlayıcı davranışlar sergileyen (örneğin, gözlerini ovuşturma, kısma veya nesneleri aşırı yakından inceleme) ya da göz teması kurmayan çocukların ilk değerlendirmesinde görsel işlev de dikkate alınmalıdır. Azalmış görme keskinliği, bakışı etkileyebilir ve eğitim ortamında özel düzenlemeler gerektirebilir.⁷⁶ Görme bozukluğu olan çocuklar ayrıca tekrarlayıcı motor davranışlar da gösterebilirler.

Duyusal değerlendirme için yaygın olarak kullanılan değerlendirme araçları (Kısa Duyusal Profil gibi), ebeveynlerin çocuklarının koku, tat, görme, işitme ve dokunma duyularına ilişkin algısını ölçmeye yardımcı olur.⁷⁷ Bu tür anketler, duysal rahatsızlık olarak kabul edilen durumları belirlemenin yanı sıra, motor hiperaktivite ve hipoaktiviteyi de duysal arayış veya duysal kaçınma davranışları şeklinde değerlendirebilir. Bu belirtiler, eş zamanlı olarak DEHB varlığına işaret edebilir. Duyusal semptomlar, genellikle daha küçük yaşlarda daha belirgindir ve OSB'nin alt tiplerini tanımlamada yardımcı olabilir.^{78, 79}

KAYNAKLAR

1. Zwaigenbaum L, Bauman ML, Fein D, et al. Early Screening of Autism Spectrum Disorder: Recommendations for Practice and Research. *Pediatrics*. 2015;136 Suppl 1:S41-59.
2. Yochum A. Autism Spectrum/Pervasive Developmental Disorder. *Prim Care*. 2016;43:285-300.
3. Zwaigenbaum L, Bauman ML, Stone WL, et al. Early Identification of Autism Spectrum Disorder: Recommendations for Practice and Research. *Pediatrics*. 2015;136 Suppl 1:S10-40.
4. Pierce K, Carter C, Weinfeld M, et al. Detecting, studying, and treating autism early: the one year well-baby check-up approach. *J Pediatr*. 2011;159:458-65.e1-6.
5. Wieckowski AT, Hamner T, Nanovic S, et al. Early and Repeated Screening Detects Autism Spectrum Disorder. *J Pediatr*. 2021;234:227-35.
6. Shaw KA, Maenner MJ, Bakian AV, et al. Early Identification of Autism Spectrum Disorder Among Children Aged 4 Years Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018. *MMWR Surveill Summ*. 2021;70:1-14.
7. Warren Z, Veenstra VanderWeele J, Stone W, et al. AHRQ Comparative Effectiveness Reviews. *Therapies for Children With Autism Spectrum Disorders*. Rockville (MD): Agency



- for Healthcare Research and Quality (US); 2011.
8. Weitlauf AS, McPheeters ML, Peters B, et al. AHRQ Comparative Effectiveness Reviews. Therapies for Children With Autism Spectrum Disorder: Behavioral Interventions Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014.
9. Hyman SL, Levy SE, Myers SM. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. *Pediatrics*. 2020;145.
10. Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. *Pediatrics*. 2007;120:1183-215.
11. Bhavnani S, Lockwood Estrin G, Arora R, et al. "I was Confused... and Still am" Barriers Impacting the Help-Seeking Pathway for an Autism Diagnosis in Urban North India: A Mixed Methods Study. *J Autism Dev Disord*. 2022;52:1778-88.
12. Malhi P, Shetty AR, Bharti B, Saini L. Parenting a child with autism spectrum disorder: A qualitative study. *Indian J Public Health*. 2022;66:121-7.
13. Lipkin PH, Macias MM. Promoting Optimal Development: Identifying Infants and Young Children With Developmental Disorders Through Developmental Surveillance and Screening. *Pediatrics*. 2020;145.
14. Robins DL, Casagrande K, Barton M, Chen CM, Dumont-Mathieu T, Fein D. Validation of the modified checklist for Autism in toddlers, revised with follow-up (M-CHAT-R/F). *Pediatrics*. 2014;133:37-45.
15. Hine JE, Allin J, Allman A, et al. Increasing Access to Autism Spectrum Disorder Diagnostic Consultation in Rural and Underserved Communities: Streamlined Evaluation Within Primary Care. *J Dev Behav Pediatr*. 2020;41:16-22.
16. McNally Keehn R, Ciccarelli M, Szczepaniak D, Tomlin A, Lock T, Swigonski N. A Statewide Tiered System for Screening and Diagnosis of Autism Spectrum Disorder. *Pediatrics*. 2020;146.
17. Sohl K, Mazurek MO, Brown R. ECHO Autism: Using Technology and Mentorship to Bridge Gaps, Increase Access to Care, and Bring Best Practice Autism Care to Primary Care. *Clin Pediatr (Phila)*. 2017;56:509-11.
18. Dalwai S, Ahmed S, Udani V, et al. Consensus Statement of the Indian Academy of Pediatrics on Evaluation and Management of Autism Spectrum Disorder. *Indian Pediatr*. 2017;54:385-93.
19. Hirvikoski T, Mittendorfer-Rutz E, Boman M, et al. Premature mortality in autism-spectrum disorder. *Br J Psychiatry*. 2016;208:232-8.
20. Kohane IS, McMurphy A, Weber G, et al. The co-morbidity burden of children and young adults with autism spectrum disorders. *PLoS One*. 2012;7:233224.
21. Tye C, Runicles AK, Whitehouse AJO, Alvares GA. Characterizing the Interplay Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative Review. *Front Psychiatry*. 2018;9:751.
22. Vorstman JAS, Parr JR, Moreno-De-Luca D, et al. Autism genetics: opportunities and challenges for clinical translation. *Nat Rev Genet*. 2017;18:362-76.
23. Pan PY, Bölte S, Kaur P, Jamil S, Jonsson U. Neurological disorders in autism: A systematic review-and-meta-analysis. *Autism*. 2021;25:812-30.
24. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism-spectrum disorders: 2013 guideline revisions. *Genet Med*. 2013;15:399-407.
25. Mandy W, Lai MC. Annual Research Review: The role of the environment in the developmental psychopathology of autism spectrum condition. *J Child Psychol Psychiatry*. 2016;57:271-92.
26. Lingen M, Albers L, Borchers M, et al. Obtaining a genetic diagnosis in a child with disability: impact on parental quality of life. *Clin Genet*. 2016;89:258-66.



27. Iglesias A, Anyane-Yeboah K, Wynn J, et al. The usefulness of whole exome sequencing in routine clinical practice. *Genet Med*. 2014;16:922-31.
28. Riggs ER, Wain KE, Riethmaier D, et al. Chromosomal microarray impacts clinical management. *Clin Genet*. 2014;85:147-53.
29. Clinical-utility of genetic and genomic services: a position statement of the American College of Medical Genetics and Genomics. *Genet Med*. 2015;17:505-7.
30. Tammimies K, Marshall CR, Walker S, Kaur G, Thiruvahindrapuram B, Lionel AC. Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. *Jama*. 2015;314:895-903.
31. Alvarez Mora MI, Calvo Escalona R, Puig Navarro O, et al. Comprehensive molecular testing in patients with high functioning autism spectrum disorder. *Mutat Res*. 2016;784:785:46-52.
32. Fernandez BA, Scherer SW. Syndromic autism spectrum disorders: moving from a clinically defined to a molecularly defined approach. *Dialogues Clin Neurosci*. 2017;19:353-71.
33. Volkmar E, Siegel M, Woodbury-Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry*. 2014;53:237-57.
34. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet*. 2010;86:749-64.
35. Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med*. 2010;12:742-5.
36. Muhle RA, Reed HE, Vo LC, et al. Clinical Diagnostic Genetic Testing for Individuals With Developmental Disorders. *J Am Acad Child Adolesc Psychiatry*. 2017;56:910-3.
37. Carter MT, Scherer SW. Autism spectrum disorder in the genetics clinic: a review. *Clin Genet*. 2013;83:399-407.
38. Persico AM, Napolioni V. Autism-genetics. *Behav Brain Res*. 2013;251:95-112.
39. Schönewolf Greulich B, Bisgaard AM, Møller RS, et al. Clinician's guide to genes associated with Rett-like phenotypes-Investigation of a Danish cohort and review of the literature. *Clin Genet*. 2019;95:221-30.
40. McBride KL, Varga EA, Pastore MT, Prior TW, Manickam K, Atkin JF. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. *Autism Res*. 2010;3:137-41.
41. Eriksson MA, Liedén A, Westerlund J, Bremer A, Wincent J, Sahlin E. Rare copy number variants are common in young children with autism spectrum disorder. *Acta Paediatr*. 2015;104:610-8.
42. McGrew SG, Peters BR, Crittendon JA, Veenstra-Vanderweele J. Diagnostic yield-of-chromosomal microarray analysis in an autism primary care practice: which guidelines to implement? *J Autism Dev Disord*. 2012;42:1582-91.
43. Roesser J. Diagnostic yield of genetic testing in children diagnosed with autism spectrum disorders at a regional referral center. *Clin Pediatr (Phila)*. 2011;50:834-43.
44. Tassone F, Choudhary NS, Tassone F, et al. Identification of expanded alleles of the FMR1 Gene in the Childhood Autism Risks-from Genes and Environment (CHARGE) study. *J Autism Dev Disord*. 2013;43:530-9.
45. Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J. De novo gene disruptions in children on the autistic spectrum. *Neuron*. 2012;74:285-99.
46. Krumm N, O'Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism genetics and molecular neuroscience. *Trends Neurosci*. 2014;37:95-105.
47. O'Roak BJ, Vives L, Fu W, et al. Multiplex targeted sequencing identifies recurrently mutated



- genes in autism spectrum disorders. *Science*. 2012;338:1619-22.
48. Filipek PA, Accardo PJ, Ashwal S, et al. Practice-parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. *Neurology*. 2000;55:468-79.
49. Moeschler JB, Shevell M. Comprehensive evaluation of the child with intellectual disability or global developmental delays. *Pediatrics*. 2014;134:e903-18.
50. El Achkar CM, Spence SJ. Clinical characteristics of children and young adults-with-co-occurring autism spectrum disorder and epilepsy. *Epilepsy Behav*. 2015;47:183-90.
51. Ghacibeh GA, Fields C. Interictal epileptiform activity and autism. *Epilepsy Behav*. 2015;47:158-62.
52. Jeste SS, Tuchman R. Autism Spectrum Disorder and Epilepsy: Two Sides of the Same Coin? *J Child Neurol*. 2015;30:1963-71.
53. Jokiranta E, Sourander A, Suominen A, Timonen-Soivio L, Brown AS, Sillanpää M. Epilepsy among children and adolescents with autism spectrum disorders:-a-population-based study. *J Autism Dev Disord*. 2014;44:2547-57.
54. Woolfenden S, Sarkozy V, Ridley G, Coory M, Williams K. A systematic review of two outcomes in autism spectrum disorder epilepsy and mortality. *Dev Med Child Neurol*. 2012;54:306-12.
55. Yasuhara A. Correlation between EEG abnormalities and symptoms of autism spectrum disorder (ASD). *Brain Dev*. 2010;32:791-8.
56. Kagan-Kushnir T, Roberts SW, Snead OC, 3rd. Screening electroencephalograms in autism spectrum disorders: evidence-based guideline. *J Child Neurol*. 2005;20:197-206.
57. Tassinari CA, Rubboli G. Cognition and paroxysmal EEG activities: from a single spike to electrical status epilepticus during sleep. *Epilepsia*. 2006;47 Suppl 2:40-3.
58. Gencpinar P, Dundar NO, Tekgul H. Electrical status epilepticus in sleep (ESES)/continuous spikes and waves during slow sleep (CSWS) syndrome in children: An electroclinical evaluation according to the EEG patterns. *Epilepsy Behav*. 2016;61:107-11.
59. Matricardi S, Verrotti A, Chiarelli F, Cerminara C, Curatolo P. Current advances in childhood absence epilepsy. *Pediatr Neurol*. 2014;50:205-12.
60. Verrotti A, Matricardi S, Rinaldi VE, Prezioso G. Neuropsychological impairment in childhood absence epilepsy: Review of the literature. *J Neurol Sci*. 2015;359:59-66.
61. Zecavati N, Spence SJ. Neurometabolic disorders and dysfunction in autism spectrum-disorders. *Curr Neurol Neurosci Rep*. 2009;9:129-36.
62. Besag FM. Epilepsy in patients with autism: links, risks and treatment challenges. *Neuropsychiatr Dis Treat*. 2018;14:1-10.
63. Frye RE, Sreenivasula S, Adams JB. Traditional and non-traditional treatments for autism spectrum disorder with seizures: an on-line survey. *BMC Pediatr*. 2011;11:37.
64. Garbarino VR, Gilman TL, Daws LC, Gould GG. Extreme enhancement or depletion of serotonin transporter function and serotonin availability in autism spectrum disorder. *Pharmacol Res*. 2019;140:85-99.
65. Hamel E. Serotonin and migraine: biology and clinical implications. *Cephalalgia*. 2007;27:1293-300.
66. Casanova MF. The minicolumnopathy of autism: A link between migraine and gastrointestinal symptoms. *Med Hypotheses*. 2008;70:73-80.
67. Jacobs H, Singhi S, Gladstein J. Medical Comorbidities in Pediatric Headache. *Semin-Pediatr Neurol*. 2016;23:60-7.
68. McGuire K, Fung LK, Hagopian L, et al. Irritability and Problem Behavior in Autism Spectrum Disorder: A Practice Pathway for Pediatric Primary Care. *Pediatrics*. 2016;137 Suppl 2:136-48.



69. Kanne SM, Gerber AJ, Quirnbach LM, Sparrow SS, Cicchetti DV, Saulnier CA. The role of adaptive behavior in autism spectrum disorders: implications for functional outcome. *J Autism Dev Disord.* 2011;41:1007-18.
70. Liss M, Harel B, Fein D, Allen D, Dunn M, Feinstein C. Predictors and correlates of adaptive functioning in children with developmental disorders. *J Autism Dev Disord.* 2001;31:219-30.
71. O'Hare A, Bremner L. Management of developmental speech and language disorders: Part 1. *Arch-Dis Child.* 2016;101:272-7.
72. Bennetto L, Keith JM, Allen PD, Luebke AE, Bennetto L, Keith JM. Children with autism spectrum disorder have reduced otoacoustic emissions at the 1 kHz mid-frequency region. *Autism Res.* 2017;10:337-45.
73. Dawes P, Bishop D. Auditory processing disorder in relation to developmental disorders of language, communication and attention: a review and critique. *Int J Lang Commun Disord.* 2009;44:440-65.
74. Bhat AN, Galloway JC, Landa RJ, et al. Relation between early motor delay and later communication delay in infants at risk for autism. *Infant Behav Dev.* 2012;35:838-46.
75. Provost B, Lopez BR, Heimerl S. A comparison of motor delays in young children: autism spectrum disorder, developmental delay, and developmental concerns. *J Autism Dev Disord.* 2007;37:321-8.
76. Anketell PM, Saunders KJ, Gallagher SM, Bailey C, Little JA. Brief Report: Vision in Children with Autism Spectrum Disorder: What Should Clinicians Expect? *J Autism Dev Disord.* 2015;45:3041-7.
77. Rogers SJ, Hepburn S, Wehner E. Parent reports of sensory symptoms in toddlers with autism and those with other developmental disorders. *J Autism Dev Disord.* 2003;33:631-42.
78. McCormick C, Hepburn S, Young GS, Rogers SJ. Sensory symptoms in-children-with-autism spectrum disorder, other developmental disorders and typical development: A longitudinal study. *Autism.* 2016;20:572-9.
79. Ausderau KK, Furlong M, Sideris J, et al. Sensory subtypes in-children-with-autism spectrum disorder: latent profile transition analysis using a national survey of sensory features. *J Child Psychol Psychiatry.* 2014;55:935-44.

OTİZM OLGULARINA TANISAL YAKLAŞIM: PSİKİYATRİK DEĞERLENDİRME

Özlem ŞİRELİ¹

GİRİŞ

Otizm spektrum bozukluğu (OSB) karşılıklı sosyal ilişki ve iletişim örüntülerinde niteliksel anormallikler, ilgi ve etkinliklerde kısıtlılık, tekrarlayan basma-kalıp davranışlarla karakterize nörogelişimsel bir bozukluktur¹. Epidemiyolojik çalışmalara göre OSB'nin yaygınlık oranı %1-2 olup güncel prevalans çalışmaları görülme sıklığının arttığına işaret etmektedir.^{2,3} OSB'de çoğunlukla belirti ve bulgular yaşamın erken dönemlerinde ortaya çıkmakta ve yaşam boyu devam etmektedir. Erken tanı, tedavi müdahalelerin etkinliği açısından hayati öneme sahiptir.

OSB hem nedensel hem klinik görünüm açısından heterojen bir yapıya sahiptir. OSB'li bireyler bilişsel ve dil gelişiminde kısıtlılık, duygusal ve davranışsal sorunlar, uyku ve yeme bozuklukları; dikkat eksikliği, anksiyete, depresyon, kendine zarar verme, saldırganlık gibi eşlik eden psikiyatrik ve diğer tıbbi hastalıklar olmak üzere birçok alanda sorun yaşayabilirler.⁴ Tanısal değerlendirmede bir çocuk ve ergen psikiyatri uzmanının yanı sıra bilişsel ve dil gelişimin ayrıntılı değerlendirilmesi için klinik psikolog, diğer tıbbi değerlendirmeler için ilgili pediatrist olmak üzere multidisipliner bir yaklaşım gereklidir.⁴

OSB'de tanısal değerlendirme süreci, psikiyatrik muayene ve psikometrik değerlendirmeler, gerekli diğer tıbbi incelemeleri kapsamaktadır. Tıbbi incelemeler, ayrıntılı gelişimsel ve tıbbi öykü, dismorfi, konjenital anomaliler açısından fizik muayene, motor beceriler, işitme ve görme muayenesi gibi temel tıbbi de-

¹ Doç. Dr., Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., ozlemsireli@cumhuriyet.edu.tr, ORCID iD: 0000-0002-5549-4154



KAYNAKLAR

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association Publishing, 2013.
2. Elsabbagh M, Divan G, Koh YJ, et al. Global prevalence of autism and other pervasive developmental disorders. *Autism Res.* 2012;5:160-79.
3. Maenner MJ, Shaw KA, Bakian AV, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018. *MMWR Surveill Summ.* 2021;70:1-16.
4. Baird G. Autism Spectrum Disorder: The NICE guidelines. *Cutting Edge Psychiatry in Practice.* 2014;4:87-97.
5. Charman T, Gotham K. Measurement Issues: Screening and diagnostic instruments for autism spectrum disorders—lessons from research and practise. *Child Adolesc Ment Health.* 2013;18:52-63.
6. Rutter ML. Progress in understanding autism: 2007–2010. *J Autism Dev Disord.* 2011;41:395-404.
7. Mukaddes NM. Otizm Spektrum Bozuklukları. İstanbul: Nobel Tıp Kitapevleri, 2013.
8. Molloy CA, Murray DS, Akers R, Mitchell T, Manning-Courtney P. Use of the Autism Diagnostic Observation Schedule (ADOS) in a clinical setting. *Autism.* 2011;15:143-162.
9. Akshoomoff N, Corsello C, Schmidt H. The role of the autism diagnostic observation schedule in the assessment of autism spectrum disorders in school and community settings. *Calif School Psychol.* 2006;11:7-19.
10. Ashwood KL, Buitelaar J, Murphy D, Spooren W, Charman T. European clinical network: autism spectrum disorder assessments and patient characterisation. *Eur Child Adolesc Psychiatry.* 2015;24:985-995.
11. Lord C, Rutter M, Dilavore P, Risi S. The autism diagnostic observation schedule: Manual. Los Angeles: Western Psychological Corporation, 1999.
12. Becker MM, Wagner MB, Bosa CA, et al. Translation and validation of Autism Diagnostic Interview-Revised (ADI-R) for autism diagnosis in Brazil. *Arq Neuropsiquiatr.* 2012;70: 185-90.
13. Öner Ö. Otizm Spektrum Bozukluğunda Tanı Süreçleri. Tohum Otizm Vakfı Değerlendirme ve Gelişim Raporları III, 2020.
14. Wing L, Leekam S, Libby S, et al. Diagnostic interview for social and communication disorders: Background, inter-rater reliability and clinical use. *J Child Psychol Psychiatry.* 2002;43:307-32.
15. Skuse D, Warrington R, Bishop D, et al. The developmental, dimensional and diagnostic interview (3di): A novel computerized assessment for autism spectrum disorders. *J Am Acad Child Adolesc Psychiatry.* 2004;43:548-558.
16. Robins DI, Fein D, Barton MI, et al. The modified check-list for autism in toddlers: An initial study investigating the early detection of autism and pervasive developmental disorders. *J Autism Dev Disord.* 2001;31:131-144.
17. Kara B, Mukaddes NM, Altinkaya I, Güntepe D, Gökçay G, Özmen M. Using the modified checklist for autism in toddlers in a well-child clinic in Turkey: Adapting the screening method based on culture and setting. *Autism.* 2014;18:331-338.
18. Schopler E, Reichler RJ, DeVellis RE, Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). *J Autism Dev Disord.* 1980;10:91-103.
19. Hergüner S, Özbaran B. Çocukluk Otizmini Derecelendirme Ölçeği. Çocuk ve Ergen Psikiyatrisinde Ölçütler ve Ölçekler: Yaygın Gelişimsel Bozukluklar Yıkıcı Davranım Bozuklukları, 2010: 37-40.



20. İncekaş Gassaloğlu S, Baykara B, Avcil S, Demiral Y. Validity and reliability analysis of Turkish version of Childhood Autism Rating Scale. *Türk Psikiyatri Derg.* 2016;27:266-274.
21. Krug DA, Arick J, Almond P. Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior. *J Child Psychol Psychiatry.* 1980;21:221-9.
22. Özdemir O, Diken İH, Diken Ö, Şekercioğlu G. Otizm Davranış Kontrol Listesi modifiye edilmiş Türkçe Versiyonu'nun geçerlik ve güvenilirlik çalışması: Pilot uygulama sonuçları *International Journal of Early Childhood Special Education.* 2013;5:168-186.
23. Rutter M, Bailey A, Lord C. The Social Communication Questionnaire (SCQ). Second printing. Western Psychological Services, 2007.
24. Avcil S, Baykara B, Baydur H, Münir KM, Emiroğlu NI. The validity and reliability of the Social Communication Questionnaire-Turkish form in autistics aged 4-18 years. *Türk Psikiyatri Derg.* 2015;26:56-64.
25. Gilliam JE. Gilliam autism rating scale: Second edition. Austin, TX: PRO-ED, 2005.
26. Diken İH, Ardic A, Diken Ö, Gilliam JE. Gilliam otistik bozukluk derecelendirme ölçeği-2 Türkçe versiyonu'nun (GOBDÖ-2-TV) geçerlik ve güvenilirliğinin araştırılması: Türkiye standardizasyon çalışması. *Eğitim ve Bilim,* 2012;37:318-328.
27. Wechsler D. Wechsler intelligence scale for children-Fourth Edition (WISC-IV). San Antonio, TX: The Psychological Corporation, 2003.
28. Oktem F, Erden G, Gencöz T, Sezgin N, Uluc S. Wechsler Çocuklar için Zeka Ölçeği-IV (WÇ-ZÖ-IV) Uygulama ve Puanlama El Kitabı Türkçe Sürümü. Ankara: Türk Psikologlar Derneği Yayınları, 2016.
29. Savaşır I, Sezgin N, Erol N. Ankara Gelişim Tarama Envanteri el kitabı [Ankara Development Screening Inventory manual]. Ankara Üniversitesi Tıp Fakültesi, 1994.
30. Frankenburg WK, Dodds J, Archer P, Shapiro H, Bresnick B. The Denver II: A major revision and restandardization of the Denver Developmental Screening Test. *Pediatrics.* 1992;89:91-7.
31. Yalaz K, Anlar B, Bayoğlu B. Denver II gelişimsel tarama testi Türkiye standardizasyonu. Ankara: Gelişimsel Çocuk Nörolojisi Derneği, 2010:11-26.
32. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales (Survey Form). Circle Pines, Minn: American Guidance Service, 1984.
33. Alpas A, Akçakın M. Vineland Uyum Davranış Ölçeği - Araştırma Formu'nun doğumdan 47 aya kadar olan Türk bebekleri için uyarlama, geçerlik ve güvenilirlik çalışması. *Türk Psikol Derg.* 2003;18:57-71.
34. Bayley N. Bayley scales of infant development. II Manual. San Antonio: Harcourt Brace, 1993.
35. Bayley N. Bayley Scales of Infant and Toddler Development-Third Edition. San Antonio, TX, USA: Harcourt Assessment, 2006.
36. Özelli LB. Bayley bebekler için zihinsel ve motor ölçeği ile bir ön çalışma. *Türk Psikol Derg.* 1978;1:3-8.
37. Katz J, Önen F, Demir N ve ark. Peabody resim kelime testi Form B. *Hacettepe Bulletin of Social Sciences and Humanities.* 1974;6:129-140.
38. Norbury CF, Paul R. Disorders of speech, language, and communication. In: Thapar A, Pine DS, Leckman JF, Scott S, Snowling MJ, Taylor E (eds). *Rutter's Child and Adolescent Psychiatry,* 2015:683-701.
39. Jackson CT, Fein D, Wolf J, et al. Responses and sustained interactions in children with mental retardation and autism. *J Autism Dev Disord.* 2003;33:115-121.
40. Morrison J. DSM-5 Made Easy the Clinician's Guide to Diagnosis. In: Şahin M (ed). Nobel Akademik Yayıncılık Eğitim ve Danışmanlık, 2016.
41. Akçakın M. Otizm El Kitabı. Ankara: Ankara Üniversitesi Basımevi, 2001.
42. Asarnow JR, Tompson MC, Goldstein MJ. Childhood-onset schizophrenia: A followup study. *Schizophren Bull.* 1994;20:599-617.



43. Driver DI, Thomas S, Gogtay N, Rapoport JL. Childhood-onset schizophrenia and early-onset schizophrenia Spectrum disorders. *Child Adolesc Psychiatr Clin N Am.* 2020;29:71-90.
44. Lord C, Bailey A. Autism Spectrum Disorders. In: Rutter M, Taylor E (eds). *Child and Adolescent Psychiatry.* London: Blackwell Science Ltd, 2002: 636-655.
45. Dow SP, Sonies BC, Scheib D, Moss SE, Leonard HL. Practical guidelines for the assessment and treatment of selective mutism. *J Am Acad Child Adolesc Psychiatry.* 1995;34:836-846.
46. Rutter M, Andersen-Wood L, Beckett C, et al. Quasi-autistic patterns following severe early global privation. *J Child Psychol Psychiatry Allied Discip.* 1999;40:537-549.
47. Nelson C A, Bos K, Gunnar MR, Sonuga-Barke EJ. The neurobiological toll of early human deprivation. In R. McCall (ed), *Children without permanent parental care: Research, practice, and policy.* Monogr Soc Res Child Dev. 2011;76:127-146.
48. Mannion A, Leader G. Comorbidity in autism spectrum disorder: A literature review. *Res Autism Spectr Disord.* 2013;7:1595-1616.
49. Khachadourian V, Mahjani B, Sandin S, et al. Comorbidities in autism spectrum disorder and their etiologies. *Transl Psychiatry.* 2023;13:71.
50. Bellardinelli C, Raza M, Taneli T. Comorbid behavioral problems and psychiatric disorders in autism spectrum disorders. *J Childhood Dev Dis.* 2016;2:11.
51. DuBois D, Ameis SH, Lai MC, Casanova MF, Desarkar P. Interoception in autism spectrum disorder: a review. *Int J Dev Neurosci.* 2016;52:104-111.
52. Rzepecka H, McKenzie K, McClure I, Murphy S. Sleep, anxiety and challenging behaviour in children with intellectual disability and/or autism spectrum disorder. *Res Dev Disabil.* 2011;32:2758-2766.
53. Mannion A, Leader G, Healy O. An investigation of comorbid psychological disorders, sleep problems, gastrointestinal symptoms and epilepsy in children and adolescents with autism spectrum disorder. *Res Autism Spectr Disord.* 2013;7:35-42.
54. Patzold LM, Richdale AL, Tonge BJ. An investigation in to sleep characteristics of children with autism and Asperger's disorder. *J Paediatr Child Health.* 1998;34:528-533.
55. Goldman SE, McGrew S, Johnson KP, Richdale AL, Clemons T, Malow BA. Sleep is associated with problem behaviors in children and adolescents with Autism Spectrum Disorders. *Res Autism Spectr Disord.* 2011;5:1223-1229.
56. Schreck KA, Williams K, Smith AF. A comparison of eating behaviors between children with and without autism. *J Autism Dev Disord.* 2004;34:433-438.
57. Hubbard KL, Anderson SE, Curtin C, Must A, Bandini LG. A comparison of food refusal related to characteristics of food in children with autism spectrum disorder and typically developing children. *J Acad Nutr Diet.* 2014;114:1981-1987.
58. Mayes SD, Zickgraf H. Atypical eating behaviors in children and adolescents with autism, ADHD, other disorders, and typical development. *Res Autism Spectr Disord.* 2019;64:76-83.
59. Emond A, Emmett P, Steer C, Golding J. Feeding symptoms, dietary patterns, and growth in young children with autism spectrum disorders. *Pediatrics.* 2010;126:337-342.
60. Kerwin ME, Eicher PS, Gelsinger J. Parental report of eating problems and gastrointestinal symptoms in children with pervasive developmental disorders. *Children's Health Car.* 2005;34:217-234.
61. Fombonne E. Epidemiology of pervasive developmental disorders. *Pediatr Res.* 2009;65: 591-598.
62. Nazeer A, Ghaziuddin M. Autism spectrum disorders: Clinical features and diagnosis. *Pediatric Clinics.* 2012;59:19-25.
63. Tonnsen BL, Boan AD, Bradley CC, Charles J, Cohen A, Carpenter LA. Prevalence of autism spectrum disorders among children with intellectual disability. *Am J Intellect Dev Disabil.* 2016;121:487-500.



64. Yoshida Y, Uchiyama T. The clinical necessity for assessing attention deficit/ hyperactivity disorder (AD/HD) symptoms in children with high-functioning pervasive developmental disorder (PDD). *Eur Child Adolesc Psychiatry*. 2004;13:307-314.
65. Goldstein S, Schwabach AJ. The comorbidity of pervasive developmental disorder and attention deficit hyperactivity disorder: Results of a retrospective chart review. *J Autism Dev Disord*. 2004;34:329-339.
66. Sinzig J, Walter D, Doepfner M. Attention deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder: symptom or syndrome? *J Atten Disord*. 2009; 13:117-126.
67. Hours C, Recasens C, Baleyte JM. ASD and ADHD comorbidity: What are we talking about? *Front Psychiatry*. 2022;13:837424.
68. Lainhart JE, Folstein SE. Affective disorders in people with autism: A review of published cases. *J Autism Dev Disord*. 1994;24:587- 601.
69. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. *J Am Acad Child Adolesc Psychiatry*. 2008;47:921-929.
70. Skinner SR, Ng C, McDonald A, Walters T. A patient with autism and severe depression: Medical and ethical challenges for an adolescent medicine unit. *Med J Aust*. 2005;183: 422- 424.
71. Magnuson KM, Constantino JN. Characterization of depression in children with autism spectrum disorders. *J Dev Behav Pediatr*. 2011;32:332-340.
72. White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. *Clin Psych Rev*. 2009;29:216-29.
73. Lever AG, Geurts HM. Psychiatric co-occurring symptoms and disorders in young, middle-aged, and older adults with autism spectrum disorder. *J Autism Dev Disord*. 2016; 46:1916-1930.
74. Costello EJ, Egger HL, Angold A. The developmental epidemiology of anxiety disorders: phenomenology, prevalence, and comorbidity. *Child Adolesc Psychiatr Clin N Am*. 2005;14:631-648.
75. Postorino V, Kerns CM, Vivanti G, Bradshaw J, Siracusano M, Mazzone L. Anxiety disorders and obsessive-compulsive disorder in individuals with autism spectrum disorder. *Curr Psychiatry Rep*. 2017;19:1-8.
76. van Steensel FJ, Heeman EJ. Anxiety levels in children with autism spectrum disorder: A meta-analysis. *J Child Fam Stud*. 2017; 26: 1753-1767.
77. Magiati I, Ong C, Lim XY, et al. Anxiety symptoms in young people with autism spectrum disorder attending special schools: associations with gender, adaptive functioning and autism symptomatology. *Autism*. 2016;20:306-320.
78. Cadman T, Spain D, Johnston P, et al. Obsessive-compulsive disorder in adults with high-functioning autism spectrum disorder: What does self-report with the OCI-R tell us? *Autism Res*. 2015;8:477-485.
79. Paula-Pérez I. Differential diagnosis between obsessive compulsive disorder and restrictive and repetitive behavioural patterns, activities and interests in autism spectrum disorder. *Rev Psiquiatr Salud Ment*. 2013;6:178-186.
80. Rumball F, Happe F, Grey N. Experience of trauma and PTSD symptoms in autistic adults: risk of PTSD development following DSM-5 and Non-DSM-5 traumatic life events. *Autism Res*. 2020;13:2122-2132.
81. Rumball F. A systematic review of the assessment and treatment of posttraumatic stress disorder in individuals with autism spectrum disorders. *Rev J Autism Dev Disord*. 2019;6:294-324.
82. Reuben KE, Stanzione CM, Singleton JL. Interpersonal trauma and posttraumatic stress in autistic adults. *Autism Adulthood*. 2021;3:247-256.



83. Li ST, Chien WC, Chung CH, Tzeng NS. Increased risk of acute stress disorder and post-traumatic stress disorder in children and adolescents with autism spectrum disorder: A nation-wide cohort study in Taiwan. *Front Psychiatry*. 2024;15:1329836.
84. Leyfer O, Folstein S, Bacalman S, et al. Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders. *J Autism Dev Disord*. 2006;36:849-861.
85. Lanphear NE. Autism diagnosis: The local context matters. *J Dev Behav Pediatr*. 2017;38:663-664.
86. Vasconcelos-Moreno MP, Prates-Baldez D, Santos-Terra J, et al. Clinical interplay between autism spectrum disorder and bipolar disorder: A narrative review. *Trends Psychiatr Psy*. 2025;47:1-9.
87. Joshi G, Biederman J, Petty C, et al. Examining the comorbidity of bipolar disorder and autism spectrum disorders: A large controlled analysis of phenotypic and familial correlates in a referred population of youth with bipolar i disorder with and without autism spectrum disorders. *J Clin Psychiatry*. 2013;74:578-586.
88. Sapmaz D, Baykal S, Akbaş S. The clinical features of comorbid pediatric bipolar disorder in children with autism spectrum disorder. *J Autism Dev Disord*. 2018;48:2800-2808.
89. Jutla A, Foss-Feig J, Veenstra-VanderWeele J. Autism spectrum disorder and schizophrenia: An updated conceptual review. *Autism Research*. 2022;15:384-412.
90. Mouridsen SE, Rich B, Isager T. Psychiatric disorders in adults diagnosed as children with atypical autism. A case control study. *J Neural Transm*. 2008;115:135-138.
91. Hommer RE, Swedo SE. Schizophrenia and autism—related disorders. *Schizophrenia Bulletin*. 2015;41:313-314.
92. Barlati S, Deste G, Ariu C, Vita A. Autism spectrum disorder and schizophrenia: Do they overlap. *Int J Emerg Ment Health Hum Resil*. 2016;18:760-763.
93. Pan PY, Bölte S, Kaur P, Jamil S, Jonsson U. Neurological disorders in autism: A systematic review and meta-analysis. *Autism*. 2020; 25:812-830.
94. Pacheva I, Ivanov I, Yordanova R, et al. Epilepsy in children with autistic spectrum disorder. *Children*. 2019;6:1-11.
95. Amiet C, Gourfinkel-An I, Bouzamondo A, et al. Epilepsy in autism is associated with intellectual disability and gender: Evidence from a meta-analysis. *Biological Psychiatry*. 2008;64:577-582.
96. Steffenburg S, Steffenburg U, Gillberg C. Autism spectrum disorders in children with active epilepsy and learning disability: Comorbidity, pre and perinatal background, and seizure characteristics. *Dev Med Child Neurol*. 2003;45:724-730.
97. Matson JL, Neal D. Seizures and epilepsy and their relationship to autism spectrum disorders. *Res Autism Spectr Disord*. 2009;3:999-1005.
98. Al-Beltagi M. Autism medical comorbidities. *World J Clin Pediatr*. 2021;10:15-28.
99. Devitt NM, Gallagher L, Reilly RB. Autism spectrum disorder (ASD) and Fragile X syndrome (FXS): Two overlapping disorders reviewed through electroencephalography-what can be interpreted from the available information? *Brain Sci*. 2015;5:92-117.
100. Oxelgren UW, Myrelið Á, Annerén G, et al. Prevalence of autism and attention-deficit-hyperactivity disorder in Down syndrome: A population-based study. *Dev Med Child Neurol*. 2017;59:276-283.
101. Mitchell R, Barton S, Harvey AS, Williams K. Risk factors for the development of autism spectrum disorder in children with tuberous sclerosis complex: Protocol for a systematic review. *Syst Rev*. 2017;6:49.
102. Genovese A, Butler MG. Clinical assessment, genetics, and treatment approaches in autism spectrum disorder (ASD). *Int J Mol Sci*. 2020;21:4726.



103. Schiff M, Benoist JF, Aïssaoui S, et al. Should metabolic diseases be systematically screened in nonsyndromic autism spectrum disorders? PLoS ONE. 2011;6:1-4.
104. Asato MR, Goldstein AC, Schiff M. Autism and inborn errors of metabolism: How much is enough? Dev. Med. Child Neurol. 2015;57:788-789.
105. Žigman T, Petković Ramadža D, Šimić G, Barić I. Inborn errors of metabolism associated with autism spectrum disorders: Approaches to intervention. Front Neurosci. 2021;15:1-11.
106. Xu G, Snetselaar LG, Jing J, Liu B, Strathearn L, Bao W. Association of food allergy and other allergic conditions with autism spectrum disorder in children. JAMA Netw Open. 2018;1:1-9.
107. Wang LW, Tancredi DJ, Thomas DW. The prevalence of gastrointestinal problems in children across the United States with autism spectrum disorders from families with multiple affected members. J Dev Behav Pediatr. 2011;32:351-360.
108. Mazurek MO, Vasa RA, Kalb LG, et al. Anxiety, sensory over-responsivity, and gastrointestinal problems in children with autism spectrum disorders. J Abnorm Child Psychol. 2013;41:165-176.
109. Leekam SR, Nieto C, Libby SJ, Wing L, Gould J. Describing the sensory abnormalities of children and adults with autism. J Autism Dev Disord. 2007;37:894-910.
110. Do B, Lynch P, Macris EM, et al. Systematic review and meta-analysis of the association of Autism Spectrum Disorder in visually or hearing impaired children. Ophthalmic Physiol Opt. 2017;37:212-224.
111. Perna J, Bellato A, Ganapathy PS, et al. Association between Autism Spectrum Disorder (ASD) and vision problems. A systematic review and meta-analysis. Mol Psychiatry. 2023;28:5011-5023.

OTİZM OLGULARINDA TEMEL LABORATUVAR TESTLERİ

Turgay ÇOKYAMAN ¹

GİRİŞ

Otizm, kendi anlamına gelen İngilizce "autism" kelimesinin çevirisidir. Otizmin karakteristik davranışsal özellikleri bilim insanları tarafından ilk kez 1943'te tanımlanmıştır.¹ Ancak Ruhsal Bozuklukların Tanısal ve İstatistiksel El Kitabı-III (DSM-III)'te ayrı bir bozukluk olarak tanımlanması 1980'i bulmuştur.² En son 2013'te DSM-V'de "gelişimsel bozukluk spektrumu" terimi otizm spektrum bozukluğuna (OSB) değiştirildiğinde yeni tanı kriterleri önerilmiştir.³ Günümüzde de adlandırma, tanı kriterleri ve olası etiyolojik mekanizmalar hakkında görüşler birtakım değişikliklere uğrayarak devam etmektedir.

OSB sosyal ve iletişim bozuklukları, dar ilgi alanları, basmakalıp ve tekrarlayıcı davranışlarla karakterize gelişimsel nöropsikiyatrik bir bozukluktur. OSB'nin yaygınlığı yalnızca Amerika Birleşik Devletleri'nde değil, aynı zamanda tüm dünyada da artmaktadır. Dolayısıyla OSB, tüm dünyada önemli bir halk sağlığı sorunu endişesi haline gelmiştir. OSB'nin etiyolojisi oldukça karmaşıktır ve çevresel, genetik ve birtakım nörolojik faktörler suçlanmaktadır.⁴ OSB, sinir sisteminin gelişimsel bozukluklarının yanı sıra nörodejeneratif hastalıklarında da görülebilmektedir.

OSB konusunda farkındalığın artması ve toplumda daha fazla tarama testinin yapılması bu hastalığın görülme sıklığının arttığına dair görüşlerin doğmasına neden olmuştur. Ancak son yıllarda yapılan çalışmalar öncekilerle kıyaslandığında toplumdaki OSB sıklığının arttığına işaret etmektedir ve özellikle

¹ Doç. Dr., Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi, Çocuk Nörolojisi BD., dtrturgay@comu.edu.tr, ORCID iD: 0000-0002-7108-6839



tanısı, önlenmesi veya tedavisinde yararlı olabilecek potansiyel biyobelirteçler olarak referans seviyelerinin hala netlik kazanmadığı görülmektedir.⁵⁷

Diğer yandan bazı araştırmalarda OSB ve çölyak hastalığı arasında zayıfta olsa bir birliktelikten bahsedilmektedir. Ancak glutenin otizm semptomlarını ve yaşam kalitesini kötüleştirmede olumsuz bir etkiye sahip olmadığı gösterilmiştir. Glutenin OSB üzerinde olası olumsuz etkilerini göstermeye çalışan araştırmaların deneysel tasarım ve uygulamaları ve de sonuçları oldukça heterojendir. Dolayısıyla bu konuda hala genel bir yorum yapılması çok mümkün değildir. Diğer taraftan gluten kısıtlama diyetleri ebeveynlerinde desteği ile OSB'li çocuklara yaygın olarak uygulanmaktadır. Bu yönü ile bakıldığında glutensiz diyetin bu yüksek kabul görme oranı daha dikkatli ve titiz araştırmaları hak etmektedir.⁵⁸

Günümüzde hızla çoğalan sosyal medya araçlarında bilimsel desteği olmayan vurgulu iddialar otizmin tedavi edilebilir bir nedenini bulma umuduyla birçok ebeveyni çeşitli laboratuvar testlerini yapmaya yönlendirmektedirler. Çölyak antikorları ve glutensiz diyet, immünolojik veya nörokimyasal anormallikler, vitamin seviyeleri gibi mikro besinler, saçtaki eser elementler, bağırsak geçirgenliği, dışkı analizi veya fekal transfer, idrar peptitleri gibi klinik testlerin yapılmasını destekleyen güçlü ve genelleşmiş kanıtlar yoktur.^{59,60}

KAYNAKLAR

1. Blacher J, Christensen L. Sowing the seeds of the autism field: Leo Kanner (1943). *Intellect Dev Disabil.* 2011;49(3):172-191. doi:10.1352/1934-9556-49.3.172.
2. Lin X, Wang G, Shen S, Zhan J. Advances in the Diagnosis and Treatment of Autism Spectrum Disorders in Children. *Altern Ther Health Med.* 2024;30(3):170-175.
3. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*; American Psychiatric Association: Washington, DC, USA, 2013.
4. Hirota T, King BH. Autism Spectrum Disorder: A Review. *JAMA.* 2023;329(2):157-168. doi:10.1001/jama.2022.23661.
5. Salari N, Rasoulpoor S, Rasoulpoor S, Shohaimi S, Jafarpour S, Abdoli N, et al. The global prevalence of autism spectrum disorder: a comprehensive systematic review and meta-analysis. *Ital J Pediatr.* 2022 Jul 8;48(1):112. doi: 10.1186/s13052-022-01310-w.
6. Talantseva OI, Romanova RS, Shurdova EM, Dolgorukova TA, Sologub PS, Titova OS, et al. The global prevalence of autism spectrum disorder: A three-level meta-analysis. *Front Psychiatry.* 2023 Feb 9;14:1071181. doi: 10.3389/fpsyt.2023.1071181.
7. Issac A, Halemani K, Shetty AP, Thimmappa L, Vr V, Kiranmayi K, et al. The global prevalence of autism spectrum disorder in children: a systematic review and meta-analysis. *Osong Public Health Res Perspect.* 2025 Feb 10. doi: 10.24171/j.phrp.2024.0286.
8. Sacco R, Camilleri N, Eberhardt J, Umla-Runge K, Newbury-Birch D. The Prevalence of Autism Spectrum Disorder in Europe (In Carotenuto M, editor), *Autism Spectrum Disorders-Recent Advances and New Perspectives* InTech-Open Access Publisher. 2022 doi: 10.5772/intechopen.108123.



9. Qin L, Wang H, Ning W, Cui M, Wang Q. New advances in the diagnosis and treatment of autism spectrum disorders. *Eur J Med Res*. 2024;29(1):322. Published 2024 Jun 10. doi:10.1186/s40001-024-01916-2.
10. Lin X, Wang G, Shen S, Zhan J. Advances in the Diagnosis and Treatment of Autism Spectrum Disorders in Children. *Altern Ther Health Med*. 2024 Mar;30(3):170-175.
11. Ornoy A, Weinstein-Fudim L, Ergaz Z. Genetic Syndromes, Maternal Diseases and Antenatal Factors Associated with Autism Spectrum Disorders (ASD). *Front Neurosci*. 2016 Jul 6;10:316. doi:10.3389/fnins.2016.00316.
12. Wisniewiecka-Kowalik B, Nowakowska BA. Genetics and epigenetics of autism spectrum disorder-current evidence in the field. *J Appl Genet*. 2019 Feb;60(1):37-47. doi: 10.1007/s13353-018-00480-w.
13. Bourgeron T. Current knowledge on the genetics of autism and propositions for future research. *C R Biol*. 2016 Jul-Aug;339(7-8):300-7. doi: 10.1016/j.crvi.2016.05.004.
14. Baumer N, Spence SJ. Evaluation and Management of the Child With Autism Spectrum Disorder. *Continuum (Minneapolis, Minn)*. 2018 Feb;24(1, Child Neurology):248-275. doi: 10.1212/CON.0000000000000578.
15. Beers AN, McBoyle M, Kakande E, Dar Santos RC, Kozak FK. Autism and peripheral hearing loss: a systematic review. *Int J Pediatr Otorhinolaryngol*. 2014 Jan;78(1):96-101. doi: 10.1016/j.ijporl.2013.10.063.
16. Do B, Lynch P, Macris EM, Smyth B, Stavrinakis S, Quinn S, et al. Systematic review and meta-analysis of the association of Autism Spectrum Disorder in visually or hearing impaired children. *Ophthalmic Physiol Opt*. 2017 Mar;37(2):212-224. doi: 10.1111/opo.12350.
17. Danesh AA, Howery S, Aazh H, Kaf W, Eshraghi AA. Hyperacusis in Autism Spectrum Disorders. *Audiol Res*. 2021 Oct 14;11(4):547-556. doi: 10.3390/audiolres11040049.
18. Stevenson M, Tedone E. Assessment of Autism Spectrum Disorders in Children with Visual Impairment and Blindness: A Scoping Review. *J Autism Dev Disord*. 2024 Mar 28. doi: 10.1007/s10803-024-06300-x.
19. Pili R, Zolo B, Farris P, Penna V, Valinotti S, Carrogu GP, et al. Autism and Visual impairment: A First Approach to a Complex Relationship. *Clin Pract Epidemiol Ment Health*. 2021 Dec 22;17:212-216. doi: 10.2174/1745017902117010212.
20. Mann A, Aghababae A, Kalitsi J, Martins D, Paloyelis Y, Kapoor RR. Neurodevelopmental impairments in children with septo-optic dysplasia spectrum conditions: a systematic review. *Mol Autism*. 2023 Jul 25;14(1):26. doi: 10.1186/s13229-023-00559-0.
21. Molinaro A, Micheletti S, Rossi A, Gitti F, Galli J, Merabet LB, et al. Autistic-Like Features in Visually Impaired Children: A Review of Literature and Directions for Future Research. *Brain Sci*. 2020 Aug 1;10(8):507. doi: 10.3390/brainsci10080507.
22. Hyman SL, Levy SE, Myers SM; Council on Children with Disabilities, Section on Developmental and Behavioral Pediatrics. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. *Pediatrics*. 2020 Jan;145(1):e20193447. doi: 10.1542/peds.2019-3447.
23. Almohmadi NH. Brain-gut-brain axis, nutrition, and autism spectrum disorders: a review. *Transl Pediatr*. 2024 Sep 30;13(9):1652-1670. doi: 10.21037/tp-24-182.
24. Rossignol DA, Frye RE. The Effectiveness of Cobalamin (B12) Treatment for Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. *J Pers Med*. 2021 Aug 11;11(8):784. doi: 10.3390/jpm11080784.
25. Vasconcelos C, Perry IS, Gottfried C, Riesgo R, Castro K. Folic acid and autism: updated evidences. *Nutr Neurosci*. 2025 Mar;28(3):273-307. doi: 10.1080/1028415X.2024.2367855.
26. Pascual-Morena C, Caverio-Redondo I, Reina-Gutiérrez S, Saz-Lara A, López-Gil JF, Martínez-Vizcaíno V. Prevalence of Neuropsychiatric Disorders in Duchenne and Becker Muscular Dystrophies: A Systematic Review and Meta-analysis. *Arch Phys Med Rehabil*. 2022;103(12):2444-2453. doi:10.1016/j.apmr.2022.05.015.



27. Lewis S, Woroch A, Hatch MK, Lozano R. Autosomal Recessive Limb-Girdle Muscular Dystrophy-3: A Case Report of a Patient with Autism Spectrum Disorder. *Genes (Basel)*. 2023;14(8):1587. doi:10.3390/genes14081587.
28. Kutluk G, Kadem N, Bektas O, Eroglu HN. A Rare Cause of Autism Spectrum Disorder: Megaconial Muscular Dystrophy. *Ann Indian Acad Neurol*. 2020;23(5):694-696. doi:10.4103/aian.AIAN_98_19.
29. Panda PK, Shikha D, Sharawat IK. Association of Autism Spectrum Disorder with Pre-symptomatic Duchenne Muscular Dystrophy: Isolated Elevation of Transaminases as a Diagnostic Clue. *Ann Indian Acad Neurol*. 2021;24(4):603-604. doi:10.4103/aian.AIAN_900_20.
30. El-Ansary A, Chirumbolo S, Bhat RS, Dadar M, Ibrahim EM, Björklund G. The Role of Lipidomics in Autism Spectrum Disorder. *Mol Diagn Ther*. 2020 Feb;24(1):31-48. doi: 10.1007/s40291-019-00430-0.
31. Qasem H, Al-Ayadhi L, Björklund G, Chirumbolo S, El-Ansary A. Impaired lipid metabolism markers to assess the risk of neuroinflammation in autism spectrum disorder. *Metab Brain Dis*. 2018 Aug;33(4):1141-1153. doi: 10.1007/s11011-018-0206-6.
32. Fields VL, Soke GN, Reynolds A, Tian LH, Wiggins L, Maenner M, et al. Pica, Autism, and Other Disabilities. *Pediatrics*. 2021 Feb;147(2):e20200462. doi: 10.1542/peds.2020-0462.
33. Schaefer GB, Mendelsohn NJ; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. *Genet Med*. 2008 Apr;10(4):301-5. doi: 10.1097/GIM.0b013e31816b5cc9. Erratum in: *Genet Med*. 2008 Jun;10(6):464.
34. de la Torre-Ubieta L, Won H, Stein JL, Geschwind DH. Advancing the understanding of autism disease mechanisms through genetics. *Nat Med*. 2016 Apr;22(4):345-61. doi: 10.1038/nm.4071.
35. Martucci M, Novelli M, Scarselli V, Di Palma F, Fiorelli F, Bernardini L, et al. Array-comparative genomic hybridization analysis in a cohort of 130 children with Autism Spectrum Disorders: A single Center Italian Study. *Clin Ter*. 2023 Nov-Dec;174(6):509-517. doi: 10.7417/CT.2023.5018.
36. Granata P, Zito A, Cocciadiferro D, Novelli A, Pessina C, Mazza T, et al. Unveiling genetic insights: Array-CGH and WES discoveries in a cohort of 122 children with essential autism spectrum disorder. *BMC Genomics*. 2024 Dec 10;25(1):1186. doi: 10.1186/s12864-024-11077-5.
37. Gogate A, Kaur K, Khalil R, Bashtawi M, Morris MA, Goodspeed K, et al. The genetic landscape of autism spectrum disorder in an ancestrally diverse cohort. *NPJ Genom Med*. 2024 Dec 4;9(1):62. doi: 10.1038/s41525-024-00444-6. Erratum in: *NPJ Genom Med*. 2024 Dec 26;9(1):72. doi: 10.1038/s41525-024-00458-0.
38. Olejniczak P. Neurophysiologic basis of EEG. *J Clin Neurophysiol*. 2006 Jun;23(3):186-9. doi: 10.1097/01.wnp.0000220079.61973.6c.
39. Lukmanji S, Manji SA, Kadhim S, Sauro KM, Wirrell EC, Kwon CS, et al. The co-occurrence of epilepsy and autism: A systematic review. *Epilepsy Behav*. 2019 Sep;98(Pt A):238-248. doi: 10.1016/j.yebeh.2019.07.037.
40. Besag FMC, Vasey MJ. Seizures and Epilepsy in Autism Spectrum Disorder. *Psychiatr Clin North Am*. 2021 Mar;44(1):51-68. doi: 10.1016/j.psc.2020.11.005.
41. Milovanovic M, Radivojevic V, Radosavljev-Kircanski J, Grujicic R, Toskovic O, Aleksić-Hil O, et al. Epilepsy and interictal epileptiform activity in patients with autism spectrum disorders. *Epilepsy Behav*. 2019 Mar;92:45-52. doi: 10.1016/j.yebeh.2018.12.011.
42. Milovanovic M, Grujicic R. Electroencephalography in Assessment of Autism Spectrum Disorders: A Review. *Front Psychiatry*. 2021 Sep 29;12:686021. doi: 10.3389/fpsy.2021.686021.
43. Kang JQ, Barnes G. A common susceptibility factor of both autism and epilepsy: functional deficiency of GABA A receptors. *J Autism Dev Disord*. 2013 Jan;43(1):68-79. doi: 10.1007/s10803-012-1543-7.



44. Johnson AJ, Shankland E, Richards T, Corrigan N, Shusterman D, Edden R, et al. Relationships between GABA, glutamate, and GABA/glutamate and social and olfactory processing in children with autism spectrum disorder. *Psychiatry Res Neuroimaging*. 2023 Dec;336:111745. doi: 10.1016/j.psychres.2023.111745.
45. Specchio N, Di Micco V, Aronica E, Auvin S, Balestrini S, Brunklaus A, et al. The epilepsy-autism phenotype associated with developmental and epileptic encephalopathies: New mechanism-based therapeutic options. *Epilepsia*. 2025 Feb 22. doi: 10.1111/epi.18209.
46. Jakimiec M, Paprocka J, Smigiel R. CDKL5 Deficiency Disorder-A Complex Epileptic Encephalopathy. *Brain Sci*. 2020 Feb 17;10(2):107. doi: 10.3390/brainsci10020107.
47. Ramani R, Fatima B, Hussain A, Shahid U, Kamani A, Bakar SMA, et al. The clinical interface of tuberous sclerosis complex and autism spectrum disorder: insights and future directions. *Neurol Sci*. 2025 Feb 25. doi: 10.1007/s10072-025-08065-2.
48. Giorgi S, Auvin S, Schoonjans AS, Turón E, Sánchez-Miranda I, Gil-Nagel A, et al. A tool for Dravet syndrome-associated neuropsychiatric comorbidities evaluation (DANCE). *Epilepsy Behav*. 2024 Sep;158:109958. doi: 10.1016/j.yebeh.2024.109958.
49. Lesca G, Möller RS, Rudolf G, Hirsch E, Hjalgrim H, Szepietowski P. Update on the genetics of the epilepsy-aphasia spectrum and role of GRIN2A mutations. *Epileptic Disord*. 2019 Jun 1;21(S1):41-47. doi: 10.1684/epd.2019.1056.
50. RoCHAT MJ, Distefano G, Maffei M, Toni F, Posar A, Scaduto MC, et al. Brain Magnetic Resonance Findings in 117 Children with Autism Spectrum Disorder under 5 Years Old. *Brain Sci*. 2020 Oct 16;10(10):741. doi: 10.3390/brainsci10100741.
51. Byrne D, Fisher A, Baker L, Twomey EL, Gorman KM. Yield of brain MRI in children with autism spectrum disorder. *Eur J Pediatr*. 2023 Aug;182(8):3603-3609. doi: 10.1007/s00431-023-05011-2.
52. Floris DL, Howells H. Atypical structural and functional motor networks in autism. *Prog Brain Res*. 2018;238:207-248. doi: 10.1016/bs.pbr.2018.06.010.
53. Zigman T, Petkovic Ramadza D, Simic G, Baric I. Inborn Errors of Metabolism Associated With Autism Spectrum Disorders: Approaches to Intervention. *Front Neurosci*. 2021 May 28;15:673600. doi: 10.3389/fnins.2021.673600.
54. Tokatly Latzer I, Hanson E, Bertoldi M, DiBacco ML, Aygun D, Afacan O, et al. The neuropsychological profile of SSADH deficiency, a neurotransmitter disorder of GABA metabolism. *Mol Genet Metab*. 2025 Mar;144(3):109051. doi: 10.1016/j.ymgme.2025.109051.
55. Ghaziuddin M, Al-Owain M. Autism spectrum disorders and inborn errors of metabolism: an update. *Pediatr Neurol*. 2013 Oct;49(4):232-6. doi: 10.1016/j.pediatrneurol.2013.05.013.
56. Michelson DJ, Shevell MI, Sherr EH, Moeschler JB, Gropman AL, Ashwal S. Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. 2011 Oct 25;77(17):1629-35. doi: 10.1212/WNL.0b013e3182345896.
57. Długosz A, Wróblewski M, Błaszak B, Szulc J. The Role of Nutrition, Oxidative Stress, and Trace Elements in the Pathophysiology of Autism Spectrum Disorders. *Int J Mol Sci*. 2025 Jan 18;26(2):808. doi: 10.3390/ijms26020808.
58. Croall ID, Hoggard N, Hadjivassiliou M. Gluten and Autism Spectrum Disorder. *Nutrients*. 2021;13(2):572. doi:10.3390/nu13020572.
59. Baj J, Flieger W, Flieger M, Forma A, Sitarz E, Skórzyńska-Dziduszko K, et al. Autism spectrum disorder: Trace elements imbalances and the pathogenesis and severity of autistic symptoms. *Neurosci Biobehav Rev*. 2021 Oct;129:117-132. doi: 10.1016/j.neubiorev.2021.07.029.
60. Li Y, Xiao P, Ding H, Wang H, Xu Q, Wang R, et al. Fecal Microbiota Transplantation in Children with Autism. *Neuropsychiatr Dis Treat*. 2024 Dec 9;20:2391-2400. doi: 10.2147/NDT.S488001.

OTİZM BİYOBELİRTEÇLERİ VE GÜNCEL GELİŞMELER

Seray AĞCA HAŞİMOĞLU¹

Tuğçe AKSU UZUNHAN²

GİRİŞ

Amerikan Pediatri Akademisi, 18 ve 24 aylık çocuklar için rutin otizm taraması önermektedir. Otizmin erken tanısında henüz sadece davranışsal özellikler değerlendirilmektedir fakat nesnel teşhis için biyobelirteçlerin varlığına ihtiyaç duyulmaktadır. Biyobelirteçler, otizm spektrum bozukluğu (OSB) için büyük bir potansiyel sunsa da bu alanda karşılaşılan metodolojik ve klinik zorluklar, biyobelirteçlerin güvenilirliğini ve klinik uygulanabilirliğini sınırlamaktadır. Bu sınırlılıklar arasında otizmin biyolojik ve klinik olarak çok heterojen bir spektruma sahip olması, tek bir biyobelirtecın tüm vakaları açıklamakta yetersiz kalması, biyobelirteçlerin farklı yaş gruplarında, kültürlerde ve ortamlarda tutarlı sonuçlar vermemesi, klinik olarak kullanılabilmesi için kolay, maliyet etkin ve yaygın erişilebilir olması sayılabilir. Mevcut biyobelirteçler genellikle karmaşık cihazlar veya spesifik uzmanlık gerektirir. Ayrıca, kullanım alanı biyobelirtecın hangi klinik bağlamda değerlendirileceğini belirleyen temel bir sorudur; tanı koyma, prognostik değerlendirme, tedavi yanıtını izleme, hastalık alt gruplarını belirleme (stratifikasyon), tedavi hedeflerini tanımlama (öngörü) ve risk değerlendirmesi (tarama) gibi farklı alanlardan hangileri için uygun olduğu belirlenmelidir.

¹ Uzm. Dr., İstanbul Atlas Üniversitesi, Tıp Fakültesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., drserayagca@gmail.com, ORCID iD: 0000-0003-3725-7494

² Dç. Dr., İstanbul Atlas Üniversitesi Tıp Fakültesi, Çocuk Nöroloji Bölümü, tugce.uzunhan@atlas.edu.tr, ORCID iD: 0000-0003-0596-2690



Biyobelirteç veritabanlarının artan kullanımı, OSB biyolojisinin daha iyi anlaşılmasını ve biyobelirteçlerin klinik doğrulama süreçlerinden geçerek teşhis ve tedavide rutin kullanıma sunulmasını hızlandırmaktadır. Çoklu-omik yaklaşımların ve büyük veri analizlerinin entegrasyonu, OSB biyobelirteç araştırmalarının gelecekteki yönünü şekillendirmekte ve daha hassas tanı araçlarının geliştirilmesine katkıda bulunmaktadır.

KAYNAKLAR

1. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. *Mol Psychiatry*. 2012;17:389-401.
2. McGrew SG, Peters BR, Crittendon JA, Veenstra-VanderWeele J. Diagnostic yield of chromosomal microarray analysis in an autism primary care practice: which guidelines to implement? *J Autism Dev Disord*. 2012;42:1582-1591.
3. Schaefer GB, Lutz RE. Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders. *Genet Med*. 2006;8:549-556.
4. Herman GE, Henninger N, Ratliff-Schaub K, Pastore M, Fitzgerald S, McBride KL. Genetic testing in autism: how much is enough? *Genet Med*. 2007;9:268-274.
5. Abdul-Rahman OA, Hudgins L. The diagnostic utility of a genetics evaluation in children with pervasive developmental disorders. *Genet Med*. 2006;8:50-54.
6. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet*. 2010;86:749-764.
7. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. *Curr Opin Genet Dev*. 2012;22:229-237.
8. Smalley SL. Autism and tuberous sclerosis. *J Autism Dev Disord*. 1998;28:407-414.
9. Bailey DB Jr, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. *Am J Med Genet A*. 2008;146:2060-2069.
10. Chaste P, Roeder K, Devlin B. The Yin and Yang of autism genetics: how rare de novo and common variations affect liability. *Annu Rev Genomics Hum Genet*. 2017;18:167-187.
11. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet*. 2019;51:431-444.
12. Acuna-Hidalgo R, Veltman JA, Hoischen A. New insights into the generation and role of de novo mutations in health and disease. *Genome Biol*. 2016;17:1-19.
13. Persico AM, Napolioni V. Autism genetics. *Behav Brain Res*. 2013;251:95-112.
14. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. *Nature*. 2009;459:569-573.
15. Perzel Mandell KA, Eagles NJ, Deep-Soboslay A, Tao R, Han S, Wilton R, et al. Molecular phenotypes associated with antipsychotic drugs in the human caudate nucleus. *Mol Psychiatry*. 2022;27:2061-2067.
16. Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. *Trends Neurosci*. 2006;29:349-358.
17. Loke YJ, Hannan AJ, Craig JM. The role of epigenetic change in autism spectrum disorders. *Front Neurol*. 2015;6:107.



18. Aref-Eshghi E, Rodenhiser DI, Schenkel LC, Lin H, Skinner C, Ainsworth P, et al. Genomic DNA methylation signatures enable concurrent diagnosis and clinical genetic variant classification in neurodevelopmental syndromes. *Am J Hum Genet.* 2018;102:156-174.
19. Wong CC, Smith RG, Hannon E, Ramaswami G, Parikshak NN, Assary E, et al. Genome-wide DNA methylation profiling identifies convergent molecular signatures associated with idiopathic and syndromic autism in post-mortem human brain tissue. *Hum Mol Genet.* 2019;28:2201-2211.
20. Nguyen A, Rauch TA, Pfeifer GP, Hu VW. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. *FASEB J.* 2010;24:3036-3048.103.
21. Wong C, Meaburn EL, Ronald A, Price T, Jeffries AR, Schalkwyk L, et al. Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. *Mol Psychiatry.* 2014;19:495-503.
22. Andrews SV, Sheppard B, Windham GC, Schieve LA, Schendel DE, Croen LA, et al. Case-control meta-analysis of blood DNA methylation and autism spectrum disorder. *Mol Autism.* 2018;9:1-11.
23. Feinberg JI, Bakulski KM, Jaffe AE, Tryggvadottir R, Brown SC, Goldman LR, et al. Paternal sperm DNA methylation associated with early signs of autism risk in an autism-enriched cohort. *Int J Epidemiol.* 2015;44:1199-1210.
24. Ladd-Acosta C, Hansen KD, Briem E, Fallin MD, Kaufmann WE, Feinberg AP. Common DNA methylation alterations in multiple brain regions in autism. *Mol Psychiatry.* 2014;19:862-871.
25. Nardone S, Sams DS, Zito A, Reuveni E, Elliott E. Dysregulation of cortical neuron DNA methylation profile in autism spectrum disorder. *Cereb Cortex.* 2017;27:5739-5754.
26. Nardone S, Sharan Sams D, Reuveni E, Getselter D, Oron O, Karpuij M, et al. DNA methylation analysis of the autistic brain reveals multiple dysregulated biological pathways. *Transl Psychiatry.* 2014;4:e433.
27. Guo B-Q, Ding S-B, Li H-B. Blood biomarker levels of methylation capacity in autism spectrum disorder: a systematic review and meta-analysis. *Acta Psychiatr Scand.* 2020;141:492-509.
28. Sun W, Poschmann J, Cruz-Herrera del Rosario R, Parikshak NN, Hajan HS, Kumar V, et al. Histone acetylome-wide association study of autism spectrum disorder. *Cell.* 2016;167:1385-1397.e11.
29. Mundalil Vasu M, Anitha A, Thanseem I, Suzuki K, Yamada K, Takahashi T, et al. Serum microRNA profiles in children with autism. *Mol Autism.* 2014;5:1-9.
30. Cirnigliaro M, Barbagallo C, Gulisano M, Domini CN, Barone R, Barbagallo D, et al. Expression and regulatory network analysis of miR-140-3p, a new potential serum biomarker for autism spectrum disorder. *Front Mol Neurosci.* 2017;10:250.
31. Cheng W, Zhou S, Zhou J, Wang X. Identification of a robust non-coding RNA signature in diagnosing autism spectrum disorder by cross-validation of microarray data from peripheral blood samples. *Medicine.* 2020;99:e19484.
32. Junaid MA, Kowal D, Barua M, Pullarkat PS, Sklower Brooks S, Pullarkat RK. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. *Am J Med Genet A.* 2004;131:11-17.
33. Broek JA, Guest PC, Rahmoune H, Bahn S. Proteomic analysis of post mortem brain tissue from autism patients: evidence for opposite changes in prefrontal cortex and cerebellum in synaptic connectivity-related proteins. *Mol Autism.* 2014;5:1-8.
34. Oztan O, Garner JP, Constantino JN, Parker KJ. Neonatal CSF vasopressin concentration predicts later medical record diagnoses of autism spectrum disorder. *Proc Natl Acad Sci U S A.* 2020;117:10609-10613.



35. Oztan O, Garner JP, Partap S, Sherr EH, Hardan AY, Farmer C, et al. Cerebrospinal fluid vasopressin and symptom severity in children with autism. *Ann Neurol*. 2018;84:611-615.
36. Carson DS, Howerton CL, Garner JP, Hyde SA, Clark CL, Hardan AY, et al. Plasma vasopressin concentrations positively predict cerebrospinal fluid vasopressin concentrations in human neonates. *Peptides*. 2014;61:12-16.
37. Ngounou Wetie AG, Wormwood KL, Russell S, Ryan JP, Darie CC, Woods AG. A pilot proteomic analysis of salivary biomarkers in autism spectrum disorder. *Autism Res*. 2015;8:338-350.
38. Suganya V, Geetha A, Sujatha S. Urine proteome analysis to evaluate protein biomarkers in children with autism. *Clin Chim Acta*. 2015;450:210-219.
39. Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingudomnukul E, et al. Sex-specific serum biomarker patterns in adults with Asperger's syndrome. *Mol Psychiatry*. 2011;16:1213-1220.
40. Sriwimol W, Limprasert P. Significant changes in plasma alpha-synuclein and beta-synuclein levels in male children with autism spectrum disorder. *Biomed Res Int*. 2018;2018:4503871.
41. Kadak MT, Cetin I, Tarakçioğlu MC, Özer ÖF, Kaçar S, Çimen B. Low serum level alpha-synuclein and tau protein in autism spectrum disorder compared to controls. *Neuropediatrics*. 2015;46:410-415.
42. Mesleh AG, Abdulla SA, El-Agnaf O. Paving the way toward personalized medicine: current advances and challenges in multi-OMICS approach in autism spectrum disorder for biomarkers discovery and patient stratification. *J Pers Med*. 2021;11:41.
43. Hammock E, Veenstra-VanderWeele J, Yan Z, Kerr TM, Morris M, Anderson GM, et al. Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems. *J Am Acad Child Adolesc Psychiatry*. 2012;51:712-721.e1.
44. Walum H, Lichtenstein P, Neiderhiser JM, Reiss D, Ganiban JM, Spotts EL, et al. Variation in the oxytocin receptor gene is associated with pair-bonding and social behavior. *Biol Psychiatry*. 2012;71:419-426.
45. Melke J, Goubran Botros H, Chaste P, Betancur C, Nygren G, Anckarsäter H, et al. Abnormal melatonin synthesis in autism spectrum disorders. *Mol Psychiatry*. 2008;13:90-98.
46. Wang L, Li J, Ruan Y, Lu T, Liu C, Jia M, et al. Sequencing ASMT identifies rare mutations in Chinese Han patients with autism. *PLoS One*. 2013;8:e53727.
47. Anderson GM, Horne WC, Chatterjee D, Cohen DJ. The hyperserotonemia of autism. *Ann N Y Acad Sci*. 1990;600:331-340.
48. McBride PA, Anderson GM, Hertzog ME, Snow ME, Thompson SM, Khait VD, et al. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. *J Am Acad Child Adolesc Psychiatry*. 1998;37:767-776.
49. Smith AM, King JJ, West PR, Ludwig MA, Donley EL, Burrier RE, et al. Amino acid dysregulation metabolites: potential biomarkers for diagnosis and individualized treatment for subtypes of autism spectrum disorder. *Biol Psychiatry*. 2019;85:345-354.
50. Liu X, Lin J, Zhang H, Khan NU, Zhang J, Tang X, et al. Oxidative stress in autism spectrum disorder—current progress of mechanisms and biomarkers. *Front Psychiatry*. 2022;13:813304.
51. Chen L, Shi XJ, Liu H, Mao X, Gui LN, Wang H, et al. Oxidative stress marker aberrations in children with autism spectrum disorder: a systematic review and meta-analysis of 87 studies (N=9109). *Transl Psychiatry*. 2021;11:15.
52. Xie X, Zhou R, Fang Z, Zhang Y, Wang Q, Liu X. Seeing beyond words: visualizing autism spectrum disorder biomarker insights. *Heliyon*. 2024;10:e30420.
53. Rossignol D, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. *Mol Psychiatry*. 2012;17:290-314.
54. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism—comparisons to typical children and correlation with autism severity. *BMC Gastroenterol*. 2011;11:1-13.



55. De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazzanetti DI, et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. *PLoS One*. 2013;8:e76993.
56. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell*. 2013;155:1451-1463.
57. Kang DW, Park JG, Ilhan ZE, Wallstrom G, LaBaer J, Adams JB, et al. Reduced incidence of *Prevotella* and other fermenters in intestinal microflora of autistic children. *PLoS One*. 2013;8:e68322.
58. Dinan TG, Stilling RM, Stanton C, Cryan JF. Collective unconscious: how gut microbes shape human behavior. *J Psychiatr Res*. 2015;63:1-9.
59. Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental delays or typical development. *J Autism Dev Disord*. 2014;44:1117-1127.
60. Shaw W. Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HP-HPA), an abnormal phenylalanine metabolite of *Clostridia* spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia. *Nutr Neurosci*. 2010;13:135-143.
61. Olesova D, Galba J, Piastansky J, Celusakova H, Repiska G, Babinska K, et al. A novel UHPLC-MS method targeting urinary metabolomic markers for autism spectrum disorder. *Metabolites*. 2020;10:443.
62. Altieri L, Neri C, Sacco R, Curatolo P, Benvenuto A, Muratori F, et al. Urinary p-cresol is elevated in small children with severe autism spectrum disorder. *Biomarkers*. 2011;16:252-260.
63. Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. *J Leukoc Biol*. 2006;80:1-15.
64. Parellada M, Andreu-Bernabeu A, Burdeus M, San Jose Caceres A, Urbiola E, Carpenter LL, et al. In search of biomarkers to guide interventions in autism spectrum disorder: a systematic review. *Am J Psychiatry*. 2023;180:23-40.
65. Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R, et al. Increased mid-gestational IFN-gamma, IL-4 and IL-5 in women bearing a child with autism: a case-control study. *Mol Autism*. 2011;2:1-11.
66. Croen LA, Braunschweig D, Haapanen L, Yoshida CK, Fireman B, Grether JK, et al. Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. *Biol Psychiatry*. 2008;64:583-588.
67. Sacco R, Lenti C, Saccani M, Curatolo P, Manzi B, Bravaccio C, et al. Cluster analysis of autistic patients based on principal pathogenetic components. *Autism Res*. 2012;5:137-147.
68. Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. *Biol Psychiatry*. 2010;68:368-376.
69. Garcia-Forn M, Boitnott A, Akpınar Z, De Rubeis S. Linking autism risk genes to disruption of cortical development. *Cells*. 2020;9:2500.
70. Pierce K, Muller RA, Ambrose J, Allen G, Courchesne E. Face processing occurs outside the fusiform face area in autism: evidence from functional MRI. *Brain*. 2001;124:2059-2073.
71. Schmitz N, Rubia K, Daly E, Smith A, Williams S, Murphy DG. Neural correlates of executive function in autistic spectrum disorders. *Biol Psychiatry*. 2006;59:7-16.
72. Kleinmans NM, Muller RA, Cohen DN, Courchesne E. Atypical functional lateralization of language in autism spectrum disorders. *Brain Res*. 2008;1221:115-125.
73. Schmitz N, Rubia K, Van Amelsvoort T, Daly E, Smith A, Murphy DG. Neural correlates of reward in autism. *Br J Psychiatry*. 2008;192:19-24.
74. Kana RK, Keller TA, Minshew NJ, Just MA. Inhibitory control in high-functioning autism: decreased activation and underconnectivity in inhibition networks. *Biol Psychiatry*. 2007;62:198-206.



75. Kaiser MD, Hudac CM, Shultz S, Lee SM, Cheung C, Berken AM, et al. Neural signatures of autism. *Proc Natl Acad Sci U S A*. 2010;107:21223-21228.
76. Belmonte MK, Gomot M, Baron-Cohen S. Visual attention in autism families: unaffected sibs share atypical frontal activation. *J Child Psychol Psychiatry*. 2010;51:259-276.
77. Li X, Zhang K, He X, Zhou J, Jin C, Shen L, et al. Structural, functional, and molecular imaging of autism spectrum disorder. *Neurosci Bull*. 2021;37:1051-1071.
78. Emerson RW, Adams C, Nishino T, Hazlett HC, Wolff JJ, Zwaigenbaum L, et al. Functional neuroimaging of high-risk 6-month-old infants predicts a diagnosis of autism at 24 months of age. *Sci Transl Med*. 2017;9:eag2882.
79. Ruggeri B, Sarkans U, Schumann G, Persico AM. Biomarkers in autism spectrum disorder: the old and the new. *Psychopharmacology*. 2014;231:1201-1216.
80. Haar S, Berman S, Behrmann M, Dinstein I. Anatomical abnormalities in autism. *Cereb Cortex*. 2016;26:1440-1452.
81. Ure AM, Treyvaud K, Thompson DK, Pascoe L, Roberts G, Lee KJ, et al. Neonatal brain abnormalities associated with autism spectrum disorder in children born very preterm. *Autism Res*. 2016;9:543-552.
82. Schumann CM, Barnes CC, Lord C, Courchesne E. Amygdala enlargement in toddlers with autism related to severity of social and communication impairments. *Biol Psychiatry*. 2009;66:942-949.
83. Shen MD, Nordahl CW, Young GS, Wootton-Gorges SL, Lee A, Liston SE, et al. Early brain enlargement and elevated extra-axial fluid in infants who develop autism spectrum disorder. *Brain*. 2013;136:2825-2835.
84. Dawson G, Carver L, Meltzoff AN, Panagiotides H, McPartland J, Webb SJ. Neural correlates of face and object recognition in young children with autism spectrum disorder, developmental delay, and typical development. *Child Dev*. 2002;73:700-717.
85. Joseph RM, Ehrman K, McNally R, Keehn B. Affective response to eye contact and face recognition ability in children with ASD. *J Int Neuropsychol Soc*. 2008;14:947-955.
86. Stuart N, Whitehouse A, Palermo R, Bothe E, Badcock N. Eye gaze in autism spectrum disorder: a review of neural evidence for the eye avoidance hypothesis. *J Autism Dev Disord*. 2023;53:1884-1905.
87. Bakeman R, Adamson LB. Coordinating attention to people and objects in mother-infant and peer-infant interaction. *Child Dev*. 1984;55:1278-1289.
88. Briskman J, Happe F, Frith U. Exploring the cognitive phenotype of autism: weak central coherence in parents and siblings of children with autism: II. Real-life skills and preferences. *J Child Psychol Psychiatry*. 2001;42:309-316.
89. Delorme R, Gousse V, Roy I, Trandafir A, Mathieu F, Mouren-Simeoni MC, et al. Shared executive dysfunctions in unaffected relatives of patients with autism and obsessive-compulsive disorder. *Eur Psychiatry*. 2007;22:32-38.
90. Wallace GL, Happe F, Giedd JN. A case study of a multiply talented savant with an autism spectrum disorder: neuropsychological functioning and brain morphometry. *Philos Trans R Soc Lond B Biol Sci*. 2009;364:1425-1432.
91. Patriquin MA, Hartwig EM, Friedman BH, Porges SW, Scarpa A. Autonomic response in autism spectrum disorder: relationship to social and cognitive functioning. *Biol Psychol*. 2019;145:185-197.
92. Fenning RM, Baker JK, Baucom BR, Erath SA, Howland MA, Moffitt J. Electrodermal variability and symptom severity in children with autism spectrum disorder. *J Autism Dev Disord*. 2017;47:1062-1072.



93. Grzadzinski R, Lord C, Sanders SJ, Werling D, Bal VH. Children with autism spectrum disorder who improve with fever: insights from the Simons Simplex Collection. *Autism Res.* 2018;11:175-184.
94. Sarker H, Tam A, Foreman M, Fay N, Dhuliawala M, Das A, et al. Detection of stereotypical motor movements in autism using a smartwatch-based system. *AMIA Annu Symp Proc.* 2018;2018:1500-1509.
95. Sadiq S, Castellanos M, Moffitt J, Shyu ML, Perry L, Messinger D, et al. Deep learning based multimedia data mining for autism spectrum disorder diagnosis. *Proc IEEE Int Conf Data Min Workshops.* 2019;2019:123-130.
96. Lind MN, Byrne ML, Wicks G, Smidt AM, Allen NB. The effortless assessment of risk states tool: an interpersonal approach to mobile sensing. *JMIR Ment Health.* 2018;5:e10334.
97. Autism Biomarkers Consortium for Clinical Trials. Autism Biomarkers Consortium [Internet]. [cited 2025 Apr 9]. Available from: <https://medicine.yale.edu/ycci/clinicaltrials/categories/children/autism-biomarkers-consortium/>
98. Simons Foundation Autism Research Initiative. SFARI [Internet]. [cited 2025 Apr 9]. Available from: <https://www.sfari.org/>
99. MSS Research. MSS Research portal [Internet]. [cited 2025 Apr 9]. Available from: <https://research.mss.ng/>
100. Autism Speaks. Autism Genetic Resource Exchange (AGRE) [Internet]. [cited 2025 Apr 9]. Available from: <https://www.autismspeaks.org/interested-becoming-agre-researcher>
101. National Institutes of Health. National Database for Autism Research (NDAR) [Internet]. [cited 2025 Apr 9]. Available from: <https://www.nih.gov/health-information/nih-clinical-research-trials-you/personal-stories/researcher-story-national-database-autism-research-ndar>
102. MindSpec. Autism Database (AutDB) [Internet]. [cited 2025 Apr 9]. Available from: <http://autism.mindspec.org/autdb/Welcome.do>
103. International Neuroimaging Data-sharing Initiative. Autism Brain Imaging Data Exchange (ABIDE) [Internet]. [cited 2025 Apr 9]. Available from: https://fcon_1000.projects.nitrc.org/indi/abide/
104. Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. *Lancet.* 2018;392:508-520.
105. Geschwind DH, State MW. Gene hunting in autism spectrum disorder: on the path to precision medicine. *Lancet Neurol.* 2015;14:1109-1120.
106. Obermeyer Z, Emanuel EJ. Predicting the future: big data, machine learning, and clinical medicine. *N Engl J Med.* 2016;375:1216-1219.
107. Schork NJ. Personalized medicine: time for one-person trials. *Nature.* 2015;520:609-611.

OTİZM OLGULARINDA NÖROGÖRÜNTÜLEME BULGULARI

Sevim TÜRAY¹
Hilal AYDIN²

GİRİŞ

Otizm spektrum bozukluğu (OSB), karmaşık bir nöro gelişimsel bozukluktur. Sosyal etkileşimde zorluklar, tekrarlayıcı ve stereotipik davranışlar ile değişen düzeylerde bilişsel eksikliklerle karakterizedir. Epidemiyolojik araştırmalar, son birkaç on yılda OSB prevalansında dünya genelinde belirgin bir artış olduğunu göstermektedir. Amerika Birleşik Devletleri'nde her 54 çocuktan birinde OSB olduğu tahmin edilmektedir.¹ Yakın tarihli bir meta-analizde, OSB prevalansı Kuzey Amerika'da %1,01, Avrupa'da %0,73 ve Asya'da %0,41 olarak bildirilmiştir. En yüksek prevalans ABD (%1,12), İsveç (%0,90) ve Danimarka'da (%0,73); en düşük prevalans ise Tayvan (%0,11), Fransa (%0,32) ve Çin'de (%0,42) saptanmıştır. Küresel olarak OSB prevalansı, 1994–1999 yılları arasında %0,25 iken, 2015–2019 yılları arasında %0,99'a yükselmiştir.²

Otizm, yaşamın erken dönemlerinde başlar; sosyal ilişkiler ve iletişimdeki eksikliklerle birlikte gecikmiş bilişsel gelişim ile kendini gösterir ve yaşam boyu devam eder. OSB'nin temel semptomları genellikle 2 yaş civarında ortaya çıkar; bu süreçte beyin anatomisi, işlevi ve bağlantısındaki gelişimsel farklılıklar davranışları etkiler.¹ Otizm, yaklaşık yarım yüzyıl önce aile ve çevresel faktörlere bağlı bir bozukluk olarak tanımlanmışken, daha sonra zihinsel yetersizlik, epileptik bozukluklar ve EEG anormallikleriyle sık birlikteliği olduğu anlaşılmıştır.⁴

¹ Doç. Dr., Düzce Üniversitesi Tıp Fakültesi, Çocuk Nöroloji BD., drsvm@yahoo.com, ORCID iD: 0000-0001-6002-052X

² Doç. Dr., Balıkesir Üniversitesi, Tıp Fakültesi, Çocuk Nöroloji AD., drhilalaydin@gmail.com, ORCID iD: 0000-0002-2448-1270



Manyetik Rezonans Spektroskopisi

Otizmde zayıf yapısal ve işlevsel bağlantıya işaret eden verilerin birikmesi bağlamında, MRS gibi beyaz ve gri maddenin bütünlüğünün biyokimyasal belirteçlerini sağlayan tekniklerin bu popülasyonda yararlı olup olamayacağı sorusu ortaya çıkmıştır. MRS, bir dizi beyin metabolitinin kantifikasyonuna izin verir. Bu teknik, diğer nöropsikiyatrik bozukluklarda yararlı olmuştur, gri ve beyaz cevherin işlevsel bozukluğuna dair öngörüler sunar. Ek olarak, MRS ölçümleri altta yatan patolojilerin biyokimyasal profiline göre belirlendiği gri ve beyaz maddedeki anormalliklerin farklı mekanizmalarını yansıtabilir ve patogenezin biyokimyasal profilinin saptanmasına yardımcı olur. Bu nedenle MRS, otizmde gri ve beyaz maddenin incelenmesine bilgi sağlamak için iyi bir adaydır.⁶¹

En sık incelenen metabolitlerden biri olan N-asetil aspartat (NAA), nöronlar, aksonlar ve olgun oligodendrositlerde bulunur. Gri maddede NAA düzeylerinin nöronal yoğunluğu yansıttığı, beyaz maddede ise aksonal bütünlüğün bir göstergesi olduğu kabul edilir.⁶² Gri maddede nöronal yoğunluk azalması, beyaz madde yollarındaki NAA düzeylerini de etkileyebilir. Otizmle ilişkili MRS çalışmalarında genellikle gri cevher hedef alınmış, burada NAA seviyelerinde düşüklük en sık raporlanan bulgu olmuştur.⁶³ Ancak bu durum, erken dönemde görülen beyin hacmi artışı ile çelişkili görünmektedir. Bu nedenle, sinaptik yoğunluk azalması, kortikal farklılaşma bozukluğu veya nöroinflamasyon gibi alternatif açıklamalar da gündeme gelmiştir.⁶⁴

KAYNAKLAR

1. Maenner MJ, Shaw KA, Baio J, Washington A, Patrick M, DiRienzo M, et al. Prevalence of autism spectrum disorder among children aged 8 years- Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2016. MMWR Surveill Summ. 2020;69(4):1-12.
2. Talantseva OI, Romanova RS, Shurdova EM, Dolgorukova TA, Sologub PS, Titova OS, et al. The global prevalence of autism spectrum disorder: A three-level meta-analysis. Front Psychiatry. 2023;14:1071181. doi:10.3389/fpsy.2023.107118.
3. Tuna Ulay H, Ertuğrul A. Neuroimaging findings in autism: A brief review. Turk Psikiyatri Derg. 2009;20(2):164-174.
4. Eigsti IM, Shapiro T. A systems neuroscience approach to autism: biological, cognitive, and clinical perspectives. Ment Retard Dev Disabil Res Rev. 2003;9(3):205-215. doi:10.1002/mrdd.10081.
5. Lainhart JE. Advances in autism neuroimaging research for the clinician and geneticist. Am J Med Genet C Semin Med Genet. 2006;142C(1):33-39. doi:10.1002/ajmg.c.30080.



6. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. *Arch Gen Psychiatry*. 2011;68(11):1095–1102. doi:10.1001/archgenpsychiatry.2011.76.
7. Yenikoyan K, Grigoryan A, Fereshetyan K, Yepremyan D. Advances in understanding the pathophysiology of autism spectrum disorders. *Behav Brain Res*. 2017;331:92–101. doi:10.1016/j.bbr.2017.04.038.
8. Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. *Brain Res*. 2011;1380:42–77. doi:10.1016/j.brainres.2010.11.078.
9. Ecker C. The neuroanatomy of autism spectrum disorder: An overview of structural neuroimaging findings and their translatability to the clinical setting. *Autism*. 2017;21(1):18–28. doi:10.1177/1362361315627136.
10. Gabard-Durnam LJ, Wilkinson CL, Kapur K, Tager-Flusberg H, Levin AR, Nelson CA. Longitudinal EEG power in the first postnatal year differentiates autism outcomes. *Nat Commun*. 2019;10(1):4188. doi:10.1038/s41467-019-12202-9.
11. Adolphs R. The neurobiology of social cognition. *Curr Opin Neurobiol*. 2001;11(2):231–239. doi:10.1016/s0959-4388(00)00202-6.
12. Courchesne E, Redcay E, Kennedy DP. The autistic brain: birth through adulthood. *Curr Opin Neurol*. 2004;17(4):489–496. doi:10.1097/01.wco.0000137542.14610.b4.
13. Jumah F, Ghannam M, Jaber M, Adeeb N, Tubbs RS. Neuroanatomical variation in autism spectrum disorder: A comprehensive review. *Clin Anat*. 2016;29(4):454–465. doi:10.1002/ca.22717.
14. Bolton PF, Roobol M, Allsopp L, Pickles A. Association between idiopathic infantile macrocephaly and autism spectrum disorders. *Lancet*. 2001;358(9283):726–727. doi:10.1016/S0140-6736(01)05903-7.
15. Bartholomeusz HH, Courchesne E, Karns CM. Relationship between head circumference and brain volume in healthy normal toddlers, children, and adults. *Neuropediatrics*. 2002;33(5):239–241. doi:10.1055/s-2002-36735.
16. Fidler DJ, Bailey JN, Smalley SL. Macrocephaly in autism and other pervasive developmental disorders. *Dev Med Child Neurol*. 2000;42(11):737–740. doi:10.1017/s0012162200001358.
17. Courchesne E, Karns CM, Davis HR, Ziccardi R, Carper RA, Tigue ZD, et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. *Neurology*. 2001;57(2):245–254. doi:10.1212/wnl.57.2.245.
18. Carper RA, Courchesne E. Inverse correlation between frontal lobe and cerebellum sizes in children with autism. *Brain*. 2000;123(4):836–844. doi:10.1093/brain/123.4.836.
19. Carper RA, Moses P, Tigue ZD, Courchesne E. Cerebral lobes in autism: Early hyperplasia and abnormal age effects. *Neuroimage*. 2002;16(4):1038–1051. doi:10.1006/nimg.2002.1095.
20. Sparks BF, Friedman SD, Shaw DW, Aylward EH, Echelard D, Artru AA, et al. Brain structural abnormalities in young children with autism spectrum disorder. *Neurology*. 2002;59(2):184–192.
21. Carper RA, Courchesne E. Localized enlargement of the frontal cortex in early autism. *Biol Psychiatry*. 2005;57(2):126–133. doi:10.1016/j.biopsych.2004.11.005.
22. Lainhart JE, Piven J, Wzorek M, Landa R, Santangelo SL, Coon H, et al. Macrocephaly in children and adults with autism. *J Am Acad Child Adolesc Psychiatry*. 1997;36(2):282–290. doi:10.1097/00004583-199702000-00020.
23. Aylward EH, Minshew NJ, Field K, Sparks BF, Singh N. Effects of age on brain volume and head circumference in autism. *Neurology*. 2002;59(2):175–183. doi:10.1212/wnl.59.2.175.
24. Friedman SD, Shaw DW, Artru AA, Richards TL, Gardner J, Dawson G, et al. Regional brain chemical alterations in young children with autism spectrum disorder. *Neurology*. 2003;60(1):100–107. doi:10.1212/01.wnl.0000031072.60720.27.



25. Piven J, Berthier ML, Starkstein SE, Nehme E, Pearlson G, Folstein S. Magnetic resonance imaging evidence for a defect of cerebral cortical development in autism. *Am J Psychiatry*. 1990;147(6):734–739. doi:10.1176/ajp.147.6.734.
26. Bolton PF, Griffiths PD. Association of tuberous sclerosis of temporal lobes with autism and atypical autism. *Lancet*. 1997;349(9049):392–395. doi:10.1016/S0140-6736(96)07001-4.
27. Hauser SL, DeLong GR, Rosman NP. Pneumographic findings in the infantile autism syndrome. A correlation with temporal lobe disease. *Brain*. 1975;98(4):667–688. doi:10.1093/brain/98.4.667.
28. Gaffney GR, Kuperman S, Tsai LY, Minchin S. Forebrain structure in infantile autism. *J Am Acad Child Adolesc Psychiatry*. 1989;28(4):534–537. doi:10.1097/00004583-198907000-00006.
29. Piven J, Arndt S, Bailey J, Haverkamp S, Andreasen NC, Palmer P. An MRI study of brain size in autism. *Am J Psychiatry*. 1995;152(8):1145–1149. doi:10.1176/ajp.152.8.1145.
30. Piven J, Bailey J, Ranson BJ, Arndt S. An MRI study of the corpus callosum in autism. *Am J Psychiatry*. 1997;154(8):1051–1056. doi:10.1176/ajp.154.8.1051.
31. Herbert MR, Ziegler DA, Deutsch CK, O'Brien LM, Lange N, Bakardjiev A, et al. Dissociations of cerebral cortex, subcortical and cerebral white matter volumes in autistic boys. *Brain*. 2003;126(Pt 5):1182–1192. doi:10.1093/brain/awg113.
32. Waiter GD, Williams JHG, Murray AD, Gilchrist A, Perrett DI, Whiten A. A voxel-based investigation of brain structure in male adolescents with autistic spectrum disorder. *Neuroimage*. 2004;22(2):619–625. doi:10.1016/j.neuroimage.2004.01.031.
33. Waiter GD, Williams JHG, Murray AD, Gilchrist A, Perrett DI, Whiten A. Structural white matter deficits in high-functioning individuals with autistic spectrum disorder: a voxel-based investigation. *Neuroimage*. 2005;24(2):455–461. doi:10.1016/j.neuroimage.2004.08.022.
34. Levitt JG, Blanton RE, Smalley S, Thompson PM, Guthrie D, McCracken JT, et al. Cortical sulcal maps in autism. *Cereb Cortex*. 2003;13(7):728–735. doi:10.1093/cercor/13.7.728.
35. Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism: a review and future directions. *Int J Dev Neurosci*. 2005;23(2–3):183–187. doi:10.1016/j.ijdevneu.2004.09.006.
36. Aylward EH, Minshew NJ, Goldstein G, Honeycutt NA, Augustine AM, Yates KO, et al. MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults. *Neurology*. 1999;53(9):2145–2150. doi:10.1212/wnl.53.9.2145.
37. Rojas DC, Bawn SD, Benkers TL, Reite ML, Rogers SJ. Smaller left hemisphere planum temporale in adults with autistic disorder. *Neurosci Lett*. 2002;328(3):237–240. doi:10.1016/S0304-3940(02)00523-6.
38. Hashimoto T, Tayama M, Murakawa K, Yoshimoto T, Miyazaki M, Harada M, et al. Development of the brainstem and cerebellum in autistic patients. *J Autism Dev Disord*. 1995;25(1):1–18. doi:10.1007/BF02178163.
39. Courchesne E, Saitoh O, Yeung-Courchesne R, Press GA, Lincoln AJ, Haas RH, et al. Abnormality of cerebellar vermal lobules VI and VII in patients with infantile autism: identification of hypoplastic and hyperplastic subgroups with MR imaging. *AJR Am J Roentgenol*. 1994;162(1):123–130. doi:10.2214/ajr.162.1.8273650.
40. Allen G, Courchesne E. Differential effects of developmental cerebellar abnormality on cognitive and motor functions in the cerebellum: an fMRI study of autism. *Am J Psychiatry*. 2003;160(2):262–73. doi:10.1176/appi.ajp.160.2.262.
41. Sears LL, Vest C, Mohamed S, Bailey J, Ranson BJ, Piven J. An MRI study of the basal ganglia in autism. *Prog Neuropsychopharmacol Biol Psychiatry*. 1999;23(4):613–24. doi:10.1016/S0278-5846(99)00020-4.



42. Tsatsanis KD, Rourke BP, Klin A, Volkmar FR, Cicchetti D, Schultz RT. Reduced thalamic volume in high-functioning individuals with autism. *Biol Psychiatry*. 2003;53(2):121-9. doi:10.1016/S0006-3223(02)01773-3.
43. Hashimoto T, Tayama M, Miyazaki M, Murakawa K, Sakurama N, Yoshimoto T, et al. Reduced midbrain and pons size in children with autism. *Tokushima J Exp Med*. 1991;38(1-2):15-8. PMID:1948997.
44. Hashimoto T, Tayama M, Miyazaki M, Murakawa K, Kuroda Y. Brainstem and cerebellar vermis involvement in autistic children. *J Child Neurol*. 1993;8(2):149-53. doi:10.1177/088307389300800209.
45. Verhoeven JS, De Cock P, Lagae L, Sunaert S. Neuroimaging of autism. *Neuroradiology*. 2010;52(1):3-14. doi:10.1007/s00234-009-0583-y.
46. Premack D, Woodruff G. Chimpanzee problem-solving: a test for comprehension. *Science*. 1978;202(4367):532-5. doi:10.1126/science.705342.
47. Rizzolatti G, Fogassi L, Gallese V. Mirrors of the mind. *Sci Am*. 2006;295(5):54-61. doi:10.1038/scientificamerican1106-54.
48. Iacoboni M, Dapretto M. The mirror neuron system and the consequences of its dysfunction. *Nat Rev Neurosci*. 2006;7(12):942-51. doi:10.1038/nrn2024.
49. Dapretto M, Davies MS, Pfeifer JH, Scott AA, Sigman M, Bookheimer SY, et al. Understanding emotions in others: mirror neuron dysfunction in children with autism spectrum disorders. *Nat Neurosci*. 2006;9(1):28-30. doi:10.1038/nn1611.
50. Bookheimer S. Functional MRI of language: new approaches to understanding the cortical organization of semantic processing. *Annu Rev Neurosci*. 2002;25:151-88. doi:10.1146/annurev.neuro.25.112701.142946.
51. Kana RK, Keller TA, Cherkassky VL, Minshew NJ, Just MA. Sentence comprehension in autism: thinking in pictures with decreased functional connectivity. *Brain*. 2006;129(Pt 9):2484-2493.
52. Dawson G, Webb SJ, McPartland J. Understanding the nature of face processing impairment in autism: insights from behavioral and electrophysiological studies. *Dev Neuropsychol*. 2005;27(3):403-424.
53. Speer L, Cook A, McMahon W, Clark E. Face processing in children with autism: effects of stimulus content and type. *Autism*. 2007;11(3):265-277.
54. Schultz RT, Gauthier I, Klin A, Fulbright RK, Anderson AW, Volkmar F, et al. Abnormal ventral temporal cortical activity during face discrimination among individuals with autism and Asperger syndrome. *Arch Gen Psychiatry*. 2000;57(4):331-340.
55. Courchesne E, Yeung-Courchesne R, Press GA, Hesselink JR, Jernigan TL. Hypoplasia of cerebellar vermal lobules VI and VII in autism. *N Engl J Med*. 1988;318(21):1349-1354.
56. Teitelbaum P, Teitelbaum O, Nye J, Fryman J, Maurer RG. Movement analysis in infancy may be useful for early diagnosis of autism. *Proc Natl Acad Sci U S A*. 1998;95(23):13982-13987.
57. Hermoye L, Saint-Martin C, Cosnard G, Lee SK, Kim J, Nassogne MC, et al. Pediatric diffusion tensor imaging: normal database and observation of the white matter maturation in early childhood. *Neuroimage*. 2006;29(2):493-504.
58. Barnea-Goraly N, Kwon H, Menon V, Eliez S, Lotspeich L, Reiss AL. White matter structure in autism: preliminary evidence from diffusion tensor imaging. *Biol Psychiatry*. 2004;55(3):323-326.
59. Alexander AL, Lee JE, Lazar M, Boudos R, DuBray MB, Oakes TR, et al. Diffusion tensor imaging of the corpus callosum in autism. *Neuroimage*. 2007;34(1):61-73.
60. Keller TA, Kana RK, Just MA. A developmental study of the structural integrity of white matter in autism. *Neuroreport*. 2007;18(1):23-27.



62. Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. *J Neurochem.* 2000;74(1):254-262.
63. Dager SR, Corrigan NM, Richards TL, Posse S. Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. *Top Magn Reson Imaging.* 2008;19(2):81-96.
64. Friedman SD, Shaw DWW, Artru AA, Dawson G, Petropoulos H, Dager SR. Gray and white matter brain chemistry in young children with autism. *Arch Gen Psychiatry.* 2006;63(7):786-794.

OTİZM OLGULARINDA TEMEL GENETİK TESTLER VE SENDROMİK NEDENLER

Hakan ERÇELEBİ¹

GİRİŞ

Otizm spektrum bozukluğu (OSB), heterojen klinik görünümü ve güçlü genetik temeli nedeniyle geniş bir genomik alanda araştırılan başlıca nörogelişimsel bozukluklardan biridir. Genetik araştırmalardaki ilerlemeler, OSB'nin sadece tek nükleotid varyantlarından değil, aynı zamanda daha büyük kromozomal yeniden düzenlemeler ve kopya sayısı varyasyonlarından (CNV) da etkilendiğini ortaya koymuştur. Yeni nesil genomik teknolojilerin (kromozomal mikroarray, trio-ekzom ve tüm genom dizileme) klinik uygulamaya girmesiyle, daha önce açıklanamayan OSB vakalarında moleküler tanı verimi önemli ölçüde artmış ve OSB'nin genetik yapısının çok daha yüksek çözünürlüklü bir karakterizasyonu mümkün hale gelmiştir. Bu gelişmeler, patojenik genomik yeniden düzenlemelerin OSB ve ilgili gelişimsel bozukluklara önemli katkısını ortaya koymuştur.¹

2000'li yılların ortalarından bu yana, yüksek çözünürlüklü genomik teknolojilerin yaygın olarak benimsenmesi, OSB'nin genomik yapısına yeni bir bakış açısı getirmiştir. Kopya sayısı varyasyonlarının insan genomunda daha önce bilindiğinden çok daha yaygın olduğu gösterilmiştir; yapısal varyantlar, bireyler arası genomik varyasyonun yaklaşık %5-10'unu oluşturur ve bu varyantların bir alt kümesi OSB, zihinsel gelişim bozuklukları ve konjenital anomalilerle doğrudan ilişkilidir. Bu bulgular, OSB etyolojisinde hem tekrarlayan hem de bireye özgü (tekrarlanmayan) de novo CNV'lerin tanısallığını vurgulamaktadır.²

¹ Öğr. Gör. Dr., Başkent Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD., Çocuk Nörolojisi BD., hakanerc1234@gmail.com, ORCID iD: 0000-0002-4286-1146



Tam penetranslı ve klinik olarak anlamlı duplikasyonlar arasında en yaygın olanı, OSB ile iyi bilinen genetik bir anomali olan 15q11.2-q13.3 bölgesindeki duplikasyondur; bunu OSB ile güçlü biçimde ilişkili 7q11.23 bölgesindeki artış (gain) izlemektedir. Eksik penetranslı duplikasyonlar ise 22q11.2, 1q21.1 ve 15q13.2-q13.3 bölgelerini içermektedir. OSB ile ilişkili en yaygın tekrarlayan CNV'ler, OSB'li bireylerin yaklaşık %1'inde tespit edilen, sırasıyla %0,42 ve %0,39 sıklıkta görülen 16p11.2 bölgesindeki mikrolelesyonlar ve mikroduplikasyonlardır. Ayrıca, sporadik OSB'li kişiler, kardeşleri OSB'li olan otistik vakalara göre nadir de novo CNV'lere sahip olma olasılıkları daha yüksektir.²⁸

Sonuç olarak, OSB'nin genetik temeli, hem yüksek etkili monogenik bozuklukları hem de daha geniş bir genomik varyasyon yelpazesini içeren çok katmanlı bir yapıya sahiptir. Kopya sayısı değişikliklerinden de novo mutasyonlara ve poligenik risk modellerine kadar uzanan bu geniş genetik çeşitlilik, OSB'nin heterojen klinik görünümünü anlamada kritik bir rol oynamaktadır. Modern genomik teknolojiler tanısal verimi belirgin şekilde artırarak hem sendromik hem de sendromik olmayan olguların etyolojik aydınlatılmasına katkı sağlamaktadır. Bu ilerlemeler, yalnızca tanısal doğruluğu artırmakla kalmayıp, aynı zamanda bireye özgü izlem, tedavi ve danışmanlık stratejilerinin geliştirilmesine zemin hazırlamaktadır. Gelecekte, ileri dizileme teknikleri ve multi-omik yaklaşımların rutin pratiğe entegrasyonu ile OSB'nin genetik mimarisinin daha kapsamlı biçimde çözüleceği ve klinik yönetimin daha da kişiselleştirilebilir hale geleceği öngörülmektedir.

KAYNAKLAR

1. Tammimies K, Marshall CR, Walker S, et al. Molecular diagnostic yield of chromosomal microarray analysis and whole-Exome sequencing in children with autism spectrum disorder. *JAMA*. 2015;314:895-903. doi:10.1001/jama.2015.10078
2. Wiśniowiecka-Kowalik B, Nowakowska BA. Genetics and epigenetics of autism spectrum disorder-current evidence in the field. *J Appl Genet*. 2019;60:37-47. doi:10.1007/s13353-018-00480-w
3. Schaefer GB, Mendelsohn NJ; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med*. 2013;15:399-407. doi:10.1038/gim.2013.32
4. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. *Curr Opin Genet Dev*. 2012;22:229-237. doi:10.1016/j.gde.2012.03.002
5. Velinov M. Genomic copy number variations in the autism Clinic-Work in progress. *Front Cell Neurosci*. 2019;13:57. doi:10.3389/fncel.2019.00057
6. Donovan AP, Basson MA. The neuroanatomy of autism - a developmental perspective. *J Anat*. 2017;230:4-15. doi:10.1111/joa.12542



7. Weiner DJ, Wigdor EM, Ripke S, et al. Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders. *Nat Genet.* 2017;49:978-985. doi:10.1038/ng.3863
8. Acero-Garcés DO, Saldarriaga W, Cabal-Herrera AM, Rojas CA, Hagerman RJ. Fragile X Syndrome in children. *Colomb Med (Cali).* 2023;54:e4005089. doi:10.25100/cm.v54i2.5089
9. Hnoonal A, Jankittunpaiboon C, Limprasert P. Screening for FMR1 CGG repeat expansion in Thai patients with autism spectrum disorder. *BioMed research international*, 2021, 4359308. doi:10.1155/2021/4359308
10. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. *JAMA.* 2004;291:460-469. doi:10.1001/jama.291.4.460
11. Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. *Genet Med.* 2019;21:2413-2421. doi:10.1038/s41436-019-0554-6
12. Iossifov I, O'Roak BJ, Sanders SJ, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature.* 2014;515:216-221. doi:10.1038/nature13908
13. Sanders SJ, Ercan-Sencicek AG, Hus V, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. *Neuron.* 2011;70:863-885. doi:10.1016/j.neuron.2011.05.002
14. Ruzzo EK, Pérez-Cano L, Jung JY, et al. Inherited and de novo genetic risk for autism impacts shared networks. *Cell.* 2019;178:850-866.e26. doi:10.1016/j.cell.2019.07.015
15. Gigante S, Gouil Q, Lucattini A, et al. Using long-read sequencing to detect imprinted DNA methylation. *Nucleic Acids Res.* 2019;47:e46. doi:10.1093/nar/gkz107
16. De Coster W, Weissensteiner MH, Sedlazeck FJ. Towards population-scale long-read sequencing. *Nat Rev Genet.* 2021;22:572-587. doi:10.1038/s41576-021-00367-3
17. Aref-Eshghi E, Kerkhof J, Pedro VP, et al. Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders. *Am J Hum Genet.* 2020;106:356-370. doi:10.1016/j.ajhg.2020.01.019
18. Butler M, Rafi S, Manzardo A. High-resolution chromosome ideogram representation of currently recognized genes for autism spectrum disorders. *Int. J. Mol. Sci.* 2015;16, 6464-6495.
19. Varghese M, Keshav N, Jacot-Descombes S, et al. Autism spectrum disorder: Neuropathology and animal models. *Acta Neuropathol.* 2017;134, 537-566.
20. Kotulska K, Jóźwiak S. Autism in monogenic disorders. *Eur. J. Paediatr. Neurol.* 2011;15, 177-180.
21. Acero-Garcés DO, Saldarriaga W, Cabal-Herrera AM, Rojas CA, Hagerman RJ. Fragile X Syndrome in Children. *Colomb. Med.* 2023, 54, e4005089.
22. Lombardo B, Pagani M, De Rosa A, et al. D-Aspartate oxidase gene duplication induces social recognition memory deficit in mice and intellectual disabilities in Humans. *Transl. Psychiatry* 2022, 12, 305.
23. Miles JH, Takahashi TN, Hong J, et al. Development and validation of a measure of dysmorphism: useful for autism subgroup classification. *Am J Med Genet A.* 2008;146A:1101-16. doi: 10.1002/ajmg.a.32244.
24. Vorstman JAS, Scherer SW. Contemplating syndromic autism. *Genet Med.* 2023 Oct;25:100919. doi: 10.1016/j.gim.2023.100919.
25. Laurvick CL, de Klerk N, Bower C, et al. Rett syndrome in Australia: a review of the epidemiology. *J Pediatr.* 2006 Mar;148:347-52. doi: 10.1016/j.jpeds.2005.10.037.
26. Dimitropoulos A, Schultz RT. Autistic-like symptomatology in Prader-Willi syndrome: a review of recent findings. *Curr Psychiatry Rep.* 2007 Apr;9:159-64. doi: 10.1007/s11920-007-0086-7.



27. Moreno-De-Luca D, Sanders SJ, Willsey AJ, et al. Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts. *Mol Psychiatry*. 2013 Oct;18:1090-5. doi: 10.1038/mp.2012.138.
28. Iakoucheva LM, Muotri AR, Sebat J. Getting to the Cores of Autism. *Cell*. 2019 Sep 5;178:1287-1298. doi: 10.1016/j.cell.2019.07.037.

RETT SENDROMU

Olca GÜNGÖR¹
Beste KİPÇAK YÜZBAŞI²

GİRİŞ

Rett sendromu (RS), olguların %96'dan fazlasında Xq28 bölgesinde yer alan MECP2 genindeki kayıp-fonksiyon varyantlarından kaynaklanan ağır bir nörogelişimsel bozukluktur.¹ Bugüne kadar 300'ü aşkın patojenik varyant tanımlanmış olup, olguların %60'ından fazlası yalnızca sekiz ortak "hotspot" mutasyonla açıklanır. Mutasyonların büyük bölümü de novo olup, erkeklerdeki MECP2 varyantları çoğunlukla ağır nörolojik fenotiplere ve sınırlı yaşam süresine yol açmaktadır. Buna karşın RS'li kızların yaklaşık %70'i erişkin yaşlara, hatta 50'li yaşlara kadar yaşayabilmektedir. MeCP2 proteini tüm dokularda bulunmakla birlikte özellikle beyinde yüksek düzeyde ifade edilir ve normal nörogelişim için kritiktir. Metillenmiş DNA'ya bağlanarak transkripsiyonel baskılamayı yapan bu protein; kromatin organizasyonu, alternatif kesim-birleştirme ve mikroRNA süreçleri gibi ek düzenleyici rollere de sahiptir.^{2,3} 2010'lu yıllara kadar RS yönetimi büyük ölçüde semptomatik yaklaşımlara dayanırken, doğal seyir çalışmalarındaki ilerlemeler klinik bulguların ortaya çıkış zamanlarını daha iyi tanımlamış ve daha hedefli önleyici stratejiler geliştirilmesine olanak sağlamıştır.^{4,5} Günümüzde kür sağlayan bir tedavi bulunmamakla birlikte, IGF-1 ilişkili bir bileşik olan trofinetide çoklu semptomlarda anlamlı iyileşme göstermiş ve RS için FDA onayı alan ilk tedavi olmuştur. Buna ek olarak farmakolojik ve gen temelli yeni tedavi yaklaşımlarının geliştirilmesi devam etmektedir.⁶

¹ Prof. Dr., Pamukkale Üniversitesi Tıp Fakültesi Çocuk Nörolojisi BD., drolcaygungorgmail.com, ORCID iD: 0000-0001-8665-6008

² Dr. Öğr. Üyesi, Dr. Pamukkale Üniversitesi Tıp Fakültesi Çocuk Nörolojisi, mbes225@hotmail.com, ORCID iD: 0000-0002-9850-931X



rinde motor fonksiyon, solunum ve yaşam süresinde belirgin iyileşmeler gösterilmiş olup ilk insan klinik çalışmaları 2022–2023 yıllarında başlamıştır.^{62,63}

B) X Kromozomu İnaktivasyonunun (XCI) Modülasyonu

Amaç, inaktif X üzerindeki sağlıklı MECP2 genini yeniden aktive etmektir. Xist RNA inhibisyonu ve CRISPR temelli epigenetik yeniden düzenleme çalışmaları preklinik aşamadadır.⁶⁴

C) Antisens Oligonükleotidler (ASO)

ASO'lar mRNA düzeyinde hatalı MECP2 transkriptlerini düzeltmeyi veya normal proteinin üretimini artırmayı hedefler. Erken preklinik sonuçlar ümit vericidir.⁶³

D) Protein stabilizasyonu ve şaperon tedavileri

Yanlış katlanan MeCP2 proteinlerinin stabilize edilmesi üzerine çalışmalar devam etmektedir.⁶⁵

E) Hücresel Tedaviler

Astrosit veya mikrogliya nakli gibi yaklaşımlar hayvan modellerinde denenmiş, ancak klinik aşamaya henüz geçmemiştir.⁶⁶

|SONUÇ

RS, nörogelişimsel bozukluklar içinde tedaviye en açık olanlardan biri kabul edilmektedir. MeCP2 biyolojisinin daha iyi anlaşılması, uygun klinik ölçütlerin geliştirilmesi ve gen tedavisi güvenlik parametrelerinin optimize edilmesi ile gelecekte daha etkili tedavilerin geliştirilmesi beklenmektedir.

|KAYNAKLAR

1. Laurvick CL, de Klerk N, Bower C, et al. Rett syndrome in Australia: a review of the epidemiology. *J Pediatr.* 2006;148:347-352.
2. Neul JL, Fang P, Barrish J, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. *Neurology.* 2008;70:1313-1321.
3. Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet.* 1999;23:185-188.
4. Fu C, Armstrong D, Marsh E, et al. Multisystem comorbidities in classic Rett syndrome: a scoping review. *BMJ Paediatr Open.* 2020;4:e000731.
5. Fu C, Percy AK, Leonard H. Consensus guidelines on managing Rett syndrome across the lifespan. *BMJ Paediatr Open.* 2020;4:e000717.
6. Neul JL, Percy AK, Glaze DG, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. *Nat Med.* 2023;29:1468-1475.



7. Petriti U, Dudman DC, Scosyrev E, Lopez-Leon S. Global prevalence of Rett syndrome: systematic review and meta-analysis. *Syst Rev*. 2023;12:5.
8. Hagberg B, Goutières F, Hanefeld F, Rett A, Wilson J. Rett syndrome: criteria for inclusion and exclusion. *Brain Dev*. 1985;7:372-373.
9. Kozinetz CA, Skender ML, MacNaughton N, et al. Epidemiology of Rett syndrome: a population-based registry. *Pediatrics*. 1993;91:445-450.
10. Kriaucionis S, Bird A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. *Nucleic Acids Res*. 2004;32:1818-1823.
11. Mnatzakanian GN, Lohi H, Munteanu I, et al. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. *Nat Genet*. 2004;36:339-341.
12. Bebbington A, Percy A, Christodoulou J, et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. *Neurology*. 2008;70:868-875.
13. Cuddapah VA, Pillai RB, Shekar KV, et al. Methyl-CpG-binding protein 2 mutation type is associated with disease severity in Rett syndrome. *J Med Genet*. 2014;51:152-158.
14. Lewis JD, Meehan RR, Henzel WJ, et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. *Cell*. 1992;69:905-914.
15. Lyst MJ, Ekiert R, Ebert DH, et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. *Nat Neurosci*. 2013;16:898-902.
16. Lagger S, Connelly J, Schweikert G, et al. MeCP2 recognizes cytosine methylated tri-nucleotide and di-nucleotide sequences to tune transcription in the mammalian brain. *PLoS Genet*. 2017;13:e1006793.
17. Banerjee A, Miller MT, Li K, Sur M, Kaufmann WE. Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder. *Brain*. 2019;142:239-248.
18. Kaufmann WE, Johnston MV, Blue ME. MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution. *Brain Dev*. 2005;27(Suppl 1):S77-S87.
19. Kaufmann WE, Stallworth JL, Everman DB, Skinner SA. Neurobiologically-based treatments in Rett syndrome: opportunities and challenges. *Expert Opin Orphan Drugs*. 2016;4:1043-1055.
20. Killian JT, Lane JB, Cutter GR, et al. Scoliosis in Rett syndrome: progression, comorbidities, and predictors. *Pediatr Neurol*. 2017;70:20-25.
21. Carter JC, Lanham DC, Pham D, Bibat GM, Naidu S, Kaufmann WE. Selective cerebral volume reduction in Rett syndrome: a multiple-approach MR imaging study. *AJNR Am J Neuroradiol*. 2008;29:436-441.
22. Xu X, Pozzo-Miller L. EEA1 restores homeostatic synaptic plasticity in hippocampal neurons from Rett syndrome mice. *J Physiol*. 2017;595:5699-5712.
23. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. *Science*. 2007;315:1143-1147.
24. Robinson L, Guy J, McKay L, et al. Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. *Brain*. 2012;135:2699-2710.
25. Ehrhart F, Coort SL, Elsenaar F, et al. Rett syndrome—biological pathways leading from MECP2 to disorder phenotypes. *Orphanet J Rare Dis*. 2016;11:158.
26. Samaco RC, Mandel G, Percy AK. Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. *Proc Natl Acad Sci USA*. 2009;106:21966-21971.
27. Blue ME, Naidu S, Johnston MV. Temporal and regional alterations in NMDA receptor expression in Mecp2-null mice. *Anat Rec*. 2011;294:1624-1634.



28. Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. *Ann Neurol*. 2010;68:944-950.
29. Mendoza J, Downs J, Wong K, Leonard H. Determinants of quality of life in Rett syndrome: new findings on associations with genotype. *J Med Genet*. 2021;58:637-644.
30. Hagberg B, Hanefeld F, Percy AK, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. *Eur J Paediatr Neurol*. 2002;6:293-297.
31. Tarquinio DC, Hou W, Berg A, et al. Age of diagnosis in Rett syndrome: patterns of recognition among diagnosticians and risk factors for late diagnosis. *Pediatr Neurol*. 2015;52:585-591.
32. Tan WH, Bird LM, Thibert RL, Williams CA. If not Angelman, what is it? A review of Angelman-like syndromes. *Am J Med Genet A*. 2014;164:975-992.
33. Neul JL. The relationship of Rett syndrome and MECP2 disorders to autism. *Dialogues Clin Neurosci*. 2012;14:253-262.
34. Tarquinio DC, Hou W, Berg A, et al. Growth failure and outcome in Rett syndrome: specific growth references. *Neurology*. 2012;79:1653-1661.
35. Percy AK. Rett syndrome: exploring the autism link. *Arch Neurol*. 2011;68:985-989.
36. Tarquinio DC, Hou W, Berg A, et al. Longitudinal course of epilepsy in Rett syndrome and related disorders. *Brain*. 2017;140:306-318.
37. Tarquinio DC, Hou W, Berg A, et al. The course of awake breathing disturbances across the lifespan in Rett syndrome. *Brain Dev*. 2018;40:515-529.
38. Neul JL, Fang P, Barrish J, et al. The array of clinical phenotypes of males with mutations in methyl-CpG-binding protein 2. *Am J Med Genet B Neuropsychiatr Genet*. 2019;180:55-67.
39. Yoon JA, Yoo Y, Lee JS, Kim YM, Shin YB. An early seizure variant type of a male Rett syndrome patient with a MECP2 p.Arg133His missense mutation. *Mol Genet Genomic Med*. 2019;7:e532.
40. Leonard H, Cobb S, Downs J. Clinical and biological progress over 50 years in Rett syndrome. *Nat Rev Neurol*. 2017;13:37-51.
41. Glaze DG, Percy AK, Skinner S, et al. Epilepsy and the natural history of Rett syndrome. *Neurology*. 2010;74:909-912.
42. Spagnoli C, Fusco C, Pisani F. Rett syndrome spectrum in monogenic developmental-epileptic encephalopathies and epilepsies: a review. *Genes*. 2021;12:1157.
43. Lane JB, Perry A, Glaze DG, et al. Clinical severity and quality of life in children and adolescents with Rett syndrome. *Neurology*. 2011;77:1812-1818.
44. Parisi L, Di Filippo T, Roccella M. The quality of life in girls with Rett syndrome. *Ment Illn*. 2016;8:6302.
45. Harrison DJ, Webb PJ. Scoliosis in the Rett syndrome: natural history and treatment. *Brain Dev*. 1990;12:154-156.
46. Killian JT, Lane JB, Cutter GR, et al. Scoliosis in Rett syndrome: progression, comorbidities, and predictors. *Pediatr Neurol*. 2017;70:20-25.
47. Killian JT, Lane JB, Cutter GR, et al. Pubertal development in Rett syndrome deviates from typical females. *Pediatr Neurol*. 2014;51:769-775.
48. Tarquinio DC, Hou W, Berg A, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. *Pediatr Neurol*. 2015;53:402-411.
49. Neul JL, Kaufmann WE, Glaze DG, et al. Top caregiver concerns in Rett syndrome and related disorders: data from the US Natural History Study. *J Neurodev Disord*. 2023;15:33.
50. Kaufmann WE, Stallworth JL, Everman DB, et al. Burden of illness in Rett syndrome: initial evaluation of a disorder-specific caregiver survey. *Orphanet J Rare Dis*. 2024;19:296. Chapleau CA, Lane J, Pozzo-Miller L, Percy AK. Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives. *Curr Clin Pharmacol*. 2013;8:358-369.



51. Buchanan CB, Stallworth JL, Percy AK, et al. Behavioral profiles in Rett syndrome: data from the Natural History Study. *Brain Dev.* 2019;41:123-134.
52. Itoh M, Ide S, Takashima S, Tanaka S. Methyl CpG-binding protein 2 directly regulates insulin-like growth factor binding protein 3 in mouse and human brains. *J Neuropathol Exp Neurol.* 2007;66:117-123.
53. Khwaja OS, Ho E, Barnes KV, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin for the treatment of Rett syndrome. *Proc Natl Acad Sci USA.* 2014;111:4596-4601.
54. Marsh ED, LaFleur B, Kelley KR, Motil KJ. Recommendations for the management of diarrhea with trofinetide use in Rett syndrome. *Expert Opin Orphan Drugs.* 2023;11:1-8.
55. Moore R, Marsh E, Stallworth J, Kaufmann W. Managing gastrointestinal symptoms resulting from treatment with trofinetide for Rett syndrome: caregiver and nurse perspectives. *Adv Ther.* 2024;41:1305-1317.
56. Keam SJ. Trofinetide: first approval. *Drugs.* 2023;83:819-824.
57. Parent H, Ferranti A, Niswender C. Trofinetide: a pioneering treatment for Rett syndrome. *Trends Pharmacol Sci.* 2023;44:740-741.
58. Nectoux J, Fardin V, Marret S, Bienvenu T. The p.Val66Met polymorphism in the BDNF gene protects against early seizures in Rett syndrome. *Neurology.* 2008;70:2145-2151.
59. Zeev BB, Bebbington A, Ho G, Leonard H, Christodoulou J. The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome. *Neurology.* 2009;72:1242-1247.
60. U.S. National Library of Medicine. *ClinicalTrials.gov* [Internet]. Bethesda (MD): National Library of Medicine; 2024 [cited 2026 Mar 25]. Available from: <https://clinicaltrials.gov/study/NCT05606614>
61. Palmieri M, Pozzer D, Landsberger N. Advanced genetic therapies for the treatment of Rett syndrome: state of the art and future perspectives. *Front Neurosci.* 2023;17:1172805.
62. Ip JPK, Mellios N, Sur M. Rett syndrome: insights into genetic, molecular and circuit mechanisms. *Nat Rev Neurosci.* 2018;19:368-382.
63. Katz DM, Bird A, Coenraads M, et al. Therapeutic approaches to Rett syndrome: progress and prospects. *Nat Rev Drug Discov.* 2016;15:687-700.
64. Grimm NB, Lee JT. Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome. *Trends Genet.* 2022;38:920-943.
65. Segatto M, Trapani L, Di Tunno I, et al. Cholesterol metabolism is altered in Rett syndrome: a study on plasma and fibroblasts. *PLoS One.* 2014;9:e104834.
66. Lioy DT, Garg SK, Monaghan CE, et al. A role for glia in the progression of Rett's syndrome. *Nature.* 2011;475:497-500.

ASPERGER SENDROMU

Mustafa DİNÇER¹
Müge AYANOĞLU²

GİRİŞ

Asperger Sendromu (AS), ilk kez DSM-IV’de; sosyal-duygusal gelişimde kısıtlılık ve farklılıklarla birlikte tekrarlayıcı davranışlar ve ilgi alanlarıyla seyreden bir bozukluktur şeklinde tanımlanmıştır. Asperger Sendromu, resmi tanımlama sistemleri olan ICD-10 (1993) ve DSM-IV’de (1994) ilk kez **“Asperger Bozukluğu”** olarak tanımlanmasından, DSM-V (2013) ve ICD-11’de (2022) ortadan kaldırılıp.^{1,2} Otizm Spektrum Bozukluğu (OSB) kapsamına alınmasına kadar her zaman bilimsel ve klinik alanda büyük ilgi uyandırmış ve tartışma yaratmıştır.¹⁻⁶ Bugüne kadar, tanı sınıflaması, fenomenolojisi, tarihsel bağlamı, doğası ve birçok alanda süregelen tartışmalar devam etmekte olup terminoloji değişmeye devam etmektedir.

TANIM VE TARİHÇE

1944’de Hans Asperger, yaşları 6-11 arasında değişen dört erkek olguda; basmakalıp, yineleyici davranışlar, motor becerilerde zorluk/sakarlık, özel ilgi alanlarına aşırı yönelme ve sosyal izolasyon olduğunu gözlemlemiş ve **“otistik psikopati”** adını verdiği bu tabloyu kişilik bozukluğu olarak tanımlamıştır. Bu belirtilerin aileleri tarafından 3 yaşından sonra fark edildiğini, çocukların zeka-

¹ Dr. Öğr. Üyesi, Adnan Menderes Üniversitesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., dincermustafamd@gmail.com, ORCID iD: 0000-0001-6056-8157

² Doç. Dr., Adnan Menderes Üniversitesi Çocuk Sağlığı ve Hastalıkları AD., Çocuk Nöroloji BD., muge.ayanoglu@adu.edu.tr, ORCID iD: 0000-0002-0556-1435



AS olsun ister YİO, sadece psikiyatrik tanılarıyla tanımlanmamalıdır. Bu bireylerin psikiyatrik değerlendirilmesi yapıldıktan sonra durumun başvuran kişi veya ailesi ile paylaşılması gerekmektedir. Bu şekilde ailenin yapması gerekenler, çocukları ile ilgili beklentileri, çocuk/ergenin kendisi ile ilgili farkındalıkları ve beklentileri gerçekçi düzeye getirilir. Tanısal değerlendirme ve uygun bilgilendirme farkındalıklarını arttırmaya katkı sağlar. AS/ YİO 'lu bireylerde müdahale stratejileri hastanın yaşına, güçlü yanlarına, zayıf yanlarına ve ihtiyaçlarına göre değişir. Bazen aileler hatta ergenler de kendileri için okuyup, araştırıp gelerek “Asperger miyim?” sorusunun cevabını almak için bile başvurabilmektedirler. Ayrıntılı değerlendirme sonrası bireyin güçlü ve yetersiz olduğu alanlar tespit edilerek takip ve tedavi ona göre düzenlenmelidir. Erken yaşlar için uygun eğitimsel programlara yönlendirmek gerekirken, daha büyük yaşlarda özellikle sosyal-iletişimsel ve uyum becerilerine göre terapötik yaklaşımlar gerekir. Okul seçimi, öğretmenler, ebeveyn ve sağlık profesyonellerinin iş birliği önemlidir. Bu bireylerin psikiyatrik takipte olmaları genel klinik gidişlerinin izleyerek uygun yönlendirmelerinin yapılmasını sağlar. Ayrıca AS/ YİO ile komorbid psikiyatrik bozukluklar sık gözlenmektedir. Bu durumlarda eş tanı ve tanıya uygun psikoterapötik müdahale önem taşımaktadır.

Son olarak, AS'nin mevcut ICD-11 ve DSM-5'te artık bir tanı kategorisi olmaması bu durumun var olmadığının göstergesi olamaz.³² Bu bireylerin ve ailelerin semptomlarını adlandırıp tanı almaya, tedavi olmaya ve destek almaya ihtiyaçları vardır. Bu ihtiyaçları korumak sınıflandırma sistemlerinin kategorik yaklaşımla tanımladığı kriterlerden daha önemlidir.

KAYNAKLAR

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). Washington: American Psychiatric Association; 2013.
2. World Health Organization. ICD-11 for mortality and morbidity statistics: 6A02 autism spectrum disorder. 2022.
3. Woodbury-Smith MR, Volkmar FR. Asperger syndrome. Eur Child Adolesc Psychiatry. 2009;18(1):2–11.
4. Cohen SB. Is Asperger Syndrome Necessarily Viewed as a Disability? Focus Autism Other Dev Disabl. 2002;17(3):186–91.
5. Freeman BJ, Cronin P. Asperger Syndrome or Autistic Disorder?: The Diagnostic Dilemma. Focus Autism Other Dev Disabl. 2002;17(3):145–51.
6. Mayes SD, Calhoun SL, Crites DL. Does DSM-IV Asperger's disorder exist? J Abnorm Child Psychol. 2001;29(3):263–71.
7. Asperger H. Die “Autistischen Psychopathen” im Kindesalter. Habilitationsschrift, eingereicht bei der medizinischen Fakultät der Wiener Universität. Arch Psychiatr Nervenkr [Internet].



- 1944;117(1):76–136. Available from: <http://www.th-hoffmann.eu/archiv/asperger/asperger.1944.pdf>
8. Kanner L. AUTISTIC DISTURBANCES OF AFFECTIVE CONTACT. 1943;217–50.
9. Wing L. Asperger's syndrome: A clinical account. *Psychol Med*. 1981;11(1):115–29.
10. Wolff S. The first account of the syndrome Asperger described? *Eur Child Adolesc Psychiatry*. 1996;5(3):119–32.
11. Sukhareva G. Shizoidnyye psixopatii v detskom vozraste [Schizoid personality disorders of childhood]. *Vopr Pedol i Det psikhonevrologii*. 1925;157–187.
12. Sher DA, Gibson JL. Pioneering, prodigious and perspicacious: Grunya Efimovna Sukhareva's life and contribution to conceptualising autism and schizophrenia. *Eur Child Adolesc Psychiatry* [Internet]. 2023;32(3):475–90. Available from: <https://doi.org/10.1007/s00787-021-01875-7>
13. Posar A, Visconti P. Grunya Efimovna Sukhareva's work in the field of autism spectrum disorder. *Eur Child Adolesc Psychiatry*. 2025;10–1.
14. Baron-Cohen S, Klin A, Silberman S, Buxbaum JD. Did Hans Asperger actively assist the Nazi euthanasia program? *Mol Autism*. 2018;9(1):1–2.
15. Sheffer E. ASPERGER'S CHILDREN The Origins of Autism in Nazi Vienna. WW Norton & Company; 2018.
16. Czech H. Hans Asperger, National Socialism, and “race hygiene” in Nazi-era Vienna. *Mol Autism*. 2018;9(1):1–43.
17. Falk D. Non-complicit: Revisiting Hans Asperger's Career in Nazi-era Vienna. *J Autism Dev Disord* [Internet]. 2020;50(7):2573–84. Available from: <https://doi.org/10.1007/s10803-019-03981-7>
18. Gillberg C. Hans Asperger: True or not? *Acta Paediatr Int J Paediatr*. 2023;112(5):896.
19. Tatzer E, Maleczek W. Was Hans Asperger Complicit in the Nazi Child Euthanasia by Participating in the Gugging Commission?: An Assessment. *Z Kinder Jugendpsychiatr Psychother*. 2024;1–11.
20. Silberman S. *NeuroTribes: The Legacy of Autism and the Future of Neurodiversity*. New York: Penguin; 2015. 544 p.
21. Barahona-Corrêa JB, Filipe CN. A concise history of asperger syndrome: The short reign of a troublesome diagnosis. *Front Psychol*. 2016;6(JAN):1–7.
22. Irwin JK, MacSween J, Kerns KA. History and evolution of the autism spectrum disorders. In: *International Handbook of Autism and Pervasive Developmental Disorders*. New York, NY: Springer New York; 2011. p. 3–16.
23. Klin A, Volkmar FR. Asperger syndrome. *Child Adolesc Psychiatr Clin N Am*. 2003;12(1):xiii–xvi.
24. Gillberg C. *A guide to Asperger syndrome*. Cambridge University Press; 2002.
25. FRED R. VOLKMAR, SALLY J. ROGERS, RHEA PAUL AKAP. *HANDBOOK OF AUTISM AND PERVASIVE DEVELOPMENTAL DISORDERS*. Vol. 2, John Wiley & Sons, Inc. 2014.
26. American Psychiatric Association (APA). *Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV)*. Washington, DC: American Psychiatric Publishing; 1994.
27. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (3rd edition, revised) (DSM-III-R)*. In Washington, DC: American Psychiatric Association; 1987.
28. Rosen NE, Lord C, Volkmar FR. The Diagnosis of Autism: From Kanner to DSM-III to DSM-5 and Beyond. *J Autism Dev Disord* [Internet]. 2021;51(12):4253–70. Available from: <https://doi.org/10.1007/s10803-021-04904-1>
29. Tantam D. Asperger's syndrome. *J child Psychol psychiatry*. 1988;29(3):245–55.



30. World Health Organization. The ICD-10 classification of mental and behavioral disorders: Diagnostic criteria for research. 1993.
31. Kamp-Becker I. Autism spectrum disorder in ICD-11—a critical reflection of its possible impact on clinical practice and research. *Mol Psychiatry* [Internet]. 2024;29(3):633–8. Available from: <http://dx.doi.org/10.1038/s41380-023-02354-y>
32. Mukaddes, Nahit M. Otizm spektrum bozuklukları. Tanı ve takip. 3. Baskı. 2023.
33. Macintosh KE, Dissanayake C. Annotation: The similarities and differences between autistic disorder and Asperger's disorder: A review of the empirical evidence. *J Child Psychol Psychiatry Allied Discip.* 2004;45(3):421–34.
34. Ghaziuddin M, Mountain-Kimchi K. Defining the intellectual profile of Asperger syndrome: Comparison with high-functioning autism. *J Autism Dev Disord.* 2004;34(3):279–84.
35. Schopler E, Mesibov, B. G, Kuncie LJ. Asperger Syndrome or High-Functioning Autism? Asperger Syndrome or High-Functioning Autism? 1998.
36. Ozonoff S, South M, Miller JN. DSM-IV-Defined Asperger Syndrome: Cognitive, Behavioral and Early History Differentiation from High Functioning Autism. *Autism.* 2000;4(1):29–46.
37. Gillberg C, Billstedt E. Autism and Asperger syndrome: Coexistence with other clinical disorders. *Acta Psychiatr Scand.* 2000;102(5):321–30.
38. Motlani V, Motlani G, Thool A. Asperger Syndrome (AS): A Review Article. *Cureus.* 2022;14(11):11–6.
39. de Giambattista C, Ventura P, Trerotoli P, Margari M, Palumbi R, Margari L. Subtyping the Autism Spectrum Disorder: Comparison of Children with High Functioning Autism and Asperger Syndrome. *J Autism Dev Disord* [Internet]. 2019;49(1):138–50. Available from: <http://dx.doi.org/10.1007/s10803-018-3689-4>
40. Mirkovic B, Gérardin P. Asperger's syndrome: What to consider? *Encephale* [Internet]. 2019;45(2):169–74. Available from: <https://doi.org/10.1016/j.encep.2018.11.005>
41. Helles A, Gillberg IC, Gillberg C, Billstedt E. Asperger syndrome in males over two decades: Quality of life in relation to diagnostic stability and psychiatric comorbidity. *Autism.* 2017;21(4):458–69.
42. Rofman E. Asperger Syndrome: Assessing and Treating High-Functioning Autism Spectrum Disorders, 2nd ed. Vol. 77, *Journal of Clinical Psychiatry.* 2016. 31–31 p.
43. Boschi A, Planche P, Hemimou C, Demily C, Vaivre-Douret L. From high intellectual potential to asperger syndrome: Evidence for differences and a fundamental overlap-A systematic review. *Front Psychol.* 2016;7(OCT).
44. Helles A, Gillberg CI, Gillberg C, Billstedt E. Asperger syndrome in males over two decades: Stability and predictors of diagnosis. *J Child Psychol Psychiatry Allied Discip.* 2015;56(6):711–8.
45. Volkmar FR. Autism Spectrum Disorders: A Handbook for Parents and Professionals. Vols. 1–2, : Volume 1: A-O: Volume 2: P-Z. 2007.
46. Manjiviona J, Prior M. Neuropsychological profiles of children with Asperger syndrome and autism. *Autism.* 1999;3(4):327–56.
47. Prior M, Leekam S, Ong B, Eisenmajer R, Wing L, Gould J, et al. Are there subgroups within the autistic spectrum? A cluster analysis of a group of children with autistic spectrum disorders. *J Child Psychol Psychiatry Allied Discip.* 1998;39(6):893–902.
48. Sharma S, Woolfson LM, Hunter SC. Confusion and inconsistency in diagnosis of Asperger syndrome: A review of studies from 1981 to 2010. *Autism.* 2012;16(5):465–86.
49. Tsai LY, Ghaziuddin M. DSM-5 ASD moves forward into the past. *J Autism Dev Disord.* 2014;44(2):321–30.
50. Magnat J, Xavier J, Zammouri I, Cohen D. Developmental coordination disorder (DCD): Clinical aspects and state of art. *Neuropsychiatr Enfance Adolesc.* 2015;63(7):446–56.



51. Mukaddes, Nahit M. Tanının Ötesinde Otizm ve Asperger. 2023.
52. Demirkaya SK, Tutkunkardaş MD, Mukaddes NM. Assessment of suicidality in children and adolescents with diagnosis of high functioning autism spectrum disorder in a Turkish clinical sample. *Neuropsychiatr Dis Treat* [Internet]. 2016;12:2921–6. Available from: <https://doi.org/10.2147/NDT.S118304>
53. Schultz RT, Gauthier I, Klin A, Fulbright RK, Anderson AW, Volkmar F, et al. Abnormal ventral temporal cortical activity during face discrimination among individuals with autism and Asperger syndrome. *Arch Gen Psychiatry*. 2000;57(4):331–40.
54. Happé F, Ehlers S, Fletcher P, Frith U, Johansson M, Gillberg C, et al. “Theory of mind” in the brain. Evidence from a PET scan study of Asperger syndrome. *Neuroreport*. 1997;8(1):197–201.
55. van Duin EDA, Zinkstok J, McAlonan G, van Amelsvoort T. White matter brain structure in Asperger’s syndrome. *Compr Guid to Autism*. 2014;
56. Lincoln A, Courchesne E, Allen M, Hanson E, Ene M. Neurobiology of Asperger syndrome: Seven case studies and quantitative magnetic resonance imaging findings. *Asperger Syndr or high-functioning autism?* 1998;145–63.
57. McKelvey JR, Lambert R, Mottron L, Shevell MI. Right-hemisphere dysfunction in Asperger’s syndrome. *J Child Neurol*. 1995;10(4):310–4.
58. Hirjak D, Wolf RC, Paternoga I, Kubera KM, Thomann AK, Stieltjes B, et al. Neuroanatomical markers of neurological soft signs in recent-onset schizophrenia and Asperger-syndrome. *Brain Topogr*. 2016;29:382–94.
59. Cederlund M, Gillberg C. One hundred males with Asperger syndrome: a clinical study of background and associated factors. *Dev Med Child Neurol*. 2004;46(10):652–60.
60. Amiet C, Gourfinkel-An I, Bouzamondo A, Tordjman S, Baulac M, Lechat P, et al. Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. *Biol Psychiatry*. 2008;64(7):577–82.
61. Mouridsen SE, Rich B, Isager T. Epilepsy in individuals with a history of Asperger’s syndrome: a Danish nationwide register-based cohort study. *J Autism Dev Disord*. 2013;43:1308–13.

OTİZMDE TEDAVİNİN GENEL İLKELERİ

Begüm YULUĞ TAŞ¹
Gonca ÖZYURT²

GİRİŞ

OSB (Otizm Spektrum Bozukluğu) tanısı alan bireylerde bulgular bir spektrum dahilinde birbirinden farklı seyreder. Bu sebeple bireyin tedavi programı kişinin bulgularına ve yetersizlik alanlarına bağlı yapılmalı, bireysel takip programı uygulanmalıdır. Tedavi ilkeleri bireyin gelişimsel özelliklerine, aile ve sosyal hayatta yaşadığı problemlere odaklanmalıdır. Tedavinin erken yaşta başlaması (<4 yaş), verilen tedavinin yoğunluğu ve kalitesi, tedavi öncesinde bireyin bilişsel kapasitesinin yeterliliği, özellikle ilk 6 yaştaki fiziksel ve tıbbi özellikleri, bireyin sosyal kaçınmasının olmaması ve aile özellikleri tedaviden faydalanımı artırdığı bilinmektedir.¹

Otizm tedavi ilkelerine bakıldığında kanıtlanmış tek bir yöntem bulunmakla birlikte, hakkında en çok kanıta dayalı bilgi bulunan yöntemin eğitsel yöntemler olduğu bilinmektedir.² Eğitsel yöntemler haricinde, bireyin bulgularına eşlik eden psikiyatrik semptomlara yönelik ilaç tedavileri ve alternatif yöntemler de bulunmaktadır. OSB çok yönlü tedavi edilmesi gereken bir nörolojik şimsel bozukluk olup, bölümde tedavi yöntemleri anlatılmaya çalışılacaktır.

¹ Uzm. Dr., İzmir Tepecik Eğitim ve Araştırma Hastanesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Kliniği, yulugbegum@gmail.com, ORCID iD: 0000-0001-7289-4355

² Doç. Dr., İzmir Katip Çelebi Üniversitesi Tıp Fakültesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., goncaenginozyurt@gmail.com, ORCID iD: 0000-0002-0508-0594



Hiperbarik Oksijen Tedavisi: Hiperbarik oksijen tedavisinin beyin hipoksik kaldığı durumlarda uygulanması, otizmin etiopatogenezi araştırılırken bir tedavi yöntemi olup olamayacağı hususunda tartışma yaratmıştır. Her iki durumun birarada görüldüğü durumlarda uygulanması hipoksik beyin bölgelerine iyi gelebilirken, hipoksinin eşlik etmediği otizimli çocuklar için faydadan çok zarar oluşturabilmektedir. Nöbetlerde artma, kulak ağrısı gibi yan etkiler görülebilmektedir. Araştırmalar otizm semptomları üzerinde etkili olmadığı yönünde kanıtlar sunmuştur.⁶¹

Neurofeedback: Bu yöntem farklı beyin dalgalarını egzersizle normale çevirmeyi kişiye öğretmeyi hedeflemektedir. Çocuğun beyin dalgaları, belirli noktalara yerleştirilen elektrotlar aracılığıyla uygun yazılıma sahip bir bilgisayara aktarılmaktadır. Bu program, beyin dalgalarını kullanıcının kolaylıkla algılayabileceği bir animasyona dönüştürmektedir. Kullanıcı, bilgisayar oyunu formatındaki bu animasyonu izlerken oyunu beyin aktivitesi ile kontrol edebilir. Dikkatini oyuna yoğunlaştırdığında, beyin uygun elektriksel aktiviteye geçtiğinden puan kazanmaya başlar; ancak dikkati dağıldığında oyun üzerindeki kontrolünü kaybeder. Ancak yapılan araştırmalar otizm semptomlarının yönetiminde kanıtlanabilir bir etkisinin bulunmadığını göstermiştir.⁶²

Diğer Alternatif Yöntemler: Hayvan terapisi, müzik, spor, masaj gibi yöntemler yan etkisi düşük olan ve kısmen faydası olabilecek yöntemlerdir. Bu yöntemler otizm tedavisi olmayacağı ebeveynlere bildirilmelidir. Eşlik eden uyku problemleri, duyuşal hassasiyet, hiperaktivite, göz kontağında kısıtlılık gibi bulgulara olumlu etkileri bulunmaktadır.

KAYNAKLAR

1. Rogers SJ, Vismara LA. Evidence-Based Comprehensive Treatments for Early Autism. *Journal of Clinical Child and Adolescent Psychology*. 2008;37(1): 8-38. doi: 10.1080/15374410701817808.
2. Mukaddes NM. *Otizm Spektrum Bozuklukları*. İstanbul: Nobel Tıp Kitabevleri; 2017.
3. Bilgiç A. Otizm Spektrum Bozuklukları. *Bebek Ruh Sağlığı (0-4 Yaş) Temel Kitabı* içinde. Ankara: Akademisyen Kitabevi; 2020. p. 459-480.
4. Smith T. Applied Behavior Analysis and Early Intensive Behavioral Intervention. *Autism Spectrum Disorders*. 2011; p:1036-1055. doi: 10.1093/med/9780195371826.003.0066.
5. Smith T, Eikeseth S. O. Ivar Iovaas: pioneer of applied behavior analysis and intervention for children with autism. *Journal of Autism and Developmental Disorders*. 2011;41(3):375-378. doi: 10.1007/s10803-010-1162-0.
6. Bellini S, Akullian J. A Meta-Analysis of Video Modeling and Video Self-Modeling Interventions for Children and Adolescents with Autism Spectrum Disorders. *Exceptional Children*. 2007;73(3): 264-287. doi: 10.1177/001440290707300301.
7. Boyd BA, McDonough SG, Rupp B, et al. Effects of a family-implemented treatment on the



- repetitive behaviors of children with autism. *Journal of Autism and Developmental Disorders*. 2011;41(10): 1330-1341. doi: 10.1007/s10803-010-1156-y.
8. Strain P, Schwartz I. ABA and the Development of Meaningful Social Relations for Young Children with Autism. *Focus on Autism and Other Developmental Disabilities*. 2001;16(2): 120-128. doi: 10.1177/108835760101600208.
 9. Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. *Pediatrics*. 2010;125(1): e17-23. doi: 10.1542/peds.2009-0958.
 10. Lovaas OI. Behavioral treatment and normal educational and intellectual functioning in young autistic children. *Journal of Consulting and Clinical Psychology*. 1987;55(1): 3-9. doi: 10.1037//0022-006x.55.1.3.
 11. Lovaas OI. The development of a treatment-research project for developmentally disabled and autistic children. *Journal of Applied Behavior Analysis*. 1993;26(4): 617-630. doi: 10.1901/jaba.1993.26-617.
 12. Eldevik S, Hastings RP, Hughes JC, et al. Meta-analysis of Early Intensive Behavioral Intervention for children with autism. *Journal of Clinical Child and Adolescent Psychology*. 2009;38(3): 439-450. doi: 10.1080/15374410902851739.
 13. Magiati I, Charman T, Howlin P. A two-year prospective follow-up study of community-based early intensive behavioural intervention and specialist nursery provision for children with autism spectrum disorders. *Journal of Child Psychology and Psychiatry*. 2007;48(8): 803-812. doi: 10.1111/j.1469-7610.2007.01756.x.
 14. Mohammadzaheri F, Koegel LK, Rezaee M, et al. A randomized clinical trial comparison between pivotal response treatment (PRT) and structured applied behavior analysis (ABA) intervention for children with autism. *Journal of Autism and Developmental Disorders*. 2014;44(11): 2769-2777. doi: 10.1007/s10803-014-2137-3.
 15. Schreibman L, Dawson G, Stahmer AC, et al. Naturalistic Developmental Behavioral Interventions: Empirically Validated Treatments for Autism Spectrum Disorder. *Journal of Autism and Developmental Disorders*. 2015;45(8): 2411-2428. doi: 10.1007/s10803-015-2407-8.
 16. Kasari C, Freeman S, Paparella T. Joint attention and symbolic play in young children with autism: a randomized controlled intervention study. *Journal of Child Psychology and Psychiatry*. 2006;47(6): 611-620. doi: 10.1111/j.1469-7610.2005.01567.x.
 17. Koegel RL, Openden D, Fredeen RM, et al. The Basics of Pivotal Response Treatment. In: Koegel RL, Koegel LK (eds.) *Pivotal Response Treatments for Autism: Communication, Social, & Academic Development*. Baltimore, MD: Brookes; 2006. p. 3-30.
 18. Koegel LK, Koegel RL, Shoshan Y, et al. Pivotal response intervention II: Preliminary long-term outcome data. *The Journal of the Association for Persons with Severe Handicaps*. 1999;24(3): 186-198. doi: 10.2511/rpsd.24.3.186.
 19. Ventola P, Friedman HE, Anderson LC, et al. Improvements in social and adaptive functioning following short-duration PRT program: a clinical replication. *Journal of Autism and Developmental Disorders*. 2014;44(11): 2862-2870. doi: 10.1007/s10803-014-2145-3.
 20. Sherer MR, Schreibman L. Individual behavioral profiles and predictors of treatment effectiveness for children with autism. *Journal of Consulting and Clinical Psychology*. 2005;73(3): 525-538. doi: 10.1037/0022-006X.73.3.525.
 21. Hardan AY, Gengoux GW, Berquist KL, et al. A randomized controlled trial of Pivotal Response Treatment Group for parents of children with autism. *Journal of Child Psychology and Psychiatry*. 2015;56(8): 884-892. doi: 10.1111/jcpp.12354.
 22. Mohammadzaheri F, Koegel LK, Rezaee M, et al. A randomized clinical trial comparison between pivotal response treatment (PRT) and structured applied behavior analysis (ABA) intervention for children with autism. *Journal of Autism and Developmental Disorders*.



- 2014;44(11): 2769-2777. doi: 10.1007/s10803-014-2137-3.
23. Koegel RL, Bimbela A, Schreibman L. Collateral effects of parent training on family interactions. *Journal of Autism and Developmental Disorders*. 1996;26(3): 347-359. doi: 10.1007/BF02172479.
24. Greenspan SI, Wieder S. Relationship-Based Early Intervention Approach to Autistic Spectrum Disorders: The Developmental, Individual Difference, Relationship-Based Model (The DIR Model). In: Amaral D, Geschwind D, Dawson G, editors. *Autism Spectrum Disorders*. Oxford: Oxford University Press; 2011. p. 1068–1080.
25. Paul R, Sutherland D. Enhancing early language in children with autism spectrum disorders. In: Volkmar FR, Paul R, Klin A, Cohen DJ, editors. *Handbook of autism and pervasive developmental disorders*. 3rd ed. New York: Wiley; 2005. p. 946–977.
26. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders: DSM-5*. 5th ed. Washington (DC): American Psychiatric Association Publishing; 2013. p. 947.
27. Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in autism spectrum disorder. *Harvard Review of Psychiatry*. 2014;22(2): 76-92. doi: 10.1097/HRP.0000000000000030.
28. Spencer D, Marshall J, Post B, et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. *Pediatrics*. 2013;132(5): 833-840. doi: 10.1542/peds.2012-3774.
29. Esbensen AJ, Greenberg JS, Seltzer MM, et al. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. *Journal of Autism and Developmental Disorders*. 2009;39(9): 1339-1349. doi: 10.1007/s10803-009-0750-3.
30. Ames CS, White SJ. Are ADHD traits dissociable from the autistic profile? Links between cognition and behaviour. *Journal of Autism and Developmental Disorders*. 2011;41(3): 357-363. doi: 10.1007/s10803-010-1049-0.
31. Kılınçaslan A, Mukaddes NM, Küçükyazıcı GS, et al. Asperger Bozukluğu Olgularında Yürütücü İşlevler ve Dikkatin Değerlendirilmesi. *Türk Psikiyatri Dergisi*. 2010;21(4): 289-299.
32. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. *Arch Gen Psychiatry*. 2005;62(11): 1266-1274. doi: 10.1001/archpsyc.62.11.1266.
33. Aman MG, Farmer CA, Hollway J, et al. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. *Child and Adolescent Psychiatric Clinics of North America*. 2008;17(4): 713-738. doi: 10.1016/j.chc.2008.06.009.
34. Harfterkamp M, Buitelaar JK, Minderaa RB, et al. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. *Journal of Child and Adolescent Psychopharmacology*. 2013;23(3): 194-199. doi: 10.1089/cap.2012.0012.
35. Propper L. Managing disruptive behaviour in autism-spectrum disorder with guanfacine. *Journal of Psychiatry & Neuroscience*. 2018;43(5): 359-360. doi: 10.1503/jpn.180039.
36. Reiersen AM, Handen B. Commentary on 'Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)'. *Evidence-Based Child Health: A Cochrane Review Journal*. 2011;6(4): 1082-1085. doi: 10.1002/ebch.786.
37. Reiersen AM, Todd RD. Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment. *Expert Review of Neurotherapeutics*. 2008;8(4): 657-669. doi: 10.1586/14737175.8.4.657.
38. Gupta N, Gupta M, Gandhi R. Buspirone in Autism Spectrum Disorder: A Systematic Review. *Cureus*. 2023;15(5): e39304. doi: 10.7759/cureus.39304.
39. Hollander E, Soorya L, Chaplin W, et al. A double-blind placebo-controlled trial of fluoxetine



- for repetitive behaviors and global severity in adult autism spectrum disorders. *American Journal of Psychiatry*. 2012;169(3): 292-299. doi: 10.1176/appi.ajp.2011.10050764.
40. Martin A, Koenig K, Anderson GM, et al. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. *Journal of Autism and Developmental Disorders*. 2003;33(1): 77-85. doi: 10.1023/a:1022234605695.
 41. Giannotti F, Cortesi F, Cerquiglini A, et al. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. *Journal of Autism and Developmental Disorders*. 2006;36(6): 741-752. doi: 10.1007/s10803-006-0116-z.
 42. Huffman LC, Sutcliffe TL, Tanner ISD, et al. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. *Journal of Developmental & Behavioral Pediatrics*. 2011;32(1): 56-68. doi: 10.1097/DBP.0b013e3182040acf.
 43. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. *Journal of Autism and Developmental Disorders*. 2006;36(8): 1101-1114. doi: 10.1007/s10803-006-0147-5.
 44. Canitano R, Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. *Neuropsychiatric Disease and Treatment*. 2008;4(4): 723-730. doi: 10.2147/ndt.s1450.
 45. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. *Journal of Child and Adolescent Psychopharmacology*. 2006;16(5): 541-548. doi: 10.1089/cap.2006.16.541.
 46. Doyle CA, McDougle CJ. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. *Dialogues in Clinical Neuroscience*. 2012;14(3): 263-279. doi: 10.31887/DCNS.2012.14.3/cdoyle.
 47. Locascio JJ, Malone RP, et al. Factors related to haloperidol response and dyskinesias in autistic children. *Psychopharmacology Bulletin*. 1991;27(2): 119-126.
 48. McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. *Journal of Clinical Psychiatry*. 2003;64(4): 16-25.
 49. Marcus CL. Pediatric sleep medicine comes into its own. *Pediatrics*. 2004;113(5):1393-4. doi:10.1542/peds.113.5.1393.
 50. Salomone E, Charman T, McConachie H, et al. Prevalence and correlates of use of complementary and alternative medicine in children with autism spectrum disorder in Europe. *European Journal of Pediatrics*. 2015;174(10): 1277-1285. doi: 10.1007/s00431-015-2531-7.
 51. Doenyas C. Mikrobiyota ve Otizm. *Türkiye Sağlık Bilim Ve Araştırmaları Dergisi*. 2019;1(2): 43-48.
 52. Kaynar AN, Yılmaz HÖ. Otizm Spektrum Bozukluğu Olan Çocuklarda Beslenme Durumunun Belirlenmesi. *Gümüşhane Üniversitesi Sağlık Bilim Dergisi*. 2020;9(2): 151-162. doi: 10.37989/gumussagbil.544033.
 53. Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. *Child and Adolescent Psychiatric Clinics of North America*. 2008;17(4): 803-820, ix. doi: 10.1016/j.chc.2008.06.004.
 54. Gao Y, Sheng C, Xie RH, et al. New Perspective on Impact of Folic Acid Supplementation during Pregnancy on Neurodevelopment/Autism in the Offspring Children - A Systematic Review. *PloS One*. 2016;11(11): e0165626. doi: 10.1371/journal.pone.0165626.
 55. Bertoglio K, Jill James S, Deprey L, et al. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. *Journal of Alternative and Complementary Medicine*. 2010;16(5): 555-560. doi: 10.1089/acm.2009.0177.
 56. Uçar K, Samur FG. Otizmin Tedavisinde Güncel Beslenme Tedavisi Yaklaşımları. *Beslenme ve*



- Diyet Dergisi*. 2017;45(1): 53-60.
57. Evangelidou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. *Journal of Child Neurology*. 2003;18(2): 113-118. doi: 10.1177/08830738030180020501.
 58. Cohen SA, Gold BD, Oliva S, et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. *Journal of Pediatric Gastroenterology and Nutrition*. 2014;59(4): 516-521. doi: 10.1097/MPG.0000000000000449.
 59. Amminger GP, Berger GE, Schäfer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. *Biological Psychiatry*. 2007;61(4): 551-553. doi: 10.1016/j.biopsych.2006.05.007.
 60. Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. *Child and Adolescent Psychiatric Clinics of North America*. 2008;17(4):803-820. doi: 10.1016/j.chc.2008.06.004.
 61. Sampanthavivat M, Singkhwa W, Chaiyakul T, et al. Hyperbaric oxygen in the treatment of childhood autism: a randomised controlled trial. *Diving and Hyperbaric Medicine*. 2012;42(3): 128-133.
 62. Holtmann M, Steiner S, Hohmann S, et al. Neurofeedback in autism spectrum disorders. *Developmental Medicine & Child Neurology*. 2011;53(11): 986-993. doi: 10.1111/j.1469-8749.2011.04043.x.

OTİZMDE DAVRANIŞSAL VE EĞİTİMSEL MÜDAHALELER

Ayla UZUN ÇİÇEK¹
Elif ABANOZ²
İlknur UCUZ³

GİRİŞ

Otizm spektrum bozukluğu (OSB) için önerilen müdahale programları çekirdek otizm belirtilerini ve birlikte ortaya çıkan ilişkili bozuklukları hafifletmeyi veya iyileştirmeyi, günlük işlevsel bağımsızlığı artırmayı, ailelere destek sağlamayı, yaşam kalitesini olumsuz etkileyen sorunlu davranışları azaltmayı ve sosyal ve toplumsal katılımı kolaylaştırmayı amaçlamaktadır. Ek olarak, bireylerin güçlü oldukları alanlarda potansiyellerini gerçekleştirmelerine yardımcı olunması hedeflenmektedir. OSB'li çocuklara yönelik müdahaleler eğitim uygulamaları, gelişimsel terapiler ve davranışsal müdahaleler aracılığıyla sağlanır.¹⁻³

Müdahale programları teorik yaklaşım ve kapsamına (örneğin, odaklanmış ve hedefli veya kapsamlı) veya ortam ve uygulanma biçimine (örneğin, bireysel veya grup/sınıf, bir profesyonel tarafından okul ortamında veya eğitilmiş bir ebeveyn tarafından ev ortamında) göre kategorize edilebilir. Müdahale için kullanılan yaklaşımlar ise davranışsal yaklaşımlar, gelişimsel yaklaşımlar, bilişsel ve eğitsel yaklaşımlar ve sosyal-ilişkisel yaklaşımlar olarak sınıflanır. Bununla birlikte çoğu müdahale programında birden fazla yaklaşım bir arada kullanılır.¹⁻³

¹ Doç. Dr., Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., dr.f.ayla@hotmail.com, ORCID iD: 0000-0003-2274-3457

² Dr. Öğr. Üyesi, Sivas Cumhuriyet Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., elifabanoz_17@hotmail.com, ORCID iD: 0000-0002-9214-4735

³ Doç. Dr., İnönü Üniversitesi Tıp Fakültesi Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., ilknur_27@yahoo.com, ORCID iD: 0000-0003-1986-4688



göre bireyselleştirilmesini, aile katılımını teşvik etmesini ve olabildiğince erken dönemde başlanmasını önermektedir.

KAYNAKLAR

1. Ameis SH, Kassee C, Corbett-Dick P, et al. Systematic review and guide to management of core and psychiatric symptoms in youth with autism. *Acta Psychiatr Scand*. 2018;138:379-400.
2. Hyman SL, Levy SE, Myers SM, et al. Identification, evaluation, and management of children with autism spectrum disorder. *Pediatrics*. 2020;145:e20193447.
3. Chung KM, Chung E, Lee H. Behavioral interventions for autism spectrum disorder: A brief review and guidelines with a specific focus on applied behavior analysis. *Soa Chongsonyon Chongsin Uihak*. 2024;35:29-38.
4. Volkmar F, Siegel M, Woodbury-Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry*. 2014;53:237-257.
5. Wong C, Odom SL, Hume KA, et al. Evidence-based practices for children, youth, and young adults with autism spectrum disorder: a comprehensive review. *J Autism Dev Disord*. 2015;45:1951-1966.
6. Subramanyam AA, Mukherjee A, Dave M, Chavda K. Clinical Practice Guidelines for Autism Spectrum Disorders. *Indian J Psychiatry*. 2019;61(Suppl 2):254-269.
7. Schreibman L, Dawson G, Stahmer AC, et al. Naturalistic developmental behavioral interventions: empirically validated treatments for autism spectrum disorder. *J Autism Dev Disord*. 2015;45:2411-2428.
8. Roane HS, Fisher WW, Carr JE. Applied Behavior Analysis as Treatment for Autism Spectrum Disorder. *J Pediatr*. 2016;175:27-32.
9. Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD): a systematic review. *Campbell Syst Rev*. 2014;10:1-116.
10. Zwaigenbaum L, Bauman ML, Choueiri R, et al. Early intervention for children with autism spectrum disorder under 3 years of age: Recommendations for practice and research. *Pediatrics*. 2015;136(Suppl 1):S60-S81.
11. Koo BK, Chung KM. Effectiveness of an early intensive behavior intervention for infants with ASD: a preliminary study. *J Korean Assoc Persons Autism*. 2018;18:1-30.
12. Caron V, Bérubé A, Paquet A. Implementation evaluation of early intensive behavioral intervention programs for children with autism spectrum disorders: A systematic review of studies in the last decade. *Eval Program Plann*. 2017;62:1-8.
13. Halder S, Mahato AK. Cognitive behavior therapy for children and adolescents: challenges and gaps in practice. *Indian J Psychol Med*. 2019;41:279-283.
14. Rotheram-Fuller E, MacMullen L. Cognitive-behavioral therapy for children with autism spectrum disorders. *Psychol Sch* 2011;48:263-271.
15. Sofronoff K, Attwood T, Hinton S, Levin I. A randomized controlled trial of a cognitive behavioural intervention for anger management in children diagnosed with Asperger syndrome. *J Autism Dev Disord* 2007;37:1203-1214.
16. Lickel A, MacLean WE Jr, Blakeley-Smith A, Hepburn S. Assessment of the prerequisite skills for cognitive behavioral therapy in children with and without autism spectrum disorders. *J Autism Dev Disord* 2012;42:992-1000.
17. Lee JD, Meadan H. Parent-mediated interventions for children with ASD in low-resource



- settings: a scoping review. *Rev J Autism Dev Disord* 2021;8:285-298.
18. Bearss K, Burrell TL, Stewart L, Scahill L. Parent Training in Autism Spectrum Disorder: What's in a Name?. *Clin Child Fam Psychol Rev*. 2015;18:170-182.
 19. Tarver J, Palmer M, Webb S, et al. Child and parent outcomes following parent interventions for child emotional and behavioral problems in autism spectrum disorders: a systematic review and meta-analysis. *Autism*. 2019;23:1630-1644.
 20. Bearss K, Johnson C, Smith T, et al. Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. *JAMA*. 2015;313:1524-1533.
 21. Lindgren S, Wacker D, Suess A, et al. Telehealth and autism: treating challenging behavior at lower cost. *Pediatrics*. 2016;137(Suppl 2):S167-S175.
 22. Lee HM, Chung KM. Effects of an early start Denver model based parent training for parents of children with autism: a preliminary study. *J Korean Assoc Persons Autism* 2020;20:23-49.
 23. Nam BR, Lee SH. The effects of mother mediated joint attention focused play on precursors of joint attention and joint attention behaviors of toddlers with autism spectrum disorders. *J Korean Assoc Persons Autism* 2014;14:21-45.
 24. Bradshaw J, Koegel LK, Koegel RL. Improving functional language and social motivation with a parent-mediated intervention for toddlers with autism spectrum disorder. *J Autism Dev Disord*. 2017;47:2443-2458.
 25. Kirkpatrick B, Louw JS, Leader G. Efficacy of parent training incorporated in behavioral sleep interventions for children with autism spectrum disorder and/or intellectual disabilities: a systematic review. *Sleep Med* 2019;53:141-152.
 26. Ekici B, Bıçakçı MY, Gürkan EN, Unay ÖS, Tatlı B. Otizmde ebeveyn aracılı yoğun müdahale yöntemi NöroPLAY. *Çocuk Dergisi*. 2019;19:158-162.
 27. Bıçakçı M, Ekici B, Dursun Ş, Kutlu Konuk F, Gürkan E, Unay Ö. NöroPLAY Yönteminin İzleminde Kullanılan NöroPLAY Oyun Davranış Değerlendirme Ölçeği ve NöroPLAY Ebeveyn Oyun Davranış Değerlendirme Ölçeğinin Geliştirilmesi. *Erken Çocukluk Çalışmaları Dergisi*. 2021;5:228-254.
 28. Solomon R, Van Egeren LA, Mahoney G, Quon Huber MS, Zimmerman P. PLAY Project Home Consultation intervention program for young children with autism spectrum disorders: a randomized controlled trial. *J Dev Behav Pediatr*. 2014;35:475-85.
 29. Fulton E, Eapen V, Crnčec R, Walter A, Rogers S. Reducing maladaptive behaviors in preschool-aged children with autism spectrum disorder using the early start denver model. *Front Pediatr*. 2014;2:40.
 30. Waddington H, Reynolds JE, Macaskill E, Curtis S, Taylor LJ, Whitehouse AJ. The effects of JASPER intervention for children with autism spectrum disorder: A systematic review. *Autism*. 2021;25:2370-2385.
 31. Divya KY, Begum F, John SE, Francis F. DIR/Floor Time in Engaging Autism: A Systematic Review. *Iran J Nurs Midwifery Res*. 2023;28:132-138.
 32. Pajareya K, Nopmaneejumruslers K. A pilot randomized controlled trial of DIR/Floortime™ parent training intervention for pre-school children with autistic spectrum disorders. *Autism*. 2011;15:563-77.
 33. Fuller EA, Oliver K, Vejnaska SF, Rogers SJ. The Effects of the Early Start Denver Model for Children with Autism Spectrum Disorder: A Meta-Analysis. *Brain Sci*. 2020;10:368.
 34. Estes A, Munson J, Rogers SJ, Greenon J, Winter J, Dawson G. Long-Term Outcomes of Early Intervention in 6-Year-Old Children With Autism Spectrum Disorder. *J Am Acad Child Adolesc Psychiatry*. 2015;54:580-587.
 35. Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. *Pediatrics*. 2010;125:e17-23.



36. Waddington H, van der Meer L, Sigafoos J. Effectiveness of the early start Denver model: a systematic review. *Rev J Autism Dev Disord* 2016;3:93-106
37. Zhou B, Xu Q, Li H, et al. Effects of parent-implemented early start Denver model intervention on Chinese toddlers with autism spectrum disorder: a non randomized controlled trial. *Autism Res* 2018;11:654-666.
38. Rogers SJ, Estes A, Lord C, et al. Effects of a brief Early Start Denver model (ESDM)-based parent intervention on toddlers at risk for autism spectrum disorders: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2012;51:1052-65.
39. Boshoff K, Bowen H, Paton H, et al. Child Development Outcomes of DIR/Floortime TM-based Programs: A Systematic Review. *Can J Occup Ther*. 2020;87:153-164.
40. Boyd BA, Hume K, McBee MT, et al. Comparative efficacy of LEAP, TEACCH and non-model-specific special education programs for preschoolers with autism spectrum disorders. *J Autism Dev Disord*. 2014;44:366-80.
41. Foster EM, Pearson E. Is inclusivity an indicator of quality of care for children with autism in special education? *Pediatrics*. 2012;130(Suppl 2):S179-S185.
42. Zhou K, Liu X, Li S, Zhang Y, An R, Ma S. The use of Treatment and Education of Autistic and Related Communication Handicapped Children in schools to improve the ability of children with autism to complete tasks independently: A single-case meta-analysis. *Child Care Health Dev*. 2024;50:e13234.
43. Sandbank M, Bottema-Beutel K, Crowley S, et al. Project AIM: Autism intervention meta-analysis for studies of young children. *Psychol Bull*. 2020;146:1-29.
44. Virues-Ortega J, Julio FM, Pastor-Barriuso R. The TEACCH program for children and adults with autism: a meta-analysis of intervention studies. *Clin Psychol Rev*. 2013;33:940-53.
45. Sanz-Cervera P, Fernández-Andrés I, Pastor-Cerezuela G, Tárraga-Mínguez R. The effectiveness of TEACCH intervention in autism spectrum disorder: a review study. *Pap Psicol* 2018;39:40-50.
46. Howley M. Outcomes of structured teaching for children on the autism spectrum: Does the research evidence neglect the bigger picture? *Journal of Research in Special Educational Needs*, 2015;15:106-119.
47. Berenguer C, Miranda A, Colomer C, Baixauli I, Roselló B. Contribution of Theory of Mind, Executive Functioning, and Pragmatics to Socialization Behaviors of Children with High-Functioning Autism. *J Autism Dev Disord*. 2018;48:430-441.
48. Cappadocia MC, Weiss JA. Review of social skills training groups for youth with Asperger syndrome and high functioning autism. *Res Autism Spectr Disord*. 2011;5:70-78.
49. Bellini S, Peters JK. Social skills training for youth with autism spectrum disorders. *Child Adolesc Psychiatr Clin N Am*. 2008;17:857-873.
50. Rao PA, Beidel DC, Murray MJ. Social skills interventions for children with Asperger's syndrome or high-functioning autism: a review and recommendations. *J Autism Dev Disord*. 2008;38:353-361.
51. Qi CH, Barton EE, Collier M, Lin YL, Montoya C. A systematic review of effects of social stories interventions for individuals with autism spectrum disorder. *Focus Autism Other Dev Disabl*. 2018;33:25-34.
52. Soares EE, Bausback K, Beard CL, Higinbotham M, Bunge EL, Gengoux GW. Social Skills Training for Autism Spectrum Disorder: a Meta-analysis of In-person and Technological Interventions. *J Technol Behav Sci*. 2021;6:166-180.
53. Shire SY, Gulsrud A, Kasari C. Increasing responsive parent child interactions and joint engagement: comparing the influence of parent-mediated intervention and parent psychoeducation. *J Autism Dev Disord*. 2016;46:1737-1747.
54. Reichow B, Steiner AM, Volkmar F. Cochrane review: social skills groups for people aged 6 to



- 21 with autism spectrum disorders (ASD). *Evid Based Child Health*. 2013;8:266-315.
55. Mirenda P. *Toward Functional Augmentative and Alternative Communication for Students With Autism: Manual Signs, Graphic Symbols, and Voice Output Communication Aids*. *Lang Speech Hear Serv Sch*. 2003;34:203-216.
56. Charlop-Christy MH, Carpenter M, Le L, LeBlanc LA, Kellet K. Using the picture exchange communication system (PECS) with children with autism: assessment of PECS acquisition, speech, social-communicative behavior, and problem behavior. *J Appl Behav Anal*. 2002;35:213-31.
57. Ostryn C, Wolfe PS, Rusch FR. A review and analysis of the picture exchange communication system (PECS) for individuals with autism spectrum disorders using a paradigm of communication competence. *Res Pract Pers Sev Disabil*. 2008;33:13-24.
58. Wahman CL, Pustejovsky JE, Ostrosky MM, Santos RM. Examining the effects of Social Stories™ on challenging behavior and prosocial skills in young children: a systematic review and metaanalysis. *Topics Early Child Spec Educ* 2022;41:267-279.
59. Binns AV, Smyth R, Andres A, Lam J, Oram Cardy J. Looking back and moving forward: A scoping review of research on preschool autism interventions in the field of speech-language pathology. *Autism Dev Lang Impair*. 2021;6:23969415211033171.
60. Ebbels SH, McCartney E, Slonims V, Dockrell JE, Norbury CF. Evidence-based pathways to intervention for children with language disorders. *Int J Lang Commun Disord*. 2019;54:3-19
61. Case-Smith J, Weaver LL, Fristad MA. A systematic review of sensory processing interventions for children with autism spectrum disorders. *Autism*. 2015;19:133-48.
62. Section On Complementary And Integrative Medicine; Council on Children with Disabilities; American Academy of Pediatrics, Zimmer M, Desch L. Sensory integration therapies for children with developmental and behavioral disorders. *Pediatrics*. 2012;129:1186-1189.
63. Baranek GT. Efficacy of sensory and motor interventions for children with autism. *J Autism Dev Disord*. 2002;32:397-422.
64. Case-Smith J, Bryan T. The effects of occupational therapy with sensory integration emphasis on preschool-age children with autism. *Am J Occup Ther*. 1999;53:489-97.
65. Lloyd M, MacDonald M, Lord C. Motor skills of toddlers with autism spectrum disorders. *Autism*. 2013;17:133-146.
66. BBilaver LA, Cushing LS, Cutler AT. Prevalence and correlates of educational intervention utilization among children with autism spectrum disorder. *J Autism Dev Disord*. 2016;46:561-571.
67. Busti Ceccarelli S, Ferrante C, Gazzola E, et al. Fundamental Motor Skills Intervention for Children with Autism Spectrum Disorder: A 10-Year Narrative Review. *Children (Basel)*. 2020;7:250.

OTİZM SPEKTRUM BOZUKLUĞUNDA FARMAKOLOJİK TEDAVİLER

Esra DEMİRCİ¹

GİRİŞ

Otizm spektrum bozukluğu (OSB)'nin küresel yaygınlığıyla ilgili yakın tarihli bir sistematik inceleme güncellemesine göre, dünya çapında yaklaşık 100 çocuktan 1'ine OSB teşhisi konmaktadır.¹ Yıllar içinde giderek artış gösteren sıklığına rağmen OSB'yi tedavi edebilecek, tüm çekirdek semptomlar üzerine etkili bir ilaç bulunmamaktadır. NICHD/National Institute of Child Health and Human Development, ABD Gıda ve İlaç Dairesi (FDA) tarafından otizm semptomlarını tedavi etmek için onay almamış hiçbir ilacın kullanımını desteklememektedir. Ancak bazı ilaçlar, özellikle belirli davranışlar olmak üzere, ASD ile ilişkili belirli semptomları ve eşlik eden durumları tedavi etmeye yardımcı olabilir. Çeşitli ilaçlar OSB semptomlarını hafifletmek için klinik denemelerden geçerken, yaygın olarak reçete edilen ilaçlar ise yeni nesil antipsikotikler, seçici serotonin geri alım inhibitörleri (SSRI'ler), stimülanlar ve alfa-2 adrenerejik agonistlerdir.³ Risperidon ve aripiprazol FDA tarafından OSB ile ilişkili semptomlar için onaylanan iki farmakolojik ajan olup; çekirdek belirtilerden ziyade rahatsızlıkla ilişkilendirilen sinirliliği/irritabiliteyi hedef almaktadır.⁴ OSB'nin temel semptomlarını tedavi eden ilaçlara dair çalışmalar devam etmektedir çünkü çok az ilaç bu semptomları etkili bir şekilde hafifletmekte ve şu anda kullanılan seçeneklerden henüz hiçbiri her bir birey için olumlu sonuç vermemektedir. Ayrıca, FDA OSB'nin temel çekirdek özelliklerini tedavi etmek için henüz bir ilacı onaylamamıştır.⁴ Çalışmalar ilaçların davranışsal terapilerle birleştirildiğinde daha etkili olduğunu göstermiştir.

¹ Prof. Dr., Erciyes Üniversitesi Tıp Fakültesi Hastanesi, Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları AD., esrademirci@erciyes.edu.tr, ORCID iD: 0000-0002-8424-4947



analizde, oksitosinin sosyal işlevsellikte ve bazı temel ASD semptomlarında iyileşmelere yol açtığını bildirilmiştir.¹¹³ 3-11 yaşlarındaki altmış çocuk ile yapılan bir çalışmada bumetanid ile Çocukluk Otizmi Derecelendirme Ölçeği puanlarında önemli ölçüde azalma raporlamıştır.¹¹⁴ 91 çocuk üzerinde yapılan başka bir randomize kontrollü çalışmada ise, stereotipik davranışlarda azalma olduğu ancak bumetanid ile çekirdek semptomlarında önemli bir iyileşme olmadığı bildirilmiştir.¹¹⁵ Çift kör, plasebo kontrollü bir çalışmada, on hafta boyunca kırk çocukta memantin tedavisinin etkilerini incelenmiş, sinirlilik, stereotipik davranış ve hiperaktivite alanlarında olumlu ilerlemeler gözlenmiştir.¹¹⁶ 2022'de yapılan sistematik bir derlemede ise OSB ile ilişkili birincil veya ikincil sonuçlar için memantin ve plasebo arasında önemli bir fark bulunmamıştır.¹¹⁷ Rivastigmin ile 12 hafta boyunca yürütülmüş bir çalışmada ifade edici konuşmada ve genel otistik davranışlarda önemli iyileşmeler gösterilmiştir.¹¹⁸ Rastgele kontrollü bir çalışmada ise, 8-17 yaş aralığındaki 34 OSB'li çocukta donepezil ile plaseboyu karşılaştırılmış, iki grup arasında otizm semptomlarında anlamlı bir fark bulunmamıştır.¹¹⁹ Genel olarak, bu farmakolojik ajanlar ile OSB tedavisine ilişkin kanıtlar kesin değildir ve daha fazla araştırma gerektirmektedir. Yine kannabidiol ile yapılan tedavilerin tekrarlayan davranışlar, sosyal etkileşim ve uyku bozuklukları gibi ilişkili komorbiditeleri iyileştirerek şiddetli OSB vakalarında fayda sağlayabileceğine dair çalışmalar.¹²⁰ bulunmakta birlikte bu alanda da daha fazla çalışmaya ihtiyaç duyulduğu aşikârdır.

KAYNAKLAR

1. Zeidan J, Fombonne E, Scora J, et al. Global prevalence of autism: a systematic review update. *Autism Res.* 2022; 15:778-790.
2. Autism Research Institute. Comorbidities of autism. 2021. Available from: <https://www.autism.org/comorbidities-of-autism/>.
3. MedicineNet. Types of autism medications and treatments. 2021. Available from: https://www.medicinenet.com/types_of_autism_medications_and_treatments/drug-class.htm. Accessed Feb 15, 2022.
4. DeFilippis M, Wagner KD. Treatment of autism spectrum disorder in children and adolescents. *Psychopharmacol Bull.* 2016; 46:18-41.
5. Autism Speaks. Medicines for treating autism's core symptoms. 2022. Available from: <https://www.autismspeaks.org/medicines-treating-autisms-core-symptoms>.
6. Lai MC, Kasseh C, Besney R, et al. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. *Lancet Psychiatry.* 2019; 6:819-829.
7. Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. *Lancet.* 2003; 362:732-734.
8. Murray ML, Hsia Y, Glaser K, et al. Pharmacological treatments prescribed to people with au-



- tism spectrum disorder in primary health care. *Psychopharmacology (Berl)*. 2014; 231:1011-1021.
9. Santosh PJ, Singh J. Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents. *BJPsych Adv*. 2016; 22:151-161.
10. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. *N Engl J Med*. 2002; 347:314-321.
11. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. *Pediatrics*. 2004; 114:e634-e641.
12. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. *Arch Gen Psychiatry*. 1998; 55:633-641.
13. Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. *J Am Acad Child Adolesc Psychiatry*. 2002; 41:140-147.
14. Troost PW, Lahuis BE, Steenhuis MP, et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. *J Am Acad Child Adolesc Psychiatry*. 2005; 44:1137-1144.
15. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized placebo-controlled double-blind study. *J Child Neurol*. 2006; 21:450-455.
16. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: safety and efficacy. *J Child Adolesc Psychopharmacol*. 2006; 16:575-587.
17. Alsayouf HA, Talo H, Biddappa ML, et al. Risperidone or aripiprazole can resolve autism core signs and symptoms in young children: case study. *Children*. 2021; 8:318.
18. Blankenship K, Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. *Pediatr Health*. 2010; 4:375-381.
19. Marcus RN, Owen R, Kamen L, et al. A placebo-controlled fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. *J Am Acad Child Adolesc Psychiatry*. 2009; 48:1110-1119.
20. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. *Pediatrics*. 2009; 124:1533-1540.
21. Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders. *Child Psychiatry Hum Dev*. 2014; 45:185-192.
22. Lamberti M, Siracusano R, Italiano D, et al. Head-to-head comparison of aripiprazole and risperidone in the treatment of ADHD symptoms in children with autistic spectrum disorder and ADHD. *Paediatr Drugs*. 2016; 18:319-329.
23. Wink LK, Early M, Schaefer T, et al. Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. *J Child Adolesc Psychopharmacol*. 2014; 24:78-82.
24. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. *J Child Adolesc Psychopharmacol*. 1999; 9:99-107.
25. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. *J Child Adolesc Psychopharmacol*. 2004; 14:287-294.
26. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. *J Clin Psychiatry*. 2004; 65:1531-1536.
27. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents



- with pervasive developmental disorders. *J Autism Dev Disord.* 2005; 35:387-391.
28. Loebel A, Brams M, Goldman RS, et al. Lurasidone for the treatment of irritability associated with autistic disorder. *J Autism Dev Disord.* 2016; 46:1153-1163.
 29. Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. *Clin Neuropharmacol.* 2011; 34:216-219.
 30. Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ. Paliperidone for irritability in autistic disorder. *J Child Adolesc Psychopharmacol.* 2010; 20:75-78.
 31. Kowalski JL, Wink LK, Blankenship K, et al. Paliperidone palmitate in a child with autistic disorder. *J Child Adolesc Psychopharmacol.* 2011; 21:491-493.
 32. Potenza MN, Holmes JP, Kanis SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. *J Clin Psychopharmacol.* 1999; 19:37-44.
 33. Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial. *Med Princ Pract.* 2008; 17:415-418.
 34. Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. *J Clin Psychopharmacol.* 2002; 22:455-456.
 35. Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. *J Am Acad Child Adolesc Psychiatry.* 2001; 40:887-894.
 36. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. *Am J Psychiatry.* 1996; 153:738.
 37. Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. *J Clin Psychiatry.* 2001; 62:479-480.
 38. Lambrey S, Falissard B, Martin-Barrero M, et al. Effectiveness of clozapine for aggression in an adolescent with autistic disorder. *J Child Adolesc Psychopharmacol.* 2010; 20:79-80.
 39. Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. *J Psychiatry Neurosci.* 2001; 26:340-341.
 40. Beherec L, Lambrey S, Quilici G, et al. Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. *J Clin Psychopharmacol.* 2011; 31:341-344.
 41. McDougle CJ, Kem DL, Posey DJ. Use of ziprasidone for maladaptive symptoms in youths with autism. *J Am Acad Child Adolesc Psychiatry.* 2002; 41:921-927.
 42. Cohen SA, Fitzgerald BJ, Khan SR, Khan A. Effect of a switch to ziprasidone in adults with autistic disorder. *J Clin Psychiatry.* 2004; 65:110-113.
 43. Goforth HW, Rao MS. Improvement in behaviour and attention in an autistic patient treated with ziprasidone. *Aust N Z J Psychiatry.* 2003; 37:775-776.
 44. Malone RP, Delaney MA, Hyman SB, Cater JR. Ziprasidone in adolescents with autism: an open-label pilot study. *J Child Adolesc Psychopharmacol.* 2007; 17:779-790.
 45. Duggal HS. Ziprasidone for maladaptive behavior and ADHD symptoms in autistic disorder. *J Child Adolesc Psychopharmacol.* 2007; 17:261-263.
 46. Millard PH, McLaren JL, Coffey DB. Lurasidone treatment in a child with autism spectrum disorder with irritability and aggression. *J Child Adolesc Psychopharmacol.* 2014; 24:354-356.
 47. Gupta M, Hoover G Jr. Lurasidone: an effective alternative for the treatment of irritability associated with autism spectrum disorder. *Cureus.* 2020; 12:e12360.
 48. Cohen IL, Campbell M, Posner D. A study of haloperidol in young autistic children. *Psychopharmacol Bull.* 1980; 16:63-65.
 49. Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism. *Am J Psychiatry.* 1984; 141:1195-1202.
 50. Locascio JJ, Malone RP, Small AM, et al. Factors related to haloperidol response and dyskinesias in autistic children. *Psychopharmacol Bull.* 1991; 27:119-126.



51. Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children and adolescents with autism. *Eur Child Adolesc Psychiatry*. 2008; 17:1-8.
52. Gencer O, Emiroglu FN, Miral S, et al. Long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. *Eur Child Adolesc Psychiatry*. 2008; 17:217-225.
53. Naruse H, Nagahata M, Nakane Y, et al. Double-blind trial of pimozide, haloperidol and placebo in children with behavioral disorders. *Acta Paedopsychiatr*. 1982; 48:173-184.
54. Ernst M, Gonzalez NM, Campbell M. Acute dystonic reaction with low-dose pimozide. *J Am Acad Child Adolesc Psychiatry*. 1993; 32:640-642.
55. Hollander E, Soorya L, Chaplin W, et al. Double-blind placebo-controlled trial of fluoxetine for repetitive behaviors in adult autism spectrum disorders. *Am J Psychiatry*. 2012 ;169:292-299.
56. Hollander E, Phillips A, Chaplin W, et al. Placebo-controlled crossover trial of fluoxetine on repetitive behaviors in childhood autism. *Neuropsychopharmacology*. 2005; 30:582-589.
57. Buchsbaum MS, Hollander E, Haznedar MM, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders. *Int J Neuropsychopharmacol*. 2001; 4:119-125.
58. Herscu P, Handen BL, Arnold LE, et al. The SOFIA study: low-dose fluoxetine on repetitive behaviors in children with autistic disorder. *J Autism Dev Disord*. 2020; 50:3233-3244.
59. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. *J Clin Psychiatry*. 1996; 57:333-336.
60. Potter LA, Scholze DA, Biag HMB, et al. Randomized controlled trial of sertraline in young children with autism spectrum disorder. *Front Psychiatry*. 2019; 10:810.
61. Alolaby RR, Jiraanont P, Durbin-Johnson B, et al. Molecular biomarkers predictive of sertraline treatment response in young children with autism spectrum disorder. *Front Genet*. 2020; 11:308.
62. Namerow L, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. *J Dev Behav Pediatr*. 2003; 24:104-108.
63. King BH, Hollander E, Sikich L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. *Arch Gen Psychiatry*. 2009; 66:583-590.
64. Owley T, Walton L, Salt J, et al. An open-label trial of escitalopram in pervasive developmental disorders. *J Am Acad Child Adolesc Psychiatry*. 2005; 44:343-348.
65. McDougle CJ, Owley T, Brune CW, et al. A pharmacogenetic study of escitalopram in autism spectrum disorders. *Autism Res*. 2010; 3:1-7.
66. Coşkun M, Öztürk M, Zoroğlu S. Escitalopram treatment in preschool children with anxiety disorders: a case series. *Bull Clin Psychopharmacol*. 2012; 22:262-267.
67. Ong LT, Chee NMZ. Psychopharmacological management of obsessive-compulsive behaviour in children and adolescents with autism spectrum disorders: a narrative review. *Egypt J Neurol Psychiatry Neurosurg*. 2024; 60:64.
68. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind placebo-controlled study of fluvoxamine in adults with autistic disorder. *Arch Gen Psychiatry*. 1996; 53:1001-1008.
69. Martin A, Koenig K, Anderson GM, Scahill L. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. *J Autism Dev Disord*. 2003; 33:77-85.
70. Sugie Y, Sugie H, Fukuda T, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. *J Autism Dev Disord*. 2005; 35:377-385.
71. Posey DJ, Litwiller M, Koburn A, McDougle CJ. Paroxetine in autism. *J Am Acad Child Ado-*



- lesc Psychiatry. 1999; 38:111-112.
72. Snead RW, Boon F, Presberg J. Paroxetine for self-injurious behavior. *J Am Acad Child Adolesc Psychiatry*. 1994; 33:909-910.
 73. Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. *J Child Adolesc Psychopharmacol*. 2001; 11:267-277.
 74. Coskun M, Karakoc S, Kircelli F, Mukaddes NM. Effectiveness of mirtazapine in inappropriate sexual behaviors in individuals with autistic disorder. *J Child Adolesc Psychopharmacol*. 2009; 19:203-206.
 75. Carminati GG, Deriaz N, Bertschy G. Low-dose venlafaxine in adolescents and young adults with autistic disorder improves self-injurious behavior and ADHD-like symptoms. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006; 30:312-315.
 76. Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders. *J Child Neurol*. 2000; 15:132-135.
 77. Carminati GG, Gerber F, Darbellay B, et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2016; 65:85-95.
 78. Gedye A. Trazodone reduced aggressive and self-injurious movements in a mentally handicapped male patient with autism. *J Clin Psychopharmacol*. 1991; 11:275-276.
 79. Blackmer AB, Feinstein JA. Management of sleep disorders in children with neurodevelopmental disorders: a review. *Pharmacotherapy*. 2016; 36:84-89.
 80. Relia S, Ekambaram V. Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities: a literature review. *Med Sci*. 2018; 6:95.
 81. Mammarella V, Orecchio S, Cameli N, et al. Using pharmacotherapy to address sleep disturbances in autism spectrum disorders. *Expert Rev Neurother*. 2023; 23:1261-1276.
 82. Kochhar P, Batty MJ, Liddle EB, et al. Autistic spectrum disorder traits in children with attention deficit hyperactivity disorder. *Child Care Health Dev*. 2011; 37:103-110.
 83. Van der Meer JMJ, Oerlemans AM, Van Steijn DJ, et al. Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one disorder? *J Am Acad Child Adolesc Psychiatry*. 2012; 51:1160-1172.
 84. Grzadzinski R, Dick C, Lord C, Bishop S. Parent-reported and clinician-observed ASD symptoms in children with ADHD. *Mol Autism*. 2016; 7:7.
 85. Salazar F, Baird G, Chandler S, et al. Co-occurring psychiatric disorders in preschool and elementary school-aged children with autism spectrum disorder. *J Autism Dev Disord*. 2015; 45:2283-2294.
 86. Joshi G, Faraone SV, Wozniak J, et al. Symptom profile of ADHD in youth with high-functioning autism spectrum disorder. *J Atten Disord*. 2017; 21:846-855.
 87. Antshel KM, Russo N. Autism spectrum disorders and ADHD: overlapping phenomenology, diagnostic issues, and treatment considerations. *Curr Psychiatry Rep*. 2019; 21:34.
 88. Scahill L, Bearss K, Sarhangian R, et al. Using a patient-centered outcome measure to test methylphenidate versus placebo in children with autism spectrum disorder. *J Child Adolesc Psychopharmacol*. 2017; 27:125-131.
 89. Pearson DA, Santos CW, Aman MG, et al. Effects of extended-release methylphenidate treatment on ADHD behaviors in children with autism spectrum disorders. *J Child Adolesc Psychopharmacol*. 2013; 23:337-351.
 90. Pearson DA, Santos CW, Aman MG, et al. Effects of extended-release methylphenidate on cognitive task performance in children with autism spectrum disorder and ADHD. *J Child Adolesc Psychopharmacol*. 2020; 30:414-426.
 91. Ghuman JK, Aman MG, Lecavalier L, et al. Randomized placebo-controlled crossover study



- of methylphenidate in preschoolers with developmental disorders. *J Child Adolesc Psychopharmacol.* 2009; 19:329-339.
92. Handen BL, Aman MG, Arnold LE, et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and ADHD. *J Am Acad Child Adolesc Psychiatry.* 2015; 54:905-915.
93. Eslamzadeh M, Hebrani P, Behdani F, et al. Efficacy of atomoxetine in autism spectrum disorders: a randomized double-blind placebo-controlled trial. *Iran J Psychiatry Behav Sci.* 2018;12.
94. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi S. Double-blind placebo-controlled study of transdermal clonidine in autism. *J Clin Psychiatry.* 1992; 53:77-82.
95. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. *J Clin Psychopharmacol.* 1992; 12:322-327.
96. Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. *Brain Dev.* 2008; 30:454-460.
97. Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. *J Dev Behav Pediatr.* 2008; 29:303-308.
98. Scahill L, McCracken JT, King BH, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. *Am J Psychiatry.* 2015; 172:1197-1206.
99. Polite LC, Scahill L, Figueroa J, et al. Extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms. *Neuropsychopharmacology.* 2018; 43:1772-1778.
100. Pliplys AV. Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. *Arch Pediatr Adolesc Med.* 1994; 148:220.
101. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. Open trial of divalproex sodium in autism spectrum disorders. *J Clin Psychiatry.* 2001; 62:530-534.
102. Hellings JA, Weckbaugh M, Nickel EJ, et al. Double-blind placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. *J Child Adolesc Psychopharmacol.* 2005; 15:682-692.
103. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for irritability in children and adolescents with autism spectrum disorders. *Neuropsychopharmacology.* 2010; 35:990-998.
104. Siegel M, Beresford CA, Bunker M, et al. Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. *J Child Adolesc Psychopharmacol.* 2014; 24:399-402.
105. Serret S, Thummler S, Dor E, et al. Lithium as rescue therapy for regression and catatonia in SHANK3 patients with autism spectrum disorder. *BMC Psychiatry.* 2015; 15:107.
106. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: randomized placebo-controlled trial. *J Autism Dev Disord.* 2001; 31:175-181.
107. Limbu B, Deb S, Roy M, et al. Randomised controlled trials of mood stabilisers for people with autism spectrum disorder: systematic review and meta-analysis. *BJPsych Open.* 2022; 8:e52.
108. Rugino TA, Samsock TC. Levetiracetam in autistic children: an open-label study. *J Dev Behav Pediatr.* 2002; 23:225-230.
109. Wasserman S, Iyengar R, Chaplin WF, et al. Levetiracetam versus placebo in childhood autism. *Int Clin Psychopharmacol.* 2006; 21:363-367.
110. Mazzone L, Ruta L. Topiramate in children with autistic spectrum disorders. *Brain Dev.* 2006; 28:668.
111. Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. *Prog Neuropsychopharmacol Biol Psychiatry.* 2010; 34:1269-1272.



112. Fuentes J, Hervás A, Howlin P, et al. ESCAP practice guidance for autism: evidence-based recommendations for diagnosis and treatment. *Eur Child Adolesc Psychiatry*. 2021; 30:961-984.
113. Huang Y, Huang X, Ebstein RP, Yu R. Intranasal oxytocin in the treatment of autism spectrum disorders: a multilevel meta-analysis. *Neurosci Biobehav Rev*. 2021; 122:18-27.
114. Lemonnier E, Degrez C, Phelep M, et al. Randomised controlled trial of bumetanide in autism in children. *Transl Psychiatry*. 2012;2:e202.
115. Sprengers JJ, van Andel DM, Zuithoff NP, et al. Bumetanide for core symptoms of autism spectrum disorder (BAMBI). *J Am Acad Child Adolesc Psychiatry*. 2021; 60:865-876.
116. Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder. *Int J Neuropsychopharmacol*. 2013; 16:783-789.
117. Brignell A, Marraffa C, Williams K, May T. Memantine for autism spectrum disorder. *Cochrane Database Syst Rev*. 2022;8:CD013845.
118. Chez MG, Aimonovitch M, Buchanan T, et al. Rivastigmine tartrate in children with autistic spectrum disorders. *J Child Neurol*. 2004; 19:165-169.
119. Ure A, Cox GR, Haslam R, Williams K. Acetylcholinesterase inhibitors for autistic spectrum disorders. *Cochrane Database Syst Rev*. 2023;6:CD013851.
120. Fortini PS, Toibaro JJ, Caraballo RH. Purified cannabidiol improves severe treatment-resistant behavioral symptoms in children with autism spectrum disorder. *Pharmacol Biochem Behav*. 2025; 249:173971.

OTİZMDE DENEYSEL TERAPÖTİK YAKLAŞIMLAR

Fatma HANCI¹
Pınar ÖZKAN KART²

GİRİŞ

Otizm spektrum bozukluğu (OSB) olan çocuklar genellikle sosyal etkileşim ve iletişim sorunları ile birlikte stereotipik davranış kalıpları gösterirler. Günümüzde, OSB tanısı konulan çocuk sayısı dünya genelinde önemli ölçüde artmaktadır. 2020’de Amerika Birleşik Devletleri’nde tahmini olarak 54 çocuktan 1’inde OSB vardı; bu, 2000’de bu tanıyı alan 150 çocuktan 1’ine göre yaklaşık %170’lik bir artıştır. Asya’da da OSB’li çocuk sayısında artış eğilimi vardır. Bu nedenle, OSB’li çocuklar için eğitim yaklaşımı ve davranış terapileri son on yılda giderek daha fazla ilgi görmüştür. Bununla birlikte eğitim ve davranış terapileri ve medikal tedavi ile aileler yeterli ve etkili tedavi aalamadıklarını düşünmekte ve tamamlayıcı, bütünleştirici ve diğer tedavi alternatifleri için arayış içine girdikleri görülmektedir. Ayrıca OSB’de etiyolojiyi temel alan bir tedavi yönteminin henüz olmaması, olası bir tedavi amacıyla tamamlayıcı ve alternatif tıp (TAT) uygulamalarının kullanılmasına yol açmaktadır.^{1,2}

Tamamlayıcı ve Bütünleştirici Yaklaşımlar

OSB’li çocuklar arasında yaygın olarak kullanılan tamamlayıcı ve alternatif tıp uygulamaları arasında özel diyetler, besin takviyeleri, şifalı bitkiler, probiyotikler, müzik terapisi, sanat terapisi, masaj terapisi, kraniyosakral terapi, şelasyon,

¹ Doç. Dr., Trabzon Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD., fatmah.arslan@gmail.com, ORCID iD: 0000-0002-1019-92072

² Uzm. Dr., Sağlık Bilimleri Üniversitesi, Trabzon Kanuni Eğitim ve Araştırma Hastanesi, Çocuk Nörolojisi Bölümü, drpınar_ozkan@yahoo.com, ORCID iD: 0000-0001-5726-737X



küçük ile orta düzeyde kalmaktadır. Dolayısıyla, bu bileşiklerin klinik kullanım-
da etkinlik ve güvenlik açısından daha kapsamlı ve güçlü çalışmalarla değeri-
lendirilmesi gerekmektedir.

KAYNAKLAR

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Association: Washington, DC, USA, 2013.
2. CDC Centers for Disease Control and Prevention. Available online: <https://www.cdc.gov/ncbddd/autism/data.html> (accessed on 5 March 2021).
3. Bilgiç A, Cöngöloğlu A (2009) Otizm spektrum bozukluklarında biyolojik temelli tamamlayıcı ve alternatif tıp uygulamaları. *Çocuk ve Gençlik Ruh Sağlığı Dergisi*, 16:153-164
4. DeFilippis M (2018) The use of complementary alternative medicine in children and adolescents with autism spectrum disorder. *Psychopharmacol Bull*, 48:40-63.
5. Shuai B, Jin H, Lin Y, Duan R, Zhao N, Li Z, et al. (2020) Safety and efficacy of complementary and alternative medicine in the treatment of autism spectrum disorder: A protocol for systematic review and meta-analysis. *Medicine (Baltimore)*, 99:e23128.
6. Hangül, Zehra, and Ali Evren Tufan. "Otizm spektrum bozukluğunda tamamlayıcı ve alternatif tedavilerin kullanımı." *Psikiyatriye Güncel Yaklaşımlar* 14.2 (2022): 165-173.
7. Pusponero HD, Ismael S, Firmansyah A, Sastroasmoro S, Vandenplas Y. Gluten and casein supplementation does not increase symptoms in children with autism spectrum disorder. *Acta Paediatr*. 2015;104:e500-e505.
8. Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. *J Autism Dev Disord*. 2006;36(3): 413-420.
10. Johnson CR, Handen BL, Zimmer M, Sacco K, Turner K. Effects of gluten free/casein free diet in young children with autism: a pilot study. *J Dev Phys Disabil*. 2011;23:213-225.
11. Whiteley P, Haracopos D, Knivsberg AM, et al. The ScanBrit randomized, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. *Nutr Neurosci*. 2010;13(2):87-100.
12. Knivsberg AM, Reichelt KL, Høien T, Nodland M. A randomised, controlled study of dietary intervention in autistic syndromes. *Nutr Neurosci*. 2002;5(4):251-261.
13. Evangelidou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. *J Child Neurol*. 2003;18(2):113-118.
14. Spilioti M, Evangelidou AE, Tramma D, et al. Evidence for treatable inborn errors of metabolism in a cohort of 187 Greek patients with autism spectrum disorder (ASD). *Front Hum Neurosci*. 2013;7:858.
15. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioral therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. *J Sleep Res*. 2012;21:700-709.
16. Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. *J Pineal Res*. 2008;44:57-64.
17. Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behavior management strategies: a



- randomized controlled crossover trial. *J Autism Dev Disord.* 2011;41:175–184.
18. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. *J Clin Sleep Med.* 2009;5(2):145–150.
 19. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. *Child Care Health Dev.* 2006;32(5):585–589.
 20. Malow B, Adkins KW, McGrew SG, et al. Melatonin for sleep in children with autism: A controlled trial examining dose, tolerability, and outcomes. *J Autism Dev Disord.* 2012;42(8):1729–1737.
 21. Campbell-McBride, Natasha. “Gut and psychologiesyndrome.” *Journal of Orthomolecular Medicine* 23.2 (2008): 90
 22. Çıkılı Y, Deniz S, Çakal B. GAPS diyetinin otizm spektrum bozukluğu olan bireyler üzerindeki etkisinin incelenmesi. *Ahmet Keleşoğlu Eğitim Fakültesi Dergisi.* 2019;1(1):1-1.
 23. Önal, S. ve Uçar, A. (2017). Otizm Spektrum Bozukluğu Tedavisinde Beslenme Yaklaşımları. *Ankara Sağlık Bilimleri Dergisi*, 6 (123), 179-194
 24. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. *Mol Psychiatry.* 2012;17(4):389–401.
 25. Bertoglio K, James SJ, Deprey L, Brule N, Hendren RL. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. *J Altern Complement Med.* 2010;16(5):555–560.
 26. 28. Hendren RL, James SJ, Widjaja F, Lawton B, Rosenblatt A, Bent S. Randomized, placebo-controlled trial of methyl B12 for children with autism. *J Child Adolesc Psychopharmacol.* 2016;26(9):774–783.
 27. Frye RE, Slaterry J, Delhey L, et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. *Mol Psychiatry.* 2016;00:1–10.
 28. Frye RE, Melnyk S, Fuchs G, et al. Effectiveness of methylcobalamin and folinic acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. *Autism Res Treat.* 2013;2013:609–705.
 29. Sun C, Zou M, Zhao D, Xia W, Wu L. Efficacy of folic acid supplementation in autistic children participating in structured teaching: an open-label trial. *Nutrients.* 2016;8(6):337.
 30. Kern JK, Miller VS, Cauller L, Kendall R, Mehta J, Dodd M. Effectiveness of N,N Dimethylglycine in autism and pervasive developmental disorder. *J Child Neurol.* 2001;16(3):169–173.
 31. 57. Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. *J Autism Dev Disord.* 1999;29(3):191–194.
 32. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. *J Altern Complement Med.* 2004;10(6):1033–1039.
 33. 59. Adams JB, Audhya T, McDonough-Means S, et al. Effect of a vitamin/mineral supplement on children and adults with autism. *BMC Pediatrics.* 2011;11:111.
 34. Azzam HME, Sayyah H, Youssef S, et al. Autism and vitamin D: and intervention study. *Middle East Current Psychiatry.* 2015;22:9–14.
 35. Feng J, Shan L, Du L, et al. Clinical improvement following vitamin D3 supplementation in autism spectrum disorder. *Nutr Neurosci.* 2016. doi:10.1080/1028415X.2015.1123847. [Epub ahead of print].
 36. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. *Prog Neuropsychopharmacol Biol Psychiatry.* 1993;17:765–774.



37. Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. *Cochrane Database*. 2005;4:CD003497.
38. Murza KA, Pavelko SL, Malani MD, Nye C. Vitamin B6-magnesium treatment for autism: the current status of the research. *Magnes Res*. 2010;23(2):115–117.
39. Stewart PA, Hyman SL, Schmidt BL, et al. Dietary supplementation in children with autism spectrum disorders: common, insufficient, and excessive. *J Acad Nutr Diet*. 2015;115(8):1237–1248.
40. Tomova A, Husarova V, Lakatosova S, et al. Gastrointestinal microbiota in children with autism in Slovakia. *Physiol Behav*. 2015;138:179–187.
41. Parracho HMRT, Gibson GR, Knott F, Bosscher D, Kleerebezem M, McCartney AL. A double-blind, placebo-controlled, crossover-designed probiotic feeding study in children diagnosed with autistic spectrum disorders. *Int J Probiotics Prebiotics*. 2010;5:69–74.
42. Kaluzna-Czaplinska J, Blaszczyk S. The level of arabinitol in autistic children after probiotic therapy. *Nutrition*. 2012;28:124–126.
43. Saad K, Eltayeb AA, Mohamad IL, et al. A randomized, placebo-controlled trial of digestive enzymes in children with autism spectrum disorders. *Clin Psychopharmacol Neurosci*. 2015;13(2):188–193.
45. Munasinghe SA, Oliff C, Finn J, Wray JA. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial. *J Autism Dev Disord*. 2010;40:1131–1138.
46. Levy SE, Souders MC, Wray J, et al. Children with autistic spectrum disorders. I: Comparison of placebo and single dose of human synthetic secretin. *Arch Dis Child*. 2003;88:731–736.
47. Williams K, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). *Cochrane Database Syst Rev*. 2012. Issue 4. Art. No: CD003495.
48. Bashir S, Al-Ayadhi LY. Effect of camel milk on thymus and activation-regulated chemokine in autistic children: double-blind study. *Pediatr Res*. 2014;75(4):559–563.
49. Al-Ayadhi LY, Elamin NE. Camel milk as a potential therapy as an antioxidant in autism spectrum disorder (ASD). *Evid Based Complement Alternat Med*. 2013. 602834.
50. Al-Ayadhi LY, Halepoto DM, Al-Dress AM, Mitwali Y, Zainah R. Behavioral benefits of camel milk in subjects with autism spectrum disorder. *J Coll Physicians Surg Pak*. 2015;25(11):819–823.
51. Wong VCN, Chen WX, Liu WL. Randomized controlled trial of electro-acupuncture for autism spectrum disorder. *Altern Med Rev*. 2010;15(2):136–146.
52. Uniform Data System for Medical Rehabilitation (UDSMR). WeeFIM System SM. Clinical Guide: Version 5.01. Buffalo, NY: University at Buffalo 2000.
53. Haley SM, Coster WJ, Ludlow LH, Haltiwanger JT, Andrellos PJ. *Pediatric Evaluation of Disability Inventory: Development, Standardization, and Administration Manual*, Version 1.0. Boston MA: PEDIResearch Group, 1992.
54. Roid GH, Miller LJ. *Leiter International Performance Scale-Revised (Leiter-R)*. Wood Dale, IL; Stoelting Co: 1997.
55. Wong VCN, Sun JG. Randomized controlled trial of acupuncture versus sham acupuncture in autism spectrum disorder. *J Altern Complement Med*. 2010;16(5):545–553.
56. Griffiths R. *The Abilities of Babies: A Study of Mental Measurements*. London: University of London Press, 1954.
57. Reynell J. *Reynell Language Developmental Scales*. Windsor, UK: NFER-Nelson, 1976.
58. Lowe M, Costello AJ. *Manual for Symbolic Play Test*. Windsor, UK: NFER-Nelson, 1976.
59. Sampanthavivat M, Singkhwa W, Chaikyul T, Karoonyawanich S, Ajpru H. Hyperbaric oxygen in the treatment of childhood autism: A randomized controlled trial. *Diving Hyperb Med*. 2012;42(3):128–133.



60. Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. *BMC Pediatr.* 2009;9:21.
61. Granpeesheh D, Tarbox J, Dixon DR, Wilke AE, Allen MS, Bradstreet JJ. Randomized trial of hyperbaric oxygen therapy for children with autism. *Res Autism Spectr Disord.* 2010;4:268–275.
62. Lord C, Rutter M, DiLavore PC, Risi S. Autism Diagnostic Observation Schedule. Los Angeles: Western Psychological Services; 1999.
63. Green VA, Pituch KA, Itchon J, Choi A, O'Reilly M, Sigafoos J. Internet survey of treatments used by parents of children with autism. *Res Dev Disabil.* 2006;27:70–84.
64. Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edentate disodium: 2003–2005. *Pediatrics.* 2006;118:534–536.
65. Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A – medical results. *BMC Clin Pharmacol.* 2009;9:16.
66. Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B – behavioral results. *BMC Clin Pharmacol.* 2009;9:17.
67. Davis TN, O'Reilly M, Kang S, et al. Chelation treatment for autism spectrum disorders: a systematic review. *Res Autism Spectr Disord.* 2012;7:49–55.
68. James S, Stevenson SW, Silove N, Williams K. Chelation for autism spectrum disorder (ASD). *Cochrane Database Syst Rev.* 2015. Issue 5. Art. No.: CD010766.
69. Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. *Mol Psychiatry.* 2016;21:1225–1231.
70. Guastella AJ, Gray KM, Rinehart NJ, et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. *J Child Psychol Psychiatry.* 2015;56(4):444–452.
71. Dadds MR, MacDonald E, Cauchi A, Williams K, Levy F, Brennan J. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. *J Autism Dev Disord.* 2014;44:521–531.
72. Gresham FM, Elliot SN. Social skills rating scale. Circle Pines, MN: American Guidance Service, 1990.
73. Maniram J, Karim SBS, Oosthuizen F, Wiafe E. Pharmacological Management of Core Symptoms and Comorbidities of Autism Spectrum Disorder in Children and Adolescents: A Systematic Review. *Neuropsychiatr Dis Treat.* 2022 Aug 7;18:1629–1644.
74. Parker KJ, Oztan O, Libove RA, et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. *Sci Transl Med.* 2019;11(491).
75. Wu G, Lupton JR, Turner ND, Fang Y-Z, Yang S. Glutathione metabolism and its implications for health. *The Journal of nutrition* 2004;134:489–492.
76. Zhou N, Yang X, Huang A, Chen Z. The potential mechanism of N-acetylcysteine in treating COVID-19. *Current pharmaceutical biotechnology* 2021;22:1584–1590.
77. Liu X, Hu Z, Zhou H. [Retracted] N-Acetylcysteine Improves Inflammatory Response in COPD Patients by Regulating Th17/Treg Balance through Hypoxia Inducible Factor-1α Pathway. *BioMed Research International* 2021;2021:6372128.
78. Fu G, Xu Q, Qiu Y, et al. Suppression of Th17 cell differentiation by misshapen/NIK-related kinase MINK1. *Journal of Experimental Medicine* 2017;214:1453–1469.
79. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. *Biological psychiatry* 2012;71:956–961.
80. Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. *BMC psychiatry*



- 2013;13:1-7.
81. Nikoo M, Radnia H, Farokhnia M, Mohammadi M-R, Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. *Clinical neuropharmacology* 2015;38:11-17.
82. Wink LK, Adams R, Wang Z, et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. *Molecular autism* 2016;7:1-9.
83. Dean OM, Gray KM, Villagonzalo K-A, et al. A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. *Australian & New Zealand Journal of Psychiatry* 2017;51:241-249.
84. Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ. GABA system dysfunction in autism and related disorders: from synapse to symptoms. *Neuroscience & Biobehavioral Reviews* 2012;36:2044-2055.
85. Osterweil EK, Krueger DD, Reinhold K, Bear MF. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. *Journal of Neuroscience* 2010;30:15616-15627.
86. Carlson GC. Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. *Pharmacology Biochemistry and Behavior* 2012;100:850-854.
87. Sanchez-Ponce R, Wang L-Q, Lu W, Von Hehn J, Cherubini M, Rush R. Metabolic and pharmacokinetic differentiation of STX209 and racemic baclofen in humans. *Metabolites* 2012;2:596-613.
88. Lal R, Sukbuntherng J, Tai EH, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. *The Journal of pharmacology and experimental therapeutics* 2009;330:911-921.
89. Aishworiya R, Valica T, Hagerman R, Restrepo B. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. *Focus* 2024;22:198-211.
90. Henderson C, Wijetunge L, Kinoshita MN, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. *Science translational medicine* 2012;4:152ra128-152ra128.
91. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. *Science translational medicine* 2012;4:152ra127-152ra127.
92. Gundersen BB, T O'Brien W, Schaffler MD, et al. Towards preclinical validation of arbaclofen (R-baclofen) treatment for 16p11. 2 deletion syndrome. *bioRxiv* 2023.
93. Bahji A, Forth E, Nasar A, Waqas A, Hawken ER, Ayub M. Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities. *Journal of Psychopharmacology* 2024;02698811241303654.
94. Roberts TP, Bloy L, Blaskey L, et al. A MEG study of acute arbaclofen (STX-209) administration. *Frontiers in Integrative Neuroscience* 2019;13:69.
95. Huang Q, Velthuis H, Pereira AC, et al. Exploratory evidence for differences in GABAergic regulation of auditory processing in autism spectrum disorder. *Translational psychiatry* 2023;13:320.
96. Veenstra-VanderWeele J, Cook EH, King BH, et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. *Neuropsychopharmacology* 2017;42:1390-1398.
97. Frye RE. Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder. *Drug, healthcare and patient safety* 2014:69-76.
98. Carlini EA. Research with marijuana in Brazil. *SciELO Brasil*, 2010: 53-54.



99. Zamberletti E, Gabaglio M, Parolaro D. The endocannabinoid system and autism spectrum disorders: insights from animal models. *International journal of molecular sciences* 2017;18:1916.
100. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. *Addiction biology* 2008;13:147-159.
101. Sagar DR, Jhaveri M, Chapman V. Targeting the cannabinoid system to produce analgesia. *Behavioral Neurobiology of the Endocannabinoid System* 2009:275-287.
102. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. *European Journal of Neuroscience* 2003;17:2750-2754.
103. Piomelli D. The molecular logic of endocannabinoid signalling. *Nature Reviews Neuroscience* 2003;4:873-884.
104. Karhson DS, Krasinska KM, Dallaire JA, et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder. *Molecular autism* 2018;9:1-6.
105. Pedrazzi JF, Ferreira FR, Silva-Amaral D, et al. Cannabidiol for the treatment of autism spectrum disorder: hope or hype? *Psychopharmacology* 2022;239:2713-2734.
106. Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives* 2009;23:597-602.
107. Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. *Life sciences* 2011;89:165-170.
108. Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* 2012;32:340-353.
109. Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. *Basic & clinical pharmacology & toxicology* 2019;124:28-31.
110. Arteaga-Henríquez G, Lugo-Marín J, Gisbert L, et al. Activation of the monocyte/macrophage system and abnormal blood levels of lymphocyte subpopulations in individuals with autism spectrum disorder: A systematic review and meta-analysis. *International journal of molecular sciences* 2022;23:14329.
111. Ahmad SF, Ansari MA, Nadeem A, et al. Involvement of CD45 cells in the development of autism spectrum disorder through dysregulation of granulocyte-macrophage colony-stimulating factor, key inflammatory cytokines, and transcription factors. *International immunopharmacology* 2020;83:106466.
112. Ceylan MF, Tural Hesapcioglu S, Yavas CP, Senat A, Erel O. Serum ischemia-modified albumin levels, myeloperoxidase activity and peripheral blood mononuclear cells in autism spectrum disorder (ASD). *Journal of Autism and Developmental Disorders* 2021;51:2511-2517.
113. Lamanna J, Meldolesi J. Autism Spectrum Disorder: Brain Areas Involved, Neurobiological Mechanisms, Diagnoses and Therapies. *International Journal of Molecular Sciences* 2024;25:2423.
114. Arteaga-Henriquez G, Gisbert L, Ramos-Quiroga JA. Immunoregulatory and/or anti-inflammatory agents for the management of core and associated symptoms in individuals with autism spectrum disorder: A narrative review of randomized, placebo-controlled trials. *CNS drugs* 2023;37:215-229.
115. Kierdorf K, Prinz M. Factors regulating microglia activation. *Frontiers in cellular neuroscience* 2013;7:44.



116. Ahmad SF, Zoheir KM, Ansari MA, et al. Dysregulation of Th1, Th2, Th17, and T regulatory cell-related transcription factor signaling in children with autism. *Molecular neurobiology* 2017;54:4390-4400.
117. Williams DM. Clinical pharmacology of corticosteroids. *Respiratory care* 2018;63:655-670.
118. Fu XQ, Cai JY, Li MJ. Prednisone may rebuild the immunologic homeostasis: Alteration of Th17 and Treg cells in the lymphocytes from rats' spleens after treated with prednisone-containing serum. *Molecular genetics & genomic medicine* 2019;7:e00800.
119. Eddy JL, Krukowski K, Janusek L, Mathews HL. Glucocorticoids regulate natural killer cell function epigenetically. *Cellular immunology* 2014;290:120-130.
120. Malek M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi M-R, Akhondzadeh S. Prednisolone as adjunctive treatment to risperidone in children with regressive type of autism spectrum disorder: a randomized, placebo-controlled trial. *Clinical Neuropharmacology* 2020;43:39-45.
121. Brito AR, Vairo GdPT, Dias APBH, Olej B, Nascimento OJM, Vasconcelos MM. Effect of prednisolone on language function in children with autistic spectrum disorder: a randomized clinical trial. *Jornal de pediatria* 2021;97:22-29.
122. Duffy FH, Shankardass A, McAnulty GB, et al. Corticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMA-ER), language, and behavior. *BMC neurology* 2014;14:1-18.
123. Murugan S, Jakka P, Namani S, Mujumdar V, Radhakrishnan G. The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation. *Journal of Biological Chemistry* 2019;294:4596-4607.
124. Aggelakopoulou M, Kourepini E, Paschalidis N, et al. ER β -dependent direct suppression of human and murine Th17 cells and treatment of established central nervous system autoimmunity by a neurosteroid. *The Journal of Immunology* 2016;197:2598-2609.
125. Ayatollahi A, Bagheri S, Ashraf-Ganjouei A, Moradi K, Mohammadi M-R, Akhondzadeh S. Does pregnenolone adjunct to risperidone ameliorate irritable behavior in adolescents with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial? *Clinical neuropharmacology* 2020;43:139-145.
126. Asadabadi M, Mohammadi M-R, Ghanizadeh A, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. *Psychopharmacology* 2013;225:51-59.
127. Villa V, Thellung S, Bajetto A, et al. Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide. *Pharmacological Research* 2016;113:500-514.
128. Singh S, Khanna D, Kalra S. Minocycline and doxycycline: more than antibiotics. *Current Molecular Pharmacology* 2021;14:1046-1065.
129. Campbell JH, Burdo TH, Autissier P, et al. Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS. *PloS one* 2011;6:e18688.
130. Florou DT, Mavropoulos A, Dardiotis E, et al. Tetracyclines diminish in vitro IFN- γ and IL-17-producing adaptive and innate immune cells in multiple sclerosis. *Frontiers in Immunology* 2021;12:739186.
131. Ghaleiha A, Alikhani R, Kazemi M-R, et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. *Journal of child and adolescent psychopharmacology* 2016;26:784-791.
132. Ruhee RT, Suzuki K. The integrative role of sulfuraphane in preventing inflammation, oxidative stress and fatigue: A review of a potential protective phytochemical. *Antioxidants* 2020;9:521.



133. Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). *Proceedings of the National Academy of Sciences* 2014;111:15550-15555.
134. Momtazmanesh S, Amirimoghaddam-Yazdi Z, Moghaddam HS, Mohammadi MR, Akhondzadeh S. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. *Psychiatry and clinical neurosciences* 2020;74:398-405.
135. Zimmerman AW, Singh K, Connors SL, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. *Molecular autism* 2021;12:38.
136. Giacobbe J, Benoiton B, Zunszain P, Pariante CM, Borsini A. The anti-inflammatory role of omega-3 polyunsaturated fatty acids metabolites in pre-clinical models of psychiatric, neurodegenerative, and neurological disorders. *Frontiers in Psychiatry* 2020;11:450833.
137. Chehimi M, Ward R, Pestel J, et al. Omega-3 polyunsaturated fatty acids inhibit IL-17A secretion through decreased ICAM-1 expression in T cells co-cultured with adipose-derived stem cells harvested from adipose tissues of obese subjects. *Molecular Nutrition & Food Research* 2019;63:1801148.
138. Bent S, Hendren RL, Zandi T, et al. Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. *Journal of the American Academy of Child & Adolescent Psychiatry* 2014;53:658-666.
139. Bent S, Bertoglio K, Ashwood P, Bostrom A, Hendren RL. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. *Journal of autism and developmental disorders* 2011;41:545-554.
140. Mankad D, Dupuis A, Smile S, et al. A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. *Molecular autism* 2015;6:1-11.
141. KURKIN, Denis V., et al. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. *PLoS One*, 2021, 16.7: e0254493.
142. Zыkov VP, Serebrennikova EB, Panchenko TN, et al. Rezul'taty mul'titsentrovogo issledovaniia éffektivnosti primeneniia korteksina pri kognitivnykh disfunktsiiakh u detei [Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children]. *Zh Nevrol Psikhiatr Im S S Korsakova*. 2018;118(3):27-31. Russian. doi: 10.17116/jnevro20181183127-31. PMID: 29652302.
143. Degtyareva VG, Drobyshhev VA, Poteryaeva EL. Effektivnost' reabilitatsionnykh meropriyati s primeneniem lekarstvennogo preparata Korteksin u detei s psikhonevrologicheskoi patologiei [The effectiveness of rehabilitation measures using the drug Cortexin in children with neuropsychiatric pathology]. *Zh Nevrol Psikhiatr Im S S Korsakova*. 2024;124(12):86-92. Russian. doi: 10.17116/jnevro202412412186. PMID: 39731376.
144. FERNELL, Elisabeth; GUSTAFSSON, Peik; GILLBERG, Christopher. Bumetanide for autism: Open-label trial in six children. *Acta paediatrica*, 2021, 110.5: 1548-1553.
145. Wang, T., Shan, L., Miao, C., Xu, Z., & Jia, F. (2021). Treatment effect of bumetanide in children with autism spectrum disorder: a systematic review and meta-analysis. *Frontiers in Psychiatry*, 12, 751575.
146. Hough, D., Mao, A. R., Aman, M., Lozano, R., Smith-Hicks, C., Martinez-Cerdeno, V., ... & Findling, R. L. (2023). Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder. *Annals of General Psychiatry*, 22(1), 45.
147. Qiu, J., Kong, X., Li, J., Yang, J., Huang, Y., Huang, M., ... & Kong, J. (2021). Transcranial direct current stimulation (tDCS) over the left dorsal lateral prefrontal cortex in children with autism spectrum disorder (ASD). *Neural plasticity*, 2021(1), 6627507.

TRANSKRANİYAL MANYETİK UYARIM (TMS)

Saban KARAYAĞIZ¹

GİRİŞ

Transkraniyal Manyetik Uyarım (TMS), beyin korteksine manyetik darbeler göndererek sinir hücrelerini uyarmak için kullanılan non-invaziv bir nöromodülasyon tekniğidir. 1985 yılında Anthony Barker ve ekibi tarafından geliştirilen TMS, nörolojik ve psikiyatrik hastalıkların tedavisinde devrim niteliğinde bir yöntem olarak kabul edilmiştir.¹

TMS 'nin Tanımı ve Tarihsel Gelişimi

Otizm Spektrum Bozukluğu (OSB), sosyal etkileşimlerde güçlük, tekrarlayıcı davranışlar ve sınırlı ilgi alanları gibi belirtilerle karakterize edilen nörogelişimsel bir bozukluktur.¹ Son yıllarda, OSB'nin nörobiyolojik temelini anlamaya yönelik çalışmalar, beyin bağlantısındaki anormalliklerin bu bozukluğun gelişiminde önemli bir rol oynadığını göstermiştir.¹ Bu bağlamda, Transkraniyal Manyetik Uyarım (TMS), beyin fonksiyonlarını modüle ederek OSB semptomlarını hafifletme potansiyeli nedeniyle dikkat çekmektedir.

TMS, elektromanyetik indüksiyon yoluyla beyin korteksine manyetik darbeler göndererek sinir hücrelerini uyandır. TMS'nin bu özellikleri, nörolojik ve psikiyatrik bozuklukların tedavisinde kullanılmasını mümkün kılmıştır. Özellikle, TMS'nin OSB'deki uygulamaları, sosyal etkileşimdeki güçlükleri ve tekrarlayıcı davranışları azaltma konusunda umut vadetmektedir.¹

Tekrarlayan TMS (rTMS) yöntemi, belirli frekans ve yoğunluklarda manyetik darbeler göndererek belirli beyin bölgelerinde uyarım sağlamak ve böylece

¹ Uzm. Dr., Psikiyatrist, TMS Klinik, ORCID iD: 0000-0002-6914-4630



Kombine tedavi yaklaşımları: TMS'nin davranışsal terapiler, farmakolojik tedaviler ve eğitim programlarıyla birlikte nasıl uygulanabileceğine dair daha fazla çalışma gereklidir.

Sonuç olarak TMS, OSB tedavisinde umut vaat eden bir yöntem olmakla birlikte, etkinliği konusunda hâlâ araştırılması gereken birçok nokta bulunmaktadır. TMS'nin bireysel farklılıklara göre uyarlanabilmesi, uzun vadeli etkilerinin netleştirilmesi ve diğer tedavi yöntemleriyle entegrasyonunun sağlanması, OSB tedavisinde daha başarılı sonuçlar elde edilmesini sağlayabilir. Gelecekte yapılacak çalışmalar, TMS'nin OSB'deki yerini daha sağlam bir şekilde belirleyecek ve klinik kullanımlarını optimize edecektir.

KAYNAKLAR

1. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. *Lancet*. 1985; 1(8437):1106-1107.
2. Pascual-Leone A, Walsh V, Rothwell J. Transcranial magnetic stimulation in cognitive neuroscience-virtual lesion, chronometry, and functional connectivity. *Current Opinion in Neurobiology*. 2000;10(2):232-237.
3. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder. *Archives of General Psychiatry*. 2010;67(5):507-516.
4. TMS in ASD Consensus Group. Transcranial magnetic stimulation in autism spectrum disorder: challenges, promise, and roadmap for future research. *Autism Research*. 2016;9(2):184-203. doi:10.1002/aur.1567
5. Oberman LM, Enticott PG, Casanova MF, et al. Transcranial magnetic stimulation in autism spectrum disorder: challenges, promise, and roadmap for future research. *Autism Research*. 2016;9(2):184-203.
6. Wang J, Barstein J, Ethridge LE, et al. Resting state EEG abnormalities in autism spectrum disorders. *Journal of Neurodevelopmental Disorders*. 2013;5(1):24.
7. Fitzgerald PB, Daskalakis ZJ. A practical guide to the use of repetitive transcranial magnetic stimulation in the treatment of depression. *Brain Stimulation*. 2012;5(3):287-296.
8. Pascual-Leone A, Tormos JM, Keenan J, et al. Study and modulation of human cortical excitability with transcranial magnetic stimulation. *Journal of Clinical Neurophysiology*. 1998;15(4):333-343.
9. Oberman LM, Rotenberg A, Pascual-Leone A. rTMS applications in autism spectrum disorders. *Journal of Child Neurology*. 2014;29(8):1112-1120.
10. Casanova MF, Baruth JM, El-Baz A, et al. Transcranial magnetic stimulation in autism spectrum disorders: neuromodulation of cortical inhibition and excitation. *Autism Research*. 2012;5(2):157-166.
11. Cullen CL, Young KM. How does transcranial magnetic stimulation influence glial cells in the central nervous system? *Frontiers in Neural Circuits*. 2016.
12. Cabrerizo M, Cabrera A, Perez JO. Induced effects of transcranial magnetic stimulation on the autonomic nervous system and the cardiac rhythm. *Neural Plasticity*. 2014;2014:349718.
13. Pashut T, Wolfus S, Friedman A, Lavidor M. Mechanisms of magnetic stimulation of central nervous system neurons. *PLOS Computational Biology*. 2011.



14. Weber M, Eisen AA, AAEM. Magnetic stimulation of the central and peripheral nervous systems. *Muscle & Nerve*. 2002;25(2):160-175.
15. Hallett M. Transcranial magnetic stimulation: a primer. *Neuron*. 2007;55(2):187-199.
16. Chervyakov AV, Chernyavsky AY. Possible mechanisms underlying the therapeutic effects of transcranial magnetic stimulation. *Frontiers in Human Neuroscience*. 2015.
17. Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. *The Lancet Neurology*. 2003;2(3):145-156.
18. Di Lazzaro V, Fox PT, Hallett M, Karabanov AN. Transcranial magnetic stimulation of the brain: What is stimulated? *Clinical Neurophysiology*. 2022.
19. Klomjai W, Katz R, Lackmy-Vallée A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). *Neuroscience Letters*. 2015.
20. Boniface S, Ziemann U. Plasticity in the human nervous system: Investigations with transcranial magnetic stimulation. 2009.
21. Enticott PG, Rinehart NJ, Tonge BJ. *A double-blind, randomized trial of transcranial magnetic stimulation in high-functioning autism spectrum disorder*. *Biol Psychiatry*, 2014.
22. Fecteau S, Agosta S, Oberman LM. *Modulating social behavior with repetitive transcranial magnetic stimulation*. *J Neurosci*, 2015.
23. Gómez L, Vidal B, Morales L. *Effects of high-frequency rTMS on language processing in ASD patients*. *Front Psychol*, 2016.
24. Baruth JM, Casanova MF. *rTMS-induced neural plasticity in autism: A case study*. *BMC Neurosci*, 2013.
25. Sokhadze EM, Casanova MF, Baruth J. *Effects of 20 Hz rTMS on executive function in ASD*. *J Neuropsych Clin Neurosci*, 2012.
26. Yang LY, Liang M. *Efficacy of repetitive TMS in children with autism*. *Child Psychiatry Hum Dev*, 2017.
27. Oberman LM, Rotenberg A. *rTMS and inhibitory control in autism*. *Autism Res*, 2016.
28. Belmonte MK, Allen G, Beckel-Mitchener A. *TMS and emotion regulation in autism*. *Neurosci Res*, 2018.
29. Grossheinrich N, Rau A, Pogarell O. Theta burst stimulation in depression. *Brain Stimulation*. 2009.
30. Lisanby SH, Luber B. Applications of TMS to therapy in psychiatry. *Journal of Clinical Neurophysiology*. 2003.
31. Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of transcranial magnetic stimulation (TMS). *Clinical Neurophysiology*. 2020;131(2):474-528.
32. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of rTMS for major depression. *The Lancet Psychiatry*. 2021;8(8):701-711.
33. Koch G, Bonni S, Casula EP, et al. Transcranial magnetic stimulation for Parkinson's disease. *Nature Reviews Neurology*. 2021;17(4):224-236.
34. Rajji TK, Fitzgerald PB, Daskalakis ZJ. Transcranial magnetic stimulation for cognitive disorders. *Neuropsychopharmacology*. 2021;46(1):212-226.
35. Sommer IE, Begemann MJ, Temmerman A, et al. rTMS for auditory hallucinations in schizophrenia. *Schizophrenia Bulletin*. 2022;48(2):213-222.
36. Oberman LM, Bonussi A. Transcranial magnetic stimulation across the lifespan: impact of developmental and degenerative processes. *Biological Psychiatry*. 2024.
37. Makala MT, Nybo C, Blum K. Pilot study of personalized transcranial magnetic stimulation for autism. *Journal of Personalized Medicine*. 2024.



38. Singh SR, Bhattacharjee S. Neuromodulation interventions in paediatric neurological disorders. *Journal of Pediatrics and Child Health*. 2024.
39. Castaño CYM, Penagos P. Transcranial Magnetic Stimulation in the Treatment of Autism Spectrum Disorder. *Current Pediatric Reviews*. 2024.
40. Massoni L. TMS and TDCS in Autism Spectrum Disorder. *Med Discoveries*. 2024.

OTİZM SPEKTRUM BOZUKLUĞU VE KÖK HÜCRE TEDAVİSİ

Mehmet CANPOLAT¹

GİRİŞ

Otizm spektrum bozukluğu (OSB) günlük hasta pratiğinde hekimlerimizin sıklıkla karşılaştığı başlıca nörogelişimsel bozukluklardandır. Multifaktöryel etyolojiye sahiptir. Bu da her vakanın diğerlerinden farklı bir etiyolojik nedene bağlı olarak ortaya çıkabileceği anlamına gelir. Bu nedenle bu vakaların tanı, etiyolojik değerlendirme ve tedavi süreçlerinin yönetimi büyük bir önem arz eder.¹ Bu bölümde OSB tanımı, patofizyolojisi, tedavisi, kök hücre tanımı, kök hücre çeşitleri ve OSB olgularında hücresel tedavi güncel literatür ¹⁻²¹⁷ eşliğinde değerlendirilmiştir.

OTİZM SPEKTRUM BOZUKLUĞU (OSB)

OSB yaşamın erken dönemlerinde başlayan, sosyal iletişimde zorluklar, tekrarlayıcı davranışlar ve kısıtlı ilgi alanları ile karakterize karmaşık bir nörogelişimsel bozukluktur. *Ruhsal Bozuklukların Tanısal ve İstatistiksel El Kitabı*, Beşinci Baskı'ya (*DSM -5*) göre bir çocuğun OSB tanı kriterlerini karşılaması için; **a-** sosyal iletişim ve etkileşimin üç alanının her birinde kalıcı eksiklikleri ve **b-** dört tipteki kısıtlı, tekrarlayıcı davranışlardan en az ikisine sahip olması gerekir.²⁻⁶ OSB, tanısı için henüz net bir biyobelirteç belirlenmediğinden *DSM-V* tanı kriterleri kullanılarak davranışsal değerlendirme yoluyla erken çocukluk döneminde teşhis edilebilir.^{3,4,8,12,100}

¹ Prof. Dr., Erciyes Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları AD., drmehmetcanpolat@gmail.com, ORCID iD: 0000-0002-2197-8433



tedavisinin uzun vadeli güvenlik ve etkinliğinin değerlendirildiği daha kapsamlı çalışmalara gereksinim halen daha devam etmektedir.^{1,59}

Önerilen Ek Okumalar

- Canpolat M. Pediatrik Nöroloji Hastalarında Kök Hücre Uygulamaları. In, Temel Pediatrik Nöroloji Tanı ve Tedavi (Kumandaş& Canpolat). Akademisyen Kitabevi, 2022. pp.719-746
- Canpolat Çocuk Nörolojisi Pratiğinde Kök Hücre Multidisipliner Yaklaşım, (Editör; Canpolat M), Akademisyen Kitabevi, 2023.

KAYNAKLAR

1. Paprocka J, Kaminiów K, Kozak S, Sztuba K, Emich-Widera E. Stem Cell Therapies for Cerebral Palsy and Autism Spectrum Disorder-A Systematic Review. *Brain Sci.* 2021 Dec 3;11(12):1606. doi: 10.3390/brainsci11121606.
2. Nabetani M, Mukai T, Taguchi A. Cell Therapies for Autism Spectrum Disorder Based on New Pathophysiology: A Review. *Cell Transplant.* 2023 Jan-Dec;32:9636897231163217. doi: 10.1177/09636897231163217.
3. Diagnostic Criteria for ASD. Health Care Providers May 8, 2025. <https://www.cdc.gov/autism/hcp/diagnosis/index.html>.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR. 5th ed. American Psychiatric Association Publishing; Washington, DC, USA: 2022. <https://doi.org/10.1176/appi.books.9780890425787>. [Google Scholar]
5. Guthrie W, Wallis K, Bennett A, Brooks E, Dudley J, Gerdes M, Pandey J, Levy SE, Schultz RT, Miller JS. Accuracy of Autism Screening in a Large Pediatric Network. *Pediatrics.* 2019 Oct;144(4):e20183963. doi: 10.1542/peds.2018-3963.
6. Blumberg SJ, Bramlett MD, Kogan MD, Schieve LA, Jones JR, Lu MC. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012. *Natl Health Stat Report.* 2013 Mar 20;(65):1-11, 1 p following 11.
7. Santos JLS, Araújo CA, Rocha CAG, Costa-Ferro ZSM, Souza BSF. Modeling Autism Spectrum Disorders with Induced Pluripotent Stem Cell-Derived Brain Organoids. *Biomolecules.* 2023 Jan 30;13(2):260. doi: 10.3390/biom13020260.
8. Vahia VN. Diagnostic and statistical manual of mental disorders 5: A quick glance. *Indian J Psychiatry.* 2013 Jul;55(3):220-3. doi: 10.4103/0019-5545.117131.
9. Maenner MJ, Shaw KA, Bakian AV, Bilder DA, Durkin MS, Esler A, Furnier SM, Hallas L, Hall-Lande J, Hudson A, Hughes MM, Patrick M, Pierce K, Poynter JN, Salinas A, Shenouda J, Vehorn A, Warren Z, Constantino JN, DiRienzo M, Fitzgerald RT, Grzybowski A, Spivey MH, Pettygrove S, Zahorodny W, Ali A, Andrews JG, Baroud T, Gutierrez J, Hewitt A, Lee LC, Lopez M, Mancilla KC, McArthur D, Schwenk YD, Washington A, Williams S, Cogswell ME. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018. *MMWR Surveill Summ.* 2021 Dec 3;70(11):1-16. doi: 10.15585/mmwr.ss7011a1.
10. Forsberg SL, Ilieva M, Maria Michel T. Epigenetics and cerebral organoids: promising directions in autism spectrum disorders. *Transl Psychiatry.* 2018 Jan 10;8(1):14. doi: 10.1038/s41398-017-0062-x.



11. Jia FY, Li TY. Editorial: Etiology and treatment for children and adolescents with autism spectrum disorder. *Front Psychiatry*. 2023 Jul 13;14:1222384. doi: 10.3389/fpsy.2023.1222384.
12. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th ed. American Psychiatric Association; Washington, DC, USA: 2013. <https://doi.org/10.1176/appi.books.9780890425596>. [Google Scholar]
13. World Health Organization. "ICD-10: The ICD-10 Classification of Mental and Behavioural Disorders: diagnostic criteria for research." *ICD-10: the ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research*. World Health Organization; Geneva, Switzerland:1993. xiii + 248 pages. ISBN 92 4154455 4 [Google Scholar]
14. Roman-Urrestarazu A, van Kessel R, Allison C, Matthews FE, Brayne C, Baron-Cohen S. Association of Race/Ethnicity and Social Disadvantage with Autism Prevalence in 7 million School Children in England. *JAMA Pediatr*. 2021;175:e210054. doi: 10.1001/jamapediatrics.2021.0054.
15. Morales Hidalgo P, Voltas Moreso N., Canals Sans J. Autism spectrum disorder prevalence and associated sociodemographic factors in the school population: EPINED study. *Autism*. 2021;25:1999–2011. doi: 10.1177/13623613211007717.
16. Toro R, Konyukh M, Delorme R, Leblond C, Chaste P, Fauchereau F, Coleman M, Leboyer M, Gillberg C, Bourgeron T. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. *Trends Genet*. 2010;26:363–372. doi: 10.1016/j.tig.2010.05.007.
17. Nabetani M, Mukai T. Future perspectives on cell therapy for autism spectrum disorder. *BIO-CELL*, 2022;46(4):873–79. <https://doi.org/10.32604/biocell.2022.018218>.
18. Robertson CE, Baron-Cohen S. Sensory perception in autism. *Nat Rev Neurosci*. 2017 Nov;18(11):671–684. doi: 10.1038/nrn.2017.112.
19. Motttron L, Dawson M, Soulières I, Hubert B, Burack J. Enhanced perceptual functioning in autism: an update, and eight principles of autistic perception. *J Autism Dev Disord*. 2006 Jan;36(1):27–43. doi: 10.1007/s10803-005-0040-7.
20. Demetriou EA, Song CY, Park SH, Pepper KL, Naismith SL, Hermens DF, Hickie IB, Thomas EE, Norton A, White D, Guastella AJ. Autism, Early Psychosis, and Social Anxiety Disorder: a transdiagnostic examination of executive function cognitive circuitry and contribution to disability. *Transl Psychiatry*. 2018 Sep 24;8(1):200. doi: 10.1038/s41398-018-0193-8.
21. Jones CRG, Simonoff E, Baird G, Pickles A, Marsden AJS, Tregay J, Happé F, Charman T. The association between theory of mind, executive function, and the symptoms of autism spectrum disorder. *Autism Res*. 2018 Jan;11(1):95–109. doi: 10.1002/aur.1873.
22. Baron-Cohen S, Leslie AM, Frith U. Does the autistic child have a "theory of mind"? *Cognition*. 1985 Oct;21(1):37–46. doi: 10.1016/0010-0277(85)90022-8.
23. Sharma A, Gokulchandran N, Sane H, Nivins S, Paranjape A, Badhe P. The Baseline Pattern and Age-related Developmental Metabolic Changes in the Brain of Children with Autism as Measured on Positron Emission Tomography/Computed Tomography Scan. *World J Nucl Med*. 2018 Apr-Jun;17(2):94–101. doi: 10.4103/wjnm.WJNM_29_17.
24. Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. *Nature*. 2008 Oct 16;455(7215):903–11. doi: 10.1038/nature07456.
25. Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. *Cold Spring Harb Perspect Biol*. 2012 Mar 1;4(3):a009886. doi: 10.1101/cshperspect.a009886.
26. Castelbaum L, Sylvester CM, Zhang Y, Yu Q, Constantino JN. On the Nature of Monozygotic Twin Concordance and Discordance for Autistic Trait Severity: A Quantitative Analysis. *Behav Genet*. 2020 Jul;50(4):263–272. doi: 10.1007/s10519-019-09987-2.
27. Cohen S, Gabel HW, Hemberg M, Hutchinson AN, Sadacca LA, Ebert DH, Harmin DA, Greenberg RS, Verdine VK, Zhou Z, Wetsel WC, West AE, Greenberg ME. Genome-wide activit-



- y-dependent MeCP2 phosphorylation regulates nervous system development and function. *Neuron*. 2011 Oct 6;72(1):72-85. doi: 10.1016/j.neuron.2011.08.022.
28. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. *Nat Rev Mol Cell Biol*. 2009 May;10(5):307-18. doi: 10.1038/nrm2672.
29. Budimirovic DB, Kaufmann WE. What can we learn about autism from studying fragile X syndrome? *Dev Neurosci*. 2011;33(5):379-94. doi: 10.1159/000330213.
30. Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, Kim TK, Grif-fith EC, Waldon Z, Maehr R, Ploegh HL, Chowdhury S, Worley PF, Steen J, Greenberg ME. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. *Cell*. 2010 Mar 5;140(5):704-16. doi: 10.1016/j.cell.2010.01.026.
31. Mabb AM, Ehlers MD. Ubiquitination in postsynaptic function and plasticity. *Annu Rev Cell Dev Biol*. 2010;26:179-210. doi: 10.1146/annurev-cellbio-100109-104129.
32. Sassone-Corsi P, Christen Y, editors. *A Time for Metabolism and Hormones* [Internet]. Cham (CH): Springer; 2016. PMID: 28892333.
33. Sullivan PF, Geschwind DH. Defining the Genetic, Genomic, Cellular, and Diagnostic Ar-chitectures of Psychiatric Disorders. *Cell*. 2019 Mar 21;177(1):162-183. doi: 10.1016/j.cell.2019.01.015.
34. Ruzzo EK, Pérez-Cano L, Jung JY, Wang LK, Kashef-Haghighi D, Hartl C, Singh C, Xu J, Ho-ekstra JN, Leventhal O, Leppä VM, Gandal MJ, Paskov K, Stockham N, Polioudakis D, Lowe JK, Prober DA, Geschwind DH, Wall DP. Inherited and De Novo Genetic Risk for Autism Im-pacts Shared Networks. *Cell*. 2019 Aug 8;178(4):850-866.e26. doi: 10.1016/j.cell.2019.07.015.
35. Parikshak NN, Swarup V, Belgard TG, Irimia M, Ramaswami G, Gandal MJ, Hartl C, Leppa V, de la Torre Ubieta L, Huang J, Lowe JK, Blencowe BJ, Horvath S, Geschwind DH. Author Correction: Genome-wide changes in lncRNA, splicing, and regional gene expression pat-terns in autism. *Nature*. 2018 Aug;560(7718):E30. doi: 10.1038/s41586-018-0295-8. Erratum for: *Nature*. 2016 Dec 15;540(7633):423-427. doi: 10.1038/nature20612.
36. Oudin A, Frondelius K, Haglund N, Källén K, Forsberg B, Gustafsson P, Malmqvist E. Prenatal exposure to air pollution as a potential risk factor for autism and ADHD. *Environ Int*. 2019 Dec;133(Pt A):105149. doi: 10.1016/j.envint.2019.105149.
37. Rossignol DA, Genuis SJ, Frye RE. Environmental toxicants and autism spectrum disorders: a systematic review. *Transl Psychiatry*. 2014 Feb 11;4(2):e360. doi: 10.1038/tp.2014.4.
38. Volk L, Chiu SL, Sharma K, Haganir RL. Glutamate synapses in human cognitive disorders. *Annu Rev Neurosci*. 2015 Jul 8;38:127-49. doi: 10.1146/annurev-neuro-071714-033821.
39. Tachibana Y, Miyazaki C, Ota E, Mori R, Hwang Y, Kobayashi E, Terasaka A, Tang J, Ka-mio Y. A systematic review and meta-analysis of comprehensive interventions for pre-school children with autism spectrum disorder (ASD). *PLoS One*. 2017 Dec 6;12(12):e0186502. doi: 10.1371/journal.pone.0186502.
40. Kubota M, Fujino J, Tei S, Takahata K, Matsuoka K, Tagai K, Sano Y, Yamamoto Y, Shimada H, Takado Y, Seki C, Itahashi T, Aoki YY, Ohta H, Hashimoto RI, Zhang MR, Suhara T, Nakamu-ra M, Takahashi H, Kato N, Higuchi M. Binding of Dopamine D1 Receptor and Noradrena-line Transporter in Individuals with Autism Spectrum Disorder: A PET Study. *Cereb Cortex*. 2020 Nov 3;30(12):6458-6468. doi: 10.1093/cercor/bhaa211.
41. Takumi T, Tamada K, Hatanaka F, Nakai N, Bolton PF. Behavioral neuroscience of autism. *Neurosci Biobehav Rev*. 2020 Mar;110:60-76. doi: 10.1016/j.neubiorev.2019.04.012.
42. Rojas DC. The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. *J Neural Transm (Vienna)*. 2014 Aug;121(8):891-905. doi: 10.1007/s00702-014-1216-0.
43. Yang JQ, Yang CH, Yin BQ. Combined the GABA-A and GABA-B receptor agonists attenua-tes autistic behaviors in a prenatal valproic acid-induced mouse model of autism. *Behav Brain*



- Res. 2021 Apr 9;403:113094. doi: 10.1016/j.bbr.2020.113094.
44. Sukhodolsky DG, Bloch MH, Panza KE, Reichow B. Cognitive-behavioral therapy for anxiety in children with high-functioning autism: a meta-analysis. *Pediatrics*. 2013 Nov;132(5):e1341-50. doi: 10.1542/peds.2013-1193.
 45. Minshawi NF. Behavioral assessment and treatment of self-injurious behavior in autism. *Child Adolesc Psychiatr Clin N Am*. 2008 Oct;17(4):875-86, x. doi: 10.1016/j.chc.2008.06.012.
 46. MacDonald R, Parry-Cruwys D, Dupere S, Ahearn W. Assessing progress and outcome of early intensive behavioral intervention for toddlers with autism. *Res Dev Disabil*. 2014 Dec;35(12):3632-44. doi: 10.1016/j.ridd.2014.08.036.
 47. Lancaster BM. Assessment and treatment of autism. *Indian J Pediatr*. 2005 Jan;72(1):45-52. doi: 10.1007/BF02760580.
 48. Huntjens A, van den Bosch LMCW, Sizoo B, Kerkhof A, Huibers MJH, van der Gaag M. The effect of dialectical behaviour therapy in autism spectrum patients with suicidality and/or self-destructive behaviour (DIASS): study protocol for a multicentre randomised controlled trial. *BMC Psychiatry*. 2020 Mar 17;20(1):127. doi: 10.1186/s12888-020-02531-1.
 49. Heyvaert M, Saenen L, Campbell JM, Maes B, Onghena P. Efficacy of behavioral interventions for reducing problem behavior in persons with autism: an updated quantitative synthesis of single-subject research. *Res Dev Disabil*. 2014 Oct;35(10):2463-76. doi: 10.1016/j.ridd.2014.06.017.
 50. Canpolat M. Pediatrik Nöroloji Hastalarında Kök Hücre Uygulamaları. In, *Temel Pediatrik Nöroloji Tanı ve Tedavi (Kumandaş& Canpolat)*. Akademisyen Kitabevi, 2022. pp.719-746
 51. Üstün CT, Dinç GT. Kök Hücre Bilimlerinde Güncel Tanımlar. In, *Canpolat, Çocuk Nörolojisi Pratiğinde Kök Hücre Multidisipliner Yaklaşım (Editör: Canpolat M)*. Akademisyen Kitabevi, Ankara, ISBN:9786253994099, 2023. pp. 19-29.
 52. Kalra K, Tomar PC, Stem Cell: Basics, Classification and Applications. *American Journal of Phytomedicine and Clinical Therapeutics (AJPCT)*, 2014;2(7):919-930.
 53. Marc HGP Raaijmakers. Overview of stem cells. Section Editor: Benjamin A Raby, MD, MPH, Deputy Editor: Jennifer S Tirnauer, MD, ©2022 UpToDate, <https://www.uptodate.com/contents/overview-of-stem-cells>, Literature review current through: Dec 2021. | This topic last updated: Jul 26, 2021.
 54. Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. *Stem Cell Res Ther*. 2019 Feb 26;10(1):68. doi: 10.1186/s13287-019-1165-5.
 55. Douglas Melton, Chapter 2 - 'Stemness': Definitions, Criteria, and Standards, Editor(s): Robert Lanza, Anthony Atala, *Essentials of Stem Cell Biology (Third Edition)*, Pages 7-17, ISBN 9780124095038, <https://doi.org/10.1016/B978-0-12-409503-8.00002-0>. (<https://www.sciencedirect.com/science/article/pii/B9780124095038000020>).
 56. Kaya MM, Tutun H. Kök Hücre Üretimi, İzolasyonu ve Tedavide Kullanımı. *Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni*, 2021;12(2):55-78. DOI: 10.38137/vftd.969798.
 57. Kolios G, Moodley Y. Introduction to stem cells and regenerative medicine. *Respiration*. 2013;85(1):3-10. doi: 10.1159/000345615.
 58. Kim SU, Lee HJ. Human Neural Stem Cell-Based Cell- and Gene-Therapy for Neurological Diseases. In: Al-Rubeai, M., Naciri, M. (eds) *Stem Cells and Cell Therapy*. Cell Engineering, vol 8. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7196-3_2, 2014., pp.21-48. .
 59. Sun JM, Kurtzberg J. Stem cell therapies in cerebral palsy and autism spectrum disorder. *Dev Med Child Neurol*. 2021 May;63(5):503-510. doi: 10.1111/dmcn.14789.
 60. Alessandrini M, Preynat-Seauve O, De Bruin K, Pepper MS. Stem cell therapy for neurological disorders. *S Afr Med J*. 2019 Sep 10;109(8b):70-77. doi: 10.7196/SAMJ.2019.v109i8b.14009.
 61. Romanov YA, Tarakanov OP, Radaev SM, Dugina TN, Ryaskina SS, Darevskaya AN, Morozova YV, Khachatryan WA, Lebedev KE, Zotova NS, Burkova AS, Sukhikh GT, Smir-



- nov VN. Human allogeneic AB0/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy. *Cytotherapy*. 2015 Jul;17(7):969-78. doi: 10.1016/j.jcyt.2015.02.010.
62. Jiao Y, Li XY, Liu J. A New Approach to Cerebral Palsy Treatment: Discussion of the Effective Components of Umbilical Cord Blood and its Mechanisms of Action. *Cell Transplant*. 2019 May;28(5):497-509. doi: 10.1177/0963689718809658.
63. Phuc PV, Ngoc VB, Lam DH, Tam NT, Viet PQ, Ngoc PK. Isolation of three important types of stem cells from the same samples of banked umbilical cord blood. *Cell Tissue Bank*. 2012 Jun;13(2):341-51. doi: 10.1007/s10561-011-9262-4.
64. McDonald CA, Fahey MC, Jenkin G, Miller SL. Umbilical cord blood cells for treatment of cerebral palsy; timing and treatment options. *Pediatr Res*. 2018 Jan;83(1-2):333-344. doi: 10.1038/pr.2017.236.
65. Novak I, Walker K, Hunt RW, Wallace EM, Fahey M, Badawi N. Concise Review: Stem Cell Interventions for People With Cerebral Palsy: Systematic Review With Meta-Analysis. *Stem Cells Transl Med*. 2016 Aug;5(8):1014-25. doi: 10.5966/sctm.2015-0372.
66. Rizk M, Aziz J, Shorr R, Allan DS. Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review of the Literature. *Biol Blood Marrow Transplant*. 2017 Oct;23(10):1607-1613. doi: 10.1016/j.bbmt.2017.05.032.
67. Forraz N, McGuckin CP. The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine. *Cell Prolif*. 2011 Apr;44 Suppl 1(Suppl 1):60-9. doi: 10.1111/j.1365-2184.2010.00729.x.
68. Matsumoto MM, Matthews KR. A Need for Renewed and Cohesive US Policy on Cord Blood Banking. *Stem Cell Rev Rep*. 2015 Dec;11(6):789-97. doi: 10.1007/s12015-015-9613-9.
69. Han MX, Craig ME. Research using autologous cord blood - time for a policy change. *Med J Aust*. 2013 Aug 19;199(4):288-99. doi: 10.5694/mja12.10835.
70. Finch-Edmondson M, Paton MCB, Webb A, Reza Ashrafi M, Blatch-Williams RK, Cox CS Jr, Crompton K, Griffin AR, Kim M, Kosmach S, Kurtzberg J, Nouri M, Ri Suh M, Sun J, Zarrabi M, Novak I. Cord Blood Treatment for Children With Cerebral Palsy: Individual Participant Data Meta-Analysis. *Pediatrics*. 2025 May 1;155(5):e2024068999. doi: 10.1542/peds.2024-068999.
71. van de Ven C, Collins D, Bradley MB, Morris E, Cairo MS. The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration. *Exp Hematol*. 2007 Dec;35(12):1753-65. doi: 10.1016/j.exphem.2007.08.017.
72. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. *Annu Rev Pathol*. 2011;6:457-78. doi: 10.1146/annurev-pathol-011110-130230.
73. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8(4):315-7. doi: 10.1080/14653240600855905.
74. Siniscalco D, Sapone A, Cirillo A, Giordano C, Maione S, Antonucci N. Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future? *J Biomed Biotechnol*. 2012;2012:480289. doi: 10.1155/2012/480289.
75. Siniscalco D, Giordano C, Galderisi U, Luongo L, Alessio N, Di Bernardo G, de Novellis V, Rossi F, Maione S. Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice. *Cell Mol Life Sci*. 2010 Feb;67(4):655-69. doi: 10.1007/s00018-009-0202-4.
76. Bianco P. "Mesenchymal" stem cells. *Annu Rev Cell Dev Biol*. 2014;30:677-704. doi: 10.1146/annurev-cellbio-100913-013132.



77. Obtulowicz P, Lech W, Strojek L, Sarnowska A, Domanska-Janik K. Induction of Endothelial Phenotype From Wharton's Jelly-Derived MSCs and Comparison of Their Vasoprotective and Neuroprotective Potential With Primary WJ-MSCs in CA1 Hippocampal Region Ex Vivo. *Cell Transplant*. 2016;25(4):715-27. doi: 10.3727/096368915X690369.
78. Lv FJ, Tuan RS, Cheung KM, Leung VY. Concise review: the surface markers and identity of human mesenchymal stem cells. *Stem Cells*. 2014 Jun;32(6):1408-19. doi: 10.1002/stem.1681.
79. Gönen BZ, Gökdemir NS. Mezenkimal Kök Hücreler ve Klinik Kullanımı. In, Canpolat, Çocuk Nörolojisi Pratiğinde Kök Hücre Multidisipliner Yaklaşım (Editör: Canpolat M). Akademi-yen Kitabevi, Ankara, ISBN:9786253994099, 2023. pp.117-125.
80. Griffin MD, Elliman SJ, Cahill E, English K, Ceredig R, Ritter T. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots? *Stem Cells*. 2013 Oct;31(10):2033-41. doi: 10.1002/stem.1452.
81. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. *Inflamm Allergy Drug Targets*. 2009 Jun;8(2):110-23. doi: 10.2174/187152809788462635.
82. Siniscalco D, Kannan S, Semprún-Hernández N, Eshraghi AA, Brigida AL, Antonucci N. Stem cell therapy in autism: recent insights. *Stem Cells Cloning*. 2018 Oct 23;11:55-67. doi: 10.2147/SCCAA.S155410.
83. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ; Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. *PLoS One*. 2012;7(10):e47559. doi: 10.1371/journal.pone.0047559.
84. Doğan A. Embryonic Stem Cells in Development and Regenerative Medicine. *Adv Exp Med Biol*. 2018;1079:1-15. doi: 10.1007/5584_2018_175.
85. Hsu YC, Lee DC, Chiu IM. Neural stem cells, neural progenitors, and neurotrophic factors. *Cell Transplant*. 2007;16(2):133-50.
86. Santilli G, Lamorte G, Carlessi L, Ferrari D, Rota Nodari L, Binda E, Delia D, Vescovi AL, De Filippis L. Mild hypoxia enhances proliferation and multipotency of human neural stem cells. *PLoS One*. 2010 Jan 5;5(1):e8575. doi: 10.1371/journal.pone.0008575.
87. Ardhanareeswaran K, Coppola G, Vaccarino F. The use of stem cells to study autism spectrum disorder. *Yale J Biol Med*. 2015 Mar 4;88(1):5-16.
88. Szablowska-Gadomska I, Bużańska L, Małcki M. Stem cell properties, current legal status and medical application. *Postepy Hig. Med. Dosw*. 2017;71:1216-1230. doi: 10.5604/01.3001.0010.7733.
89. Brigida AL, Siniscalco D. Induced pluripotent stem cells as a cellular model for studying Down Syndrome. *J Stem Cells Regen Med*. 2016 Nov 29;12(2):54-60. doi: 10.46582/jsrm.1202009.
90. Augustyniak J, Zychowicz M, Podobinska M, Barta T, Buzanska L. Reprogramming of somatic cells: possible methods to derive safe, clinical-grade human induced pluripotent stem cells. *Acta Neurobiol Exp (Wars)*. 2014;74(4):373-82. doi: 10.55782/ane-2014-2000.
91. Rao MS, Malik N. Assessing iPSC reprogramming methods for their suitability in translational medicine. *J Cell Biochem*. 2012 Oct;113(10):3061-8. doi: 10.1002/jcb.24183.
92. Nori S, Okada Y, Nishimura S, Sasaki T, Itakura G, Kobayashi Y, Renault-Mihara F, Shimizu A, Koya I, Yoshida R, Kudoh J, Koike M, Uchiyama Y, Ikeda E, Toyama Y, Nakamura M, Okano H. Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition. *Stem Cell Reports*. 2015 Mar 10;4(3):360-73. doi: 10.1016/j.stemcr.2015.01.006.
93. Attwood SW, Edel MJ. iPS-Cell Technology and the Problem of Genetic Instability-Can It Ever Be Safe for Clinical Use? *J Clin Med*. 2019 Feb 28;8(3):288. doi: 10.3390/jcm8030288.
94. Linda K, Fiuza C, Nadif Kasri N. The promise of induced pluripotent stem cells for neuro-



- developmental disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2018 Jun 8;84(Pt B):382-391. doi: 10.1016/j.pnpbp.2017.11.009.
95. Alessio N, Brigida AL, Peluso G, Antonucci N, Galderisi U, Siniscalco D. Stem Cell-Derived Exosomes in Autism Spectrum Disorder. *Int J Environ Res Public Health*. 2020 Feb 4;17(3):944. doi: 10.3390/ijerph17030944.
96. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem*. 1987 Jul 5;262(19):9412-20.
97. Borges FT, Reis LA, Schor N. Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. *Braz J Med Biol Res*. 2013 Oct;46(10):824-30. doi: 10.1590/1414-431X20132964.
98. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 2018 Nov 23;7(1):1535750. doi: 10.1080/20013078.2018.1535750.
99. Harrell CR, Volarevic A, Djonov V, Volarevic V. Mesenchymal Stem Cell-Derived Exosomes as New Remedy for the Treatment of Neurocognitive Disorders. *Int J Mol Sci*. 2021 Feb 1;22(3):1433. doi: 10.3390/ijms22031433.
100. Darwish M, El Hajj R, Khayat L, Alaaeddine N. Stem Cell Secretions as a Potential Therapeutic Agent for Autism Spectrum Disorder: A Narrative Review. *Stem Cell Rev Rep*. 2024 Jul;20(5):1252-1272. doi: 10.1007/s12015-024-10724-4.
101. Kathuria A, Nowosiad P, Jagasia R, Aigner S, Taylor RD, Andreae LC, Gatford NJF, Lucchesi W, Srivastava DP, Price J. Stem cell-derived neurons from autistic individuals with SHANK3 mutation show morphogenetic abnormalities during early development. *Mol Psychiatry*. 2018 Mar;23(3):735-746. doi: 10.1038/mp.2017.185.
102. Nestor MW, Phillips AW, Artimovich E, Nestor JE, Hussman JP, Blatt GJ. Human Inducible Pluripotent Stem Cells and Autism Spectrum Disorder: Emerging Technologies. *Autism Res*. 2016 May;9(5):513-35. doi: 10.1002/aur.1570.
103. Tania M, Khan MA, Xia K. Recent advances in animal model experimentation in autism research. *Acta Neuropsychiatr*. 2014 Oct;26(5):264-71. doi: 10.1017/neu.2013.58.
104. Segal-Gavish H, Karvat G, Barak N, Barzilay R, Ganz J, Edry L, Aharoni I, Offen D, Kimchi T. Mesenchymal Stem Cell Transplantation Promotes Neurogenesis and Ameliorates Autism Related Behaviors in BTBR Mice. *Autism Res*. 2016 Jan;9(1):17-32. doi: 10.1002/aur.1530.
105. Perets N, Segal-Gavish H, Gothelf Y, Barzilay R, Barhum Y, Abramov N, Hertz S, Morozov D, London M, Offen D. Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism. *Behav Brain Res*. 2017 Jul 28;331:254-260. doi: 10.1016/j.bbr.2017.03.047.
106. Ha S, Park H, Mahmood U, Ra JC, Suh YH, Chang KA. Human adipose-derived stem cells ameliorate repetitive behavior, social deficit and anxiety in a VPA-induced autism mouse model. *Behav Brain Res*. 2017 Jan 15;317:479-484. doi: 10.1016/j.bbr.2016.10.004.
107. Gobshtis N, Tfilin M, Wolfson M, Fraifeld VE, Turgeman G. Transplantation of mesenchymal stem cells reverses behavioural deficits and impaired neurogenesis caused by prenatal exposure to valproic acid. *Oncotarget*. 2017 Mar 14;8(11):17443-17452. doi: 10.18632/oncotarget.15245.
108. Hsiao EY, McBride SW, Chow J, Mazmanian SK, Patterson PH. Modeling an autism risk factor in mice leads to permanent immune dysregulation. *Proc Natl Acad Sci U S A*. 2012 Jul 31;109(31):12776-81. doi: 10.1073/pnas.1202556109.
109. Weick JP, Liu Y, Zhang SC. Human embryonic stem cell-derived neurons adopt and regulate the activity of an established neural network. *Proc Natl Acad Sci U S A*. 2011 Dec



- 13;108(50):20189-94. doi: 10.1073/pnas.1108487108.
110. Höing S, Rudhard Y, Reinhardt P, Glatza M, Stehling M, Wu G, Peiker C, Böcker A, Parga JA, Bunk E, Schwamborn JC, Slack M, Sternecker J, Schöler HR. Discovery of inhibitors of microglial neurotoxicity acting through multiple mechanisms using a stem-cell-based phenotypic assay. *Cell Stem Cell*. 2012 Nov 2;11(5):620-32. doi: 10.1016/j.stem.2012.07.005.
111. Kaya M, Karasalihoğlu S, Ustün F, Gültekin A, Cermik TE, Fazlıoğlu Y, Türe M, Yiğitbaşı ON, Berkarda S. The relationship between 99mTc-HMPAO brain SPECT and the scores of real life rating scale in autistic children. *Brain Dev*. 2002 Mar;24(2):77-81. doi: 10.1016/s0387-7604(02)00006-2.
112. Calió ML, Marinho DS, Ko GM, Ribeiro RR, Carbonel AF, Oyama LM, Ormanji M, Guirao TP, Calió PL, Reis LA, Simões Mde J, Lisbôa-Nascimento T, Ferreira AT, Bertoncini CR. Transplantation of bone marrow mesenchymal stem cells decreases oxidative stress, apoptosis, and hippocampal damage in brain of a spontaneous stroke model. *Free Radic Biol Med*. 2014 May;70:141-54. doi: 10.1016/j.freeradbiomed.2014.01.024.
113. Wada N, Gronthos S, Bartold PM. Immunomodulatory effects of stem cells. *Periodontol* 2000. 2013 Oct;63(1):198-216. doi: 10.1111/prd.12024.
114. Siniscalco D, Bradstreet JJ, Sych N, Antonucci N. Perspectives on the use of stem cells for autism treatment. *Stem Cells Int*. 2013;2013:262438. doi: 10.1155/2013/262438.
115. Gesundheit B, Ashwood P, Keating A, Naor D, Melamed M, Rosenzweig JP. Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. *Med Hypotheses*. 2015 Mar;84(3):169-77. doi: 10.1016/j.mehy.2014.12.016.
116. Jaimes Y, Naaldijk Y, Wenk K, Leovsky C, Emmrich F. Mesenchymal Stem Cell-Derived Microvesicles Modulate Lipopolysaccharides-Induced Inflammatory Responses to Microglia Cells. *Stem Cells*. 2017 Mar;35(3):812-823. doi: 10.1002/stem.2541.
117. Ooi YY, Dheen ST, Tay SS. Paracrine effects of mesenchymal stem cells-conditioned medium on microglial cytokines expression and nitric oxide production. *Neuroimmunomodulation*. 2015;22(4):233-42. doi: 10.1159/000365483.
118. Nguyen Thanh L, Nguyen HP, Ngo MD, Bui VA, Dam PTM, Bui HTP, Ngo DV, Tran KT, Dang TTT, Duong BD, Nguyen PAT, Forsyth N, Heke M. Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder. *Stem Cells Transl Med*. 2021 Jan;10(1):14-26. doi: 10.1002/sctm.20-0102. Epub 2020 Sep 9. Erratum in: *Stem Cells Transl Med*. 2021 Dec;10(12):1721. doi: 10.1002/sct3.13043.
119. Sharma A, Gokulchandran N, Sane H, Nagrajan A, Paranjape A, Kulkarni P, Shetty A, Mishra P, Kali M, Biju H, Badhe P. Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study. *Stem Cells Int*. 2013;2013:623875. doi: 10.1155/2013/623875.
120. Dawson G, Sun JM, Davlantis KS, Murias M, Franz L, Troy J, Simmons R, Sabatos-DeVito M, Durham R, Kurtzberg J. Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial. *Stem Cells Transl Med*. 2017 May;6(5):1332-1339. doi: 10.1002/sctm.16-0474.
121. Dawson G, Sun JM, Baker J, Carpenter K, Compton S, Deaver M, Franz L, Heilbron N, Herold B, Horrigan J, Howard J, Kosinski A, Major S, Murias M, Page K, Prasad VK, Sabatos-DeVito M, Sanfilippo F, Sikich L, Simmons R, Song A, Vermeer S, Waters-Pick B, Troy J, Kurtzberg J. A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder. *J Pediatr*. 2020 Jul;222:164-173.e5. doi: 10.1016/j.jpeds.2020.03.011.
122. Lv YT, Zhang Y, Liu M, Qiuwaxi JN, Ashwood P, Cho SC, Huan Y, Ge RC, Chen XW, Wang ZJ, Kim BJ, Hu X. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. *J Transl Med*. 2013 Aug 27;11:196. doi: 10.1186/1479-5876-11-196.



123. Liu Q, Chen MX, Sun L, Wallis CU, Zhou JS, Ao LJ, Li Q, Sham PC. Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders. *World J Stem Cells*. 2019 Feb 26;11(2):55-72. doi: 10.4252/wjsc.v11.i2.55.
124. Qu J, Liu Z, Li L, Zou Z, He Z, Zhou L, Luo Y, Zhang M, Ye J. Efficacy and Safety of Stem Cell Therapy in Children With Autism Spectrum Disorders: A Systematic Review and Meta-Analysis. *Front Pediatr*. 2022 May 4;10:897398. doi: 10.3389/fped.2022.897398.
125. Stancioiu FA, Bogdan R, Ivanescu B, Dumitrescu R. Autologous cord blood vs individualized supplements in autistic spectrum disorder: CORDUS study results. *World J Clin Pediatr*. 2025 Mar 9;14(1):96643. doi: 10.5409/wjcp.v14.i1.96643.
126. Kabatas S, Civelek E, Savrunlu EC, Karaaslan U, Yıldız Ö, Karaöz E. Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation. *World J Methodol*. 2025 Mar 20;15(1):95857. doi: 10.5662/wjm.v15.i1.95857.
127. Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. *Stem Cells*. 2007 Mar;25(3):646-54. doi: 10.1634/stemcells.2006-0208.
128. Lee H, Yun S, Kim IS, Lee IS, Shin JE, Park SC, Kim WJ, Park KI. Human fetal brain-derived neural stem/progenitor cells grafted into the adult epileptic brain restrain seizures in rat models of temporal lobe epilepsy. *PLoS One*. 2014 Aug 8;9(8):e104092. doi: 10.1371/journal.pone.0104092.
129. Kelly S, Bliss TM, Shah AK, Sun GH, Ma M, Foo WC, Masel J, Yenari MA, Weissman IL, Uchida N, Palmer T, Steinberg GK. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. *Proc Natl Acad Sci U S A*. 2004 Aug 10;101(32):11839-44. doi: 10.1073/pnas.0404474101.
130. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. *N Engl J Med*. 2001 Mar 8;344(10):710-9. doi: 10.1056/NEJM200103083441002.
131. Bradstreet JJ, Sych N, Antonucci N, Klunnik M, Ivankova O, Matyashchuk I, Demchuk M, Siniscalco D. Efficacy of fetal stem cell transplantation in autism spectrum disorders: an open-labeled pilot study. *Cell Transplant*. 2014;23 Suppl 1:S105-112. doi: 10.3727/096368914X684916.
132. Kassir I, Vaknin-Dembinsky A, Karussis D. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection. *Curr Stem Cell Res Ther*. 2011 Mar;6(1):63-8. doi: 10.2174/157488811794480762.
133. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, McIntosh KR. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. *J Biomed Sci*. 2005;12(1):47-57. doi: 10.1007/s11373-004-8183-7.
134. Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. *Immunol Cell Biol*. 2013 Jan;91(1):32-9. doi: 10.1038/icb.2012.64.
135. Karussis D, Petrou P, Kassir I. Clinical experience with stem cells and other cell therapies in neurological diseases. *J Neurol Sci*. 2013 Jan 15;324(1-2):1-9. doi: 10.1016/j.jns.2012.09.031.
136. Ding DC, Chang YH, Shyu WC, Lin SZ. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. *Cell Transplant*. 2015;24(3):339-47. doi: 10.3727/096368915X686841.
137. Xu Y, Huang S, Ma K, Fu X, Han W, Sheng Z. Promising new potential for mesenchymal stem cells derived from human umbilical cord Wharton's jelly: sweat gland cell-like differentiative capacity. *J Tissue Eng Regen Med*. 2012 Aug;6(8):645-54. doi: 10.1002/term.468.
138. Alessio N, Pipino C, Mandatori D, Di Tomo P, Ferone A, Marchiso M, Melone MAB, Peluso G, Pandolfi A, Galderisi U. Mesenchymal stromal cells from amniotic fluid are less prone to



- senescence compared to those obtained from bone marrow: An in vitro study. *J Cell Physiol.* 2018 Nov;233(11):8996-9006. doi: 10.1002/jcp.26845.
139. Witkowska-Zimny M, Wrobel E. Perinatal sources of mesenchymal stem cells: Wharton's jelly, amnion and chorion. *Cell Mol Biol Lett.* 2011 Sep;16(3):493-514. doi: 10.2478/s11658-011-0019-7.
140. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, Redl H, Rubin JP, Yoshimura K, Gimble JM. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). *Cytotherapy.* 2013 Jun;15(6):641-8. doi: 10.1016/j.jcyt.2013.02.006.
141. Frese L, Dijkman PE, Hoerstrup SP. Adipose Tissue-Derived Stem Cells in Regenerative Medicine. *Transfus Med Hemother.* 2016 Jul;43(4):268-274. doi: 10.1159/000448180.
142. Zhou F, Gao S, Wang L, Sun C, Chen L, Yuan P, Zhao H, Yi Y, Qin Y, Dong Z, Cao L, Ren H, Zhu L, Li Q, Lu B, Liang A, Xu GT, Zhu H, Gao Z, Ma J, Xu J, Chen X. Human adipose-derived stem cells partially rescue the stroke syndromes by promoting spatial learning and memory in mouse middle cerebral artery occlusion model. *Stem Cell Res Ther.* 2015 May 9;6(1):92. doi: 10.1186/s13287-015-0078-1. Erratum in: *Stem Cell Res Ther.* 2019 Mar 6;10(1):76. doi: 10.1186/s13287-019-1198-9.
143. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell.* 2006 Aug 25;126(4):663-76. doi: 10.1016/j.cell.2006.07.024.
144. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell.* 2007 Nov 30;131(5):861-72. doi: 10.1016/j.cell.2007.11.019.
145. Medvedev SP, Shevchenko AI, Zakian SM. Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine. *Acta Naturae.* 2010 Jul;2(2):18-28.
146. Sharma AK, Gokulchandran N, Kulkarni PP, Sane HM, Sharma R, Jose A, Badhe PB. Cell transplantation as a novel therapeutic strategy for autism spectrum disorders: a clinical study. *Am J Stem Cells.* 2020 Dec 25;9(5):89-100.
147. Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism. *Stem Cells Transl Med.* 2018 Apr;7(4):333-341. doi: 10.1002/sctm.17-0042.
148. Li Q, Chen CF, Wang DY, Lü YT, Huan Y, Fang SX, Han Y, Ge RC, Chen XW. Changes in growth factor levels in the cerebrospinal fluid of autism patients after transplantation of human umbilical cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells. *Genet Mol Res.* 2016 May 23;15(2). doi: 10.4238/gmr.15027526. Retraction in: *Genet Mol Res.* 2016 Oct 7;15(4). doi: 10.4238/gmr.1504004.
149. Sun JM, Kurtzberg J. Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism. *Pediatr Res.* 2018 Jan;83(1-2):364-371. doi: 10.1038/pr.2017.254.
150. Villarreal-Martínez L, González-Martínez G, Sáenz-Flores M, Bautista-Gómez AJ, González-Martínez A, Ortiz-Castillo M, Robles-Sáenz DA, Garza-López E. Stem Cell Therapy in the Treatment of Patients With Autism Spectrum Disorder: a Systematic Review and Meta-analysis. *Stem Cell Rev Rep.* 2022 Jan;18(1):155-164. doi: 10.1007/s12015-021-10257-0.
151. Murias M, Major S, Compton S, Buttinger J, Sun JM, Kurtzberg J, Dawson G. Electrophysiological Biomarkers Predict Clinical Improvement in an Open-Label Trial Assessing Efficacy of Autologous Umbilical Cord Blood for Treatment of Autism. *Stem Cells Transl Med.* 2018 Nov;7(11):783-791. doi: 10.1002/sctm.18-0090.



152. Nguyen LT, Nguyen PM, Nguyen HP, Bui HT, Dao LTM, Van Pham M, Hoang CK, Nguyen PT, Nguyen TTP, Nguyen ATP, Hoang VT, Bui HTP, Vuong NK, Van Ngo D. Outcomes of autologous bone marrow mononuclear cell administration combined with educational intervention in the treatment of autism spectrum disorder: a randomized, open-label, controlled phase II clinical trial. *Stem Cell Res Ther.* 2025 May 30;16(1):268. doi: 10.1186/s13287-025-04404-4.
153. Kimberly LH. Carpenter, Samantha Major, Catherine Tallman, Lyon W. Chen, Lauren Franz, Jessica Sun, Joanne Kurtzberg, Allen Song, Geraldine Dawson, White Matter Tract Changes Associated with Clinical Improvement in an Open-Label Trial Assessing Autologous Umbilical Cord Blood for Treatment of Young Children with Autism, *Stem Cells Translational Medicine*, Volume 8, Issue 2, February 2019, Pages 138–147, <https://doi.org/10.1002/sctm.18-0251>
154. Wong CM, Tan CS, Riard N, Padmini YS, Daniel LM, Prasath A, Tan AM, Tan TC, Sultana R, Lam JCM. Autologous umbilical cord blood infusion for the treatment of autism in young children: A within-subjects open label study on safety (assessed via caregiver report) and efficacy. *Autism Res.* 2024 Aug;17(8):1721-1734. doi: 10.1002/aur.3187.
155. Riordan NH, Hincapié ML, Morales I, Fernández G, Allen N, Leu C, Madrigal M, Paz Rodríguez J, Navarro N. Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels. *Stem Cells Transl Med.* 2019 Oct;8(10):1008-1016. doi: 10.1002/sctm.19-0010. Epub 2019 Jun 11. Retraction in: *Stem Cells Transl Med.* 2021 Dec;10(12):1717. doi: 10.1002/sct3.13044.
156. Adnan M, Motiwala F, Trivedi C, Chaudhari G, Mansuri Z, Jain S. Human Umbilical Cord Blood Infusions in the Management of Autism Spectrum Disorder. *Prim Care Companion CNS Disord.* 2022 Jun 2;24(3):21r03042. doi: 10.4088/PCC.21r03042.
157. Carpenter KLH, Major S, Tallman C, Chen LW, Franz L, Sun J, Kurtzberg J, Song A, Dawson G. White Matter Tract Changes Associated with Clinical Improvement in an Open-Label Trial Assessing Autologous Umbilical Cord Blood for Treatment of Young Children with Autism. *Stem Cells Transl Med.* 2019 Feb;8(2):138-147. doi: 10.1002/sctm.18-0251.
158. Michael Murias, Samantha Major, Scott Compton, Jessica Buttinger, Jessica M. Sun, Joanne Kurtzberg, Geraldine Dawson, Electrophysiological Biomarkers Predict Clinical Improvement in an Open-Label Trial Assessing Efficacy of Autologous Umbilical Cord Blood for Treatment of Autism, *Stem Cells Translational Medicine*, Volume 7, Issue 11, November 2018, Pages 783–791, <https://doi.org/10.1002/sctm.18-0090>
159. Sharifzadeh N, Ghasemi A, Tavakol Afshari J, Moharari F, Soltanifar A, Talaei A, Pouryousof HR, Nahidi M, Fayyazi Bordbar MR, Ziaee M. Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial. *Asia Pac Psychiatry.* 2021 Jun;13(2):e12445. doi: 10.1111/appy.12445.
160. Hughes HK, R J Moreno, Ashwood P. Innate immune dysfunction and neuroinflammation in autism spectrum disorder (ASD). *Brain Behav Immun.* 2023 Feb;108:245-254. doi: 10.1016/j.bbi.2022.12.001.
161. Sun JM, Dawson G, Franz L, Howard J, McLaughlin C, Kistler B, Waters-Pick B, Meadows N, Troy J, Kurtzberg J. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. *Stem Cells Transl Med.* 2020 Oct;9(10):1137-1146. doi: 10.1002/sctm.19-0434.
162. Shabab T, Khanabdali R, Moghadamtousi SZ, Kadir HA, Mohan G. Neuroinflammation pathways: a general review. *Int J Neurosci.* 2017 Jul;127(7):624-633. doi: 10.1080/00207454.2016.1212854.
163. Inga Jácome MC, Morales Chacón LM, Vera Cuesta H, Maragoto Rizo C, Whilby Santiesteban M, Ramos Hernandez L, Noris García E, González Fraguela ME, Fernandez Verdecia CI, Vegas Hurtado Y, et al. Peripheral Inflammatory Markers Contributing to Comorbidities in



- Autism. *Behavioral Sciences*. 2016; 6(4):29. <https://doi.org/10.3390/bs6040029>
164. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. *Ann Neurol*. 2005 Jan;57(1):67-81. doi: 10.1002/ana.20315. Erratum in: *Ann Neurol*. 2005 Feb;57(2):304.
165. Goines PE, Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. *Neurotoxicol Teratol*. 2013 Mar-Apr;36:67-81. doi: 10.1016/j.ntt.2012.07.006.
166. Cianciulli A, Porro C, Calvello R, Trotta T, Lofrumento DD, Panaro MA. Microglia Mediated Neuroinflammation: Focus on PI3K Modulation. *Biomolecules*. 2020 Jan 14;10(1):137. doi: 10.3390/biom10010137.
167. Ashwood P, Anthony A, Torrente F, Wakefield AJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. *J Clin Immunol*. 2004 Nov;24(6):664-73. doi: 10.1007/s10875-004-6241-6.
168. Liao X, Liu Y, Fu X, Li Y. Postmortem Studies of Neuroinflammation in Autism Spectrum Disorder: a Systematic Review. *Mol Neurobiol*. 2020 Aug;57(8):3424-3438. doi: 10.1007/s12035-020-01976-5.
169. Masi A, Breen EJ, Alvares GA, Glozier N, Hickie IB, Hunt A, Hui J, Beilby J, Ravine D, Wray J, Whitehouse AJO, Guastella AJ. Cytokine levels and associations with symptom severity in male and female children with autism spectrum disorder. *Mol Autism*. 2017 Dec 2;8:63. doi: 10.1186/s13229-017-0176-2.
170. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. *Brain Behav Immun*. 2011 Jan;25(1):40-5. doi: 10.1016/j.bbi.2010.08.003.
171. Wei H, Chadman KK, McCloskey DP, Sheikh AM, Malik M, Brown WT, Li X. Brain IL-6 elevation causes neuronal circuitry imbalances and mediates autism-like behaviors. *Biochim Biophys Acta*. 2012 Jun;1822(6):831-42. doi: 10.1016/j.bbdis.2012.01.011.
172. Meyer U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. *Biol Psychiatry*. 2014 Feb 15;75(4):307-15. doi: 10.1016/j.biopsych.2013.07.011.
173. Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, Hoeffler CA, Littman DR, Huh JR. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. *Science*. 2016 Feb 26;351(6276):933-9. doi: 10.1126/science.aad0314.
174. Lucchina L, Depino AM. Altered peripheral and central inflammatory responses in a mouse model of autism. *Autism Res*. 2014 Apr;7(2):273-89. doi: 10.1002/aur.1338.
175. Heo Y, Zhang Y, Gao D, Miller VM, Lawrence DA. Aberrant immune responses in a mouse with behavioral disorders. *PLoS One*. 2011;6(7):e20912. doi: 10.1371/journal.pone.0020912.
176. Rose S, Melnyk S, Pavliv O, Bai S, Nick TG, Frye RE, James SJ. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. *Transl Psychiatry*. 2012 Jul 10;2(7):e134. doi: 10.1038/tp.2012.61.
177. Siddiqui MF, Elwell C, Johnson MH. Mitochondrial Dysfunction in Autism Spectrum Disorders. *Autism Open Access*. 2016 Sep 27;6(5):1000190. doi: 10.4172/2165-7890.1000190.
178. Kumar S, Verma R, Tyagi N, Gangenahalli G, Verma YK. Therapeutics effect of mesenchymal stromal cells in reactive oxygen species-induced damages. *Hum Cell*. 2022 Jan;35(1):37-50. doi: 10.1007/s13577-021-00646-5.
179. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. *Pediatrics*. 2004 Nov;114(5):e634-41. doi: 10.1542/peds.2003-0264-F.



180. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. *Pediatrics*. 2009 Dec;124(6):1533-40. doi: 10.1542/peds.2008-3782.
181. Sharma SR, Gonda X, Tarazi FI. Autism Spectrum Disorder: Classification, diagnosis and therapy. *Pharmacol Ther*. 2018 Oct;190:91-104. doi: 10.1016/j.pharmthera.2018.05.007.
182. Park SR, Kim JW, Jun HS, Roh JY, Lee HY, Hong IS. Stem Cell Secretome and Its Effect on Cellular Mechanisms Relevant to Wound Healing. *Mol Ther*. 2018 Feb 7;26(2):606-617. doi: 10.1016/j.ymthe.2017.09.023.
183. Araújo, B., Silva, R.C., Domingues, S., Salgado, A.J., Teixeira, F.G. Mesenchymal Stem Cell Secretome: A Potential Biopharmaceutical Component to Regenerative Medicine?. In: Haider, K.H. (eds) *Handbook of Stem Cell Therapy*. Springer, Singapore. 2022, pp. 1-33, https://doi.org/10.1007/978-981-16-6016-0_46-1
184. Md Fadilah NI, Mohd Abdul Kader Jailani MS, Badrul Hisham MAI, Sunthar Raj N, Shamsuddin SA, Ng MH, Fauzi MB, Maarof M. Cell secretomes for wound healing and tissue regeneration: Next generation acellular based tissue engineered products. *J Tissue Eng*. 2022 Jul 28;13:20417314221114273. doi: 10.1177/20417314221114273.
185. Blatt GJ. The neuropathology of autism. *Scientifica (Cairo)*. 2012;2012:703675. doi: 10.6064/2012/703675.
186. Reiersen AM, Todd RD. Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment. *Expert Rev Neurother*. 2008 Apr;8(4):657-69. doi: 10.1586/14737175.8.4.657.
187. Kang X, Zuo Z, Hong W, Tang H, Geng W. Progress of Research on Exosomes in the Protection Against Ischemic Brain Injury. *Front Neurosci*. 2019 Oct 29;13:1149. doi: 10.3389/fnins.2019.01149.
188. Li Q, Wang H, Peng H, Huyan T, Cacalano NA. Exosomes: Versatile Nano Mediators of Immune Regulation. *Cancers (Basel)*. 2019 Oct 14;11(10):1557. doi: 10.3390/cancers11101557.
189. Geffen Y, Perets N., Horev R., Yudin D., Oron O., Elliott E., Marom E., Danon U., Offen D. Exosomes derived from adipose mesenchymal stem cells: a potential non-invasive intranasal treatment for autism, *Cytotherapy*, Volume 22, Issue 5, Supplement, 2020, Page S49, ISSN 1465-3249, <https://doi.org/10.1016/j.jcyt.2020.03.059>. (<https://www.sciencedirect.com/science/article/pii/S1465324920301237>)
190. Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. *BMC Neurosci*. 2008 Dec 10;9 Suppl 3(Suppl 3):S5. doi: 10.1186/1471-2202-9-S3-S5.
191. Chavez B, Chavez-Brown M, Rey JA. Role of risperidone in children with autism spectrum disorder. *Ann Pharmacother*. 2006 May;40(5):909-16. doi: 10.1345/aph.1G389.
192. Liang Y, Duan L, Xu X, Li X, Liu M, Chen H, Lu J, Xia J. Mesenchymal Stem Cell-Derived Exosomes for Treatment of Autism Spectrum Disorder. *ACS Appl Bio Mater*. 2020 Sep 21;3(9):6384-6393. doi: 10.1021/acsabm.0c00831.
193. Zhang X, Liu T, Hou X, Zhou Z, Zhang F, Ma H, Wu X, Jiang J. Exosomes secreted by mesenchymal stem cells delay brain aging by upregulating SIRT1 expression. *Sci Rep*. 2023 Aug 14;13(1):13213. doi: 10.1038/s41598-023-40543-5.
194. Heo JS, Choi Y, Kim HO. Adipose-Derived Mesenchymal Stem Cells Promote M2 Macrophage Phenotype through Exosomes. *Stem Cells Int*. 2019 Nov 5;2019:7921760. doi: 10.1155/2019/7921760.
195. Perets N, Betzer O, Shapira R, Brenstein S, Angel A, Sadan T, Ashery U, Popovtzer R, Offen D. Golden Exosomes Selectively Target Brain Pathologies in Neurodegenerative and Neurodevelopmental Disorders. *Nano Lett*. 2019 Jun 12;19(6):3422-3431. doi: 10.1021/acs.nanolett.8b04148.



196. Hashem S, Nisar S, Bhat AA, Yadav SK, Azeem MW, Bagga P, Fakhro K, Reddy R, Frenneaux MP, Haris M. Genetics of structural and functional brain changes in autism spectrum disorder. *Transl Psychiatry*. 2020 Jul 13;10(1):229. doi: 10.1038/s41398-020-00921-3.
197. Perets N, Oron O, Herman S, Elliott E, Offen D. Exosomes derived from mesenchymal stem cells improved core symptoms of genetically modified mouse model of autism Shank3B. *Mol Autism*. 2020 Aug 17;11(1):65. doi: 10.1186/s13229-020-00366-x.
198. Siniscalco D, Cirillo A, Bradstreet JJ, Antonucci N. Epigenetic findings in autism: new perspectives for therapy. *Int J Environ Res Public Health*. 2013 Sep 11;10(9):4261-73. doi: 10.3390/ijerph10094261.
199. Stankovic I, Smit P, Cross J, Wolujewicz P, Greening D, Colak D. Extracellular Vesicle Profiling Reveals Novel Autism Signatures in Patient-Derived Forebrain Organoids. *Res Sq [Preprint]*. 2025 May 13;rs.3.rs-6573757. doi: 10.21203/rs.3.rs-6573757/v1. Update in: *Transl Psychiatry*. 2025 Oct 10;15(1):393. doi: 10.1038/s41398-025-03607-w.
200. Sharma P, Mesci P, Carromeu C, McClatchy DR, Schiapparelli L, Yates JR 3rd, Muotri AR, Cline HT. Exosomes regulate neurogenesis and circuit assembly. *Proc Natl Acad Sci U S A*. 2019 Aug 6;116(32):16086-16094. doi: 10.1073/pnas.1902513116.
201. Squillaro T, Hayek G, Farina E, Cipollaro M, Renieri A, Galderisi U. A case report: bone marrow mesenchymal stem cells from a Rett syndrome patient are prone to senescence and show a lower degree of apoptosis. *J Cell Biochem*. 2008 Apr 15;103(6):1877-85. doi: 10.1002/jcb.21582.
202. Gottfried C, Bambini-Junior V, Francis F, Riesgo R, Savino W. The Impact of Neuroimmune Alterations in Autism Spectrum Disorder. *Front Psychiatry*. 2015 Sep 9;6:121. doi: 10.3389/fpsy.2015.00121.
203. Perets N, Hertz S, London M, Offen D. Intranasal administration of exosomes derived from mesenchymal stem cells ameliorates autistic-like behaviors of BTBR mice. *Mol Autism*. 2018 Nov 21;9:57. doi: 10.1186/s13229-018-0240-6.
204. Zhang R, Cai Y, Xiao R, Zhong H, Li X, Guo L, Xu H, Fan X. Human amniotic epithelial cell transplantation promotes neurogenesis and ameliorates social deficits in BTBR mice. *Stem Cell Res Ther*. 2019 May 31;10(1):153. doi: 10.1186/s13287-019-1267-0.
205. Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. *Biomark Res*. 2019 Apr 4;7:8. doi: 10.1186/s40364-019-0159-x.
206. Batrakova EV, Kim MS. Development and regulation of exosome-based therapy products. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2016 Sep;8(5):744-57. doi: 10.1002/wnan.1395.
207. Sivanesan S, Tan A, Jeyaraj R, Lam J, Gole M, Hardan A, Ashkan K, Rajadas J. Pharmaceuticals and Stem Cells in Autism Spectrum Disorders: Wishful Thinking? *World Neurosurg*. 2017 Feb;98:659-672. doi: 10.1016/j.wneu.2016.09.100.
208. Kou M, Huang L, Yang J, Chiang Z, Chen S, Liu J, Guo L, Zhang X, Zhou X, Xu X, Yan X, Wang Y, Zhang J, Xu A, Tse HF, Lian Q. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? *Cell Death Dis*. 2022 Jul 4;13(7):580. doi: 10.1038/s41419-022-05034-x.
209. Gotoh S, Kawabori M, Fujimura M. Intranasal administration of stem cell-derived exosomes for central nervous system diseases. *Neural Regen Res*. 2024 Jun 1;19(6):1249-1255. doi: 10.4103/1673-5374.385875.
210. Simberlund J, Ferretti CJ, Hollander E. Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential promises. *World J Biol Psychiatry*. 2015 Sep;16(6):368-375. doi: 10.3109/15622975.2015.1067372.
211. Wikarska A, Roszak K, Roszek K. Mesenchymal Stem Cells and Purinergic Signaling in Autism Spectrum Disorder: Bridging the Gap between Cell-Based Strategies and Neuro-Immu-



- ne Modulation. *Biomedicines*. 2024 Jun 13;12(6):1310. doi: 10.3390/biomedicines12061310.
212. Li S, Zhang J, Sun L, Yang Z, Liu X, Liu J, Liu X. Mesenchymal stem cell-derived extracellular vesicles: current advances in preparation and therapeutic applications for neurological disorders. *Front Cell Dev Biol*. 2025 Aug 18;13:1626996. doi: 10.3389/fcell.2025.1626996.
213. Moore D, Meays BM, Madduri LSV, Shahjin F, Chand S, Niu M, Albahrani A, Guda C, Pendyala G, Fox HS, Yelamanchili SV. Downregulation of an Evolutionary Young miR-1290 in an iPSC-Derived Neural Stem Cell Model of Autism Spectrum Disorder. *Stem Cells Int*. 2019 May 2;2019:8710180. doi: 10.1155/2019/8710180.
214. Fakouri A, Razavi ZS, Mohammed AT, Hussein AHA, Afkhami H, Hooshier MH. Applications of mesenchymal stem cell-exosome components in wound infection healing: new insights. *Burns Trauma*. 2024 Aug 13;12:tkae021. doi: 10.1093/burnst/tkae021.
215. Ghasemi M, Alizadeh E, Saei Arezoumand K, Fallahi Motlagh B, Zarghami N. Ciliary neurotrophic factor (CNTF) delivery to retina: an overview of current research advancements. *Artif Cells Nanomed Biotechnol*. 2018 Dec;46(8):1694-1707. doi: 10.1080/21691401.2017.1391820.
216. Ma ZJ, Yang JJ, Lu YB, Liu ZY, Wang XX. Mesenchymal stem cell-derived exosomes: Toward cell-free therapeutic strategies in regenerative medicine. *World J Stem Cells*. 2020 Aug 26;12(8):814-840. doi: 10.4252/wjsc.v12.i8.814.
217. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. *Science*. 2020 Feb 7;367(6478):eaau6977. doi: 10.1126/science.aau6977.

OTİZM SPEKTRUM BOZUKLUĞUNDA GENETİK VE MOLEKÜLER TEMELLİ TEDAVİ YAKLAŞIMLARI

Elif Perihan ÖNCEL¹

Pınar GENÇPINAR²

|OTİZMİN GENETİK YÜZÜ VE TERAPÖTİK DÖNÜŞÜM

Otizm spektrum bozukluğu (OSB), son on yılda nörogelişimsel bozukluklar arasında en yoğun genetik araştırma alanlarından biri haline gelmiştir. Gelişmiş genomik teknolojilerin (ör. tüm ekzom/tüm genom dizileme, kromozom mikrodizi analizleri) klinik pratiğe girmesiyle hem sendromik hem de non-sendromik olgularda monogenik nedenler giderek daha sık tanımlanmaktadır. Bu bulgular, OSB'nin yalnızca davranışsal belirtilerle tanımlanan klinik bir sendrom değil, moleküler düzeyde heterojen bir biyolojik bozukluklar spektrumu olduğunu ortaya koymaktadır.¹

Günümüzde CRISPR (Bacterial Clustered Regularly Interspaced Palindromic Repeats (CRISPR)/Cas) tabanlı gen düzenleme sistemleri, antisens oligonükleotid (ASO) tedavileri, epigenetik modülatörler ve metabolik yollara yönelik farmakolojik müdahaleler; OSB ile ilişkili spesifik genetik varyantları veya bozulmuş hücresel mekanizmaları hedef alabilen yeni nesil terapötik stratejiler olarak öne çıkmaktadır. Bu yaklaşım, semptom odaklı geleneksel tedavi anlayışından, genetik ve moleküler hedefi olan kişiselleştirilmiş tedavi paradigmasına geçişin temelini oluşturmaktadır.²

¹ Uzm. Dr., Ankara Etlik Şehir Hastanesi, Çocuk Nöroloji BD., Çocuk Nöroloji Kliniği, peri_elif@hotmail.com, ORCID iD: 0000-0002-6126-4048

² Prof. Dr., İzmir Katip Çelebi Üniversitesi Çocuk Nöroloji BD., İzmir Katip Çelebi Üniversitesi Sinirbilimleri Uygulama ve Araştırma Merkezi, Çocuk Nöroloji Kliniği, pinargencpinar@gmail.com, ORCID iD: 0000-0002-8299-6926



- **Multidisipliner yaklaşım:** Etik kurullar, genetik danışmanlar, pediatrik nörologlar ve psikiyatristler iş birliğiyle hem güvenlik hem de klinik etkinlik sağlanmalıdır.

Araştırma ve Translasyonel Perspektif

- **Preklinikten kliniğe geçiş:** Fare ve insan hücre modellerinde elde edilen genetik ve epigenetik hedefli bulgular, kontrollü klinik çalışmalara taşınmalıdır.
- **Biyobelirteç tabanlı takip:** OSB'de tedavi yanıtının değerlendirilmesinde epigenetik, metabolik ve nörofizyolojik biyobelirteçler kullanılabilir.
- **Uzun dönem izlem:** Tedavinin etkinliği kadar, nörogelişimsel güvenlik, olası yan etkiler ve fenotip değişiklikleri izlenmelidir.

Gelecek Perspektifi

- **Hedefe yönelik tedavilerin yaygınlaşması:** Monogenik alt tipler ve genetik olarak belirlenmiş risk gruplarında terapötik müdahaleler, kişiselleştirilmiş OSB yönetimini mümkün kılacaktır.
- **Çevresel ve metabolik modülasyon:** Beslenme, mikrobiyota ve metabolik destek ile epigenetik ve sinaptik fonksiyonun optimize edilmesi hem semptomları azaltabilir hem de nörogelişimsel devrelerin sağlığını destekleyebilir.
- **Etik ve sosyal sorumluluk:** Biyoteknolojik müdahalelerin uygulanması sırasında toplumsal, etik ve hukuki boyutlar göz ardı edilmemelidir.

KAYNAKLAR

1. Belenska-Todorova L, Zamfirov M, Todorov T, Ateşin S, Sleptsova M, Pavlova Z, Kadiyska T, Maver A, Peterlin B, Todorova A. Exome Study of Single Nucleotide Variations in Patients with Syndromic and Non-Syndromic Autism Reveals Potential Candidate Genes for Diagnostics and Novel Single Nucleotide Variants. *Cells*. 2025 Jun 17;14(12):915. doi: 10.3390/cells14120915. PMID: 40558542; PMCID: PMC12191266.
2. Sandhu A, Kumar A, Rawat K, Gautam V, Sharma A, Saha L. Modernising autism spectrum disorder model engineering and treatment via CRISPR-Cas9: A gene reprogramming approach. *World J Clin Cases*. 2023 May 16;11(14):3114-3127. doi: 10.12998/wjcc.v11.i14.3114. PMID: 37274051; PMCID: PMC10237133.
3. Roberts JE, Bradshaw J, Will E, Hogan AL, McQuillin S, Hills K. Emergence and rate of autism in fragile X syndrome across the first years of life. *Dev Psychopathol*. 2020 Oct;32(4):1335-1352. doi: 10.1017/S0954579420000942. PMID: 33161907; PMCID: PMC8080303.
4. Percy AK. Rett syndrome: exploring the autism link. *Arch Neurol*. 2011 Aug;68(8):985-9. doi: 10.1001/archneurol.2011.149. PMID: 21825235; PMCID: PMC3674963.
5. Hunt A, Shepherd C. A prevalence study of autism in tuberous sclerosis. *J Autism Dev Disord*. 1993 Jun;23(2):323-39. doi: 10.1007/BF01046223. PMID: 8331050.



6. Dias C, Mo A, Cai C, Sun L, Cabral K, Brownstein CA, Rockowitz S, Walsh CA. Cell- type-specific effects of autism-associated 15q duplication syndrome in the human brain. *Am J Hum Genet.* 2024 Aug 8;111(8):1544-1558. doi: 10.1016/j.ajhg.2024.07.002. Epub 2024 Jul 29. PMID: 39079538; PMCID: PMC11339625.
7. Phelan K, Rogers RC, Boccuto L. Phelan-McDermid Syndrome-SHANK3 Related. 2005 May 11 [Updated 2024 Jun 6]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK1198/?utm_source=chatgpt.com
8. Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. *Lancet Psychiatry.* 2015 Oct;2(10):909-16. doi: 10.1016/S2215-0366(15)00376-4. Epub 2015 Sep 1. PMID: 26341300.
9. Apte M, Kumar A. Correlation of mutated gene and signalling pathways in ASD. *IBRO Neurosci Rep.* 2023 Mar 27;14:384-392. doi: 10.1016/j.ibneur.2023.03.011. PMID: 37101819; PMCID: PMC10123338.
10. Zhang Y, Tang R, Hu ZM, Wang XH, Gao X, Wang T, Tang MX. Key Synaptic Pathology in Autism Spectrum Disorder: Genetic Mechanisms and Recent Advances. *J Integr Neurosci.* 2024 Sep 29;23(10):184. doi: 10.31083/j.jin2310184. PMID: 39473158.
11. Vyas Y, Cheyne J, Lee K, Jung Y, Montgomery JM. Shankopathies in the developing brain in autism spectrum disorders. *Front Neurosci.* 2021;15:775431. doi:10.3389/fnins.2021.775431
12. Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, Penn O, Witherspoon K, Gerdtz J, Baker C, Vulto-van Silfhout AT, Schuurs-Hoeijmakers JH, Fichera M, Bosco P, Buono S, Alberti A, Failla P, Peeters H, Steyaert J, Vissers LELM, Francescato L, Mefford HC, Rosenfeld JA, Bakken T, O’Roak BJ, Pawlus M, Moon R, Shendure J, Amaral DG, Lein E, Rankin J, Romano C, de Vries BBA, Katsanis N, Eichler EE. Disruptive CHD8 mutations define a subtype of autism early in development. *Cell.* 2014 Jul 17;158(2):263-276. doi: 10.1016/j.cell.2014.06.017. Epub 2014 Jul 3. PMID: 24998929; PMCID: PMC4136921.
13. Holder JL Jr, Hamdan FF, Michaud JL. SYNGAP1-Related Intellectual Disability. 2019 Feb 21. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK537721/>
14. Leblond CS, Le TL, Malesys S, Cliquet F, Tabet AC, Delorme R, Rolland T, Bourgeron T. Operative list of genes associated with autism and neurodevelopmental disorders based on database review. *Mol Cell Neurosci.* 2021 Jun;113:103623. doi: 10.1016/j.mcn.2021.103623. Epub 2021 Apr 29. PMID: 33932580.
15. Wang T, Kim CN, Bakken TE, Gillentine MA, Henning B, Mao Y, Gilissen C; SPARK Consortium; Nowakowski TJ, Eichler EE. Integrated gene analyses of de novo variants from 46,612 trios with autism and developmental disorders. *Proc Natl Acad Sci U S A.* 2022 Nov 15;119(46):e2203491119. doi: 10.1073/pnas.2203491119. Epub 2022 Nov 9. PMID: 36350923; PMCID: PMC9674258.
16. Kereszturi É. Diversity and Classification of Genetic Variations in Autism Spectrum Disorder. *Int J Mol Sci.* 2023 Nov 26;24(23):16768. doi: 10.3390/ijms242316768. PMID: 38069091; PMCID: PMC10706722.
17. Rolland T, Cliquet F, Anney RJL, Moreau C, Traut N, Mathieu A, Huguet G, Duan J, Warrier V, Portalier S, Dry L, Leblond CS, Douard E, Amsellem F, Malesys S, Maruani A, Toro R, Børglum AD, Grove J, Baron-Cohen S, Packer A, Chung WK, Jacquemont S, Delorme R, Bourgeron T. Phenotypic effects of genetic variants associated with autism. *Nat Med.* 2023 Jul;29(7):1671-1680. doi: 10.1038/s41591-023-02408-2. Epub 2023 Jun 26. PMID: 37365347; PMCID: PMC10353945.



18. Dong ZF, Tang LJ, Deng GF, Zeng T, Liu SJ, Wan RP, Liu T, Zhao QH, Yi YH, Liao WP, Long YS. Transcription of the human sodium channel SCN1A gene is repressed by a scaffolding protein RACK1. *Mol Neurobiol*. 2014 Oct;50(2):438-48. doi: 10.1007/s12035-014-8633-9. Epub 2014 Jan 17. PMID: 24436055.
19. Ghanbarian H, Aghamiri S, Eftekhary M, Wagner N, Wagner KD. Small Activating RNAs: Towards the Development of New Therapeutic Agents and Clinical Treatments. *Cells*. 2021 Mar 8;10(3):591. doi: 10.3390/cells10030591. PMID: 33800164; PMCID: PMC8001863.
20. Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, Zhu S, Yang L, Chen LL. Circular intronic long noncoding RNAs. *Mol Cell*. 2013 Sep 26;51(6):792-806. doi: 10.1016/j.molcel.2013.08.017. Epub 2013 Sep 12. PMID: 24035497.
21. Di Leva F, Arnoldi M, Santarelli S, Massonot M, Lemée MV, Bon C, Pellegrini M, Castellini ME, Zarantonello G, Messina A, Bozzi Y, Bernier R, Zucchelli S, Casarosa S, Dassi E, Ronzitti G, Golzio C, Morandell J, Gustincich S, Espinoza S, Biagioli M. SINEUP RNA rescues molecular phenotypes associated with CHD8 suppression in autism spectrum disorder model systems. *Mol Ther*. 2025 Mar 5;33(3):1180-1196. doi: 10.1016/j.ymthe.2024.12.043. Epub 2024 Dec 30. PMID: 39741407; PMCID: PMC11897779.
22. Wijnant KN, Nadif Kasri N, Vissers LELM. Systematic analysis of genetic and phenotypic characteristics reveals antisense oligonucleotide therapy potential for one- third of neuro-developmental disorders. *Genome Med*. 2025 May 21;17(1):59. doi: 10.1186/s13073-025-01477-x. PMID: 40400017; PMCID: PMC12096787.
23. Tran SS, Jun HI, Bahn JH, Azghadi A, Ramaswami G, Van Nostrand EL, Nguyen TB, Hsiao YE, Lee C, Pratt GA, Martínez-Cerdeño V, Hagerman RJ, Yeo GW, Geschwind DH, Xiao X. Widespread RNA editing dysregulation in brains from autistic individuals. *Nat Neurosci*. 2019 Jan;22(1):25-36. doi: 10.1038/s41593-018-0287-x. Epub 2018 Dec 17. PMID: 30559470; PMCID: PMC6375307.
24. Rinnamom JR, Kim SY, Fisk JR, Song Z, Nakai H, Jeng S, McWeeney SK, Mandel G. In Vivo Repair of a Protein Underlying a Neurological Disorder by Programmable RNA Editing. *Cell Rep*. 2020 Jul 14;32(2):107878. doi: 10.1016/j.celrep.2020.107878. PMID: 32668243; PMCID: PMC7449137.
25. Bajikar SS, Sztainberg Y, Trostle AJ, Tirumala HP, Wan YW, Harrop CL, Bengtsson JD, Carvalho CMB, Pehlivan D, Suter B, Neul JL, Liu Z, Jafar-Nejad P, Rigo F, Zoghbi HY. Modeling antisense oligonucleotide therapy in MeCP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels. *Hum Mol Genet*. 2024 Nov 8;33(22):1986-2001. doi: 10.1093/hmg/ddae135. PMID: 39277796; PMCID: PMC11555823
26. Shao Y, Sztainberg Y, Wang Q, Bajikar SS, Trostle AJ, Wan YW, Jafar-Nejad P, Rigo F, Liu Z, Tang J, Zoghbi HY. Antisense oligonucleotide therapy in a humanized mouse model of MeCP2 duplication syndrome. *Sci Transl Med*. 2021 Mar 3;13(583):eaaz7785. doi: 10.1126/scitranslmed.aaz7785. PMID: 33658357; PMCID: PMC8976688.
27. Batty P, Lillicrap D. Adeno-associated viral vector integration: implications for long-term efficacy and safety. *J Thromb Haemost*. 2024 Nov;22(11):2945-2960. doi: 10.1016/j.jtha.2024.07.012. Epub 2024 Aug 2. PMID: 39097231.
28. Muhuri M, Levy DI, Schulz M, McCarty D, Gao G. Durability of transgene expression after rAAV gene therapy. *Mol Ther*. 2022 Apr 6;30(4):1364-1380. doi: 10.1016/j.ymthe.2022.03.004. Epub 2022 Mar 10. PMID: 35283274; PMCID: PMC9077371.
29. Meng L, Ward AJ, Chun S, Bennett CF, Beaudet AL, Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. *Nature*. 2015 Feb 19;518(7539):409-12. doi: 10.1038/nature13975. Epub 2014 Dec 1. PMID: 25470045; PMCID: PMC4351819.
30. <https://www.businesswire.com/news/home/20250611150485/en/First-patient-dosed-in-pivotal-Phase-3-REVEAL-clinical-study-of-ION582-in-Angelman-syndrome>



31. Shah S, Sharp KJ, Raju Ponny S, Lee J, Watts JK, Berry-Kravis E, Richter JD. Antisense oligonucleotide rescue of CCG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP. *Proc Natl Acad Sci U S A*. 2023 Jul 4;120(27):e2302534120. doi: 10.1073/pnas.2302534120. Epub 2023 Jun 26. PMID: 37364131; PMCID: PMC10319035)
32. <https://dupmecp2.eu/en/attune-recruitment/>
33. Han Z, Chen C, Christiansen A, Ji S, Lin Q, Anumonwo C, Liu C, Leiser SC, Meena, Aznarez I, Liao G, Isom LL. Antisense oligonucleotides increase *Scn1a* expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. *Sci Transl Med*. 2020 Aug 26;12(558):eaaz6100. doi: 10.1126/scitranslmed.aaz6100. PMID: 32848094.
34. Lim KH, Han Z, Jeon HY, Kach J, Jing E, Weyn-Vanhentenryck S, Downs M, Corrionero A, Oh R, Scharner J, Venkatesh A, Ji S, Liao G, Ticho B, Nash H, Aznarez I. Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression. *Nat Commun*. 2020 Jul 9;11(1):3501. doi: 10.1038/s41467-020-17093-9. PMID: 32647108; PMCID: PMC7347940.
35. <https://aesnet.org/abstractslisting/zorevunersen-stk-001-demonstrates-potential-for-disease-modification-including-reductions-in-seizures-and-improvements-in-cognition-and-behavior-in-children-and-adolescents-with-dravet-syndrome-ds>
36. Kantor A, McClements ME, MacLaren RE. CRISPR-Cas9 DNA Base-Editing and Prime-Editing. *Int J Mol Sci*. 2020 Aug 28;21(17):6240. doi: 10.3390/ijms21176240. PMID: 32872311; PMCID: PMC7503568.
37. Weuring W, Geerligs J, Koeleman BPC. Gene Therapies for Monogenic Autism Spectrum Disorders. *Genes (Basel)*. 2021 Oct 22;12(11):1667. doi: 10.3390/genes12111667. PMID: 34828273; PMCID: PMC8617899.
38. Bozorg Qomi S, Asghari A, Mojarrad M. An Overview of the CRISPR-Based Genomic- and Epigenome-Editing System: Function, Applications, and Challenges. *Adv Biomed Res*. 2019 Aug 21;8:49. doi: 10.4103/abr.abr_41_19. PMID: 31516887; PMCID: PMC6712897.
39. Zheng Y, Li Y, Zhou K, Li T, VanDusen NJ, Hua Y. Precise genome-editing in human diseases: mechanisms, strategies and applications. *Signal Transduct Target Ther*. 2024 Feb 26;9(1):47. doi: 10.1038/s41392-024-01750-2. PMID: 38409199; PMCID: PMC10897424.
40. Ozlu C, Bailey RM, Sinnott S, Goodspeed KD. Gene Transfer Therapy for Neurodevelopmental Disorders. *Dev Neurosci*. 2021;43(3-4):230-240. doi: 10.1159/000515434. Epub 2021 Apr 21. PMID: 33882495.
41. Adhikari A, Copping NA, Beegle J, Cameron DL, Deng P, O'Geen H, Segal DJ, Fink KD, Silverman JL, Anderson JS. Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells. *Hum Mol Genet*. 2021 Jun 9;30(12):1067-1083. doi: 10.1093/hmg/ddab104. PMID: 33856035; PMCID: PMC8188406.
42. Delling JP, Boeckers TM. Comparison of SHANK3 deficiency in animal models: phenotypes, treatment strategies, and translational implications. *J Neurodev Disord*. 2021 Nov 16;13(1):55. doi: 10.1186/s11689-021-09397-8. PMID: 34784886; PMCID: PMC8594088.
43. <https://patentscope.wipo.int/search/en/WO2024178401>
44. Veenstra-VanderWeele J, O'Reilly KC, Dennis MY, Uribe-Salazar JM, Amaral DG. Translational Neuroscience Approaches to Understanding Autism. *Am J Psychiatry*. 2023 Apr 1;180(4):265-276. doi: 10.1176/appi.ajp.20230153. PMID: 37002692.
45. Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, Hnisz D, Li CH, Yuan B, Xu C, Li Y, Vershkov D, Cacace A, Young RA, Jaenisch R. Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene. *Cell*. 2018 Feb 22;172(5):979-992.e6. doi: 10.1016/j.cell.2018.01.012. Epub 2018 Feb 15. PMID: 29456084; PMCID: PMC6375087.
46. Colasante G, Lignani G, Brusco S, Di Berardino C, Carpenter J, Giannelli S, Valassina N, Bido S, Ricci R, Castoldi V, Marenga S, Church T, Massimino L, Morabito G, Benfenati F, Schor-



- ge S, Leocani L, Kullmann DM, Broccoli V. dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice. *Mol Ther*. 2020 Jan 8;28(1):235-253. doi: 10.1016/j.ymthe.2019.08.018. Epub 2019 Sep 3. PMID: 31607539; PMCID: PMC6952031)
47. Gholamalizadeh H, Amiri-Shahri M, Rasouli F, Ansari A, Baradaran Rahimi V, Reza Askari V. DNA Methylation in Autism Spectrum Disorders: Biomarker or Pharmacological Target? *Brain Sci*. 2024 Jul 23;14(8):737. doi: 10.3390/brainsci14080737. PMID: 39199432; PMCID: PMC11352561.
48. Zhubi A, Cook EH, Guidotti A, Grayson DR. Epigenetic mechanisms in autism spectrum disorder. *Int Rev Neurobiol*. 2014;115:203-44. doi: 10.1016/B978-0-12-801311-3.00006-8. PMID: 25131546.
49. Levenson JM, Roth TL, Lubin FD, Miller CA, Huang IC, Desai P, Malone LM, Sweatt JD. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. *J Biol Chem*. 2006 Jun 9;281(23):15763-73. doi: 10.1074/jbc.M511767200. Epub 2006 Apr 10. PMID: 16606618.
50. Matt SM, Zimmermann JD, Lawson MA, Bustamante AC, Uddin M, Johnson RW. Inhibition of DNA Methylation With Zebularine Alters Lipopolysaccharide-Induced Sickness Behavior and Neuroinflammation in Mice. *Front Neurosci*. 2018 Sep 18;12:636. doi: 10.3389/fnins.2018.00636. PMID: 30279646; PMCID: PMC6153314.
51. Gao Y, Aljazi MB, Wu Y, He J. Vorinostat, a histone deacetylase inhibitor, ameliorates the sociability and cognitive memory in an Ash1L-deletion-induced ASD/ID mouse model. *Neurosci Lett*. 2021 Nov 1;764:136241. doi: 10.1016/j.neulet.2021.13624. Epub 2021 Sep 10. PMID: 34509565; PMCID: PMC8572157.
52. Chen E, Schmitt J, McIntosh G, Young BP, Lian T, Liu J, Chen KK, Liston JB, MacDonald L, Wang B, Medina Giro S, Boehme B, Das M, Indran S, Chao JT, Rogic S, Pavlidis P, Allan DW, Loewen CJR. Revealing function-altering MeCP2 mutations in individuals with autism spectrum disorder using yeast and *Drosophila*. *Genetics*. 2025 Jun 23:iyaf121. doi: 10.1093/genetics/iyaf121. Epub ahead of print. PMID: 40546018.
53. Kumar V, Kundu S, Singh A, Singh S. Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective. *Curr Neuropharmacol*. 2022;20(1):158-178. doi: 10.2174/1570159X19666210609160017. PMID: 34151764; PMCID: PMC9199543.
54. Awamleh Z, Choufani S, Wu W, Rots D, Dingemans AJM, Nadif Kasri N, Boronat S, Ibañez-Mico S, Cuesta Herraiz L, Ferrer I, Martínez Carrascal A, Pérez-Jurado LA, Aznar Lain G, Ortigoza-Escobar JD, de Vries BBA, Koolen DA, Weksberg R. A new blood DNA methylation signature for Koolen-de Vries syndrome: Classification of missense KANSL1 variants and comparison to fibroblast cells. *Eur J Hum Genet*. 2024 Mar;32(3):324-332. doi: 10.1038/s41431-024-01538-6. Epub 2024 Jan 29. Erratum in: *Eur J Hum Genet*. 2024 Mar;32(3):366. doi: 10.1038/s41431-024-01561-7. PMID: 38282074; PMCID: PMC10923882.
55. https://omim-org.translate.google.com/entry/615873?_x_tr_sl=en&_x_tr_tl=tr&_x_tr_hl=tr&_x_tr_pto=tc
56. Coffee B, Zhang F, Ceman S, Warren ST, Reines D. Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome. *Am J Hum Genet*. 2002 Oct;71(4):923-32. doi: 10.1086/342931. Epub 2002 Sep 13. PMID: 12232854; PMCID: PMC378545.
57. Lui JC, Baron J. Epigenetic Causes of Overgrowth Syndromes. *J Clin Endocrinol Metab*. 2024 Jan 18;109(2):312-320. doi: 10.1210/clinem/dgad420. PMID: 37450557; PMCID: PMC11032252.
58. Li X, Zhang Y, Wang L, Lin Y, Gao Z, Zhan X, Huang Y, Sun C, Wang D, Liang S, Wu L. Integrated Analysis of Brain Transcriptome Reveals Convergent Molecular Pathways in Au-



- tism Spectrum Disorder. *Front Psychiatry*. 2019 Oct 8;10:706. doi: 10.3389/fpsyt.2019.00706. PMID: 31649562; PMCID: PMC6795181.
59. Sugathan A, Biagioli M, Golzio C, Erdin S, Blumenthal I, Manavalan P, Ragavendran A, Brand H, Lucente D, Miles J, Sheridan SD, Stortchevoi A, Kellis M, Haggarty SJ, Katsanis N, Gusella JF, Talkowski ME. CHD8 regulates neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. *Proc Natl Acad Sci U S A*. 2014 Oct 21;111(42):E4468-77. doi: 10.1073/pnas.1405266111. Epub 2014 Oct 7. PMID: 25294932; PMCID: PMC4210312.
60. Xu Q, Liu YY, Wang X, Tan GH, Li HP, Hulbert SW, Li CY, Hu CC, Xiong ZQ, Xu X, Jiang YH. Autism-associated CHD8 deficiency impairs axon development and migration of cortical neurons. *Mol Autism*. 2018 Dec 19;9:65. doi: 10.1186/s13229-018-0244-2. PMID: 30574290; PMCID: PMC6299922.
61. Weissberg O, Elliott E. The Mechanisms of CHD8 in Neurodevelopment and Autism Spectrum Disorders. *Genes (Basel)*. 2021 Jul 26;12(8):1133. doi: 10.3390/genes12081133. PMID: 34440307; PMCID: PMC8393912.
62. Wells C, Sorgenfrei J, Johnson SL, Albertson D, Rutter J, Baker SA. Gene delivery of AGAT and GAMT boosts creatine levels in creatine transporter deficiency patient fibroblasts. *PLoS One*. 2025 May 8;20(5):e0319350. doi: 10.1371/journal.pone.0319350. PMID: 40338959; PMCID: PMC12061113.
63. Baker SA, Gajera CR, Wawro AM, Corces MR, Montine TJ. GATM and GAMT synthesize creatine locally throughout the mammalian body and within oligodendrocytes of the brain. *Brain Res*. 2021 Nov 1;1770:147627. doi: 10.1016/j.brainres.2021.147627. Epub 2021 Aug 19. PMID: 34418357.
64. Jerow LG, Krueger DA, Gross C, Danzer SC. Somatic mosaicism and interneuron involvement in mTORopathies. *Trends Neurosci*. 2025 May;48(5):362-376. doi:10.1016/j.tins.2025.02.009. Epub 2025 Mar 22. PMID: 40121168; PMCID: PMC12078011.
65. Hwang SK, Lee JH, Yang JE, Lim CS, Lee JA, Lee YS, Lee K, Kaang BK. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation. *Mol Brain*. 2016 May 23;9(1):56. doi: 10.1186/s13041-016-0222-6. PMID: 27216612; PMCID: PMC4878062.
66. <https://clinicaltrials.gov/study/NCT01730209>
67. Hu LY, Shi XY, Yang XF, Liu MJ, Zou LP. Rapamycin/Sirolimus Improves the Behavior of an 8-Year-Old Boy With Nonsyndromic Autism Spectrum Disorder. *Am J Ther*. 2020 Feb 20;28(5):e608-e610. doi: 10.1097/MJT.0000000000001131. PMID: 34491961.
68. Hussein MH, Alameen AA, Ansari MA, AlSharari SD, Ahmad SF, Attia MSM, Sarawi WS, Nadeem A, Bakheet SA, Attia SM. Semaglutide ameliorated autism-like behaviors and DNA repair efficiency in male BTBR mice by recovering DNA repair gene expression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2024 Dec 20;135:111091. doi: 10.1016/j.pnpbp.2024.111091. Epub 2024 Jul 18. PMID: 39032854.
69. Yang MJ, Jia M, Cai M, Feng X, Huang LN, Yang JJ. Central neuropeptides as key modulators of astrocyte function in neurodegenerative and neuropsychiatric disorders. *Psychopharmacology (Berl)*. 2025 Jun 19. doi: 10.1007/s00213-025-06840-9. Epub ahead of print. PMID: 40536717.)
70. Huang H, Weng H, Zhou K, Wu T, Zhao BS, Sun M, Chen Z, Deng X, Xiao G, Auer F, Klemm L, Wu H, Zuo Z, Qin X, Dong Y, Zhou Y, Qin H, Tao S, Du J, Liu J, Lu Z, Yin H, Mesquita A, Yuan CL, Hu YC, Sun W, Su R, Dong L, Shen C, Li C, Qing Y, Jiang X, Wu X, Sun M, Guan JL, Qu L, Wei M, Müschen M, Huang G, He C, Yang J, Chen J. Histone H3 trimethylation at lysine 36 guides m6A RNA modification co- transcriptionally. *Nature*. 2019 Mar;567(7748):414-419. doi: 10.1038/s41586-019-1016-7. Epub 2019 Mar 13. PMID: 30867593; PMCID:



- PMC6438714.
71. Okazaki S, Kimura R, Otsuka I, Funabiki Y, Murai T, Hishimoto A. Epigenetic clock analysis and increased plasminogen activator inhibitor-1 in high-functioning autism spectrum disorder. *PLoS One*. 2022 Feb 3;17(2):e0263478. doi: 10.1371/journal.pone.0263478. PMID: 35113965; PMCID: PMC8812940.
72. Nardone S, Sams DS, Reuveni E, Getselter D, Oron O, Karpuj M, Elliott E. DNA methylation analysis of the autistic brain reveals multiple dysregulated biological pathways. *Transl Psychiatry*. 2014 Sep 2;4(9):e433. doi: 10.1038/tp.2014.70. PMID: 25180572; PMCID: PMC4203003.
73. Ramaswami G, Won H, Gandal MJ, Haney J, Wang JC, Wong CCY, Sun W, Prabhakar S, Mill J, Geschwind DH. Integrative genomics identifies a convergent molecular subtype that links epigenomic with transcriptomic differences in autism. *Nat Commun*. 2020 Sep 25;11(1):4873. doi: 10.1038/s41467-020-18526-1. PMID: 32978376; PMCID: PMC7519165.
74. Schmidt RJ, Iosif AM, Guerrero Angel E, Ozonoff S. Association of Maternal Prenatal Vitamin Use With Risk for Autism Spectrum Disorder Recurrence in Young Siblings. *JAMA Psychiatry*. 2019 Apr 1;76(4):391-398. doi: 10.1001/jamapsychiatry.2018.3901. PMID: 30810722; PMCID: PMC6450282.
75. Avram OE, Bratu EA, Curis C, Moroianu LA, Drima E. Modifiable Nutritional Biomarkers in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis of Vitamin D, B12, and Homocysteine Exposure Spanning Prenatal Development Through Late Adolescence. *Int J Mol Sci*. 2025 May 6;26(9):4410. doi: 10.3390/ijms26094410. PMID: 40362647; PMCID: PMC12072606.
76. De Marzio M, Lasky-Su J, Chu SH, Prince N, Litonjua AA, Weiss ST, Kelly RS, Glass KR. The metabolic role of vitamin D in children's neurodevelopment: a network study. *Sci Rep*. 2024 Jul 23;14(1):16929. doi: 10.1038/s41598-024-67835-8. PMID: 39043876; PMCID: PMC11266698.
77. Frye RE, Melnyk S, Fuchs G, Reid T, Jernigan S, Pavliv O, Hubanks A, Gaylor DW, Walters L, James SJ. Effectiveness of methylcobalamin and folinic Acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. *Autism Res Treat*. 2013;2013:609705. doi: 10.1155/2013/609705. Epub 2013 Oct 12. PMID: 24224089; PMCID: PMC3810468.
78. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, Frazier TW, Tirouvanziam R. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. *Biol Psychiatry*. 2012 Jun 1;71(11):956-61. doi: 10.1016/j.biopsych.2012.01.014. Epub 2012 Feb 18. PMID: 22342106; PMCID: PMC4914359.
79. Adams JB, Bhargava A, Coleman DM, Frye RE, Rossignol DA. Ratings of the Effectiveness of Nutraceuticals for Autism Spectrum Disorders: Results of a National Survey. *J Pers Med*. 2021 Aug 31;11(9):878. doi: 10.3390/jpm11090878. PMID: 34575655; PMCID: PMC8470413.

OTİZM SPEKTRUM BOZUKLUĞU VE EPİLEPSİ

Sait AÇIK¹
Furkan DONBALOĞLU²
Şenay HASPOLAT³

EPİLEPSİ

Epilepsi, farklı nöbet tiplerinin görüldüğü ve her yaş grubunu etkileyen yaygın bir nörolojik hastalıktır.

Beyindeki anormal, aşırı veya eşzamanlı nöronal deşarjlar sonucunda ortaya çıkan geçici belirti ve bulgulara epileptik nöbet denir.¹ İlkinin üzerinden 24 saatten uzun zaman geçmiş, iki veya daha fazla tetiklenmemiş nöbet varlığı, epilepsi olarak tanımlanır. Bu tanım, Uluslararası Epilepsi ile Savaş Derneği'nin 2014 yılında yayınladığı raporda genişletilmiş; on yıl içinde tekrarlama olasılığı yüksek olan (>%60) tek tetiklenmemiş (ya da refleks) nöbet ve özgül bir epilepsi sendromu tanısı alan durumlar da bu tanıma eklenmiştir.²

Epilepsi Prevelansı

Epilepsi, anormal nöronal deşarjlar sonucunda oluşan ve tekrarlayan nöbetlerin görüldüğü sık rastlanan nörolojik bir hastalıktır. Görülme sıklığı çocuklar ve adolesanlarda yaklaşık olarak 20-124/100.000 civarındadır. Ayrıca, yirmi yaşına kadar olan popülasyonun %5'i en az bir nöbet geçirmektedir.³

Prevalans çalışmalarıyla elde edilen bulgular, özellikle halk sağlığı planlamalarına önemli katkılar sağladığından oldukça değerlidir. Günümüzde, tüm

¹ Uzm. Dr., Antalya Şehir Hastanesi saitopen@yahoo.com, ORCID iD: 0000-0002-1177-8438

² Uzm. Dr., Akdeniz Üniversitesi Hastanesi, Çocuk Nöroloji Kliniği, drfurkandonbaloglu@gmail.com, ORCID iD: 0000-0002-3252-9342

³ Prof. Dr., Akdeniz Üniversitesi Hastanesi, Çocuk Nöroloji Kliniği, shaspolat222@gmail.com, ORCID iD: 0000-0003-3596-1816



KAYNAKLAR

1. Fisher RS, Boas WVE, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia*. 2005;46(4):470-2.
2. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia*. 2014;55(4):475-82.
3. Hauser WA. Epidemiology of epilepsy in children. *Neurosurgery clinics of North America*. 1995;6(3):419-30.
4. SN Y. Epilepsi insidansı, prevalansı ve risk faktörleri In: *Epilepsi*. Eds: Bora İ Yeni SN Gürses C Nobel Tıp Kitabevleri İstanbul. 2008:65-72.
5. Maenner MJ. Prevalence and characteristics of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2018. *MMWR Surveillance Summaries*. 2021;70.
6. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. *MMWR Surveill Summ*. 2012;61(3):1-19.
7. Deshmukh V, Mohapatra A, Gulati S, Nair M, Bhutani V, Silberberg D, editors. Prevalence of neuro-developmental disorders in India. *Proceedings of International Meeting for Autism Research*; 2013.
8. Baio J. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years—Autism and developmental disabilities monitoring network, 11 sites, United States, 2010. *MMWR Surveill Summ*. 2014;63(2):1-21.
9. Lukmanji S, Manji SA, Kadhim S, et al. The co-occurrence of epilepsy and autism: A systematic review. *Epilepsy & Behavior*. 2019;98:238-48.
10. Berg AT, Plioplys S. Epilepsy and autism: is there a special relationship? *Epilepsy & Behavior*. 2012;23(3):193-8.
11. Holder Jr JL, Hamdan FF, Michaud JL. SYNGAP1-related intellectual disability. 2019.
12. Bozzi Y, Provenzano G, Casarosa S. Neurobiological bases of autism–epilepsy comorbidity: a focus on excitation/inhibition imbalance. *European Journal of Neuroscience*. 2018;47(6):534-48.
13. Lee BH, Smith T, Paciorkowski AR. Autism spectrum disorder and epilepsy: Disorders with a shared biology. *Epilepsy & Behavior*. 2015;47:191-201.
14. Specchio N, Pietrafusa N, Trivisano M, et al. Autism and epilepsy in patients with tuberous sclerosis complex. *Frontiers in Neurology*. 2020;11:639.
15. Tuchman R, editor What is the relationship between autism spectrum disorders and epilepsy? *Seminars in pediatric neurology*; 2017: Elsevier.
16. Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. *Pediatrics*. 2010;125(1):e17-e23.
17. McCue LM, Flick LH, Twyman KA, Xian H, Conturo TE. Prevalence of non-febrile seizures in children with idiopathic autism spectrum disorder and their unaffected siblings: a retrospective cohort study. *BMC neurology*. 2016;16:1-9.
18. Amiet C, Gourfinkel-An I, Bouzamondo A, et al. Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. *Biological psychiatry*. 2008;64(7):577-82.
19. Tuchman R, Rapin I. Epilepsy in autism. *The Lancet Neurology*. 2002;1(6):352-8.
20. Viscidi EW, Triche EW, Pescosolido MF, et al. Clinical characteristics of children with autism spectrum disorder and co-occurring epilepsy. *PloS one*. 2013;8(7):e67797.
21. Ballaban-Gil K, Tuchman R. Epilepsy and epileptiform EEG: association with autism and



- language disorders. *Mental retardation and developmental disabilities research reviews*. 2000;6(4):300-8.
22. Danielsson S, Gillberg IC, Billstedt E, Gillberg C, Olsson I. Epilepsy in young adults with autism: a prospective population-based follow-up study of 120 individuals diagnosed in childhood. *Epilepsia*. 2005;46(6):918-23.
 23. Blackmon K, Bluvstein J, MacAllister WS, et al. Treatment resistant epilepsy in autism spectrum disorder: increased risk for females. *Autism Research*. 2016;9(2):311-20.
 24. Thomas S, Hovinga ME, Rai D, Lee BK. Brief report: prevalence of co-occurring epilepsy and autism spectrum disorder: the US National Survey of Children's Health 2011–2012. *Journal of autism and developmental disorders*. 2017;47:224-9.
 25. Su C-C, Chi MH, Lin S-H, Yang YK. Bidirectional association between autism spectrum disorder and epilepsy in child and adolescent patients: a population-based cohort study. *European child & adolescent psychiatry*. 2016;25:979-87.
 26. H. H. Autism and epilepsy: a retrospective follow-up study. *Brain and Development*. 2007;29(8):486-90.
 27. Kanner L. Autistic disturbances of affective contact. *Nervous child*. 1943;2(3):217-50.
 28. Tuchman R, Cuccaro M, Alessandri M. Autism and epilepsy: historical perspective. *Brain and Development*. 2010;32(9):709-18.
 29. Ghacibeh GA, Fields C. Interictal epileptiform activity and autism. *Epilepsy & Behavior*. 2015;47:158-62.
 30. Spence SJ, Schneider MT. The role of epilepsy and epileptiform EEGs in autism spectrum disorders. *Pediatric research*. 2009;65(6):599-606.
 31. Tuchman R. Treatment of seizure disorders and EEG abnormalities in children with autism spectrum disorders. *Journal of autism and developmental disorders*. 2000;30:485-9.
 32. Peng J, Zhou Y, Wang K. Multiplex gene and phenotype network to characterize shared genetic pathways of epilepsy and autism. *Scientific reports*. 2021;11(1):952.
 33. Kanemura H, Sano F, Tando T, Sugita K, Aihara M. Can EEG characteristics predict development of epilepsy in autistic children? *European Journal of Paediatric Neurology*. 2013;17(3):232-7.
 34. Steffenburg S. Psychiatric disorders in children and adolescents with active epilepsy and mental retardation. *Arch Neurol*. 1996;53:904-12.
 35. Kanemura H, Sano F, Ohyama T, Sugita K, Aihara M. Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. *European journal of paediatric neurology*. 2014;18(4):482-8.
 36. Rossi PG, Parmeggiani A, Bach V, Santucci M, Visconti P. EEG features and epilepsy in patients with autism. *Brain and Development*. 1995;17(3):169-74.
 37. Akshoomoff N, Farid N, Courchesne E, Haas R. Abnormalities on the neurological examination and EEG in young children with pervasive developmental disorders. *Journal of autism and developmental disorders*. 2007;37:887-93.
 38. Chez MG, Chang M, Krasne V, Coughlan C, Kominsky M, Schwartz A. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. *Epilepsy & Behavior*. 2006;8(1):267-71.
 39. Kim HL, Donnelly JH, Tournay AE, Book TM, Filipek P. Absence of seizures despite high prevalence of epileptiform EEG abnormalities in children with autism monitored in a tertiary care center. *Epilepsia*. 2006;47(2):394-8.
 40. García-Peñas J. Autismo, epilepsia y patología del lóbulo temporal. *Rev Neurol*. 2009;48(Supl 2):S35-45.
 41. Kanemura H, Sano F, Tando T, Sugita K, Aihara M. Repeated seizures induce prefrontal growth disturbance in frontal lobe epilepsy. *Brain and Development*. 2012;34(3):175-80.



42. Hughes R, Poon W-Y, Harvey AS. Limited role for routine EEG in the assessment of staring in children with autism spectrum disorder. *Archives of Disease in Childhood*. 2015;100(1):30-3.
43. Şanlıdağ B, Donbaloğlu F, Sari Yanartaş M, Şekeroğlu B, Yılmaz A, Köken ÖY. High-frequency oscillations in autism spectrum disorder: are they related to clinical severity? *Cerebral Cortex*. 2025;35(4):bhaf068.
44. Burack JA, Volkmar FR. Development of low-and high-functioning autistic children. *Journal of Child Psychology and Psychiatry*. 1992;33(3):607-16.
45. Auvin S, Cilio MR, Vezzani A. Current understanding and neurobiology of epileptic encephalopathies. *Neurobiology of disease*. 2016;92:72-89.
46. Desprairies C, Dozières-Puyravel B, Ilea A, et al. Early identification of epileptic encephalopathy with continuous spikes-and-waves during sleep: A case-control study. *European Journal of Paediatric Neurology*. 2018;22(5):837-44.
47. Tuchman RF, Rapin I. Regression in pervasive developmental disorders: seizures and epileptiform electroencephalogram correlates. *Pediatrics*. 1997;99(4):560-6.
48. Hrdlicka M, Komarek V, Propper L, et al. Not EEG abnormalities but epilepsy is associated with autistic regression and mental functioning in childhood autism. *European child & adolescent psychiatry*. 2004;13:209-13.
49. Dash D, Sharma A, Yuvraj K, et al. Can home video facilitate diagnosis of epilepsy type in a developing country? *Epilepsy Research*. 2016;125:19-23.
50. Auvin S. Management of childhood epilepsy. *Presse Medicale (Paris, France)*. 1983. 2011;40(3):287-92.
51. Douglas JF, Sanders KB, Benneyworth MH, et al. Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder. *Journal of autism and developmental disorders*. 2013;43:1243-7.
52. Frye RE, Sreenivasula S, Adams JB. Traditional and non-traditional treatments for autism spectrum disorder with seizures: an on-line survey. *BMC pediatrics*. 2011;11:1-18.
53. Hirota T, Veenstra-VanderWeele J, Hollander E, Kishi T. Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis. *Journal of autism and developmental disorders*. 2014;44:948-57.
54. Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. *Therapeutic advances in neurological disorders*. 2011;4(6):385-407.

OTİZM SPEKTRUM BOZUKLUĞU VE DİKKAT EKSİKLİĞİ HİPERAKTİVİTE BOZUKLUĞU: TANI VE TEDAVİ

Ezgi KARAGÖZ TANIGÖR¹
Gonca ÖZYURT²

TANI

Dikkat eksikliği/hiperaktivite bozukluğu (DEHB) ve otizm spektrum bozukluğu (OSB), genellikle çocukluk çağında başlayan nörogelişimsel bozukluklardır.

DSM-IV'e göre OSB olan bireye DEHB tanısı konulamamaktadır. DSM-5'te bu durum değiştirilmiş iki bozukluğun eş tanısı olarak konulmasına izin verilmiştir. Güncel bilgilere göre DEHB/OSB sık görülen komorbid bozukluklardır. DEHB'li her 8 gençten yaklaşık 1'inin OSB'ye sahip olduğunu bildirmiştir.¹ DEHB, OSB'li çocuklarda en yaygın komorbid bozukluktur ve komorbidite oranları %40-70 aralığında yer almaktadır.² Bozuklukların temel semptomlarındaki farklılıklara rağmen, birçok çalışma DEHB tanısı almış çocuk ve ergenlerde otizm semptomlarının yüksek seviyelerde olduğunu bildirmiştir.³

DEHB ve OSB'de davranışsal, bilişsel ve nörobiyolojik açıdan benzerlikler olduğu görülmektedir.⁴ İki bozuklukta da genetik faktörler önemli rol oynamaktadır. Dil gelişiminde gecikme, sosyal-iletişim becerileri zayıflığı, duyuşal aşırı duyarlılık, emosyon regülasyonu, dikkat problemleri, karşı olma-karşı gelme davranışları gibi sorunlar DEHB ve OSB olan hastalarda ortak olarak görülebilen semptomlardır.⁵ Ayrıca DEHB'li hastaların ailelerinde geniş otizm fenotipi bulgularının normal popülasyondan daha sık olduğu belirtilmiştir.⁶

¹ İzmir Katip Çelebi Üniversitesi, Tıp Fakültesi, Atatürk Eğitim Araştırma Hastanesi Çocuk ve Ergen Psikiyatrisi, ezgi.karagoztanigor@gmail.com, ORCID iD: 0000-0002-5483-3863

² İzmir Katip Çelebi Üniversitesi, Tıp Fakültesi, Çocuk ve Ergen Psikiyatrisi, goncaenginozyurt@gmail.com, ORCID iD: 0000-0002-0508-0594



tedavisi işlevselliği önemli ölçüde iyileştirmektedir.²⁵ DEHB-OSB komorbiditesinde rutin tedavi önerilmektedir. OSB-DEHB komorbiditesinde metilfenidat ilk sıra tercih olarak yer alsa da bir metaanaliz; OSB-DEHB komorbiditesinde, OSB'nin eşlik etmediği DEHB tedavisine göre metilfenidatın etki büyüklüğünün daha düşük olduğunu göstermiştir (sırasıyla ES=0.67 ve 1.03).²⁶ Bu olgularda metilfenidat etkinliğinin daha düşük, yan etkilerinin ise daha fazla olabileceği belirtilmiştir.^{2, 27} OSB'de metilfenidat kullanımı sırasında sosyal geri çekilme, depresyon ve sinirlilik gibi daha yüksek oranda yan etkiler olduğu belirtilmiştir.²⁸

Cochrane incelemesinde metilfenidatın, OSB'li gençlerde hiperaktivite ve dürtüsellik azalttığı, dikkat eksikliği üzerinde daha zayıf bir etkisinin olduğu ve temel OSB semptomlarını etkilemediği belirtilmektedir.²⁹ Orta dozlar, düşük dozlara kıyasla DEHB semptomlarında daha belirgin iyileşme sağlamaktadır. Klinik deneyimlere dayanarak, bu popülasyonda ilaçların düşük dozlarda başlatılması ve normalden daha dikkatli titre edilmesi gerektiği önerilmektedir.²⁵

Metilfenidat birinci basamak tedavi olarak önerilirken, atomoksetin ve guanfasin de etkilidir. Atomoksetin uyku üzerinde nötr bir etkiye sahipken, uzatılmış salımlı guanfasin karşıt davranışlarda küçük bir azalma sağlasa da anksiyete ve uyku sorunları açısından fark yaratmaz.³⁰ Risperidon ve aripiprazolün bu popülasyonda hiperaktiviteyi kontrol etmede etkili olduğunu bildirilse de genel olarak psikostimülanlara göre daha büyük bir yan etki profiline (metabolik değişiklikler, kilo alımı) sahiptirler.³¹

Psikososyal müdahalenin ilaç tedavisine ek fayda sağlamadığına dair bazı veriler olsa da, genellikle ilaç ve psikososyal yaklaşımların birlikte kullanılması önerilmektedir.^{32, 33}

KAYNAKLAR

1. Jensen CM, Steinhausen H-C. Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. *ADHD Atten Defic Hyperact Disord* 2015;7:27-38.
2. Antshel KM, Zhang-James Y, Faraone SV. The comorbidity of ADHD and autism spectrum disorder. *Expert Rev Neurother*. 2013;13(10):1117-28.
3. Cooper M, Martin J, Langley K, Hamshire M, Thapar A. Autistic traits in children with ADHD index clinical and cognitive problems. *Eur Child Adolesc Psychiatry*. 2014;23:23-34.
4. Brieber S, Neufang S, Bruning N, Kamp-Becker I, Remschmidt H, Herpertz-Dahlmann B, et al. Structural brain abnormalities in adolescents with autism spectrum disorder and patients with attention deficit/hyperactivity disorder. *J Child Psychol Psychiatry*. 2007;48(12):1251-8.
5. Clark T, Feehan C, Tinline C, Vostanis P. Autistic symptoms in children with attention defi-



- cit-hyperactivity disorder. *Eur Child Adolesc Psychiatry*. 1999;8(1):50-5.
6. Ghirardi L, Brikell I, Kuja-Halkola R, Freitag CM, Franke B, Asherson P, et al. The familial co-aggregation of ASD and ADHD: a register-based cohort study. *Mol Psychiatry*. 2018;23(2):257-62.
7. Ghirardi L, Pettersson E, Taylor MJ, Freitag CM, Franke B, Asherson P, et al. Genetic and environmental contribution to the overlap between ADHD and ASD trait dimensions in young adults: a twin study. *Psychol Med*. 2019;49(10):1713-21.
8. Musser ED, Hawkey E, Kachan-Liu SS, Lees P, Rouillet JB, Goddard K, et al. Shared familial transmission of autism spectrum and attention-deficit/hyperactivity disorders. *J Child Psychol Psychiatry*. 2014;55(7):819-27.
9. Jokiranta-Olkonien E, Cheslack-Postava K, Sucksdorff D, Suominen A, Gyllenberg D, Chudal R, et al. Risk of psychiatric and neurodevelopmental disorders among siblings of probands with autism spectrum disorders. *JAMA psychiatry*. 2016;73(6):622-9.
10. Rommelse NN, Altink ME, Fliers EA, Martin NC, Buschgens CJ, Hartman CA, et al. Comorbid problems in ADHD: degree of association, shared endophenotypes, and formation of distinct subtypes. Implications for a future DSM. *J Abnorm Child Psychol*. 2009;37:793-804.
11. Smalley SL, Kustanovich V, Minassian SL, Stone JL, Ogdie MN, McGough JJ, et al. Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism. *Am J Hum Genet* 2002;71(4):959-63.
12. Hale TS, Hariri AR, McCracken JT. Attention-deficit/hyperactivity disorder: Perspectives from neuroimaging. *Ment Retard Dev Disabil Res Rev*. 2000;6(3):214-9.
13. Eliez S, Reiss AL. Annotation: MRI neuroimaging of childhood psychiatric disorders: a selective review. *J Child Psychol Psychiatry*. 2000;41(6):679-94.
14. Geurts HM, Verté S, Oosterlaan J, Roeyers H, Sergeant JA. How specific are executive functioning deficits in attention deficit hyperactivity disorder and autism? *Journal of child psychology and psychiatry*. 2004;45(4):836-54.
15. Craig F, Margari F, Legrottaglie AR, Palumbi R, De Giambattista C, Margari L. A review of executive function deficits in autism spectrum disorder and attention-deficit/hyperactivity disorder. *Neuropsychiatr Dis Treat*. 2016;1191-202.
16. Happé F, Booth R, Charlton R, Hughes C. Executive function deficits in autism spectrum disorders and attention-deficit/hyperactivity disorder: examining profiles across domains and ages. *Brain Cogn*. 2006;61(1):25-39.
17. Kilincaslan A, Mukaddes NM, Küçükyazici GS, Gürvit H. Assessment of executive/attentional performance in Asperger's disorder. *Turk Psikiyatri Derg*. 2010;21(4):289.
18. Smith T, Iadarola S. Evidence base update for autism spectrum disorder. *J Clin Child Adolesc Psychol*. 2015;44(6):897-922.
19. Goode AP, Coeytaux RR, Maslow GR, Davis N, Hill S, Namdari B, et al. Nonpharmacologic treatments for attention-deficit/hyperactivity disorder: a systematic review. *Pediatrics*. 2018;141(6).
20. Caye A, Swanson JM, Coghill D, Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. *Mol Psychiatry*. 2019;24(3):390-408.
21. Gagliardi L, Rusconi F, Bellù R, Zanini R, Network IN. Association of maternal hypertension and chorioamnionitis with preterm outcomes. *Pediatrics*. 2014;134(1):e154-e61.
22. Mansour R, Dovi AT, Lane DM, Loveland KA, Pearson DA. ADHD severity as it relates to comorbid psychiatric symptomatology in children with Autism Spectrum Disorders (ASD). *Res Dev Disabil*. 2017;60:52-64.
23. Kamimura-Nishimura K, Froehlich T, Chirdkiatgumchai V, Adams R, Fredstrom B, Manning P. Autism spectrum disorders and their treatment with psychotropic medications in a nationally representative outpatient sample: 1994–2009. *Ann Epidemiol*. 2017;27(7):448-53. e1.



24. Yamamuro K, Tsujii N, Ota T, Kishimoto T, Iida J. Pharmacotherapy for the treatment of aggression in pediatric and adolescent patients with autism spectrum disorder comorbid with attention-deficit hyperactivity disorder: A questionnaire survey of 571 psychiatrists. *Psychiatry Clin Neurosci*. 2017;71(8):554-61.
25. Canadian A. Resource Alliance (CADDRA): Canadian ADHD Practice Guidelines. Toronto: CADDRA. 2018.
26. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. *Eur Child Adolesc Psychiatry*. 2010;19:353-64.
27. Ercan E. Türkiye DEHB uzman görüşü raporu: Dikkat eksikliği hiperaktivite bozukluğu uzman görüşü raporu. Türkiye; 2013.
28. Reichow B, Volkmar FR, Bloch MH. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. *J Autism Dev Disord*. 2013;43:2435-41.
29. Sturman N, Deckx L, van Driel ML. Methylphenidate for children and adolescents with autism spectrum disorder. *Cochrane Database of Systematic Reviews*. 2017(11).
30. Hollway JA, Mendoza-Burcham M, Andridge R, Aman MG, Handen B, Arnold LE, et al. Atomoxetine, parent training, and their effects on sleep in youth with autism spectrum disorder and attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol*. 2018;28(2):130-5.
31. Medicines N, UK PC. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. 2015.
32. Arnold LE, Ober N, Aman MG, Handen B, Smith T, Pan X, et al. A 1.5-year follow-up of parent training and atomoxetine for attention-deficit/hyperactivity disorder symptoms and non-compliant/disruptive behavior in autism. *J Child Adolesc Psychopharmacol*. 2018;28(5):322-30.
33. Mahajan R, Bernal MP, Panzer R, Whitaker A, Roberts W, Handen B, et al. Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders. *Pediatrics*. 2012;130(Supplement_2):S125-S38.

OTİZM VE UYKU BOZUKLUKLARI: TANI VE TEDAVİ

Taha ÖZÇELİK¹
Ebru ARHAN²

GİRİŞ

Otizm spektrum bozuklukları (OSB), sosyal etkileşim ve iletişim bozuklukları, ilgi alanlarının azlığı ve tekrarlayıcı davranışlar ile karakterize nörogelişimsel bozukluklardır. OSB'li çocuklar, normal gelişim gösteren çocuklara kıyasla yüksek oranda uyku bozuklukları yaşarlar. OSB'li çocukların %80' inde uyku kalite ve süresi ile ilgili bozukluklar vardır. Uyku problemleri hem çocukların hem de ailelerinin yaşam kalitesini önemli ölçüde etkilemektedir.¹

OSB'de uyku problemlerinin hem davranış hem de psikopatoloji ile ilişkili olduğu gösterilmiştir. Bu ilişki biyopsikososyal bir etkileşimin varlığını düşündürmektedir. OSB'de uyku problemleri, eşlik eden davranışsal bozukluklar (ör. sınırlı ve tekrarlayıcı davranışlar, kendine zarar verme, saldırganlık, stereotipi) ve psikopatoloji ile (ör. DEHB, anksiyete, depresyon) bağlantıları esas alınarak tanımlanmaktadır.

OSB'li çocuklarda uyku, en yaygın tıbbi takip nedenlerinden biridir. Hatta davranışsal bozukluklar veya saldırganlık nedeni ile yapılan başvurularda, öncelikli olarak uyku ile ilgili sorgulama iyi bir başlangıç noktasıdır. Uykusuzluk OSB'nin temel belirtilerinde artışa neden olur ve bu durum, OSB'li çocuklarda uyku bozukluklarını yönetmeyi zorlaştırır. OSB'nin temel belirtilerinin çoğu uykuyu olumsuz etkileyebilir ve kötü uyku, bu belirtileri daha da kötüleştirerek kısır bir döngü oluşturabilir.

¹ Uzm. Dr., Gazi Üniversitesi Tıp Fakültesi Hastanesi, Çocuk Nöroloji Kliniği, tahaozcelik934@gmail.com.tr, ORCID iD: 0000-0002-1075-4231

² Prof. Dr., Gazi Üniversitesi Tıp Fakültesi Hastanesi, Çocuk Nöroloji Kliniği, petekarhan@yahoo.com.tr, ORCID iD: 0000-0001-8950-8588



KAYNAKLAR

1. Reynolds AM, Malow BA. Sleep and Autism Spectrum Disorders. *Pediatr Clin North Am.* 2011 Jun;58(3):685–98.
2. Ballester P, Richdale AL, Baker EK, et al. Sleep in autism: A biomolecular approach to aetiology and treatment. *Sleep Med Rev.* 2020 Dec;54:101357.
3. Özbudak P, Arhan E. Uyku Fizyolojisi ve Ontogenezi. *Çocuklarda Uyku Sağlığı ve Bozuklukları - Türkiye Klinikleri.* 2020;1:1–11.
4. Mazzone L, Postorino V, Siracusano M, et al. The Relationship between Sleep Problems, Neurobiological Alterations, Core Symptoms of Autism Spectrum Disorder, and Psychiatric Comorbidities. *J Clin Med.* 2018 May 3;7(5):102.
5. Clément O, Sapin E, Libourel PA, et al. The Lateral Hypothalamic Area Controls Paradoxical (REM) Sleep by Means of Descending Projections to Brainstem GABAergic Neurons. *The Journal of Neuroscience.* 2012 Nov 21;32(47):16763–74.
6. McCauley JL, Olson LM, Delahanty R, 1-Mb 15q12 GABA(A) et al. A linkage disequilibrium map of the 1-Mb 15q12 GABA_A receptor subunit cluster and association to autism. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.* 2004 Nov 15;131B(1):51–9.
7. Baker EK, Richdale AL. Examining the Behavioural Sleep-Wake Rhythm in Adults with Autism Spectrum Disorder and No Comorbid Intellectual Disability. *J Autism Dev Disord.* 2017 Apr 3;47(4):1207–22.
8. Adrien J. Neurobiological bases for the relation between sleep and depression. *Sleep Med Rev.* 2002 Oct;6(5):341–51.
9. Stenberg D. Neuroanatomy and neurochemistry of sleep. *Cellular and Molecular Life Sciences.* 2007 May 15;64(10):1187–204.
10. Deutsch SI, Urbano MR, Neumann SA, et al. Cholinergic Abnormalities in Autism. *Clin Neuropharmacol.* 2010 May;33(3):114–20.
11. Richdale AL, Baglin CL. Self-report and caregiver-report of sleep and psychopathology in children with high-functioning autism spectrum disorder: A pilot study. *Dev Neurorehabil.* 2015 Jul 4;18(4):272–9.
12. Purcell AE, Jeon OH, Zimmerman AW, et al. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. *Neurology.* 2001 Nov 13;57(9):1618–28.
13. Souders MC, Mason TBA, Valladares O, et al. Sleep Behaviors and Sleep Quality in Children with Autism Spectrum Disorders. *Sleep.* 2009 Dec;32(12):1566–78.
14. Morgan B, Nageye F, Masi G, et al. Sleep in adults with Autism Spectrum Disorder: a systematic review and meta-analysis of subjective and objective studies. *Sleep Med.* 2020 Jan;65:113–20.
15. Montazeri F, de Bildt A, Dekker V, et al. Network Analysis of Behaviors in the Depression and Autism Realms: Inter-Relationships and Clinical Implications. *J Autism Dev Disord.* 2020 May;50(5):1580–95.
16. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. *Chest.* 2014 Nov;146(5):1387–94.
17. Borbély AA, Daan S, Wirz-Justice A, et al. The two-process model of sleep regulation: a reappraisal. *J Sleep Res.* 2016 Apr;25(2):131–43.
18. Malow BA, McGrew SG, Harvey M, et al. Impact of treating sleep apnea in a child with autism spectrum disorder. *Pediatr Neurol.* 2006 Apr;34(4):325–8.
19. Poyrazoğlu HG. REM Uyku Parasomnileri. *Çocuklarda Uyku Sağlığı ve Bozuklukları - Türkiye Klinikleri.* 2020;1:22–6.



20. Sidhu N, Wong Z, Bennett AE, et al. Sleep Problems in Autism Spectrum Disorder. *Pediatr Clin North Am.* 2024 Apr;71(2):253–68.
21. Pedük Y, Per H. NREM Parasomniler. *Çocuklarda Uyku Sağlığı ve Bozuklukları - Türkiye Klinikleri.* 2020;1:17–21.
22. Schreck KA, Mulick JA. Parental report of sleep problems in children with autism. *J Autism Dev Disord.* 2000;30(2):127–35.
23. Mazurek MO, Dovgan K, Neumeyer AM, et al. Course and Predictors of Sleep and Co-occurring Problems in Children with Autism Spectrum Disorder. *J Autism Dev Disord.* 2019 May;49(5):2101–15.
24. Johnson CR, Smith T, DeMand A, et al. Exploring sleep quality of young children with autism spectrum disorder and disruptive behaviors. *Sleep Med.* 2018 Apr;44:61–6.
25. Owens JA, Spirito A, McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. *Sleep.* 2000 Dec 15;23(8):1043–51.
26. Kitanishi N, Bordini D, Ribeiro MV V, et al. Validating the Child Behavior Checklist 1.5-5 as a screening tool for autism spectrum disorder. *Autism.* 2024 Oct 29;13623613241293088.
27. Hirata I, Mohri I, Kato-Nishimura K, et al. Sleep problems are more frequent and associated with problematic behaviors in preschoolers with autism spectrum disorder. *Res Dev Disabil.* 2016;49–50:86–99.
28. Reed HE, McGrew SG, Artibee K, et al. Parent-based sleep education workshops in autism. *J Child Neurol.* 2009 Aug;24(8):936–45.
29. Campino C, Valenzuela FJ, Torres-Farfan C, et al. Melatonin Exerts Direct Inhibitory Actions on ACTH Responses in the Human Adrenal Gland. *Hormone and Metabolic Research.* 2011 May 17;43(05):337–42.
30. Andersen IM, Kaczmarska J, McGrew SG, et al. Melatonin for insomnia in children with autism spectrum disorders. *J Child Neurol.* 2008 May;23(5):482–5.
31. Malow BA, Findling RL, Schroder CM, et al. Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder. *J Am Acad Child Adolesc Psychiatry.* 2021 Feb;60(2):252–261.e3.
32. Altun H, Cömertoğlu Arslan S. Current Pharmacological Treatment for Sleep Disorders in Children and Adolescents with Autism Spectrum Disorder. *European Journal of Therapeutics.* 2024 Feb 12;30(2):227–39.
33. de Mendonça FMR, de Mendonça GPRR, Souza LC, et al. Benzodiazepines and Sleep Architecture: A Systematic Review. *CNS Neurol Disord Drug Targets.* 2023 Feb;22(2):172–9.
34. Jamadarkhana S, Gopal S. Clonidine in adults as a sedative agent in the intensive care unit. *J Anaesthesiol Clin Pharmacol.* 2010 Oct;26(4):439–45.
35. Posey DJ, Guenin KD, Kohn AE, et al. A Naturalistic Open-Label Study of Mirtazapine in Autistic and Other Pervasive Developmental Disorders. *J Child Adolesc Psychopharmacol.* 2001 Sep;11(3):267–77.

OTİZM VE ZİHİNSEL YETERSİZLİK: TANI VE TEDAVİ

Dilek ÇAVUŞOĞLU¹

GİRİŞ

Zihinsel yetersizlik (ZY) ve otizm spektrum bozuklukları (OSB), batı ülkelerinde %2-3 iken genel popülasyonda %1 sıklığında görülen majör nörogelişimsel bozukluklardır.¹⁻³ Zihinsel yetersizlik (ZY), 18 yaşından önce hem zihinsel işlevlerde hem de adaptif davranışlarda önemli sınırlamalarla tanımlanır ve genellikle 70'in altında bir Zeka Bölümü (IQ) ile tanımlanır.^{4,5} Otizm spektrum bozuklukları (OSB), iletişim ve sosyal etkileşimdeki eksiklikler, kısıtlı ve tekrarlayan davranışlar, ilgi alanları ve aktiviteler dahil olmak üzere bir dizi davranışsal fenotip için kullanılan kolektif bir terimdir(1). Zihinsel yetersizlik (ZY) ve OSB sıklıkla birlikte görülür; OSB hastalarının %70'inde ZY görülürken, ZY hastalarının ise %40'ında OSB saptandığı bildirilmiştir.^{5,6}

Genetik olarak, hem ZY hem de OSB son derece heterojen bir grup olup içerisinde, moleküler yollar ve ağlar bulunmakta ve örtüşen fenotiplere sahip varyantları birbirine bağlamaktadır. Kromozomal mikrodizi analizi nedensel sapmaların yaklaşık %20'sini ve (üçlü) tüm ekzom dizilemesini yaklaşık %40'ını tespit etmekte ancak, ZY'nin önemli bir kısmı ve OSB hastalarının çoğunluğu genetik tanı almadan kalmaktadır. İkisinin birlikte olduğu genetik nedenlerin başında Frajil X sendromu ((OMIM # 300624), Angelman sendromu (OMIM #105830) ve Rett sendromu ((OMIM #312750) gelmektedir.¹

Otizm spektrum bozukluğu (OSB) ve zihinsel yetersizliği (ZY) olan çocuklar, normal gelişim gösteren akranlarına kıyasla orantısız bir şekilde daha yüksek

¹ Doç. Dr., Afyonkarahisar Sağlık Bilimleri Üniversite Hastanesi, Tıp Fakültesi, Çocuk Nöroloji BD., dilekcavusoglu83@gmail.com, ORCID iD: 0000-0003-4924-5300



lanacağı ve ne zaman geri çekileceği, problemli davranışın nasıl engelleneceği ve yeniden yönlendirileceği ve diğer tedavi bileşenleri de içerir.

SONUÇ

Otizm Spektrum Bozukluğu (OSB) ve ZY olan çocuklarda sorunlu davranış, oldukça karmaşık ve heterojen bir durumdur. Gelişimsel bir engelin varlığına ek olarak, sorunlu davranışın ortaya çıkma ve sürdürülme riskini artıran çeşitli başka faktörler de vardır. Sorunlu davranış genellikle tıbbi veya psikiyatrik durumlar gibi biyolojik faktörlerin, operant öğrenme süreçleri aracılığıyla sorunlu davranışı güçlendiren deneyimlerle etkileşiminin ürünüdür. Araştırmalar, çoğu durumda problem davranışın sosyal pekiştirme koşulları tarafından sürdürüldüğünü, ancak uyarlanabilir davranış ve psikiyatrik koşullardaki eksikliklerin birçok durumda muhtemelen bir rol oynadığını göstermektedir. Nörodavranışsal bir bakım modeli, problem davranışın muhtemelen genetik anormallikler, psikiyatrik ve nörolojik işlev bozukluğu, pekiştirmenin mevcudiyeti gibi çevresel değişkenler ve sorunlu davranış ortaya çıkarabilecek ve pekiştirebilecek sosyal etkileşimler gibi birden fazla belirleyiciye sahip olduğunu kabul eder. Bundan, değerlendirme sürecinin bu katkıda bulunan faktörlerin rolünü belirlemeye çalışması ve bu bilgiyi bireyselleştirilmiş müdahaleler tasarlamak için kullanması gerektiği sonucu çıkar. Özetle, sosyal ve çevresel değişkenlerden, sorunlu davranış için pekiştirme davranış geçmişlerini kapsayan bütünleştirici yaklaşım, beceri eksikliklerinden kaynaklanan sorunları ele almak için davranışsal müdahalelerin ve ayrıca nöropsikiyatrik işlev bozukluğundan kaynaklanan sorunları ele almak için farmakolojik ajanların kullanımı gerekmektedir.

KAYNAKLAR

1. Coll-Tané M, Krebbers A, Castells-Nobau A, et al. Intellectual disability and autism spectrum disorders 'on the fly': insights from Drosophila. *Dis Model Mech*. 2019;12(5):dmm039180. doi: 10.1242/dmm.039180.
2. Bourke J, de Klerk N, Smith T, et al. Population-Based Prevalence of Intellectual Disability and Autism Spectrum Disorders in Western Australia: A Comparison With Previous Estimates. *Medicine (Baltimore)*. 2016;95(21):e3737.
3. Kong Y, Zhou W, Sun Z. Nuclear receptor corepressors in intellectual disability and autism. *Mol Psychiatry*. 2020;25(10):2220-2236.
4. Ropers HH. Genetics of early onset cognitive impairment. *Annu Rev Genomics Hum Genet*. 2010;11:161-187.



5. Bruno LP, Doddato G, Valentino F, et al. New Candidates for Autism/Intellectual Disability Identified by Whole-Exome Sequencing. *Int J Mol Sci.* 2021;22(24).
6. La Malfa G, Lassi S, Bertelli M, et al. Autism and intellectual disability: a study of prevalence on a sample of the Italian population. *J Intellect Disabil Res.* 2004;48(Pt 3):262-267.
7. Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. *Arch Pediatr Adolesc Med.* 2006;160(8):825-830.
8. Newcomb ET, Hagopian LP. Treatment of severe problem behaviour in children with autism spectrum disorder and intellectual disabilities. *Int Rev Psychiatry.* 2018;30(1):96-109.
9. Emerson E, Kiernan C, Alborz A, et al. The prevalence of challenging behaviors: a total population study. *Res Dev Disabil.* 2001;22(1):77-93.
10. Soke GN, Rosenberg SA, Hamman RF, et al. Brief Report: Prevalence of Self-injurious Behaviors among Children with Autism Spectrum Disorder-A Population-Based Study. *J Autism Dev Disord.* 2016;46(11):3607-3614.
11. Anderson C, Law JK, Daniels A, et al. Occurrence and family impact of elopement in children with autism spectrum disorders. *Pediatrics.* 2012;130(5):870-877.
12. McGuire K, Fung LK, Hagopian L, et al. Irritability and Problem Behavior in Autism Spectrum Disorder: A Practice Pathway for Pediatric Primary Care. *Pediatrics.* 2016;137 Suppl 2:S136-148.
13. Wachtel LE, Hagopian LP. Psychopharmacology and applied behavioral analysis: tandem treatment of severe problem behaviors in intellectual disability and a case series. *Isr J Psychiatry Relat Sci.* 2006;43(4):265-274.
14. Baer DM, Wolf MM, Risley TR. Some current dimensions of applied behavior analysis. *J Appl Behav Anal.* 1968;1(1):91-97.
15. Sallows GO, Graupner TD. Intensive behavioral treatment for children with autism: four-year outcome and predictors. *Am J Ment Retard.* 2005;110(6):417-438.
16. Smith T, Groen AD, Wynn JW. Randomized trial of intensive early intervention for children with pervasive developmental disorder. *Am J Ment Retard.* 2000;105(4):269-285.
17. Expert Consensus Guideline Series: Treatment of psychiatric and behavioral problems in mental retardation. *Am J Ment Retard.* 2000;105(3):159-226.
18. Nicholson J, Konstantinidi E, Furniss F. On some psychometric properties of the questions about behavioral function (QABF) scale. *Res Dev Disabil.* 2006;27(3):337-352.
19. Matson JL, Tureck K, Rieske R. The Questions About Behavioral Function (QABF): current status as a method of functional assessment. *Res Dev Disabil.* 2012;33(2):630-634.
20. Thompson RH, Iwata BA. A comparison of outcomes from descriptive and functional analyses of problem behavior. *J Appl Behav Anal.* 2007;40(2):333-338.
21. Beavers GA, Iwata BA, Lerman DC. Thirty years of research on the functional analysis of problem behavior. *J Appl Behav Anal.* 2013;46(1):1-21.
22. Jennett H, Jann K, Hagopian LP. Evaluation of response blocking and re-presentation in a competing stimulus assessment. *J Appl Behav Anal.* 2011;44(4):925-929.
23. Carr JE, Severtson JM, Lepper TL. Noncontingent reinforcement is an empirically supported treatment for problem behavior exhibited by individuals with developmental disabilities. *Res Dev Disabil.* 2009;30(1):44-57.
24. Richman DM, Barnard-Brak L, Grubb L, et al. Meta-analysis of noncontingent reinforcement effects on problem behavior. *J Appl Behav Anal.* 2015;48(1):131-152.
25. Piazza CC, Adelinis JD, Hanley GP, et al. An evaluation of the effects of matched stimuli on behaviors maintained by automatic reinforcement. *J Appl Behav Anal.* 2000;33(1):13-27.
26. Kurtz PF, Chin MD, Huete JM, et al. Functional analysis and treatment of self-injurious behavior in young children a summary of 30 cases. *J Appl Behav Anal.* 2003;36(2):205-219.



27. Greer BD, Fisher WW, Saini V, et al. Functional communication training during reinforcement schedule thinning: An analysis of 25 applications. *J Appl Behav Anal.* 2016;49(1):105-121.
28. Hagopian LP, Adelinis JD. Response blocking with and without redirection for the treatment of pica. *J Appl Behav Anal.* 2001;34(4):527-530.
29. Falcomata TS, Roane HS, Hovanetz AN, et al. An evaluation of response cost in the treatment of inappropriate vocalizations maintained by automatic reinforcement. *J Appl Behav Anal.* 2004;37(1):83-87.
30. Fisher WW, Thompson RH, Hagopian LP, et al. Facilitating tolerance of delayed reinforcement during functional communication training. *Behav Modif.* 2000;24(1):3-29.
31. Stokes TF, Baer DM. An implicit technology of generalization. *J Appl Behav Anal.* 1977;10(2):349-367.
32. Miles NI, Wilder DA. The effects of behavioral skills training on caregiver implementation of guided compliance. *J Appl Behav Anal.* 2009;42(2):405-410.

OTİZM SPEKTRUM BOZUKLUĞUNDA DİL VE İLETİŞİM BOZUKLUKLARI: TANI VE TEDAVİ

Yunus Emre DÖNMEZ¹
Serkan KIRIK²

GİRİŞ

Otizm spektrum bozukluğu (OSB); sosyal ilişki, iletişim ve bilişsel gelişimde gecikme ya da sapma ile kendini gösteren ve genellikle yaşamın ilk yıllarında başlayan nöropsikiyatrik bir bozukluk olup dil ve iletişim becerilerindeki sorunlar hastalığın ana belirti kümesini oluşturmaktadır.¹

Kavram olarak dil, iletişim kurulmasına olanak sağlayan kurallar ve semboller sistemidir.² İletişim ise en önemli unsurunu dil becerilerinin oluşturduğu, düşünceleri, duyguları ve fikirleri anlamada ve ifade etmede kullanılan tüm becerilerin koordineli kullanımını gerektiren bireyler arasındaki sosyal etkileşim biçimidir.^{3,4}

Sağlıklı çocuklarda 0-6 yaş aralığında dil gelişimi dört temel aşamada gelişmektedir.

1. Söz Öncesi/Konuşma Öncesi Dönem (0-12 ay): Bebeklerin başlarda refleks olarak sonrasında ise iletişim kurmak amacıyla çıkardıkları ilk temel seslerin olduğu dönemdir. Bu dönem kendi içerisinde yenidoğan dönemi (0-2 ay), gıgıldama dönemi (2-4 ay), mırıldanma dönemi (4-6 ay), mırıldanmanın tekrarı dönemi (7-9 ay), başkalarının seslerini taklit dönemi (9-11 ay) ve ses-sözcükler dönemi (11-14 ay) olmak üzere sınıflandırılabilir.
2. Konuşma Dönemi (12-24 ay): Sözcük üretmenin ve konuşmanın başladığı

¹ Doç. Dr., İnönü Üniversitesi Tıp Fakültesi, Çocuk Psikiyatrisi AD., yunus.donmez@inonu.edu.tr, ORCID iD: 0000-0002-7785-2805

² Doç. Dr., SBÜ Elazığ Fethi Sekin Şehir Hastanesi, Çocuk Nöroloji Kliniği, srknkrk@hotmail.com, ORCID iD: 0000-0002-8658-2448



mektedir. Bu nedenle, çocukların daha zengin bir dil ortamına maruz kalması, daha iyi dil becerileri geliştirmelerine katkı sağlar.

OSB olan çocukların, kelime öğrenme ortamında tipik olarak mevcut olan sosyal-pragmatik ipuçlarını kullanma yetisinde ciddi şekilde zorlandığı bilinmektedir. Müdahale için bir yaklaşım, çocuğun dikkat ve motivasyon süreçlerini geliştirerek, sosyal ipuçlarını daha iyi kullanmasını sağlamak olabilir. Ancak sosyal-pragmatik yaklaşım, bu çocuklarda dil öğrenimini iyileştirmenin başka bir önemli yolunun çevreyi yeniden düzenleyerek, çocuğun erişebileceği sosyal ipuçlarını daha belirgin hale getirmek olduğunu öne sürer. Bu nedenle, müdahale araştırmalarının yalnızca çocuğa değil, onun içinde bulunduğu çevreye de odaklanması gerekir. Buradaki amaç, çocuğun öğrenmesini daha verimli destekleyen ince ayarlı etkileşimlerin nasıl sağlanabileceğini belirlemektir.

Bu tür müdahaleler, ebeveynlerin çocuklarının gelişen becerilerine sürekli olarak uyum sağlamasını öğretmeyi içerebilir. Örneğin, ebeveynler kelime anlamlarını öğrenmede giderek genişleyen bir sosyal-pragmatik ipucu yelpazesine odaklanarak çocuklarına rehberlik edebilirler.

KAYNAKLAR

1. Demir AÇ. Otizm Spektrum Bozukluğu. Özcan Ö (ed.) Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları içinde. Malatya: İnönü Üniversitesi Yayınevi; 2018. p. 109-116
2. Harley TA. The Psychology of Language From Data to Theory. 3th ed. NY: Psychology Press; 2008.
3. McLaughlin S. Introduction to Language Development. Canada: Thomson Delmar Learning; 2005.
4. Diken Ö. Otizm spektrum bozukluğu: İletişim ve dil. Ankara: Pegem Akademi Yayıncılık; 2020.
5. Bleile KM. Manual of articulation and phonological disorders: Infancy through adulthood. United States: Cengage Learning, Inc.; 2004.
6. Owens RE. Language development: An introduction. 7th ed. New York: Pearson International Edition; 2008.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
8. Zeanah CH. Infant-parent relationship assessment. Zeanah CH (ed.), In: Handbook of infant mental health. New York: Guilford Press; 2000. p. 222-235.
9. Lord C, Rutter M, DiLavore P, et al. Autism diagnostic observation schedule. 2nd ed. Los Angeles (CA): Western Psychological Services; 2012.
10. Rutter M, Le Couteur A, Lord C. Autism diagnostic interview-revised. Los Angeles (CA): Western Psychological Services; 2003.
11. Schopler E, Reichler RJ, Renner BR. CARS: childhood autism rating scale. Los Angeles (CA): Western Psychological Services; 1988.



12. Sparrow SS, Balla DA, Cicchetti DV. Vineland adaptive behavior scales (survey form). Circle Pines (MN): American Guidance Service; 1984.
13. Savaşır I, Sezgin N, Erol N. Ankara gelişim tarama envanteri. 1st ed. Ankara: Türk Psikologlar Derneği; 1994.
14. Anlar B, Bayoğlu BU, Yalaz K. Denver II gelişimsel tarama testi: Türk çocuklarına uyarlanması ve standardizasyonu. Ankara: Gelişimsel Çocuk Nörolojisi Derneği; 2009.
15. National Institute for Health and Care Excellence. Autism: The management and support of children and young people on the autism spectrum [Internet]. London: NICE; 2013 [cited 2025 Feb 25]. Available from: <http://guidance.nice.org.uk>
16. Myers SM, Johnson CP, Council on Children with Disabilities. Management of children with autism spectrum disorders. Pediatrics. 2007;120(5): 1162-1182.
17. Agency for Healthcare Research and Quality. Quality indicators [Internet]. Rockville (MD): AHRQ; 2011 [cited 2025 Feb 25]. Available from: <http://www.qualityindicators.ahrq.gov>
18. Le Couteur A, Szatmari P. Autism spectrum disorder. Thapar A, Pine DS, Leckman JF, Scott S, Snowling MJ, Taylor E (editors), In: Rutter's child and adolescent psychiatry. 6th ed. Chichester: John Wiley & Sons; 2015. p. 674-687.
19. Lovaas OI. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol. 1987;55(1): 3-9.
20. Case-Smith J, Arbesman M. Evidence-based review of interventions for autism used in or of relevance to occupational therapy. Am J Occup Ther. 2008;62(4): 416-429.
21. Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. PLoS Med. 2011;8(1): e1000393.
22. Virues-Ortega J, Julio FM, Pastor-Barriuso R. The TEACCH program for children and adults with autism: a meta-analysis of intervention studies. Clin Psychol Rev. 2013;33(8): 940-953.
23. Reichow B, Volkmar FR. Social skills interventions for individuals with autism: evaluation for evidence-based practices within a best evidence synthesis framework. J Autism Dev Disord. 2010;40(2): 149-166.

OTİZMDE DİYET VE BESLENME

Gamze YURTDAS DEPBOYLU¹
Gülşah KANER²

GİRİŞ

Dünya Sağlık Örgütü'ne (DSÖ) göre otizm spektrum bozukluğu (OSB) yaklaşık olarak her 100 çocuktan 1'ini etkilemekte ve tipik olarak yaşamın ilk beş yılı içerisinde teşhis edilmektedir.¹ Günümüzde OSB'ye yönelik tedaviler temel olarak erken dönemde psikososyal müdahaleler ve farmakolojik müdahalelere odaklanmaktadır. Ancak, OSB'li çocukların erken gelişim dönemlerinde bu tedavilerle yoğun bir şekilde müdahale edilmesine rağmen, bazı semptomlar üzerindeki faydalı etkiler anlamlı değildir. Bu nedenle, aileler diyet müdahaleleri gibi alternatif tedaviler aramaktadır.²

OSB'li çocuklar arasında beslenme sorunları yaygındır. Bu çocuklar genellikle anormal yeme alışkanlıkları ile doku, renk, koku, kıvam ve tada dayalı seçicilik de dâhil olmak üzere besine karşı duyuşal hassasiyet sergileyebilmektedir.³ Bunun yanı sıra, OSB'li çocuklarda bağırsak geçirgenliğinde artış, değişmiş mikrobiyota, intestinal inflamasyon, mikrobiyal çoğalma, aminoasit dengesizliği, oksidatif stres, karbonhidrat sindirim enzimi aktivitesinin azlığı gibi gastro-intestinal sisteme ilişkin sorunlar da bildirilmiştir.⁴ Literatürde ketojenik diyet, glutensiz-kazeinsiz diyet, spesifik karbonhidrat diyeti, Feingold diyeti, Candida vücut ekoloji diyetinin yanı sıra probiyotikler, çoklu doymamış yağ asitleri, A, C, B6, B12 vitaminleri, magnezyum ve folat takviyelerinin OSB'nin yönetiminde

¹ Doç. Dr., İzmir Katip Çelebi Üniversitesi, Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, gmzyurtdas@hotmail.com, ORCID iD: 0000-0001-5410-7231

² Prof. Dr., İzmir Katip Çelebi Üniversitesi, Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, kanergulsah@gmail.com, ORCID iD: 0000-0001-5882-6049



ta-analizde omega-3 yağ asidinin 8 yaşında veya daha küçük OSB'li çocuklarda konuşma bozukluğu ve hiperaktiviteyi kontrol etmek için faydalı bir takviye olabileceğini ortaya koymuştur.⁴⁵ Genellikle yapılan çalışmalarda, omega-3 takviyesinin OSB'nin belirli davranışsal semptomlarını yönetmede umut vaat ettiği gösterilmiştir. Ancak, OSB'nin heterojenliği, omega-3 takviyesine farklı yanıtlar verilmesine katkıda bulunmakta ve fayda sağlama olasılığı en yüksek olan alt grupların belirlenmesini gerekli kılmaktadır. İdeal EPA/DHA oranı ve dozu belirsizliğini korumakta olup, çalışmalarda günde 300 mg ile 2000 mg arasında değişen dozlar kullanılmaktadır. Omega-3 yağ asitleri, OSB'nin belirli semptomlarını ele almak için güvenli ve erişilebilir bir müdahale olarak umut vaat etmektedir. Daha fazla yüksek kaliteli araştırma ile takviye, kişiselleştirilmiş tedavi stratejilerinin değerli bir bileşeni haline gelebilir.³⁸

KAYNAKLAR

1. World Health Organization. Autism spectrum disorders [Internet]. Geneva: World Health Organization; 2023 [cited 2025 Mar 11]. Available from: <https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorder>
2. Quan L, Xu X, Cui Y, Han H, Hendren RL, Zhao L, et al. A systematic review and meta-analysis of the benefits of a gluten-free diet and/or casein-free diet for children with autism spectrum disorder. *Nutr Rev.* 2022;80:1237-46.
3. Esposito M, Mirizzi P, Fadda R, Pirollo C, Ricciardi O, Mazza M, et al. Food Selectivity in Children with Autism: Guidelines for Assessment and Clinical Interventions. *Int J Environ Res Public Health.* 2023;20:5092
4. Naralan Y. Otizm Spektrum Bozukluğunda Beslenme ve Diyet Yaklaşımları. In: Hocaoglu Ç, editor. *Nütrisyonel Psikiyatri: Beslenme ile Ruh Sağlığını İyileştirmeye Doğru*. Ankara: Türkiye Klinikleri; 2024. p. 94-100.
5. Karhu E, Zukerman R, Eshraghi RS, Mittal J, Deth RC, Castejon AM, et al. Nutritional interventions for autism spectrum disorder. *Nutr Rev.* 2023;26:130-41.
6. Pinto-Silva R, Nunes Costa AM, Tello-Rodrigues I. Feeding problems in children with autism spectrum disorders: a systematic review. *Speech, Language and Hearing.* 2023;26(2):130-41.
7. Pérez-Cabral ID, Bernal-Mercado AT, Islas-Rubio AR, Suárez- Jiménez GM, Robles-García M, Puebla-Duarte AL, et al. Exploring Dietary Interventions in Autism Spectrum Disorder. *Foods.* 2024;13.
8. Adıye Gülçin SC, Cansu Ö Z. A Traditional Review of the Role of Nutrition in the Autism Spectrum Disorder. *Türkiye Klin Saglik Bilim Derg.* 2021;6:965-72.
9. Baraskewich J, von Ranson KM, McCrimmon A, McMorris CA. Feeding and eating problems in children and adolescents with autism: A scoping review. *Autism.* 2021;25:1505-19.
10. Marí-Bauset S, Zazpe I, Mari-Sanchis A, LlopisGonzález A, Morales-Suárez-Varela M. Food selectivity in autism spectrum disorders: a systematic review. *j Child Neurol.* 2014;29:1554-61.
11. Batu Z, Akhalil M, Çiftçi S. Nutrition Therapy Approaches in Children with Autism Spectrum Disorder. *Farabi Tip Derg.* 2023;2:33-42.



12. Narzisi A, Masi G, Grossi E. Nutrition and Autism Spectrum Disorder: Between False Myths and Real Research-Based Opportunities. *Nutrients*. 17;13:2068.
13. Curtin C, Anderson SE, Must A, Bandini L. The prevalence of obesity in children with autism: a secondary data analysis using nationally representative data from the National Survey of Children's Health. *BMC Pediatr*. 2010;10:11.
14. Wang L, Shen W, Yao H, Zheng R, Chen W, Zhang W. Association between Autism Spectrum Disorder and Food Allergy: A Systematic Review and Meta-analysis. *Autism Research*. 2021;14:220-230.
15. Bakırhan H. Otizm Spektrum Bozukluğunda Tıbbi Beslenme Tedavisi. Vakalarla Öğreniyorum: Çocuk Hastalıklarında Tıbbi Beslenme Tedavisi-3. Şanlıer N (editör) Ankara: Hedef CS Basın Yayın 2020: 308-339.
16. Sönmez D HÇ. Nütrisyonel Psikiyatri: Beslenme ile Ruh Sağlığını İyileştirmeye Doğru. In: Ç. H, editor. Beslenme ve ruh sağlığı Ankara: Türkiye Klinikleri; 2024. p. 1-8.
17. Varesio C, Grumi S, Zanaboni MP, Mensi MM, Chiappedi M, Pasca L, et al. Ketogenic Dietary Therapies in Patients with Autism Spectrum Disorder: Facts or Fads? A Scoping Review and a Proposal for a Shared Protocol. *Nutrients*. 2021;13:2057.
18. Albers J, Kraja G, Eller D, Eck K, McBrien D, Bain JM. Assessing the feasibility of using the ketogenic diet in autism spectrum disorder. *J Hum Nutr Diet*. 2023;36:1303-1315.
19. Lim JM, Letchumanan V, Tan LT, Hong KW, Wong SH, Ab Mutalib NS, et al. Ketogenic Diet: A Dietary Intervention via Gut Microbiome Modulation for the Treatment of Neurological and Nutritional Disorders (a Narrative Review). *Nutrients*. 2022; 14:3566.
20. Mentzelou M, Dakanalis A, Vasios GK, Gialeli M, Papadopoulou SK, Giaginis C. The Relationship of Ketogenic Diet with Neurodegenerative and Psychiatric Diseases: A Scoping Review from Basic Research to Clinical Practice. *Nutrients*. 2023;15:2270.
21. Kim DY, Simeone KA, Simeone TA, Pandya JD, Wilke JC, Ahn Y, et al. Ketone bodies mediate antiseizure effects through mitochondrial permeability transition. *Ann Neurol*. 2015;78:77-87.
22. Alam S, Westmark CJ, McCullagh EA. Diet in treatment of autism spectrum disorders. *Front Neurosci*. 2022;16:1031016.
23. Öztürk E, Aslan Çin NN, Cansu A, Akyol A. Ketogenic diet as a therapeutic approach in autism spectrum disorder: a narrative review. *Metab Brain Dis*. 2024;40:67.
24. Doenyaş C. Dietary interventions for autism spectrum disorder: New perspectives from the gut-brain axis. *Physiol Behav*. 2018;194:577-82.
25. Trivedi MS, Shah JS, Al-Mughairy S, Hodgson NW, Simms B, Trooskens GA, et al. Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. *J Nutr Biochem*. 2014;25:1011-1018.
26. Ramaekers VT, Sequeira JM, Blau N, Quadros EV. A milk-free diet downregulates folate receptor autoimmunity in cerebral folate deficiency syndrome. *Dev Med Child Neurol*. 2008;50:346-352.
27. Williams BL, Hornig M, Buie T, Bauman ML, Cho Paik M, Wick I, et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. *PLoS One*. 2011;6:e24585.
28. Barnhill K, Devlin M, Moreno HT, Potts A, Richardson W, Schutte C, et al. Brief Report: Implementation of a Specific Carbohydrate Diet for a Child with Autism Spectrum Disorder and Fragile X Syndrome. *J Autism Dev Disord*. 2020;50:1800-1808.
29. Ābele S, Meija L, Folkmanis V, Tzivian L. Specific carbohydrate diet and dietary supplements for children with autistic spectrum disorder. *Proc Latv Acad Sci B Nat Exact Appl Sci*. 2021;75:417-425.
30. Matthews JS, Adams JB. Ratings of the Effectiveness of 13 Therapeutic Diets for Autism Spectrum Disorder: Results of a National Survey. *J Pers Med*. 2023;13:1448



31. Ozgur EG, Balci S. Might the fungus candida albicans a risk factor for autism? A meta-analysis study. *Afr Health Sci.* 2023;23:230-235.
32. Herman A, Herman AP. Could Candida Overgrowth Be Involved in the Pathophysiology of Autism? *J Clin Med.* 2022;11:442
33. Önal S, Sachadyn-Król M, Kostecka M. A Review of the Nutritional Approach and the Role of Dietary Components in Children with Autism Spectrum Disorders in Light of the Latest Scientific Research. *Nutrients.* 2023;15:4852
34. Adams JB, Kirby J, Audhya T, Whiteley P, Bain J. Vitamin/mineral/micronutrient supplement for autism spectrum disorders: a research survey. *BMC Pediatr.* 2022;22:590.
35. Khan F, Rahman MS, Akhter S, Momen ABI, Raihan SG. Vitamin B6 and magnesium on neurobehavioral status of autism spectrum disorder: a randomized, double-blind, placebo controlled study. *Bangladesh Journal of Medicine.* 2021;32:12-18.
36. Li B, Xu Y, Zhang X, Zhang L, Wu Y, Wang X, et al. The effect of vitamin D supplementation in treatment of children with autism spectrum disorder: a systematic review and meta-analysis of randomized controlled trials. *Nutr Neurosci.* 2022;25:835-845.
37. Raghavan R, Riley AW, Volk H, Caruso D, Hironaka L, Sices L, et al. Maternal Multivitamin Intake, Plasma Folate and Vitamin B(12) Levels and Autism Spectrum Disorder Risk in Offspring. *Paediatr Perinat Epidemiol.* 2018;32:100-111.
38. Długosz A, Wróblewski M, Błaszczak B, Szulc J. The Role of Nutrition, Oxidative Stress, and Trace Elements in the Pathophysiology of Autism Spectrum Disorders. *Int J Mol Sci.* 2025;26:808
39. Zhang S, Han F, Wang Q, Fan F. Probiotics and Prebiotics in the Treatment of Autism Spectrum Disorder: A Narrative Review. *J Integr Neurosci.* 2024;23:20.
40. Meguid NA, Mawgoud YIA, Björklund G, Mehanne NS, Anwar M, Effat BAE, et al. Molecular Characterization of Probiotics and Their Influence on Children with Autism Spectrum Disorder. *Mol Neurobiol.* 2022;59:6896-6902.
41. Shaaban SY, El Gendy YG, Mehanna NS, El-Senousy WM, El- Feki HSA, Saad K, et al. The role of probiotics in children with autism spectrum disorder: A prospective, open-label study. *Nutr Neurosci.* 2018;21:676-681.
42. Grimaldi R, Gibson GR, Vulevic J, Giallourou N, Castro-Mejía JL, Hansen LH, et al. A prebiotic intervention study in children with autism spectrum disorders (ASDs). *Microbiome.* 2018;6:133.
43. Jiang Y, Dang W, Nie H, Kong X, Jiang Z, Guo J. Omega-3 polyunsaturated fatty acids and/or vitamin D in autism spectrum disorders: a systematic review. *Front Psychiatry.* 2023;14:1238973.
44. Doaei S, Bourbour F, Teymoori Z, Jafari F, Kalantari N, Abbas Torki S, et al. The effect of omega-3 fatty acids supplementation on social and behavioral disorders of children with autism: a randomized clinical trial. *Pediatr Endocrinol Diabetes Metab.* 2021;27:12-18.
45. Abbasi H, Parhiz A, Khoshdooz S, Bakhshimoghaddam F, Doaei S, Gholamalizadeh M. Impact of omega-3 fatty acid supplementation on clinical manifestations in autism spectrum disorders: an umbrella review of meta-analyses. *Nutr Res Rev.* 2025;38:546-557.

OTİZM SPEKTRUM BOZUKLUĞU OLGULARINDA YAŞAM KALİTESİ

*Fatma Duygu ÖZTÜRK ÖNSAL¹
Nilüfer ELDEŞ HACİFAZLIOĞLU²
Şaziye Senem BAŞGÜL³*

GİRİŞ

Yaşam kalitesi (YK) Yunan filozofları Platon ve Aristo'dan itibaren irdelenen bir olgudur ve toplumların ulaşmayı amaçladığı en önemli evrensel hedeflerden birisidir. Dünya Sağlık Örgütü (WHO) tarafından 'Bireyin yaşamdaki konumunu yaşadıkları kültür ve değer sistemleri bağlamında hedefleri, beklentileri ve endişelerine göre algılaması olarak' tanımlanmıştır.¹ YK kavramı, yalnızca bireyin refahını artırmaya yönelik bir rehber sunmakla kalmaz, aynı zamanda insanların olumlu değişimler yapmak için iş birliği yapmasını sağlayan ortak bir dil işlevi de görür.² YK fiziksel, psikolojik ve sosyal bileşenlerin, bireysel özellikler ve çevresel değişkenler tarafından etkilendiği çok boyutlu bir kavramdır. Bu nedenle bireylerin fiziksel sağlığı, psikolojik durumu, bağımsızlık düzeyi, sosyal ilişkileri, kişisel inançları ve çevrenin belirgin özellikleriyle olan ilişkileri YK'ini değerlendirirken dikkate alınmalıdır.³

OSB spektrum bozukluğu (OSB), sözel ya da sözel olmayan iletişimde zorluk, sosyal etkileşimde bozukluk ile tekrarlayıcı davranışlar ve kısıtlı ilgi alanı ile karakterize nörogelişimsel bir bozukluktur.^{3,4} OSB'ye epilepsi nöbeti, dikkat eksikliği ve hiperaktivite, davranış, beslenme ve uyku bozuklukları eşlik edebilir.

¹ Dr., Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi, drduyguozturkconsal@gmail.com, ORCID iD: 0000-0002-7816-5089

² Doç. Dr., Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi, niluferhacifazlioglu@gmail.com, ORCID iD: 0000-0001-8828-8587

³ Prof. Dr., Hasan Kalyoncu Üniversitesi, Psikoloji Bölümü, senembasgul@gmail.com, ORCID iD: 0000-0002-5205-0275



SONUÇ

“İyi bir YK herkes için temel bir hak olup gerçekçi ve ulaşılabilir bir hedeftir”. Bu bireylerin yaşam kalitesini iyileştirmek için, YK üzerinde olumlu ve olumsuz etkisi olan faktörleri bilmemiz gerekmektedir. Ailelerin bilinçlendirilmesi, çocuklarının ihtiyaçlarını daha iyi anlamalarına ve onlara daha iyi destek olmalarına yardımcı olacaktır. Ebeveynlerin stres yönetimi ve başa çıkma mekanizmaları konusunda desteklenmesi, ailenin genel refahını artıracaktır. OSB’li çocukların ve ailelerinin yaşam kalitesini artırmak için, bireysel ve toplumsal desteklerin güçlendirilmesi önemlidir. Okul, iş yeri ve sosyal alanlarda hem ebeveynlerin hem de çocukların refahını artıracak kapsayıcı politikalar ve destek sistemleri, bu ailelerin yaşamlarını daha sürdürülebilir hale getirebilir ve yaşam kalitelerini artırılabilir. Destek hizmetleri, farklı yaş seviyelerindeki değişen ihtiyaçlarını karşılayacak şekilde uyarlanmalıdır. Toplumların OSB konusunda bilinçlendirilmesi çocukların ev, okul ve sosyal yaşamda daha fazla kabul görmelerini ve sosyal hayata daha kolay uyum sağlamalarını destekleyerek OSB’li çocukların kendi potansiyellerini gerçekleştirmelerine, bağımsızlık kazanmalarına, sosyal becerilerini geliştirmelerine, kendilerinin ve ailelerinin yaşam kalitelerinin artmasına katkı sağlayacaktır. Tüm bunlarla birlikte toplumsal refahımız da artacaktır.

KAYNAKLAR

1. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res. 1993 Apr;2(2):153-9. PMID: 8518769.
2. Hong J, Bishop-Fitzpatrick L, Smith LE, Greenberg JS, Mailick MR. Factors Associated with Subjective Quality of Life of Adults with Autism Spectrum Disorder: Self-Report Versus Maternal Reports. J Autism Dev Disord. 2016 Apr;46(4):1368-78. doi: 10.1007/s10803-015-2678-0. PMID: 26707626; PMCID: PMC4788526.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. American Psychiatric Publishing, 2013. DSM-5, doi-org.db29.lincweb.org/10.1176/appi.
4. Mesibov G, Shea V, Schopler E, Adams L, Merkler E, Burgess S, Mosconi M, Chapman S, Tanner C, Bourgondien M. (2004). The Culture of Autism. 10.1007/978-0-306-48647-0_3.
5. Bent S, Wahlberg J, Chen Y, Widjaja F, McDonald MG, Hendren RL. Quality of Life Among School-Age Children With Autism: The Oak Hill School Outcomes Study. Semin Pediatr Neurol. 2020 Jul;34:100808. doi: 10.1016/j.spen.2020.100808. Epub 2020 Mar 5. PMID: 32446439.
6. Vasilopoulou E, Nisbet J. (2016). The quality of life of parents of children with autism spectrum disorder: A systematic review. Research in Autism Spectrum Disorders. 23. 10.1016/j.rasd.2015.11.008.



7. Emerson E. Mothers of children and adolescents with intellectual disability: social and economic situation, mental health status, and the self-assessed social and psychological impact of the child's difficulties. *J Intellect Disabil Res.* 2003 May-Jun;47(Pt 4-5):385-99. doi: 10.1046/j.1365-2788.2003.00498.x. PMID: 12787168.
8. Gray D, Holden W. (2009). Psycho-social well-being among parents of children with autism. *Journal of Intellectual and Developmental Disability.* 18. 83-93. 10.1080/07263869200034841.
9. Hyman SL, Levy SE, Myers SM; Council on Children with Disabilities, Section on Developmental and Behavioral Pediatrics. Executive Summary: Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. *Pediatrics.* 2020 Jan;145(1):e20193448. doi: 10.1542/peds.2019-3448. Epub 2019 Dec 16. PMID: 31843858.
10. Güller B, Yaylacı F. Otizm Spektrum Bozukluğu Tanılı Çocukların Ebeveynlerinde Yaşam Kalitesi, Kaygı, Depresyon Düzeyleri ve İlişkili Faktörler. *Uludağ Tıp Derg.* Eylül 2022;48(2):217-224. doi:10.32708/uutfd.1124107
11. Wehmeyer ML (ed.), *The Oxford Handbook of Positive Psychology and Disability*, Oxford Library of Psychology (2013; online edn, Oxford Academic, 16 Dec. 2013), doi.org/10.1093/oxfordhb/9780195398786.001.0001
12. Unwin G, Deb S. Caregiver's concerns-quality of life scale (CC-QoLS): development and evaluation of psychometric properties. *Res Dev Disabil.* 2014 Oct;35(10):2329-40. doi: 10.1016/j.ridd.2014.05.018. Epub 2014 Jun 19. PMID: 24952373.
13. Kapp SK. Social Support, Well-being, and Quality of Life Among Individuals on the Autism Spectrum. *Pediatrics.* 2018 Apr;141(Suppl 4):S362-S368. doi: 10.1542/peds.2016-4300N. PMID: 29610418.
14. Ravens-Sieberer U, Gosch A, Rajmil L, Erhart M, Bruil J, Duer W, Auquier P, Power M, Abel T, Czemy L, Mazur J, Czimbalmo A, Tountas Y, Hagquist C, Kilroe J, KIDSCREEN Group E. KIDSCREEN-52 quality-of-life measure for children and adolescents. *Expert Rev Pharmacoecon Outcomes Res.* 2005 Jun;5(3):353-64. doi: 10.1586/14737167.5.3.353. PMID: 19807604.
15. Sparrow SS, Cicchetti DV, Balla DA. (2005). *Vineland adaptive behavior scales* (2nd ed.). Circle Pines, MN: American Guidance Service.
16. Harrison P, Oakland T. *Adaptive Behavior Assessment System, Third Edition (ABAS-3)*. Western Psychological Services.
17. Bronfenbrenner U. *The Ecology of Human Development: Experiments by Nature and Design*. Cambridge, MA: Harvard University Press. ISBN 0-674-22457-4.
18. Ricon T, Sorek R, Engel-Yeger B. (2017). Association between Sensory Processing by Children with High Functioning Autism Spectrum Disorder and their Daily Routines. *OJOT: The Open Journal of Occupational Therapy.* 5. 10.15453/2168-6408.1337.
19. Bundy AC, Shia S, Qi L, Miller LJ. How does sensory processing dysfunction affect play? *Am J Occup Ther.* 2007 Mar-Apr;61(2):201-8. doi: 10.5014/ajot.61.2.201. PMID: 17436842.
20. Hayes SA, Watson SL. The impact of parenting stress: a meta-analysis of studies comparing the experience of parenting stress in parents of children with and without autism spectrum disorder. *J Autism Dev Disord.* 2013 Mar;43(3):629-42. doi: 10.1007/s10803-012-1604-y. PMID: 22790429.
21. Yazıcı KU. (2020). Otizm Spektrum Bozukluğu Tanılı Olguların Tipik Gelişim Gösteren Kardeşlerinde Depresif Özellikler ve Yaşam Kalitesinin Değerlendirilmesi: Tedavinin Kardeşlerdeki Bulgular Üzerine Etkisi. *Fırat Tıp Dergisi*, 25(1), 23-33.
22. Case-Smith J, Weaver L, Fristad M. (2014). A systematic review of sensory processing interventions for children with autism spectrum disorders. *Autism*, 19(2), 133-148. https://doi.org/10.1177/1362361313517762
23. Ahmed S, Waseem H, Sadaf A, Ashiq R, Basit H, Rose S. (2021). Daily Living Tasks Affected by Sensory and Motor Problems in Children with Autism Aged 5-12 Years. 92. 10.7176/JHMN/92-02.



24. Parham L. (1998). The Relationship of Sensory Integrative Development to Achievement in Elementary Students: Four-Year Longitudinal Patterns. *OTJR: Occupation, Participation and Health*. 18. 105-127. 10.1177/153944929801800304.
25. Beighley J, Matson J, Rieske R, Adams H. (2013). Food selectivity in children with and without an autism spectrum disorder: Investigation of diagnosis and age. *Research in developmental disabilities*. 34. 3497-3503. 10.1016/j.ridd.2013.07.026.
26. Baraskewich J, von Ranson KM, McCrimmon A, McMorris CA. Feeding and eating problems in children and adolescents with autism: A scoping review. *Autism*. 2021 Aug;25(6):1505-1519. doi: 10.1177/1362361321995631. Epub 2021 Mar 2. PMID: 33653157; PMCID: PMC8323334.
27. Kodak T, Piazza CC. Assessment and behavioral treatment of feeding and sleeping disorders in children with autism spectrum disorders. *Child Adolesc Psychiatr Clin N Am*. 2008 Oct;17(4):887-905, x-xi. doi: 10.1016/j.chc.2008.06.005. PMID: 18775376.
28. Bandini LG, Anderson SE, Curtin C, Cermak S, Evans EW, Scampini R, Maslin M, Must A. Food selectivity in children with autism spectrum disorders and typically developing children. *J Pediatr*. 2010 Aug;157(2):259-64. doi: 10.1016/j.jpeds.2010.02.013. Epub 2010 Apr 1. PMID: 20362301; PMCID: PMC2936505.
29. American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.
30. Souders MC, Mason TB, Valladares O, Bucan M, Levy SE, Mandell DS, Weaver TE, Pinto-Martin J. Sleep behaviors and sleep quality in children with autism spectrum disorders. *Sleep*. 2009 Dec;32(12):1566-78. doi: 10.1093/sleep/32.12.1566. PMID: 20041592; PMCID: PMC2786040.
31. Verhoeff ME, Blanken LME, Kocevskaja D, Mileva-Seitz VR, Jaddoe VWV, White T, Verhulst F, Luijk MPCM, Tiemeier H. The bidirectional association between sleep problems and autism spectrum disorder: a population-based cohort study. *Mol Autism*. 2018 Jan 30;9:8. doi: 10.1186/s13229-018-0194-8. PMID: 29423134; PMCID: PMC5791216.
32. Uren J, Richdale AL, Cotton SM, Whitehouse AJO. (2019). Sleep problems and anxiety from 2 to 8 years and the influence of autistic traits: a longitudinal study. *Eur Child Adolesc Psychiatry* 28:1117-1127. 10.1007/s00787-019-01275-y
33. Cevher Z, Kurnaz E. (2024). Otizm Spektrum Bozukluğu Olan Çocuklarda Duyusal İşleme Bozuklukları. *Cumhuriyet Uluslararası Eğitim Dergisi*, 13(3), 710-723. <https://doi.org/10.30703/cije.1437401>
34. Malow BA, Katz T, Reynolds AM, Shui A, Carno M, Connolly HV, Coury D, Bennett AE. Sleep Difficulties and Medications in Children With Autism Spectrum Disorders: A Registry Study. *Pediatrics*. 2016 Feb;137 Suppl 2:S98-S104. doi: 10.1542/peds.2015-2851H. PMID: 26908483.
35. Cortesi F, Giannotti F, Ivanenko A, Johnson K. Sleep in children with autistic spectrum disorder. *Sleep Med*. 2010 Aug;11(7):659-64. doi: 10.1016/j.sleep.2010.01.010. Epub 2010 Jul 4. PMID: 20605110.
36. Doo S, Wing YK. Sleep problems of children with pervasive developmental disorders: correlation with parental stress. *Dev Med Child Neurol*. 2006 Aug;48(8):650-5. doi: 10.1017/S001216220600137X. PMID: 16836776.
37. Ebisawa T. Circadian rhythms in the CNS and peripheral clock disorders: human sleep disorders and clock genes. *J Pharmacol Sci*. 2007 Feb;103(2):150-4. doi: 10.1254/jphs.fmj06003x5. Epub 2007 Feb 14. PMID: 17299246.
38. Birleşmiş Milletler Çocuk Haklarına Dair Sözleşmesi - 1989/unicetfuk.org
39. Buie T, Campbell DB, Fuchs GJ 3rd, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. *Pediatrics*. 2010 Jan;125 Suppl



- 1:S1-18. doi: 10.1542/peds.2009-1878C. PMID: 20048083.
40. Tuchman R, Cuccaro M, Alessandri M. Autism and epilepsy: historical perspective. *Brain Dev.* 2010 Oct;32(9):709-18. doi: 10.1016/j.braindev.2010.04.008. Epub 2010 May 26. PMID: 20510557.
 41. Romero M, Aguilar JM, Del-Rey-Mejías Á, Mayoral F, Rapado M, Peciña M, et al. Psychiatric comorbidities in autism spectrum disorder: a comparative study between DSM-IV-TR and DSM-5 diagnosis. *Int J Clin Heal Psychol.* (2016) 16:266-75. doi: 10.1016/j.ijchp.2016.03.001
 42. Kurth JA. (2015). Educational Placement of Students With Autism: The Impact of State of Residence. *Focus on Autism and Other Developmental Disabilities*, 30(4), 249-256. <https://doi.org/10.1177/1088357614547891>
 43. Resmi Gazete, 7 Temmuz 2018, Sayı: 30471; Kanun Numarası: 5378, 1/7/2005, Sayı: 25868, Cilt: 44.
 44. Arslan A, Ulaş AH, Coşkun MK. (2020). Özel Eğitimde Aile Eğitimine Yönelik Bir Derleme Çalışması. *Ekev Akademi Dergisi*(84), 21-38.
 45. Mundy P, Sigman M, Kasari C. A longitudinal study of joint attention and language development in autistic children. *J Autism Dev Disord.* 1990 Mar;20(1):115-28. doi: 10.1007/BF02206861. PMID: 2324051.
 46. Diener ML, Anderson L, Wright CA, Dunn ML. (2015). Sibling relationships of children with autism spectrum disorder in the context of everyday life and a strength-based program. *Journal of Family Study*, 24, 1060-1072. doi: 10.1007/s10826-014-9915-6
 47. Hartley SL, Barker ET, Seltzer MM, Floyd F, Greenberg J, Orsmond G, Bolt D. The relative risk and timing of divorce in families of children with an autism spectrum disorder. *J Fam Psychol.* 2010 Aug;24(4):449-57. doi: 10.1037/a0019847. PMID: 20731491; PMCID: PMC2928572.
 48. Fiske KE. *Autism and the Family: Understanding and Supporting Parents and Siblings.* First edition. New York: W.W. Norton & Company, 2017.
 49. Koçer A, Kucur F. (2022). Otizmlı Çocuğu Olan Ailelerin Zorunlu Eğitim Sonrası Süreçte Karşılaştıkları Sorunların Sosyal Hizmet Perspektifinden Değerlendirilmesi ve Çözüm Önerileri. *Sosyal Siyaset Konferansları Dergisi*(82), 439-465. <https://doi.org/10.26650/jspc.2022.82.10501994>
 50. Şengül Erdem H, Fazlıoğlu Y. (2020). Otizm Spektrum Bozukluğu Olan Çocukların Kardeşlerinin Psiko-sosyal Özelliklerinin Projektif Testlerle Değerlendirilmesi. *Ankara Üniversitesi Eğitim Bilimleri Fakültesi Özel Eğitim Dergisi*, 21(3), 537-559. <https://doi.org/10.21565/ozelgitimdergisi.601445>
 51. *International Review of Research in Mental Retardation*, 1st Edition, Volume 37. Glidden LM, Seltzer MM. October 26, 2009. ISBN: 9780080922584
 52. Wymbs B, Pelham W, Molina B, Gnagy E, Wilson T, Greenhouse J. (2008). Rate and Predictors of Divorce Among Parents of Youths With ADHD. *Journal of consulting and clinical psychology*. 76. 735-44. 10.1037/a0012719.
 53. Altieri MJ, von Kluge S. Searching for acceptance: challenges encountered while raising a child with autism. *J Intellect Dev Disabil.* 2009 Jun;34(2):142-52. doi: 10.1080/13668250902845202. PMID: 19404835.
 54. Messinger D, Young GS, Ozonoff S, Dobkins K, Carter A, Zwaigenbaum L, et al. Beyond autism: a baby siblings research consortium study of high-risk children at three years of age. *J Am Acad Child Adolesc Psychiatry.* 2013 Mar;52(3):300-308.e1. doi: 10.1016/j.jaac.2012.12.011. Epub 2013 Feb 8. PMID: 23452686; PMCID: PMC3625370.
 55. Orsmond GI, Fulford D. Adult Siblings Who Have a Brother or Sister with Autism: Between-Family and Within-Family Variations in Sibling Relationships. *J Autism Dev Disord.* 2018 Dec;48(12):4090-4102. doi: 10.1007/s10803-018-3669-8. PMID: 29971655; PMCID: PMC7386436.



56. Moss P, Eirinaki V, Savage S, Howlin P. (2019). Growing older with autism - The experiences of adult siblings of individuals with autism. *Research in Autism Spectrum Disorders*. 63. 42-51. 10.1016/j.rasd.2018.10.005.
57. Meadan H, Stoner J, Angell M. (2009). Review of Literature Related to the Social, Emotional, and Behavioral Adjustment of Siblings of Individuals with Autism Spectrum Disorder. *J Dev Phys Disabil*. 22. 83-100. 10.1007/s10882-009-9171-7.
58. Bontinck C, Warreyn P, Pael S, Demurie E, Roeyers H. (2018). The early development of infant siblings of children with autism spectrum disorder: Characteristics of sibling interactions. *PLOS ONE*. 13. e0193367. 10.1371/journal.pone.0193367.
59. Leaf J, Cihon J, Ferguson J, Gerhardt P. (2022). Handbook of Quality of Life for Individuals with Autism Spectrum Disorder: An Introduction. 10.1007/978-3-030-98507-3_1.
60. Siegel M, Doyle K, Chemelski B, et al. Specialized Inpatient Psychiatry Units for Children with Autism and Developmental Disorders: A United States Survey. *J Autism Dev Disord* 42, 1863-1869 (2012). <https://doi.org/10.1007/s10803-011-1426-3>
61. Machado Junior SB, Celestino MI, Serra JP, Caron J, Pondé MP. Risk and protective factors for symptoms of anxiety and depression in parents of children with autism spectrum disorder. *Dev Neurorehabil*. 2016 Jun;19(3):146-53. doi: 10.3109/17518423.2014.925519. Epub 2014 Jun 20. PMID: 24950424.
62. Allik H, Larsson JO, Smedje H. Health-related quality of life in parents of school-age children with Asperger Syndrome or High-Functioning Autism. *Health Qual Life Outcomes*. 2006 Jan 4;4:1. doi: 10.1186/1477-7525-4-1. PMID: 16393335; PMCID: PMC1360061.

OTİZMDE ADLİ SORUNLAR VE YÖNETİMİ

Elif AKÇAY¹
Meryem Hilal ALTAŞ²
Nesrin CEYLAN³

GİRİŞ

Otizm Spektrum Bozukluğu (OSB), erken çocukluk döneminde başlayan ve yaşam boyu süren, sosyal iletişim ve etkileşimde kalıcı yetersizlikler ile sınırlı, tekrarlayıcı davranış örüntüleri ile karakterize edilen nörogelişimsel bir bozuktur.^{1,2} Tanı genellikle sosyal iletişimde azalma, göz teması kuramama, ortak dikkat kurmakta yetersizlik, oyun becerilerinde kısıtlılık, duyuşal farklılıklar (hipo- ya da hipersensitivite), tekrarlayıcı hareketler ve davranışlar gibi belirtilerin bir arada gözlemlenmesiyle konulur. Klinik yelpazesi oldukça geniş olan OSB, bireyler arasında belirgin şekilde farklılaşan bilişsel, dilsel ve davranışsal özellikler sergileyebilir; bu nedenle “spektrum” terimi, bozukluğun heterojen doğasını yansıtmaktadır.³ Bu özellikler gelişimsel sürecin erken dönemlerinde fark edilebilmekle birlikte, bireyin yaşına, bilişsel kapasitesine ve çevresel etkileşimlerine göre farklı düzeylerde ortaya çıkabilir.⁴ Ayrıca, OSB’ye sıklıkla dikkat eksikliği ve hiperaktivite bozukluğu (DEHB), anksiyete bozuklukları ve zihinsel yetersizlik gibi eş tanılar eşlik edebilmektedir.⁵ Güncel verilere göre, OSB’nin küresel prevalansı yaklaşık %1 civarındadır.⁶ Amerika Birleşik Devletleri’nde 2023 yılında *Centers for Disease Control and Prevention* (CDC) tarafından yayımlanan verilere göre, 8 yaşındaki her 31 çocukta yaklaşık 1’inde (%3,2) OSB olduğu-

¹ Dr. Öğr. Üyesi, Sağlık Bilimleri Üniversitesi, Ankara Bilkent Şehir Hastanesi, Çocuk ve Ruh Sağlığı ve Hastalıkları AD., elifbayram07@gmail.com, ORCID iD: 0000-0002-4673-6254

² Uzm. Dr., Sağlık Bilimleri Üniversitesi, Ankara Bilkent Şehir Hastanesi, Çocuk Nöroloji Kliniği, dr.hilalaltas@gmail.com, ORCID iD: 0000-0003-3177-7018

³ Prof. Dr., Sağlık Bilimleri Üniversitesi, Ankara Bilkent Şehir Hastanesi, Çocuk Nöroloji Kliniği, drnesrineceylan@hotmail.com, ORCID iD: 0000-0001-5844-1261



KAYNAKLAR

1. APA (American Psychiatric Association). Diagnostic and statistical manual of mental disorders (5th ed., text rev.)2022.
2. APA (American Psychiatric Association). Diagnostic and statistical manual of mental disorders: DSM-5: Washington, DC: American Psychiatric Association; 2013.
3. Lord C, Brugha TS, Charman T, et al. Autism spectrum disorder. Nat Rev Dis Primers. 2020;6(1):5. Published 2020 Jan 16.
4. Fombonne E. Editorial: The rising prevalence of autism. J Child Psychol Psychiatry. 2018;59(7):717-720.
5. Simonoff E, Pickles A, Charman T, et al. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921-929.
6. WHO (The World Health Organization). Autism 2023 [Available from: <https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders>].
7. CDC (Centers for Disease Control and Prevention). Data and Statistics on Autism Spectrum Disorder 2025. Available from: https://www.cdc.gov/autism/data-research/?CDC_AA-ref_Val=https://www.cdc.gov/ncbddd/autism/data.html.
8. King C, Murphy GH. A systematic review of people with autism spectrum disorder and the criminal justice system. J Autism Dev Disord. 2014;44(11):2717-2733.
9. Kristiansson M, Sorman K. Autism spectrum disorders: legal and forensic psychiatric aspects and reflections. Clinical Neuropsychiatry: Journal of Treatment Evaluation. 2008;5(1):55-61.
10. Barry-Walsh JB, Mullen PE. Forensic aspects of Asperger's Syndrome. J Forens Psychiatry Psychol. 2004;15(1):96-107.
11. Freckelton I. Autism spectrum disorder: forensic issues and challenges for mental health professionals and courts. J Appl Res Intellect Disabil. 2013;26(5):420-434.
12. Woodbury-Smith M, Dein K. Autism spectrum disorder (ASD) and unlawful behaviour: where do we go from here?. J Autism Dev Disord. 2014;44(11):2734-2741.
13. Diagnostic and statistical manual of mental disorders (4th ed.) [press release]. 1994.
14. McPartland JC, Reichow B, Volkmar FR. Sensitivity and specificity of proposed DSM-5 diagnostic criteria for autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(4):368-383.
15. Fitzgerald M. Callous/unemotional traits and Asperger's syndrome?. J Am Acad Child Adolesc Psychiatry. 2003;42(9):1011.
16. Mayes SD, Calhoun SL, Crites DL. Does DSM-IV Asperger's disorder exist?. J Abnorm Child Psychol. 2001;29(3):263-271.
17. Ghaziuddin M. Should the DSM V drop Asperger syndrome? J Autism Dev Disord. 2010;40(9):1146-8.
18. Maras K, Marshall I, Sands C. Mock Juror Perceptions of Credibility and Culpability in an Autistic Defendant. J Autism Dev Disord. 2019;49(3):996-1010.
19. Maras K, Crane L, Walker I, et al. Brief report: Perceived credibility of autistic witnesses and the effect of diagnostic information on credibility ratings. Res Autism Spectr Disord. 2019;68:101442.
20. Gudjonsson GH, Murphy GH, Clare IC. Assessing the capacity of people with intellectual disabilities to be witnesses in court. Psychol Med. 2000;30(2):307-314.
21. Allely C. Autism Spectrum Disorders in the Criminal Justice System: Police Interviewing, the Courtroom and the Prison Environment. 2016. p. 1-13.
22. Maras KL, Bowler DM. Eyewitness testimony in autism spectrum disorder: a review. J Autism Dev Disord. 2014;44(11):2682-2697.



23. Woodhouse E, Hollingdale J, Davies L, et al. Identification and support of autistic individuals within the UK Criminal Justice System: a practical approach based upon professional consensus with input from lived experience. *BMC Med.* 2024;22(1):157. Published 2024 Apr 12.
24. Allen D, Evans C, Hider A, et al. Offending behaviour in adults with Asperger syndrome. *J Autism Dev Disord.* 2008;38(4):748-758.
25. Ashworth S. Autism is underdiagnosed in prisoners. *BMJ.* 2016;353:i3028. Published 2016 Jun 2.
26. Vinter L, Dillon G, Winder B. 'People don't like you when you're different': exploring the prison experiences of autistic individuals. *Psychology Crime and Law.* 2020;29.

OTİZMDE İLAÇ REHBERİ

Özlem ATEŞ YAMAN¹
 Mehmet CANPOLAT²
 Nihal OLGAÇ DÜNDAR³

İLAÇ ADI: ARİPİRAZOL

FDA, 2009 yılında psikotropik bir ilaç olan aripiprazolü (Abilify, Bristol-Myers Squibb ve jenerikleri) 6-17 yaş arası OSB'li çocuklarda sinirlilik tedavisi için onaylamıştır.¹ Bu ilaç aynı zamanda şizofreni, bipolar I bozukluk, majör depresif bozukluk ve Tourette sendromu tedavisinde de kullanılmaktadır.

- **İlaç formu:** Ülkemizde 1 mililitresinde 1 mg aripiprazol içeren 150 ml'lik so-lüsyon formu, 5-10-15-20-30 mg'lık tablet formları, 5-10-15-30 mg'lık ağızda dağılan tablet formları ve 400 mg uzun salınımlı aripiprazol içeren enjektabl flakon formu bulunmaktadır.²
- **Endikasyonu:** FDA onayına göre aripiprazolün endikasyonları:^{3,4}
 - 13 yaş ve üzeri şizofreni tedavisi
 - 10 yaş ve üzeri mani ve mikst epizod tedavisi
 - 6 yaş ve üstünde otizm ile ilişkili agresyon tedavisi
- **Kontrendikasyonlar:** Aripiprazol veya ilacın herhangi bir bileşenine karşı bilinen aşırı duyarlılık durumunda kontrendikedir.
- **Mekanizma:** Etki mekanizması tam olarak bilinmemekle birlikte, dopamin tip 2 (D2) ve serotonin tip 1A (5-HT1A) reseptörlerinde kısmi agonist ak-

¹ Dr., İzmir Şehir Hastanesi, Çocuk Nöroloji Kliniği, ozlem.ates.1989@gmail.com, ORCID iD: 0009-0001-9414-2231

² Prof. Dr., Erciyes Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları AD., drmehmetcanpolat@gmail.com, ORCID iD: 0000-0002-2197-8433

³ Prof. Dr., İzmir Katip Çelebi Üniversitesi Çocuk Nöroloji BD., Sinirbilimleri Uygulama ve Araştırma Merkezi, nodundar@gmail.com, ORCID iD: 0000-0002-5902-3501



KAYNAKLAR

1. Bristol-Myers Squibb. U.S. Food and Drug Administration approves aripiprazole for the treatment of irritability associated with autistic disorder in pediatric patients (ages 6–17 years). 2009.
2. Çocuk ve ergenlerde görülen psikotik bozuklukların tedavisinde kullanılan atipik antipsikotikler. *Türkiye Klinikleri J Med Sci*. 2016;1(3):39-53.
3. Stahl SM. *Essential Psychopharmacology: Prescriber's Guide*. 5th ed. Cambridge: Cambridge University Press; 2014.
4. Vitiello B. Principles in using psychotropic medication in children and adolescents. In: Rey JM, editor. *IACAPAP e-Textbook of Child and Adolescent Mental Health*. Geneva: International Association for Child and Adolescent Psychiatry and Allied Professions; 2012.
5. Bristol-Myers Squibb. Abilify (aripiprazole) prescribing information. Princeton (NJ): Bristol-Myers Squibb; 2014.
6. Doğançün B, Karaçetin G, Kayaalp L. Çocuk ve ergenlerde aripiprazol kullanımıyla ilgili bir gözden geçirme. *Çocuk ve Gençlik Ruh Sağlığı Dergisi*. 2008;15(3):163-75.
7. Harrison TS, Perry MC. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. *Drugs*. 2004;64:1715-36.
8. Eli Lilly and Company. Prozac (fluoxetine) prescribing information. Indianapolis (IN); 2014.
9. Sohel AJ, Shutter MC, Patel P, et al. Fluoxetine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
10. Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM. Antidepressants for inflammatory bowel disease. *Cochrane Database Syst Rev*. 2019;4:CD012680.
11. Dhenain T, Côté F, Coman T. Serotonin and orthodontic tooth movement. *Biochimie*. 2019;161:73-79.
12. Burch R. Antidepressants for preventive treatment of migraine. *Curr Treat Options Neurol*. 2019;21(4):18.
13. Crone C, Fochtmann LJ, Attia E, Boland R, Escobar J, Fornari V, et al. APA guideline for eating disorders. *Am J Psychiatry*. 2023;180(2):167-71.
14. Mullen S. Major depressive disorder in children and adolescents. *Ment Health Clin*. 2018;8(6):275-83.
15. Bahar MA, Kamp J, Borgsteede SD, Hak E, Wilffert B. CYP2D6 mediated drug-drug interaction with fluoxetine/paroxetine. *Br J Clin Pharmacol*. 2018;84(12):2704-15.
16. Deodhar M, Rihani SBA, Darakjian L, Turgeon J, Michaud V. Mechanism of fluoxetine-mediated CYP2D6 inhibition. *Pharmaceutics*. 2021;13(2).
17. Robertson OD, Coronado NG, Sethi R, Berk M, Dodd S. Neuroprotective pharmacotherapies in mental illness. *Early Interv Psychiatry*. 2019;13(5):1032-49.
18. Cao B, Zhu J, Zuckerman H, Rosenblatt JD, Brietzke E, Pan Z, et al. Pharmacological interventions targeting anhedonia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019;92:109-17.
19. Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. *Ann Palliat Med*. 2012.
20. Chokhawala K, Stevens L. Antipsychotic medications. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
21. Ortho-McNeil Pharmaceutical Inc. Haldol (haloperidol) prescribing information. Raritan (NJ); 2009.
22. MacDonald K, Wilson MP, Minassian A, et al. A retrospective analysis of intramuscular haloperidol and olanzapine in the treatment of agitation. *Gen Hosp Psychiatry*. 2010;32:443-45.
23. Clinton JE, Sterner S, Stelmachers Z, et al. Haloperidol for sedation of disruptive emergency patients. *Ann Emerg Med*. 1987;16:319-22.
24. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal symptoms.



- yramidal side effects in bipolar disorder and schizophrenia: a systematic review. *J Clin Psychopharmacol.* 2008;28(2):203-9.
25. Meyers RS, Thackray J, Matson KL, McPherson C, Lubsch L, Hellinga RC, Hoff DS. Key potentially inappropriate drugs in pediatrics: the KIDs list. *J Pediatr Pharmacol Ther.* 2020;25(3):175-91.
 26. Rahman S, Marwaha R. Haloperidol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
 27. Kahlon S, Lee C, Chirugi R, Worku Hassen G. Angioneurotic edema associated with haloperidol. *Case Rep Emerg Med.* 2012;2012:725461.
 28. Strain A. Angioedema of the tongue due to haloperidol. *Am J Emerg Med.* 2022;53:284.e5-284.e6.
 29. Masiran R. Persistent oromandibular dystonia and angioedema secondary to haloperidol. *BMJ Case Rep.* 2017.
 30. Pouget JG, Shams TA, Tiwari AK, Müller DJ. Pharmacogenetics and outcome with antipsychotic drugs. *Dialogues Clin Neurosci.* 2014;16(4):555-66.
 31. Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM. CYP2C19 and CYP2D6 metabolizer status with antidepressant and antipsychotic exposure. *JAMA Psychiatry.* 2021;78(3):270-80.
 32. Kumar B, Prakash A, Sewal RK, et al. Drug therapy in autism: a present and future perspective. *Pharmacol Rep.* 2012;64:1291-304.
 33. Novartis Pharmaceuticals. Clozaril (clozapine) prescribing information. East Hanover (NJ): Novartis Pharmaceuticals; 2014.
 34. Haidary HA, Padhy RK. Clozapine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
 35. Güler AS, Yazgan MY. Antipsikotikler. In: Çuhadaroglu Çetin F, et al., editors. *Çocuk ve Er-gen Psikiyatrisi Temel Kitabı*. 1. baskı. Ankara: Çocuk ve Gençlik Ruh Sağlığı Derneği; 2008. p.617-30.
 36. Stahl SM. Antipsikotik ajanlar. In: Stahl'ın Temel Psikofarmakolojisi: Sinirbilimsel Temeli ve Pratik Uygulaması. 4. baskı. İstanbul: İstanbul Tıp Kitabevi; 2014. p.129-327.
 37. Correll CU. Antipsychotic agents: traditional and atypical. In: Martin A, Scahill L, Kratochvil CJ, editors. *Pediatric Psychopharmacology: Principles and Practice*. 2nd ed. New York: Oxford University Press; 2011. p.312-38.
 38. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. *N Engl J Med.* 1991;324(11):746-54.
 39. Takeuchi H, Powell V, Geisler S, DeSanti M, Fervaha G, Agid O, Kane JM, Remington G. Clozapine administration in clinical practice: once-daily versus divided dosing. *Acta Psychiatr Scand.* 2016;134(3):234-40.
 40. Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics. *J Pineal Res.* 2012;52(4):437-45.
 41. Savage RA, Zafar N, Yohannan S, et al. Melatonin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
 42. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, Cardinali DP. Physiological effects of melatonin. *Prog Neurobiol.* 2008;85(3):335-53.
 43. Lallanne S, Fougerou-Leurent C, Anderson GM, Schroder CM, Nir T, Chokron S, Delorme R, et al. Melatonin in autism spectrum disorder. *Int J Mol Sci.* 2021;22(3):1490.
 44. Andersen LP, Gögenur I, Rosenberg J, Reiter RJ. The safety of melatonin in humans. *Clin Drug Investig.* 2016;36(3):169-75.
 45. Rubio-Sastre P, Scheer FA, Gómez-Abellán P, Madrid JA, Garaulet M. Acute melatonin administration impairs glucose tolerance. *Sleep.* 2014;37(10):1715-21.



46. Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM. Melatonin and immune system. *Int J Mol Sci*. 2013;14(4):8638-53.
47. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. Melatonin and reactive oxygen species. *J Pineal Res*. 2007;42:28-42.
48. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin. *Eur J Clin Pharmacol*. 2015;71(8):901-9.
49. Novartis Pharmaceuticals. Ritalin (methylphenidate) prescribing information. East Hanover (NJ); 2013.
50. Janssen Pharmaceuticals. Concerta (extended-release methylphenidate) prescribing information. Titusville (NJ); 2013.
51. Trenque T, Herlem E, Abou Taam M, Drame M. Methylphenidate off-label use and safety. *Springerplus*. 2014;3:286.
52. Thorpy MJ, Hiller G. The medical and economic burden of narcolepsy. *Am Health Drug Benefits*. 2017;10(5):233-41.
53. Capp PK, Pearl PL, Conlon C. Methylphenidate HCl therapy for ADHD. *Expert Rev Neurother*. 2005;5(3):325-31.
54. Verghese C, Patel P, Abdijadid S. Methylphenidate. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
55. Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, et al. ADHD clinical practice guideline. *Pediatrics*. 2011;128(5):1007-22.
56. Spiller HA, Hays HL, Aleguas A. Overdose of drugs for ADHD: clinical presentation and management. *CNS Drugs*. 2013;27(7):531-43.
57. Poulton AS, Bui Q, Melzer E, Evans R. Stimulant medication effects on growth and bone age in children with ADHD. *Int Clin Psychopharmacol*. 2016;31(2):93-99.
58. Sahakian BJ, Bruhl AB, Cook J, Killikelly C, Savulich G, Piercy T, et al. Cognitive enhancement in neuropsychiatric disorders. *Philos Trans R Soc B Biol Sci*. 2015;370(1677):20140214.
59. Güler AS, Yazgan MY. Antipsikotikler. In: Çuhadaroglu Çetin F, et al., editors. *Çocuk ve Er-gen Psikiyatrisi*
60. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. *J Child Adolesc Psychopharmacol*. 2006;16:575-87.
61. Meltzer HY, Gadaleta E. Contrasting typical and atypical antipsychotic drugs. *Focus (Am Psychiatr Publ)*. 2021;19(1):3-13.
62. McNeil SE, Gibbons JR, Cogburn M. Risperidone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
63. Shafiq S, Pringsheim T. Using antipsychotics for behavioral problems in children. *Expert Opin Pharmacother*. 2018;19:1475-88.
64. Correll CU. Antipsychotic agents: traditional and atypical. In: Martin A, Scahill L, Kratochvil CJ, editors. *Pediatric Psychopharmacology: Principles and Practice*. 2nd ed. New York: Oxford University Press; 2011. p.312-38.
65. Wyeth Pharmaceuticals. Effexor XR (venlafaxine hydrochloride) prescribing information. Philadelphia (PA); 2014.
66. Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal symptoms after SNRI discontinuation. *Psychother Psychosom*. 2018;87(4):195-203.
67. Guideline Development Panel. Clinical practice guideline for treatment of depression. *Am Psychol*. 2022;77(6):770-80.
68. Dean L. Venlafaxine therapy and CYP2D6 genotype. In: *Medical Genetics Summaries*. Bethesda (MD): NCBI; 2015.



69. Alomari NA, Bedaiwi SK, Ghasib AM, Kabbarah AJ, Alnefaie SA, Hariri N, et al. Social anxiety disorder: associated conditions and therapeutic approaches. *Cureus*. 2022;14(12):e32687.
70. Saad MA, El-Sahar AE, Sayed RH, Elbaz EM, Helmy HS, Senousy MA. Venlafaxine mitigates depressive-like behavior in rats. *Neurotherapeutics*. 2019;16(2):404-15.
71. Zosen D, Kondratskaya E, Kaplan-Arabaci O, Haugen F, Paulsen RE. Escitalopram and venlafaxine effects on BDNF promoter IV. *Neurochem Int*. 2023;169:105571.
72. Mansouri MT, Naghizadeh B, Ghorbanzadeh B, Alboghobeish S, Amirgholami N, Housh-mand G, Cauli O. Venlafaxine prevents morphine tolerance. *Exp Neurol*. 2018;303:134-41.
73. Castrén E, Monteggia LM. Brain-derived neurotrophic factor signaling in depression. *Biol Psychiatry*. 2021;90(2):128-36.
74. Singh D, Saadabadi A. Venlafaxine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
75. Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE. PharmGKB summary: venlafaxine pathway. *Pharmacogenet Genomics*. 2014;24(1):62-72.